[
    {
        "id": 7,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 0,
        "content": "NCCN Guidelines focus on Head and Neck Cancers."
    },
    {
        "id": 69,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss the multidisciplinary team and support services (TEAM-1)."
    },
    {
        "id": 70,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss cancer of the oral cavity (including mucosal lip) (OR-1)."
    },
    {
        "id": 71,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss cancer of the oropharynx (ORPH-1)."
    },
    {
        "id": 72,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss p16-negative cancer of the oropharynx (ORPH-2)."
    },
    {
        "id": 73,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss p16 (HPV)-positive cancer of the oropharynx (ORPHPV-1)."
    },
    {
        "id": 74,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss cancer of the hypopharynx (HYPO-1)."
    },
    {
        "id": 75,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss cancer of the nasopharynx (NASO-1)."
    },
    {
        "id": 76,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss systemic therapy for nasopharyngeal cancers (NASO-B)."
    },
    {
        "id": 77,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss cancer of the glottic larynx (GLOT-1)."
    },
    {
        "id": 78,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss cancer of the supraglottic larynx (SUPRA-1)."
    },
    {
        "id": 79,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss ethmoid sinus tumors (ETHM-1)."
    },
    {
        "id": 80,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss maxillary sinus tumors (MAXI-1)."
    },
    {
        "id": 81,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss very advanced head and neck cancer (ADV-1)."
    },
    {
        "id": 82,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss recurrent/persistent very advanced head and neck cancer (ADV-3)."
    },
    {
        "id": 83,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss occult primary (OCC-1)."
    },
    {
        "id": 84,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss salivary gland tumors (SALI-1)."
    },
    {
        "id": 85,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss systemic therapy for salivary gland tumors (SALI-B)."
    },
    {
        "id": 86,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss mucosal melanoma (MM-1)."
    },
    {
        "id": 87,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines provide follow-up recommendations (FOLL-A)."
    },
    {
        "id": 88,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss principles of imaging (IMG-A)."
    },
    {
        "id": 89,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss principles of surgery (SURG-A)."
    },
    {
        "id": 90,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss principles of radiation techniques (RAD-A)."
    },
    {
        "id": 91,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss principles of systemic therapy for non-nasopharyngeal cancers (SYST-A)."
    },
    {
        "id": 92,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss principles of nutrition: management and supportive care (NUTR-A)."
    },
    {
        "id": 93,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss principles of oral/dental evaluation and management (DENT-A)."
    },
    {
        "id": 94,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 2,
        "content": "The NCCN Guidelines discuss staging (ST-1)."
    },
    {
        "id": 96,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 3,
        "content": "NCCN Guidelines Version 2.2024 is a version of the NCCN Guidelines for Head and Neck Cancers."
    },
    {
        "id": 110,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 3,
        "content": "OR-3 includes clinical staging and selected patients who decline or are unfit for surgery."
    },
    {
        "id": 112,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 3,
        "content": "A pathway for concurrent systemic therapy/RT or definitive RT was removed in OR-3."
    },
    {
        "id": 113,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 3,
        "content": "A pathway for post systemic therapy/RT or RT neck evaluation was removed in OR-3."
    },
    {
        "id": 114,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 3,
        "content": "A pathway for recurrent or persistent disease was removed in OR-3."
    },
    {
        "id": 115,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 3,
        "content": "A follow-up for very advanced head and neck cancer was added in OR-3."
    },
    {
        "id": 117,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 3,
        "content": "NASO-B includes recurrent, unresectable, oligometastatic, or metastatic disease with no surgery or RT option."
    },
    {
        "id": 118,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 3,
        "content": "A preferred first-line regimen was added in NASO-B."
    },
    {
        "id": 120,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 3,
        "content": "A preferred subsequent-line regimen was added in NASO-B."
    },
    {
        "id": 132,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 4,
        "content": "HYPO-2 includes a modified treatment of primary and neck option."
    },
    {
        "id": 134,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 4,
        "content": "HYPO-3 includes a modified treatment of primary and neck option."
    },
    {
        "id": 136,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 4,
        "content": "HYPO-5 includes a modified treatment of primary and neck option."
    },
    {
        "id": 138,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 4,
        "content": "NASO-A includes a note about hyperfractionation for locally advanced nasopharyngeal carcinoma."
    },
    {
        "id": 140,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 4,
        "content": "NASO-B includes a recurrent, unresectable, oligometastatic, or metastatic disease option."
    },
    {
        "id": 142,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 4,
        "content": "SUPRA-2 includes a modified treatment of primary and neck option."
    },
    {
        "id": 146,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 4,
        "content": "ETHM-1 includes a new footnote."
    },
    {
        "id": 148,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 4,
        "content": "ETHM-2 includes a primary treatment option."
    },
    {
        "id": 162,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "ADV-1 was updated to include concurrent systemic therapy/RT as a preferred option for treatment of primary and neck."
    },
    {
        "id": 163,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "PS2 was modified to include concurrent systemic therapy/RT as a preferred option."
    },
    {
        "id": 164,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "SALI-2 was updated to include complete resection as an option for adenoid cystic intermediate or higher grade, with a category of evidence modified for RT for T1 disease from 2B to 2A."
    },
    {
        "id": 165,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "SALI-3 was updated to include complete resection as an option for adenoid cystic, with a category of evidence modified for RT from 2B to 2A."
    },
    {
        "id": 166,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "SALI-B was updated to include androgen receptor (AR) therapy for AR+ tumors as useful in certain circumstances."
    },
    {
        "id": 167,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "Abiraterone was added as a regimen for AR+ tumors."
    },
    {
        "id": 168,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "Goserelin was added as a regimen for AR+ tumors with a category of evidence of 2B."
    },
    {
        "id": 169,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "Axitinib + avelumab was added as a regimen for ACC with a category of evidence of 2B."
    },
    {
        "id": 170,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "Fam-trastuzumab deruxtecan-nxki was modified to have a category of evidence of 2A."
    },
    {
        "id": 171,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "FOLL-A was updated to include annual evaluation of panhypopituitarism following RT to the skull base."
    },
    {
        "id": 172,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "IMG-A was updated to include CT with contrast as an imaging option."
    },
    {
        "id": 173,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "CT imaging of the chest can be performed with or without contrast, as clinically indicated."
    },
    {
        "id": 174,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "MRI is performed with and without contrast, unless contraindicated."
    },
    {
        "id": 175,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "CT is complementary to MRI for head and neck cancers for certain conditions."
    },
    {
        "id": 176,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "CT is used to evaluate cortical bone erosion or periosteal invasion in oral cavity cancer."
    },
    {
        "id": 177,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "CT is used to evaluate cartilage invasion in laryngeal cancer."
    },
    {
        "id": 178,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "CT is used to evaluate bony erosion/destruction in sinonasal and skull base lesions."
    },
    {
        "id": 179,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "MRI is used to evaluate the extent of bone marrow invasion or in patients with extensive dental amalgam that may obscure the anatomy on CT in oral cavity cancer."
    },
    {
        "id": 180,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "MRI is used to assess skull base invasion and cranial nerve involvement in nasopharyngeal cancer."
    },
    {
        "id": 181,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 5,
        "content": "MRI is used to evaluate skull base or intracranial or orbital invasion, and to differentiate tumor from obstructed sinuses in sinonasal cancer."
    },
    {
        "id": 187,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Sub-bullet 4 was modified to include any head and neck cancer with cranial nerve symptoms or radiographic perineural tumor spread as a possibility."
    },
    {
        "id": 188,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Bullet 5 was modified to state that US of the neck is a well-established tool useful for nodal surveillance."
    },
    {
        "id": 189,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "US is generally widely available, safe, fast, inexpensive, and an accurate modality for examination of the neck for any suspicious nodal disease."
    },
    {
        "id": 190,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "A clear margin is no longer defined as the distance from the invasive tumor front that is 5 mm or more from the resected margin."
    },
    {
        "id": 191,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "A close margin is no longer defined as the distance from the invasive tumor front to the resected margin that is less than 2\u20135 mm, depending on the anatomic site involved."
    },
    {
        "id": 192,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "There is no universal definition for what constitutes a clear/close margin."
    },
    {
        "id": 193,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Distance in mm to achieve clinically acceptable margins is influenced by tumor primary site, histology, and HPV status in oropharyngeal cancer and following neoadjuvant therapy."
    },
    {
        "id": 195,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Hyperfractionation for locally advanced nasopharyngeal carcinoma involves IMRT total dose of 65 Gy, in 54 fractions, twice daily, with an irradiation interval of 6\u20138 hours."
    },
    {
        "id": 197,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "The choice of systemic therapy should be individualized based on patient characteristics (eg, PS, goals of therapy)."
    },
    {
        "id": 198,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Next-generation sequencing (NGS) genomic profiling, including testing for CPS, may be considered to guide patient treatment options, including clinical trials."
    },
    {
        "id": 199,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Docetaxel (if cisplatin ineligible) is a useful regimen in certain circumstances for Primary Systemic Therapy + Concurrent RT."
    },
    {
        "id": 200,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Carboplatin/paclitaxel/cetuximab (category 2B) is a useful regimen in certain circumstances for Induction/Sequential Systemic Therapy."
    },
    {
        "id": 202,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Docetaxel/cisplatin/fluorouracil (category 2B) was added as a regimen for Induction/Sequential Systemic Therapy."
    },
    {
        "id": 203,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Docetaxel (if cisplatin ineligible) is a useful regimen in certain circumstances for Postoperative Systemic Therapy/RT."
    },
    {
        "id": 204,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Pembrolizumab/platinum (cisplatin or carboplatin)/paclitaxel (category 2B) is a modified regimen for Other recommended regimens."
    },
    {
        "id": 205,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Cetuximab/pembrolizumab (category 2B) is a modified regimen for Squamous cell carcinoma."
    },
    {
        "id": 206,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Paclitaxel/cetuximab is a added regimen for Squamous cell carcinoma."
    },
    {
        "id": 207,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Nivolumab/ipilimumab (CPS \u226520 and first-line only) (category 2B) is a added regimen for Squamous cell carcinoma."
    },
    {
        "id": 208,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 6,
        "content": "Docetaxel/cetuximab (category 2B) is a added regimen for Squamous cell carcinoma."
    },
    {
        "id": 211,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancers is complex."
    },
    {
        "id": 212,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "All patients with head and neck cancers need access to the full range of support services and specialists with expertise in the comprehensive care of patients with head and neck cancer for optimal treatment and follow-up."
    },
    {
        "id": 213,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "Outcomes are improved when patients with head and neck cancers are treated in high-volume centers."
    },
    {
        "id": 214,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "Follow-up should be performed by a physician and other health care professionals with expertise in the comprehensive care and prevention of treatment sequelae."
    },
    {
        "id": 215,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "Follow-up should include a comprehensive head and neck exam."
    },
    {
        "id": 216,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve head and neck surgery."
    },
    {
        "id": 217,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve radiation oncology."
    },
    {
        "id": 218,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve medical oncology."
    },
    {
        "id": 219,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve plastic and reconstructive surgery."
    },
    {
        "id": 220,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve specialized nursing care."
    },
    {
        "id": 221,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve dentistry/prosthodontics."
    },
    {
        "id": 222,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve physical medicine and rehabilitation."
    },
    {
        "id": 223,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve speech and swallowing therapy."
    },
    {
        "id": 244,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve speech and swallowing therapy."
    },
    {
        "id": 224,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve clinical social work."
    },
    {
        "id": 225,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve clinical nutrition."
    },
    {
        "id": 226,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve pathology (including cytopathology)."
    },
    {
        "id": 227,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve diagnostic and interventional radiology."
    },
    {
        "id": 228,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve adjunctive services."
    },
    {
        "id": 229,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve neurosurgery."
    },
    {
        "id": 230,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve ophthalmology."
    },
    {
        "id": 231,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve psychiatry."
    },
    {
        "id": 232,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve addiction services."
    },
    {
        "id": 233,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve audiology."
    },
    {
        "id": 245,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve audiology."
    },
    {
        "id": 234,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve palliative care."
    },
    {
        "id": 235,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve pain management."
    },
    {
        "id": 236,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve general medical care."
    },
    {
        "id": 237,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve pain and symptom management."
    },
    {
        "id": 238,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve nutritional support."
    },
    {
        "id": 239,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve enteral feeding."
    },
    {
        "id": 240,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve oral nutrition."
    },
    {
        "id": 241,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve dental care for RT effects."
    },
    {
        "id": 242,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve xerostomia management."
    },
    {
        "id": 243,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve smoking and alcohol cessation."
    },
    {
        "id": 246,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve tracheotomy care."
    },
    {
        "id": 247,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve wound management."
    },
    {
        "id": 248,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve depression assessment and management."
    },
    {
        "id": 249,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve social work and case management."
    },
    {
        "id": 250,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve care coordination."
    },
    {
        "id": 251,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve supportive care."
    },
    {
        "id": 252,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 7,
        "content": "The comprehensive care of patients with head and neck cancer may involve physical therapy (lymphedema management)."
    },
    {
        "id": 263,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "H&P should include documentation and quantification of tobacco use history."
    },
    {
        "id": 264,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "H&P should include documentation and quantification of alcohol use and counseling."
    },
    {
        "id": 265,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "All patients who currently smoke should be advised to quit smoking."
    },
    {
        "id": 266,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "Those who formerly smoked should be advised to remain abstinent from smoking."
    },
    {
        "id": 267,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "Additional cessation support can be found in the NCCN Guidelines for Smoking Cessation."
    },
    {
        "id": 268,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "Patients should be screened for depression according to the NCCN Guidelines for Distress Management."
    },
    {
        "id": 269,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The oral cavity includes buccal mucosa, floor of mouth, oral tongue, alveolar ridge, retromolar trigone, and hard palate."
    },
    {
        "id": 270,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes history and physical including a complete head and neck exam."
    },
    {
        "id": 271,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes mirror and fiberoptic examination as clinically indicated."
    },
    {
        "id": 272,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes biopsy."
    },
    {
        "id": 273,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes chest CT with or without contrast as clinically indicated."
    },
    {
        "id": 274,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes CT with contrast and/or MRI with and without contrast of primary and neck as clinically indicated."
    },
    {
        "id": 275,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes consideration of FDG-PET/CT as clinically indicated."
    },
    {
        "id": 276,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes examination under anesthesia with endoscopy as clinically indicated."
    },
    {
        "id": 277,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes preanesthesia studies as clinically indicated."
    },
    {
        "id": 278,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes dental/prosthodontic evaluation including Panorex or dental CT without contrast as clinically indicated."
    },
    {
        "id": 279,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes nutrition, speech and swallowing evaluation/therapy as clinically indicated."
    },
    {
        "id": 280,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes smoking cessation counseling."
    },
    {
        "id": 281,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes fertility/reproductive counseling as clinically indicated."
    },
    {
        "id": 282,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes screening for hepatitis B as clinically indicated."
    },
    {
        "id": 283,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "The workup includes multidisciplinary consultation as clinically indicated."
    },
    {
        "id": 284,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "Image-guided needle biopsy of cystic neck nodes may offer better diagnostic yield than fine-needle aspiration by palpation alone for initial diagnosis."
    },
    {
        "id": 285,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 8,
        "content": "A core biopsy would allow for ancillary immune-genomic testing for unresectable or metastatic disease where there is a plan for systemic therapy."
    },
    {
        "id": 298,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Buccal mucosa, floor of mouth, oral tongue, alveolar ridge, retromolar trigone, and hard palate are types of oral cavity cancers."
    },
    {
        "id": 299,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Clinical staging, treatment of primary and neck, adjuvant treatment, and follow-up are parts of the NCCN Guidelines for Cancer of the Oral Cavity."
    },
    {
        "id": 300,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "T1\u20132, N0 is a clinical stage of cancer."
    },
    {
        "id": 302,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Resection of primary and + sentinel lymph node biopsy are treatment options for T1\u20132, N0 cancer."
    },
    {
        "id": 303,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Surgery is a preferred treatment option for T1\u20132, N0 cancer."
    },
    {
        "id": 305,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Definitive RT is a treatment option for SLN pN0 cancer."
    },
    {
        "id": 306,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Neck dissection is a treatment option if SLN pN+ or SLN identification is unsuccessful."
    },
    {
        "id": 307,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "No positive nodes and no adverse pathologic features are characteristics of a type of cancer."
    },
    {
        "id": 308,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "One positive node without adverse pathologic features is a characteristic of a type of cancer."
    },
    {
        "id": 309,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 341,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 310,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Positive margin is an adverse pathologic feature."
    },
    {
        "id": 311,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Extranodal extension \u00b1 positive margin is an adverse pathologic feature."
    },
    {
        "id": 312,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Consider RT is a treatment option for certain types of cancer."
    },
    {
        "id": 313,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Systemic therapy/RT is a treatment option for certain types of cancer."
    },
    {
        "id": 314,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Re-resection if feasible and consider radiation therapy if negative margins is a treatment option."
    },
    {
        "id": 315,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Consider systemic therapy/RT is a treatment option."
    },
    {
        "id": 317,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 9,
        "content": "Recurrent or persistent disease is a type of cancer."
    },
    {
        "id": 330,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Neck dissection is generally not indicated for T1\u20133,N0 mucosal lip."
    },
    {
        "id": 331,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "The affected areas in the oral cavity include buccal mucosa, floor of mouth, oral tongue, alveolar ridge, retromolar trigone, and hard palate."
    },
    {
        "id": 332,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Clinical staging, treatment of primary and neck, adjuvant treatment, and follow-up are important considerations for cancer of the oral cavity."
    },
    {
        "id": 333,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "T3,N0; T1\u20133,N1\u20133; T4a,N0\u20133 are classifications for cancer of the oral cavity."
    },
    {
        "id": 334,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Surgery is the preferred treatment for T3,N0; T1\u20133,N1\u20133; T4a,N0\u20133."
    },
    {
        "id": 335,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Clinical trials are an alternative treatment for T3,N0; T1\u20133,N1\u20133; T4a,N0\u20133."
    },
    {
        "id": 336,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "N0,N1, N2a\u2013b, N3 are classifications for neck nodes."
    },
    {
        "id": 337,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Resection of primary and bilateral neck dissection are treatments for N0,N1, N2a\u2013b, N3."
    },
    {
        "id": 338,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "N2c (bilateral) is a classification for neck nodes."
    },
    {
        "id": 339,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Resection of primary and bilateral neck dissection are treatments for N2c (bilateral)."
    },
    {
        "id": 340,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "No adverse pathologic features are a consideration for treatment."
    },
    {
        "id": 342,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Consideration of RT is a treatment option for adverse pathologic features."
    },
    {
        "id": 343,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Systemic therapy/RT are treatments for adverse pathologic features."
    },
    {
        "id": 344,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "RT is a treatment option for extranodal extension and positive margin."
    },
    {
        "id": 345,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Systemic therapy/RT are treatments for other risk features."
    },
    {
        "id": 346,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Re-resection is a treatment option if feasible and negative margins are achieved."
    },
    {
        "id": 347,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "RT is a treatment option if negative margins are achieved."
    },
    {
        "id": 348,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Positive margin is a consideration for treatment."
    },
    {
        "id": 349,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Selected patients who decline surgery are a consideration for treatment."
    },
    {
        "id": 350,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Principles of Radiation Therapy are outlined in OR-A."
    },
    {
        "id": 351,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 10,
        "content": "Principles of Systemic Therapy for Non-Nasopharyngeal Cancers are outlined in SYST-A."
    },
    {
        "id": 363,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "For doses >70 Gy, some clinicians feel that the fractionation should be slightly modified to minimize toxicity."
    },
    {
        "id": 365,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "Brachytherapy should be performed at centers where there is expertise in this modality."
    },
    {
        "id": 366,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "The American Brachytherapy Society has recommendations for high-dose-rate brachytherapy for head-neck carcinomas."
    },
    {
        "id": 367,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "GEC-ESTRO has recommendations for brachytherapy for head and neck squamous cell carcinomas."
    },
    {
        "id": 369,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "The interval between HDR fractions should be at least 6 hours."
    },
    {
        "id": 370,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "The planning target volume (PTV) includes high-risk areas such as primary tumor and involved lymph nodes."
    },
    {
        "id": 371,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "The fractionation for high-risk areas is 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)."
    },
    {
        "id": 372,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "Concomitant boost accelerated RT is an option for high-risk areas."
    },
    {
        "id": 373,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "Hyperfractionation is an option for high-risk areas."
    },
    {
        "id": 375,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "Interstitial brachytherapy is considered for selected cases."
    },
    {
        "id": 376,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "Low dose-rate (LDR) brachytherapy is an option."
    },
    {
        "id": 377,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "High dose-rate (HDR) brachytherapy is an option."
    },
    {
        "id": 378,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 11,
        "content": "Either intensity-modulated RT (IMRT) or 3D conformal RT (3D-CRT) is recommended for unresectable disease."
    },
    {
        "id": 391,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 12,
        "content": "44\u201350 Gy in 3D-CRT and sequentially planned IMRT or 54\u201363 Gy with IMRT dose painting technique is suggested for radiation therapy."
    },
    {
        "id": 392,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 12,
        "content": "The dose per fraction depends on the radiation therapy technique used."
    },
    {
        "id": 402,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 12,
        "content": "Postoperative radiation therapy or concurrent systemic therapy/radiation therapy is recommended for high-risk patients."
    },
    {
        "id": 403,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 12,
        "content": "The preferred interval between resection and postoperative radiation therapy is \u22646 weeks."
    },
    {
        "id": 405,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 12,
        "content": "High-risk patients have adverse pathologic features such as positive margins."
    },
    {
        "id": 406,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 12,
        "content": "High-risk patients receive 60\u201366 Gy of radiation therapy."
    },
    {
        "id": 407,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 12,
        "content": "Low to intermediate risk patients receive 44\u201350 Gy to 54\u201363 Gy of radiation therapy."
    },
    {
        "id": 408,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 12,
        "content": "IMRT is the preferred radiation therapy technique."
    },
    {
        "id": 410,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 12,
        "content": "T1\u2013T2 simple lip lesions are treated with postoperative radiation therapy as per non-melanoma skin cancers."
    },
    {
        "id": 424,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "H&P should include documentation and quantification of tobacco use history."
    },
    {
        "id": 425,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "H&P should include documentation and quantification of alcohol use and counseling."
    },
    {
        "id": 426,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "All patients who currently smoke should be advised to quit smoking."
    },
    {
        "id": 427,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Those who formerly smoked should be advised to remain abstinent from smoking."
    },
    {
        "id": 430,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Image-guided needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis."
    },
    {
        "id": 431,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "For unresectable or metastatic disease where there is a plan for systemic therapy, a core biopsy would allow for ancillary immune-genomic testing."
    },
    {
        "id": 432,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Tumor human papillomavirus (HPV) testing by p16 immunohistochemistry is required."
    },
    {
        "id": 433,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "H&P is required and should include a complete head and neck exam."
    },
    {
        "id": 434,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Biopsy of primary site or fine-needle aspiration of the neck is required."
    },
    {
        "id": 435,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "CT with contrast and/or MRI with and without contrast of primary and neck is required."
    },
    {
        "id": 436,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "EUA with endoscopy is recommended as clinically indicated."
    },
    {
        "id": 438,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "FDG-PET/CT is recommended as clinically indicated."
    },
    {
        "id": 439,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Chest CT with or without contrast is recommended as clinically indicated."
    },
    {
        "id": 440,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Dental evaluation including Panorex is recommended as clinically indicated."
    },
    {
        "id": 441,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Nutrition, speech and swallowing evaluation/therapy, and audiogram are recommended as clinically indicated."
    },
    {
        "id": 442,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Smoking cessation counseling is recommended as clinically indicated."
    },
    {
        "id": 443,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Fertility/reproductive counseling is recommended as clinically indicated."
    },
    {
        "id": 444,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Screening for hepatitis B is recommended as clinically indicated."
    },
    {
        "id": 445,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Multidisciplinary consultation is recommended as clinically indicated."
    },
    {
        "id": 446,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "T1\u20132,N0 or T0\u20132,N1 (single node \u22643 cm) and p16 (HPV)-positive patients have a specific treatment plan."
    },
    {
        "id": 447,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "T0\u20132,N1 (single node >3 cm, or 2 or more ipsilateral nodes \u22646 cm), or T1\u20132,N2 or T3,N0\u20132 patients have a specific treatment plan."
    },
    {
        "id": 448,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 13,
        "content": "Unresectable or unfit for surgery or metastatic (M1) disease initial presentation patients have a specific treatment plan."
    },
    {
        "id": 473,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 14,
        "content": "Tumors in the base of tongue, posterior pharyngeal wall, and soft palate require consideration of bilateral neck treatment."
    },
    {
        "id": 474,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 14,
        "content": "Tumors of the tonsil invading the tongue base require consideration of bilateral neck treatment."
    },
    {
        "id": 488,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 14,
        "content": "pN0 and no adverse pathologic features is a condition."
    },
    {
        "id": 489,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 14,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 490,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 14,
        "content": "Systemic therapy/RT is a treatment option."
    },
    {
        "id": 491,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 14,
        "content": "Re-resection, if feasible, is a treatment option."
    },
    {
        "id": 492,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 14,
        "content": "RT is a treatment option."
    },
    {
        "id": 493,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 14,
        "content": "Consider systemic therapy/RT is a treatment option."
    },
    {
        "id": 502,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 14,
        "content": "pN1 without other adverse pathologic features is a condition."
    },
    {
        "id": 503,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 14,
        "content": "Consider RT is a treatment option."
    },
    {
        "id": 515,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "Tumors in the base of tongue, posterior pharyngeal wall, and soft palate require consideration of bilateral neck treatment as do tumors of the tonsil invading the tongue base."
    },
    {
        "id": 546,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Principles of Surgery are outlined in SURG-A."
    },
    {
        "id": 516,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "Principles of Radiation Therapy are outlined in ORPH-A."
    },
    {
        "id": 547,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Principles of Radiation Therapy are outlined in ORPH-A."
    },
    {
        "id": 517,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "Clinical staging is part of the treatment of primary and neck disease."
    },
    {
        "id": 518,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "Adjuvant treatment is part of the treatment of primary and neck disease."
    },
    {
        "id": 519,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "Recurrent or persistent disease is treated according to the ADV-3 guidelines."
    },
    {
        "id": 524,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 563,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 525,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "Systemic therapy/RT is an option for recurrent or persistent disease."
    },
    {
        "id": 526,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "RT is an option for recurrent or persistent disease."
    },
    {
        "id": 527,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "Principles of Systemic Therapy for Non-Nasopharyngeal Cancers are outlined in SYST-A."
    },
    {
        "id": 548,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Principles of Systemic Therapy for Non-Nasopharyngeal Cancers are outlined in SYST-A."
    },
    {
        "id": 530,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate is part of the treatment guidelines."
    },
    {
        "id": 531,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "Post Systemic Therapy/RT or RT Neck Evaluation is part of the follow-up guidelines (FOLL-A, 2 of 2)."
    },
    {
        "id": 532,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 15,
        "content": "Follow-up is part of the guidelines (FOLL-A, 1 of 2)."
    },
    {
        "id": 544,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Tumors in the base of tongue, posterior pharyngeal wall, and soft palate require consideration of bilateral neck treatment."
    },
    {
        "id": 577,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Tumors in the base of tongue, posterior pharyngeal wall, and soft palate require consideration of bilateral neck treatment."
    },
    {
        "id": 549,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Clinical staging is a part of the treatment of primary and neck."
    },
    {
        "id": 550,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Adjuvant treatment is a part of the treatment of primary and neck."
    },
    {
        "id": 551,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Concurrent systemic therapy and radiation therapy are treatment options for p16-negative T1\u20134a,N2\u20133."
    },
    {
        "id": 552,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Resection of primary and ipsilateral or bilateral neck dissection are treatment options for p16-negative T1\u20134a,N2\u20133."
    },
    {
        "id": 553,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Clinical trials are treatment options for p16-negative T1\u20134a,N2\u20133."
    },
    {
        "id": 554,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "No adverse pathologic features are a consideration in treatment."
    },
    {
        "id": 555,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Adverse pathologic features include extranodal extension and/or positive margin."
    },
    {
        "id": 556,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Other risk features are a consideration in treatment."
    },
    {
        "id": 557,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Systemic therapy and radiation therapy are treatment options."
    },
    {
        "id": 558,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Follow-up is outlined in FOLL-A, 1 of 2."
    },
    {
        "id": 559,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Recurrent or persistent disease is treated according to ADV-3."
    },
    {
        "id": 560,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate have specific treatment options."
    },
    {
        "id": 561,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Induction chemotherapy followed by radiation therapy or systemic therapy/radiation therapy are treatment options."
    },
    {
        "id": 562,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 16,
        "content": "Post Systemic Therapy/RT or RT Neck Evaluation is outlined in FOLL-A, 2 of 2."
    },
    {
        "id": 581,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Pathologic staging criteria differ from clinical staging criteria in HPV-mediated oropharyngeal cancer."
    },
    {
        "id": 582,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "For pathologic stage following resection, the AJCC 8th edition provides appropriate staging criteria."
    },
    {
        "id": 583,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "CLINICAL STAGING is a section in the NCCN Guidelines Version 2.2024."
    },
    {
        "id": 584,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "TREATMENT OF PRIMARY AND NECK is a section in the NCCN Guidelines Version 2.2024."
    },
    {
        "id": 585,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "ADJUVANT TREATMENT is a section in the NCCN Guidelines Version 2.2024."
    },
    {
        "id": 586,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Recurrent or persistent disease is addressed in section ADV-3."
    },
    {
        "id": 587,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Follow-up is addressed in sections FOLL-A, 1 of 2 and FOLL-A, 2 of 2."
    },
    {
        "id": 589,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Resection of primary and ipsilateral or bilateral selective neck dissection is a treatment option."
    },
    {
        "id": 590,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, one positive node >3 cm or multiple positive nodes, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 591,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Systemic therapy/RT or RT is a treatment option."
    },
    {
        "id": 592,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Re-resection, if feasible, or Systemic therapy/RT or RT is a treatment option."
    },
    {
        "id": 593,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "RT is a treatment option."
    },
    {
        "id": 594,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Systemic therapy/RT or RT is a treatment option with a category 2B rating."
    },
    {
        "id": 595,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Adverse pathologic features are an area of active research in the context of HPV+ disease."
    },
    {
        "id": 596,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "The definition of an adverse pathologic feature in the context of HPV+ disease includes the presence and extent of extranodal extension, and the number of involved nodes."
    },
    {
        "id": 597,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "The recommendations for patients at high risk with extranodal extension + positive margins are based on randomized studies involving patients for whom the HPV status of their tumors was not specified."
    },
    {
        "id": 598,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "No adverse pathologic features is a category of patients."
    },
    {
        "id": 599,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate is a type of cancer."
    },
    {
        "id": 600,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Post Systemic Therapy/RT or RT Neck Evaluation is a section in the NCCN Guidelines Version 2.2024."
    },
    {
        "id": 602,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 17,
        "content": "Clinical trials are a treatment option."
    },
    {
        "id": 608,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "NCCN believes that the best management of any patient with cancer is in a clinical trial."
    },
    {
        "id": 631,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 19,
        "content": "NCCN believes that the best management of any patient with cancer is in a clinical trial."
    },
    {
        "id": 659,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "NCCN believes that the best management of any patient with cancer is in a clinical trial."
    },
    {
        "id": 697,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "NCCN believes that the best management of any patient with cancer is in a clinical trial."
    },
    {
        "id": 609,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "Participation in clinical trials is especially encouraged."
    },
    {
        "id": 698,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "Participation in clinical trials is especially encouraged."
    },
    {
        "id": 610,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "The clinical staging definitions are based on the AJCC 8th edition for oropharynx cancer."
    },
    {
        "id": 638,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 19,
        "content": "The clinical staging definitions are based on the AJCC 8th edition for oropharynx cancer."
    },
    {
        "id": 611,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "Definitions for nodal staging criteria previously used in clinical trials (AJCC 7th edition) on the management of oropharynx cancer are included."
    },
    {
        "id": 612,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "Principles of Surgery are described in SURG-A."
    },
    {
        "id": 613,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "Tumors in the base of tongue, posterior pharyngeal wall, and soft palate require consideration of bilateral neck treatment."
    },
    {
        "id": 641,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 19,
        "content": "Tumors in the base of tongue, posterior pharyngeal wall, and soft palate require consideration of bilateral neck treatment."
    },
    {
        "id": 683,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Tumors in the base of tongue, posterior pharyngeal wall, and soft palate require consideration of bilateral neck treatment."
    },
    {
        "id": 614,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "Tumors of the tonsil invading the tongue base require consideration of bilateral neck treatment."
    },
    {
        "id": 642,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 19,
        "content": "Tumors of the tonsil invading the tongue base require consideration of bilateral neck treatment."
    },
    {
        "id": 684,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Tumors of the tonsil invading the tongue base require consideration of bilateral neck treatment."
    },
    {
        "id": 615,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "Principles of Radiation Therapy are described in ORPH-A."
    },
    {
        "id": 616,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "Principles of Systemic Therapy for Non-Nasopharyngeal Cancers are described in SYST-A."
    },
    {
        "id": 617,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "p16 (HPV)-positive oropharynx cancer has specific clinical staging criteria."
    },
    {
        "id": 618,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "T0\u00e2\u20ac\u201c2,N1 (single node \u00e2\u2030\u00a43 cm) oropharynx cancer can be treated with resection of primary and ipsilateral or bilateral neck dissection."
    },
    {
        "id": 619,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "T0\u00e2\u20ac\u201c2,N1 (single node \u00e2\u2030\u00a43 cm) oropharynx cancer can be treated with definitive RT."
    },
    {
        "id": 620,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "T0\u00e2\u20ac\u201c2,N1 (single node \u00e2\u2030\u00a43 cm) oropharynx cancer can be treated with concurrent systemic therapy/RT."
    },
    {
        "id": 621,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "T0\u00e2\u20ac\u201c2,N1 (single node \u00e2\u2030\u00a43 cm) oropharynx cancer can be treated with clinical trials."
    },
    {
        "id": 622,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, one positive node >3 cm or multiple positive nodes, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 646,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 19,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, one positive node >3 cm or multiple positive nodes, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 623,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "Pathologic staging criteria differ from clinical staging criteria in HPV-mediated oropharyngeal cancer."
    },
    {
        "id": 645,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 19,
        "content": "Pathologic staging criteria differ from clinical staging criteria in HPV-mediated oropharyngeal cancer."
    },
    {
        "id": 688,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Pathologic staging criteria differ from clinical staging criteria in HPV-mediated oropharyngeal cancer."
    },
    {
        "id": 624,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "For pathologic stage following resection, see AJCC 8th edition for appropriate staging criteria."
    },
    {
        "id": 625,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "The definition of an adverse pathologic feature in the context of HPV+ disease is an area of active research."
    },
    {
        "id": 647,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 19,
        "content": "The definition of an adverse pathologic feature in the context of HPV+ disease is an area of active research."
    },
    {
        "id": 690,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "The definition of an adverse pathologic feature in the context of HPV+ disease is an area of active research."
    },
    {
        "id": 626,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 18,
        "content": "The recommendations for patients at high risk with extranodal extension + positive margins are based on randomized studies involving patients for whom the HPV status of their tumors was not specified."
    },
    {
        "id": 648,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 19,
        "content": "The recommendations for patients at high risk with extranodal extension + positive margins are based on randomized studies involving patients for whom the HPV status of their tumors was not specified."
    },
    {
        "id": 691,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "The recommendations for patients at high risk with extranodal extension + positive margins are based on randomized studies involving patients for whom the HPV status of their tumors was not specified."
    },
    {
        "id": 668,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "p16 (HPV)-positive oropharyngeal cancer has specific treatment guidelines."
    },
    {
        "id": 669,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "T0\u00e2\u20ac\u201c3,N3 or T4,N0\u00e2\u20ac\u201c3 oropharyngeal cancer has specific treatment guidelines."
    },
    {
        "id": 670,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Concurrent systemic therapy/RTn,o is a preferred treatment for p16 (HPV)-positive oropharyngeal cancer."
    },
    {
        "id": 671,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Resection of primary and ipsilateral or bilateral neck dissectionk,l,u is a treatment option for p16 (HPV)-positive oropharyngeal cancer."
    },
    {
        "id": 672,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Clinical trials are a treatment option for p16 (HPV)-positive oropharyngeal cancer."
    },
    {
        "id": 673,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "No adverse pathologic featuresr,s have specific treatment guidelines."
    },
    {
        "id": 674,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Adverse pathologic featuresr,s have specific treatment guidelines."
    },
    {
        "id": 675,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Extranodal extension and/or positive margin is an adverse pathologic feature."
    },
    {
        "id": 676,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Other risk featuresr,s are considered in treatment guidelines."
    },
    {
        "id": 677,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Systemic therapy/RTn,o,t is a treatment option for p16 (HPV)-positive oropharyngeal cancer."
    },
    {
        "id": 678,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "RTn is a treatment option for p16 (HPV)-positive oropharyngeal cancer."
    },
    {
        "id": 679,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Consider systemic therapy/RTn,o is a treatment option for p16 (HPV)-positive oropharyngeal cancer."
    },
    {
        "id": 680,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Follow-up (FOLL-A, 1 of 2) is a part of the treatment guidelines."
    },
    {
        "id": 681,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Recurrent or persistent disease (ADV-3) has specific treatment guidelines."
    },
    {
        "id": 682,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Principles of Surgery (SURG-A) are considered in treatment guidelines."
    },
    {
        "id": 685,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Principles of Radiation Therapy (ORPH-A) are considered in treatment guidelines."
    },
    {
        "id": 686,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A) are considered in treatment guidelines."
    },
    {
        "id": 687,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Induction chemotherapy is considered in treatment guidelines."
    },
    {
        "id": 689,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Adverse pathologic features are defined as extranodal extension, positive margins, close margins, pT3 or pT4 primary, one positive node >3 cm or multiple positive nodes, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 692,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Resection is not recommended for those with clinical evidence of fixed or matted nodes or obvious extranodal extension, and concurrent systemic therapy/RT is preferred."
    },
    {
        "id": 693,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Base of Tongue/Tonsil/Posterior Pharyngeal Wall/Soft Palate has specific treatment guidelines."
    },
    {
        "id": 694,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Induction chemotherapy followed by RTn is a treatment option."
    },
    {
        "id": 695,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 20,
        "content": "Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2) is a part of the treatment guidelines."
    },
    {
        "id": 702,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "For doses >70 Gy, some clinicians feel that the fractionation should be slightly modified."
    },
    {
        "id": 706,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "Radiation therapy can be definitive or concurrent with systemic therapy."
    },
    {
        "id": 707,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "PTV for high-risk patients includes primary tumor and involved lymph nodes."
    },
    {
        "id": 708,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "Fractionation for high-risk patients can be 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)."
    },
    {
        "id": 709,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "Concomitant boost accelerated RT can be used for high-risk patients."
    },
    {
        "id": 710,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "Hyperfractionation can be used for T2,N0\u00e2\u20ac\u201c1 disease."
    },
    {
        "id": 711,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "PTV for low to intermediate risk patients includes sites of suspected subclinical spread."
    },
    {
        "id": 712,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "Fractionation for low to intermediate risk patients can be 44\u00e2\u20ac\u201c50 Gy (2.0 Gy/fraction)."
    },
    {
        "id": 713,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "IMRT is the preferred radiation technique for cancers of the oropharynx."
    },
    {
        "id": 715,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "Concurrent systemic therapy/RT typically uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks."
    },
    {
        "id": 716,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "Concurrent systemic therapy/RT with carboplatin and 5-FU uses standard fractionation plus 3 cycles of chemotherapy."
    },
    {
        "id": 717,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "Systemic therapy/RT carries a high toxicity burden and requires close attention to published reports."
    },
    {
        "id": 733,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "Postoperative radiation therapy is recommended."
    },
    {
        "id": 734,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "The preferred interval between resection and postoperative RT is \u00e2\u2030\u00a46 weeks."
    },
    {
        "id": 735,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "PTV is used for high-risk patients with adverse pathologic features."
    },
    {
        "id": 736,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "High-risk patients receive 60\u00e2\u20ac\u201c66 Gy (2.0 Gy/fraction) in 6\u00e2\u20ac\u201c6.5 weeks."
    },
    {
        "id": 737,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "Low to intermediate risk patients receive 44\u00e2\u20ac\u201c50 Gy (2.0 Gy/fraction) to 54\u00e2\u20ac\u201c63 Gy (1.6\u00e2\u20ac\u201c1.8 Gy/fraction)."
    },
    {
        "id": 738,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "De-escalation to 50 Gy may be considered in patients with p16 (HPV)-positive oropharynx cancer."
    },
    {
        "id": 739,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "Either IMRT or 3D-CRT is recommended for cancers of the oropharynx."
    },
    {
        "id": 714,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 21,
        "content": "Proton therapy is an area of active investigation."
    },
    {
        "id": 740,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "Proton therapy is an area of active investigation."
    },
    {
        "id": 741,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "Proton therapy may be considered when normal tissue constraints cannot be met by photon-based therapy."
    },
    {
        "id": 742,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "Proton therapy may be considered when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes."
    },
    {
        "id": 743,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "Adverse pathologic features for p16(HPV)-negative disease include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 744,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 22,
        "content": "Adverse pathologic features for p16 (HPV)-positive disease include extranodal extension, positive margins, close margins, pT3 or pT4 primary, one positive node >3 cm or multiple positive nodes, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 753,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 23,
        "content": "P16 expression correlates with HPV status in geographic regions where HPV is etiologically responsible for a high proportion of cancers."
    },
    {
        "id": 754,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 23,
        "content": "Confirmatory HPV direct testing is recommended, especially for clinical trials."
    },
    {
        "id": 755,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 23,
        "content": "Clinical centers are recommended to ascertain concordance rate of p16 and direct HPV testing."
    },
    {
        "id": 756,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 23,
        "content": "P16 IHC alone may be used as a surrogate, but concordance rate of p16 and direct HPV testing may vary by region."
    },
    {
        "id": 757,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 23,
        "content": "Distinguishing p16+ patients by HPV tumor status informs prognosis."
    },
    {
        "id": 758,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 23,
        "content": "Patients with p16+ and HPV+ tumors have an improved prognosis compared to patients with p16+ and HPV-negative tumors."
    },
    {
        "id": 777,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "A H&P should include documentation and quantification of tobacco use history."
    },
    {
        "id": 778,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "A H&P should include quantification of tobacco use history in pack years smoked."
    },
    {
        "id": 779,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "A H&P should include documentation and quantification of alcohol use."
    },
    {
        "id": 780,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "A H&P should include counseling about tobacco use and alcohol use."
    },
    {
        "id": 781,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "All patients who currently smoke should be advised to quit smoking."
    },
    {
        "id": 782,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "Those who formerly smoked should be advised to remain abstinent from smoking."
    },
    {
        "id": 785,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "A complete head and neck exam should be performed."
    },
    {
        "id": 786,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "A mirror and/or fiberoptic examination should be performed as clinically indicated."
    },
    {
        "id": 787,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "Biopsy of primary site or FNA of neck should be performed."
    },
    {
        "id": 788,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "CT with contrast and/or MRI with and without contrast of primary and neck should be performed."
    },
    {
        "id": 789,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "EUA with endoscopy should be performed."
    },
    {
        "id": 790,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "Chest CT with or without contrast should be performed as clinically indicated."
    },
    {
        "id": 791,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "FDG-PET/CT should be considered as clinically indicated."
    },
    {
        "id": 800,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "T1,N0, and selected T2,N0 are amenable to larynx-preserving surgery."
    },
    {
        "id": 802,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "T4b,N0\u00e2\u20ac\u201c3 or unresectable nodal disease or unfit for surgery."
    },
    {
        "id": 803,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "Metastatic disease at initial presentation."
    },
    {
        "id": 804,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "Image-guided needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis."
    },
    {
        "id": 805,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 24,
        "content": "A core biopsy would allow for ancillary immune-genomic testing for unresectable or metastatic disease where there is a plan for systemic therapy."
    },
    {
        "id": 824,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Most T1,N0 and selected T2,N0 cancers are amenable to larynx-preserving surgery."
    },
    {
        "id": 825,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Definitive RTh or Partial laryngopharyngectomy is a treatment option for T1,N0 and selected T2,N0 cancers."
    },
    {
        "id": 826,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Ipsilateral or bilateral neck dissection is a treatment option for T1,N0 and selected T2,N0 cancers."
    },
    {
        "id": 827,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Hemithyroidectomy is a treatment option for T1,N0 and selected T2,N0 cancers."
    },
    {
        "id": 828,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Pretracheal and ipsilateral paratracheal lymph node dissection is a treatment option for T1,N0 and selected T2,N0 cancers."
    },
    {
        "id": 830,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Recurrent or Persistent Disease is a type of disease."
    },
    {
        "id": 831,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Follow-up is necessary for patients with pN0 and no adverse pathologic features."
    },
    {
        "id": 832,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 856,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 891,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 27,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 833,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Systemic therapy/RTh is a treatment option for patients with adverse pathologic features."
    },
    {
        "id": 834,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Re-resection is a treatment option for patients with recurrent or persistent disease."
    },
    {
        "id": 835,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "RTh is a treatment option for patients with recurrent or persistent disease."
    },
    {
        "id": 836,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Consider systemic therapy/RTh is a treatment option for patients with T2 cancers."
    },
    {
        "id": 837,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Post Systemic Therapy/RT or RT Neck Evaluation is necessary for patients after treatment."
    },
    {
        "id": 838,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "pN1 without other adverse pathologic features is a type of disease."
    },
    {
        "id": 839,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 25,
        "content": "Consider RTh is a treatment option for patients with pN1 without other adverse pathologic features."
    },
    {
        "id": 860,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "T2\u20133,N0\u20133 requires pharyngectomy with partial or total laryngectomy."
    },
    {
        "id": 861,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "T1,N+ requires induction chemotherapy or partial or total laryngopharyngectomy."
    },
    {
        "id": 864,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "Response after induction chemotherapy is discussed in HYPO-4."
    },
    {
        "id": 865,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "pN0 and no adverse pathologic features require a specific treatment."
    },
    {
        "id": 866,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "Adverse pathologic features require a specific treatment."
    },
    {
        "id": 867,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "Extranodal extension and/or positive margin are risk features."
    },
    {
        "id": 869,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "Systemic therapy/RTh is a category 1 treatment."
    },
    {
        "id": 870,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "RTh is a treatment option."
    },
    {
        "id": 871,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "CT or MRI of primary and neck is required."
    },
    {
        "id": 872,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "Principles of Systemic Therapy for Non-Nasopharyngeal Cancers are discussed in SYST-A."
    },
    {
        "id": 873,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "In randomized clinical trials, assessment of response has been done after 2 or 3 cycles."
    },
    {
        "id": 894,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 27,
        "content": "In randomized clinical trials, assessment of response has been done after 2 or 3 cycles."
    },
    {
        "id": 874,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "When using concurrent systemic therapy/RT, the preferred agent is cisplatin."
    },
    {
        "id": 875,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "Recurrent or persistent disease is discussed in ADV-3."
    },
    {
        "id": 876,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "Post Systemic Therapy/RT or RT Neck Evaluation is discussed in FOLL-A."
    },
    {
        "id": 877,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 26,
        "content": "pN1 without other adverse pathologic features requires a specific treatment."
    },
    {
        "id": 902,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "NCCN believes that the best management of any patient with cancer is in a clinical trial."
    },
    {
        "id": 943,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 29,
        "content": "NCCN believes that the best management of any patient with cancer is in a clinical trial."
    },
    {
        "id": 979,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "NCCN believes that the best management of any patient with cancer is in a clinical trial."
    },
    {
        "id": 903,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "Participation in clinical trials is especially encouraged by NCCN."
    },
    {
        "id": 944,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 29,
        "content": "Participation in clinical trials is especially encouraged by NCCN."
    },
    {
        "id": 911,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "There are adverse pathologic features, including extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion, discussed in the NCCN Guidelines Version 2.2024."
    },
    {
        "id": 918,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "T4a, N0\u20133 is a type of cancer."
    },
    {
        "id": 919,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "Induction chemotherapy is a type of treatment for cancer."
    },
    {
        "id": 920,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "Total laryngopharyngectomy + ipsilateral or bilateral neck dissection \u00b1 hemi- or total thyroidectomy, after ipsilateral or bilateral paratracheal lymph node dissection is a type of treatment for cancer."
    },
    {
        "id": 921,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "Concurrent systemic therapy/RTh is a type of treatment for cancer."
    },
    {
        "id": 922,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "Clinical trial is a type of treatment for cancer."
    },
    {
        "id": 924,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "Extranodal extension and/or positive margin are risk features."
    },
    {
        "id": 928,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "CT with contrast or MRI with and without contrast of primary and neck is a type of imaging."
    },
    {
        "id": 930,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "In randomized clinical trials, assessment of response has been done after 2 or 3 cycles."
    },
    {
        "id": 931,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "When using concurrent systemic therapy/RT, the preferred agent is cisplatin."
    },
    {
        "id": 932,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "Cisplatin is a type of chemotherapy."
    },
    {
        "id": 926,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "Systemic therapy/RTh is a type of treatment for cancer."
    },
    {
        "id": 927,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "RTh is a type of treatment for cancer."
    },
    {
        "id": 935,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "Post Systemic Therapy/RT or RT Neck Evaluation is a section in the NCCN Guidelines Version 2.2024, abbreviated as FOLL-A."
    },
    {
        "id": 929,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 28,
        "content": "Recurrent or persistent disease is discussed in the NCCN Guidelines Version 2.2024, abbreviated as ADV-3."
    },
    {
        "id": 970,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 29,
        "content": "Principles of Radiation Therapy is discussed in HYPO-A."
    },
    {
        "id": 971,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 29,
        "content": "Principles of Surgery is discussed in SURG-A."
    },
    {
        "id": 967,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 29,
        "content": "Principles of Systemic Therapy for Non-Nasopharyngeal Cancers is discussed in SYST-A."
    },
    {
        "id": 972,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 29,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 988,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Particular attention to speech and swallowing is needed during therapy."
    },
    {
        "id": 989,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "For doses >70 Gy, some clinicians feel that the fractionation should be slightly modified to minimize toxicity."
    },
    {
        "id": 991,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Eisbruch A, Harris J, Garden AS, et al. published a multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22)."
    },
    {
        "id": 992,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Eisbruch A, Harris J, Garden AS, et al. published their findings in Int J Radiat Oncol Biol Phys 2010;76:1333-1338."
    },
    {
        "id": 995,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m2."
    },
    {
        "id": 997,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Ang KK, Harris J, Wheeler R, et al. published a study on human papillomavirus and survival of patients with oropharyngeal cancer in N Engl J Med 2010;363:24-35."
    },
    {
        "id": 998,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "When carboplatin and 5-FU are used, the recommended regimen is standard fractionation plus 3 cycles of chemotherapy."
    },
    {
        "id": 999,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Bourhis J, Sire C, Graff P, et al. published a study on concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02)."
    },
    {
        "id": 1000,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Bourhis J, Sire C, Graff P, et al. published their findings in Lancet Oncol 2012;13:145-153."
    },
    {
        "id": 1002,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "The use of concurrent systemic therapy/RT carries a high toxicity burden."
    },
    {
        "id": 1003,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Multiagent chemotherapy will likely further increase the toxicity burden."
    },
    {
        "id": 1006,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "DEFINITIVE RT Alone is an option."
    },
    {
        "id": 1007,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "PTV High risk includes primary tumor and involved lymph nodes."
    },
    {
        "id": 1008,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Fractionation for high-risk PTV includes 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)."
    },
    {
        "id": 1011,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Concomitant boost accelerated RT is an option for high-risk PTV."
    },
    {
        "id": 1012,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Concomitant boost accelerated RT can be 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)."
    },
    {
        "id": 1014,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Hyperfractionation is an option for high-risk PTV."
    },
    {
        "id": 1015,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Hyperfractionation can be 81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)."
    },
    {
        "id": 1016,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Low to intermediate risk PTV includes sites of suspected subclinical spread."
    },
    {
        "id": 1018,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "CONCURRENT SYSTEMIC THERAPY/RT is an option."
    },
    {
        "id": 1019,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "PTV High risk for CONCURRENT SYSTEMIC THERAPY/RT typically uses 70 Gy (2.0 Gy/fraction)."
    },
    {
        "id": 1021,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 30,
        "content": "Either IMRT (preferred) or 3D-CRT is recommended for CONCURRENT SYSTEMIC THERAPY/RT."
    },
    {
        "id": 1030,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 31,
        "content": "Particular attention to speech and swallowing is needed during therapy."
    },
    {
        "id": 1031,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 31,
        "content": "44\u201350 Gy in 3D-CRT and sequentially planned IMRT or 54\u201363 Gy with IMRT dose painting technique is suggested."
    },
    {
        "id": 1032,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 31,
        "content": "The dose per fraction depends on the technique used."
    },
    {
        "id": 1042,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 31,
        "content": "POSTOPERATIVE is a section in the NCCN Guidelines Version 2.2024."
    },
    {
        "id": 1043,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 31,
        "content": "RT or Concurrent Systemic Therapy/RT is a treatment option for postoperative care."
    },
    {
        "id": 1044,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 31,
        "content": "The preferred interval between resection and postoperative RT is \u22646 weeks."
    },
    {
        "id": 1045,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 31,
        "content": "PTV is a term used in the context of postoperative RT."
    },
    {
        "id": 1046,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 31,
        "content": "High risk is defined as adverse pathologic features such as positive margins."
    },
    {
        "id": 1047,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 31,
        "content": "Low to intermediate risk is defined as sites of suspected subclinical spread."
    },
    {
        "id": 1048,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 31,
        "content": "Either IMRT or 3D-CRT is recommended for postoperative RT."
    },
    {
        "id": 1055,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "All patients who currently smoke should be advised to quit smoking."
    },
    {
        "id": 1056,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Those who formerly smoked should be advised to remain abstinent from smoking."
    },
    {
        "id": 1057,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Tobacco use history should be documented and quantified in terms of pack years smoked."
    },
    {
        "id": 1058,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Alcohol use and counseling should be included in the history and physical examination."
    },
    {
        "id": 1059,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Screening for depression is recommended according to the NCCN Guidelines for Distress Management."
    },
    {
        "id": 1060,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Image-guided needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis."
    },
    {
        "id": 1061,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "A core biopsy would allow for ancillary immune-genomic testing for unresectable or metastatic disease where there is a plan for systemic therapy."
    },
    {
        "id": 1062,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Principles of Imaging are outlined in IMG-A."
    },
    {
        "id": 1063,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "A complete head and neck exam, including mirror examination as clinically indicated, is part of the clinical staging."
    },
    {
        "id": 1064,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Nasopharyngeal fiberoptic examination is part of the clinical staging."
    },
    {
        "id": 1065,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Biopsy of primary site or FNA of the neck is part of the clinical staging."
    },
    {
        "id": 1066,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "MRI with and without contrast of skull base to clavicle \u00b1 CT of skull base/neck with contrast is used to evaluate skull base erosion."
    },
    {
        "id": 1067,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Imaging for distant metastases with FDG-PET/CT and/or chest CT with contrast is part of the clinical staging."
    },
    {
        "id": 1068,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Epstein-Barr virus (EBV)/DNA testing should be considered as part of the clinical staging."
    },
    {
        "id": 1069,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Dental/prosthodontic evaluation should be considered as clinically indicated."
    },
    {
        "id": 1070,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Nutrition, speech and swallowing evaluations/therapy should be considered as clinically indicated."
    },
    {
        "id": 1071,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Audiogram should be considered as clinically indicated."
    },
    {
        "id": 1072,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Ophthalmologic and endocrine evaluation should be considered as clinically indicated."
    },
    {
        "id": 1073,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Smoking cessation counseling should be considered as clinically indicated."
    },
    {
        "id": 1074,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Fertility/reproductive counseling should be considered as clinically indicated."
    },
    {
        "id": 1075,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Screening for hepatitis B should be considered as clinically indicated."
    },
    {
        "id": 1076,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Multidisciplinary consultation should be considered as clinically indicated."
    },
    {
        "id": 1077,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "For nonkeratinizing or undifferentiated histology, consider testing for EBV in tumor and blood."
    },
    {
        "id": 1078,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "Common means for detecting EBV in pathologic specimens include ISH for EBV-encoded RNA (EBER) or immunohistochemical staining for latent membrane protein (LMP)."
    },
    {
        "id": 1079,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "The EBV DNA load within the serum or plasma may be quantified using PCR targeting genomic sequences of the EBV DNA such as BamHI-W, Epstein-Barr virus nuclear antigen (EBNA), or LMP."
    },
    {
        "id": 1080,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 32,
        "content": "The EBV DNA load may reflect prognosis and change in response to therapy."
    },
    {
        "id": 1103,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 33,
        "content": "Definitive RT to nasopharynx and elective RT to neck is a treatment option for Nasopharyngeal Cancers."
    },
    {
        "id": 1108,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 33,
        "content": "Concurrent systemic therapy/RT is a treatment option for Nasopharyngeal Cancers."
    },
    {
        "id": 1106,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 33,
        "content": "Induction chemotherapy followed by systemic therapy/RT is a treatment option for Nasopharyngeal Cancers."
    },
    {
        "id": 1107,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 33,
        "content": "Concurrent systemic therapy/RT followed by adjuvant chemotherapy is a treatment option for Nasopharyngeal Cancers."
    },
    {
        "id": 1109,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 33,
        "content": "Induction or adjuvant chemotherapy is considered for Nasopharyngeal Cancers with high-risk features."
    },
    {
        "id": 1111,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 33,
        "content": "Post systemic therapy/RT or RT neck evaluation is outlined in FOLL-A."
    },
    {
        "id": 1120,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Principles of Radiation Therapy are discussed in NASO-A."
    },
    {
        "id": 1121,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Systemic Therapy for Nasopharyngeal Cancers is discussed in NASO-B."
    },
    {
        "id": 1124,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Clinical staging, treatment of primary and neck, and follow-up are discussed in the NCCN Guidelines."
    },
    {
        "id": 1126,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Induction chemotherapy is recommended for T1\u20134,N0\u20133,M1 cancer if the patient has a performance status of 0\u20131."
    },
    {
        "id": 1127,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Radiation therapy or cisplatin/RT is recommended for T1\u20134,N0\u20133,M1 cancer if the patient has a performance status of 0\u20131."
    },
    {
        "id": 1128,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Concurrent cisplatin + RT is recommended for T1\u20134,N0\u20133,M1 cancer if the patient has a performance status of 0\u20131."
    },
    {
        "id": 1129,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Systemic therapy is recommended for T1\u20134,N0\u20133,M1 cancer if the patient has a performance status of 0\u20132."
    },
    {
        "id": 1130,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Definitive RT to primary and regional nodes is recommended if there is a complete response or near complete response."
    },
    {
        "id": 1131,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Definitive RT to oligometastases is recommended as indicated."
    },
    {
        "id": 1132,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Continued systemic therapy is recommended if there is not a complete response or near complete response."
    },
    {
        "id": 1133,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Follow-up is recommended for oligometastatic disease."
    },
    {
        "id": 1134,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Best supportive care is recommended for widely metastatic disease with poor performance status."
    },
    {
        "id": 1135,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 34,
        "content": "Best supportive care is recommended for recurrent or persistent disease."
    },
    {
        "id": 1143,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 35,
        "content": "Care should be taken to avoid critical neural structures."
    },
    {
        "id": 1144,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 35,
        "content": "1.8 Gy/fraction can be considered for doses to avoid critical neural structures."
    },
    {
        "id": 1145,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 35,
        "content": "For doses >70 Gy, some clinicians feel that the fractionation should be slightly modified to minimize toxicity."
    },
    {
        "id": 1151,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 35,
        "content": "The dose per fraction depends on the technique used."
    },
    {
        "id": 1153,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 35,
        "content": "Radiation therapy can be used definitively for T1,N0 or patients who are not eligible to receive chemotherapy."
    },
    {
        "id": 1154,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 35,
        "content": "PTV is used for high-risk primary tumor and involved lymph nodes."
    },
    {
        "id": 1159,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 35,
        "content": "Concurrent systemic therapy/RT is preferred for patients eligible for chemotherapy."
    },
    {
        "id": 1163,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 35,
        "content": "IMRT is recommended for cancers of the nasopharynx to minimize dose to critical structures."
    },
    {
        "id": 1164,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 35,
        "content": "Proton therapy can be considered when normal tissue constraints cannot be met by photon-based therapy."
    },
    {
        "id": 1165,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 35,
        "content": "Proton therapy can be considered when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes."
    },
    {
        "id": 1171,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "The choice of systemic therapy for nasopharyngeal cancers should be individualized based on patient characteristics."
    },
    {
        "id": 1172,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Patient characteristics that influence the choice of systemic therapy include performance status and goals of therapy."
    },
    {
        "id": 1175,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin + RT without adjuvant chemotherapy is a category 2B recommendation for stage T3\u20134,N1\u20133,M0 or any T,N2\u20133,M0 disease."
    },
    {
        "id": 1176,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin + RT without adjuvant chemotherapy is a category 2A recommendation for all other stages when indicated."
    },
    {
        "id": 1177,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Gemcitabine/cisplatin is a preferred regimen for induction/sequential systemic therapy."
    },
    {
        "id": 1178,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Gemcitabine/cisplatin is a category 1 recommendation for EBV-associated disease."
    },
    {
        "id": 1179,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Gemcitabine/cisplatin is a category 2A recommendation for non\u2013EBV-associated disease."
    },
    {
        "id": 1180,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Docetaxel/cisplatin/5-FU is a preferred regimen for induction/sequential systemic therapy."
    },
    {
        "id": 1181,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Docetaxel/cisplatin/5-FU is a category 1 recommendation for EBV-associated disease."
    },
    {
        "id": 1182,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Docetaxel/cisplatin/5-FU is a category 2A recommendation for non\u2013EBV-associated disease."
    },
    {
        "id": 1183,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin/5-FU is an other recommended regimen for induction/sequential systemic therapy."
    },
    {
        "id": 1184,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Docetaxel/cisplatin is an other recommended regimen for induction/sequential systemic therapy."
    },
    {
        "id": 1185,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Docetaxel/cisplatin is a category 2B recommendation."
    },
    {
        "id": 1186,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin is typically used with concurrent systemic therapy/RT."
    },
    {
        "id": 1187,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Carboplatin is typically used with concurrent systemic therapy/RT."
    },
    {
        "id": 1188,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin + RT followed by cisplatin/5-FU is a preferred regimen for systemic therapy/RT followed by adjuvant chemotherapy."
    },
    {
        "id": 1189,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin + RT followed by cisplatin/5-FU is a category 1 recommendation."
    },
    {
        "id": 1190,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin + RT followed by carboplatin/5-FU is an other recommended regimen for systemic therapy/RT followed by adjuvant chemotherapy."
    },
    {
        "id": 1191,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin + RT without adjuvant chemotherapy is an other recommended regimen for systemic therapy/RT followed by adjuvant chemotherapy."
    },
    {
        "id": 1192,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin + RT without adjuvant chemotherapy is a category 2B recommendation."
    },
    {
        "id": 1193,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin + RT followed by capecitabine is an other recommended regimen for systemic therapy/RT followed by adjuvant chemotherapy."
    },
    {
        "id": 1194,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin + RT followed by capecitabine is a category 2B recommendation."
    },
    {
        "id": 1195,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Carboplatin may be used as an alternative to cisplatin if cisplatin is ineligible or intolerant."
    },
    {
        "id": 1196,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Carboplatin + RT followed by carboplatin/5-FU is a useful regimen in certain circumstances."
    },
    {
        "id": 1197,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Platinum-based regimens are recommended for reirradiation + concurrent systemic therapy."
    },
    {
        "id": 1198,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin/gemcitabine is a preferred regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1199,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin/gemcitabine is a category 1 recommendation."
    },
    {
        "id": 1200,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin/gemcitabine + toripalimab-tpzi is a preferred regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1202,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin/gemcitabine + other PD-1 inhibitor is a preferred regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1203,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin/gemcitabine + other PD-1 inhibitor is a category 1 recommendation."
    },
    {
        "id": 1204,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Toripalimab-tpzi is a subsequent-line regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1205,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Toripalimab-tpzi is a category 1 recommendation."
    },
    {
        "id": 1206,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin/5-FU is an other recommended regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1207,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin or carboplatin/docetaxel is an other recommended regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1208,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Carboplatin/cetuximab is an other recommended regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1209,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Gemcitabine/carboplatin is an other recommended regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1210,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Cisplatin is a single agent regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1211,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Carboplatin is a single agent regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1212,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Paclitaxel is a single agent regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1213,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Docetaxel is a single agent regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1214,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "5-FU is a single agent regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1215,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Methotrexate is a single agent regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1216,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Gemcitabine is a single agent regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1217,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Capecitabine is a single agent regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1218,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Nivolumab is a subsequent-line regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1219,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Nivolumab is a category 2B recommendation."
    },
    {
        "id": 1220,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Pembrolizumab is a subsequent-line regimen for recurrent, unresectable, oligometastatic, or metastatic disease."
    },
    {
        "id": 1221,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Pembrolizumab is a category 2B recommendation."
    },
    {
        "id": 1222,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 36,
        "content": "Pembrolizumab is a useful regimen in certain circumstances for tumor mutational burden-high tumors."
    },
    {
        "id": 1321,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "A complete workup may not be indicated for Tis,T1, but H&P examination and biopsy are required."
    },
    {
        "id": 1322,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Direct laryngoscopy under anesthesia is generally recommended for all cases of Cancer of the Glottic Larynx."
    },
    {
        "id": 1323,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "H&P should include documentation and quantification of tobacco use history, as well as alcohol use and counseling."
    },
    {
        "id": 1324,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "All patients who currently smoke should be advised to quit smoking, and those who formerly smoked should be advised to remain abstinent from smoking."
    },
    {
        "id": 1327,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "A complete head and neck exam is required for clinical staging."
    },
    {
        "id": 1328,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "A biopsy of primary site or FNA of the neck is required for clinical staging."
    },
    {
        "id": 1329,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "CT with contrast and thin angled cuts through larynx and/or MRI with and without contrast of primary and neck is required for clinical staging."
    },
    {
        "id": 1330,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "EUA with endoscopy is required for clinical staging."
    },
    {
        "id": 1331,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Chest CT with or without contrast may be considered as clinically indicated."
    },
    {
        "id": 1332,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "FDG-PET/CT may be considered as clinically indicated."
    },
    {
        "id": 1333,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Preanesthesia studies may be required as clinically indicated."
    },
    {
        "id": 1334,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Pulmonary function evaluation may be required for conservation surgery candidates."
    },
    {
        "id": 1335,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Videostrobe may be considered for select patients."
    },
    {
        "id": 1336,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Dental evaluation is required according to the Principles of Dental Evaluation and Management."
    },
    {
        "id": 1337,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Nutrition, speech and swallowing evaluation/therapy is required according to the Principles of Nutrition: Management and Supportive Care."
    },
    {
        "id": 1338,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Audiogram is required."
    },
    {
        "id": 1339,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Smoking cessation counseling is required."
    },
    {
        "id": 1340,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Fertility/reproductive counseling is required according to the NCCN Guidelines for Adolescent and Young Adult Oncology."
    },
    {
        "id": 1341,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Screening for hepatitis B is required."
    },
    {
        "id": 1342,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Multidisciplinary consultation is required as clinically indicated."
    },
    {
        "id": 1343,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Carcinoma in situ is amenable to larynx-preserving surgery."
    },
    {
        "id": 1344,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "T1\u2013T2,N0 or select T3,N0 are amenable to larynx-preserving surgery."
    },
    {
        "id": 1345,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "T3 requiring total laryngectomy is amenable to total laryngectomy."
    },
    {
        "id": 1346,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "T3 requiring total laryngectomy is amenable to total laryngectomy."
    },
    {
        "id": 1347,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "T4a disease is not amenable to surgery."
    },
    {
        "id": 1348,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "T4b,N0\u20133 or unresectable nodal disease or unfit for surgery is not amenable to surgery."
    },
    {
        "id": 1349,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Metastatic disease at initial presentation is not amenable to surgery."
    },
    {
        "id": 1350,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "Image-guided needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis."
    },
    {
        "id": 1351,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 39,
        "content": "A core biopsy would allow for ancillary immune-genomic testing for unresectable or metastatic disease where there is a plan for systemic therapy."
    },
    {
        "id": 1362,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Nodal disease in glottic tumors is rare."
    },
    {
        "id": 1365,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension."
    },
    {
        "id": 1371,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Carcinoma in situ is a type of cancer discussed in the NCCN Guidelines Version 2.2024."
    },
    {
        "id": 1372,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Larynx-preserving surgery is a treatment option for carcinoma in situ."
    },
    {
        "id": 1373,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Endoscopic resection is a preferred treatment option for carcinoma in situ."
    },
    {
        "id": 1374,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "RT is an alternative treatment option for carcinoma in situ."
    },
    {
        "id": 1375,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Partial laryngectomy or endoscopic or open resection is a treatment option for carcinoma in situ."
    },
    {
        "id": 1376,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Neck dissection is a treatment option for carcinoma in situ."
    },
    {
        "id": 1377,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "No adverse pathologic features are present in some cases of carcinoma in situ."
    },
    {
        "id": 1378,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Adverse pathologic features are present in some cases of carcinoma in situ."
    },
    {
        "id": 1379,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Extranodal extension is an adverse pathologic feature."
    },
    {
        "id": 1380,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Positive margin is an adverse pathologic feature."
    },
    {
        "id": 1381,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Other risk features are present in some cases of carcinoma in situ."
    },
    {
        "id": 1382,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Observation is a treatment option for carcinoma in situ with no adverse pathologic features."
    },
    {
        "id": 1383,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Systemic therapy or RT is a treatment option for carcinoma in situ with adverse pathologic features."
    },
    {
        "id": 1384,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Re-resection is a treatment option for carcinoma in situ with adverse pathologic features."
    },
    {
        "id": 1385,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "RT is a treatment option for carcinoma in situ with adverse pathologic features."
    },
    {
        "id": 1386,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Follow-up is necessary for carcinoma in situ."
    },
    {
        "id": 1387,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "Recurrent or persistent disease is a possible outcome of carcinoma in situ."
    },
    {
        "id": 1388,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "pN1 without other risk features is a type of carcinoma in situ."
    },
    {
        "id": 1389,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 40,
        "content": "RT is a treatment option for pN1 without other risk features."
    },
    {
        "id": 1414,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "The NCCN Guidelines Version 2.2024 is about Cancer of the Glottic Larynx."
    },
    {
        "id": 1481,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 44,
        "content": "The NCCN Guidelines Version 2.2024 is about Cancer of the Glottic Larynx."
    },
    {
        "id": 1415,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "There are principles of Radiation Therapy (GLOT-A)."
    },
    {
        "id": 1416,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "There are principles of Surgery (SURG-A)."
    },
    {
        "id": 1405,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 41,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension."
    },
    {
        "id": 1417,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension."
    },
    {
        "id": 1458,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension."
    },
    {
        "id": 1487,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 44,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension."
    },
    {
        "id": 1419,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "There are guidelines for Clinical Staging."
    },
    {
        "id": 1420,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "There are guidelines for Adjuvant Treatment."
    },
    {
        "id": 1421,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "There are guidelines for Treatment of Primary and Neck."
    },
    {
        "id": 1422,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "There are guidelines for Follow-up."
    },
    {
        "id": 1423,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "There are guidelines for Recurrent or persistent disease (ADV-3)."
    },
    {
        "id": 1425,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection can be performed."
    },
    {
        "id": 1426,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "No adverse pathologic features are present in some cases."
    },
    {
        "id": 1427,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "Adverse pathologic features are present in some cases."
    },
    {
        "id": 1428,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "Extranodal extension and/or positive margin are risk features."
    },
    {
        "id": 1429,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "There are other risk features."
    },
    {
        "id": 1430,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "Systemic therapy/RT is recommended for some cases (category 1)."
    },
    {
        "id": 1431,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "RT is recommended for some cases."
    },
    {
        "id": 1432,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "Systemic therapy/RT can be considered for some cases."
    },
    {
        "id": 1433,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "Cisplatin is the preferred agent when using concurrent systemic therapy/RT (category 1)."
    },
    {
        "id": 1434,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "There are principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)."
    },
    {
        "id": 1435,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "There is a discussion on induction chemotherapy."
    },
    {
        "id": 1436,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "CT (with contrast) or MRI (with and without contrast) of primary and neck can be performed."
    },
    {
        "id": 1437,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "Recurrent or persistent disease (ADV-3) can be treated."
    },
    {
        "id": 1438,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2) can be performed."
    },
    {
        "id": 1439,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 42,
        "content": "pN1 without other risk features can be treated with RT."
    },
    {
        "id": 1455,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Response after induction chemotherapy is a principle of radiation therapy."
    },
    {
        "id": 1456,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Principles of Radiation Therapy are described in GLOT-A."
    },
    {
        "id": 1457,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Principles of Surgery are described in SURG-A."
    },
    {
        "id": 1459,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Response assessment is a part of NCCN Guidelines Version 2.2024."
    },
    {
        "id": 1460,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Primary site CR is a type of response."
    },
    {
        "id": 1461,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Primary site PR is a type of response."
    },
    {
        "id": 1462,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Primary site < PR is a type of response."
    },
    {
        "id": 1463,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Definitive RT is a type of radiation therapy."
    },
    {
        "id": 1464,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Systemic therapy/RT is a type of therapy."
    },
    {
        "id": 1465,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Laryngectomy is a type of surgery."
    },
    {
        "id": 1466,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Unresectable nodal disease is a type of disease."
    },
    {
        "id": 1467,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Principles of Systemic Therapy for Non-Nasopharyngeal Cancers are described in SYST-A."
    },
    {
        "id": 1468,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Assessment of response has been done after 2 or 3 cycles in randomized clinical trials."
    },
    {
        "id": 1454,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Recurrent or persistent disease is a type of disease."
    },
    {
        "id": 1469,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 43,
        "content": "Recurrent or persistent disease is a type of disease."
    },
    {
        "id": 1493,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 44,
        "content": "T4a,N0\u20133 patients who decline surgery may undergo Surgery, including ipsilateral or bilateral neck dissection; thyroidectomy to clear central compartment nodes, especially when there is thyroid cartilage with gross invasion of the thyroid gland and significant subglottic extension."
    },
    {
        "id": 1494,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 44,
        "content": "T4a,N0\u20133 patients who decline surgery may undergo concurrent systemic therapy/RT or clinical trial for function-preserving surgical or RT management or induction chemotherapy."
    },
    {
        "id": 1496,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 44,
        "content": "Recurrent or persistent disease patients may undergo CT (with contrast) or MRI (with and without contrast) of primary and neck."
    },
    {
        "id": 1497,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 44,
        "content": "No adverse pathologic features patients may undergo RT."
    },
    {
        "id": 1498,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 44,
        "content": "Adverse pathologic features patients may undergo systemic therapy/RT."
    },
    {
        "id": 1499,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 44,
        "content": "Extranodal extension and/or positive margin patients may undergo systemic therapy/RT."
    },
    {
        "id": 1500,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 44,
        "content": "Other risk features patients may undergo RT or consider systemic therapy/RT."
    },
    {
        "id": 1502,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 44,
        "content": "pN1 without other risk features patients may undergo RT."
    },
    {
        "id": 1503,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 44,
        "content": "There are Principles of Systemic Therapy for Non-Nasopharyngeal Cancers in the NCCN Guidelines Version 2.2024."
    },
    {
        "id": 1511,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "The NCCN Guidelines are for Cancer of the Glottic Larynx."
    },
    {
        "id": 1517,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Gowda RV, Henk JM, Mais KL, et al. wrote about Three weeks radiotherapy for T1 glottic cancer."
    },
    {
        "id": 1524,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Tis,N0: 60.75 Gy (2.25 Gy/fraction) to 66 Gy (2.0 Gy/fraction) is a recommended dose."
    },
    {
        "id": 1525,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "T1,N0: 63 Gy (2.25 Gy/fraction, preferred) to 66 Gy (2.0 Gy/fraction) or 50 Gy (3.12 Gy/fraction) to 52 Gy (3.28 Gy/fraction) is a recommended dose."
    },
    {
        "id": 1526,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "T2,N0: 65.25 (2.25 Gy/fraction) to 70 Gy (2.0 Gy/fraction) is a recommended dose."
    },
    {
        "id": 1527,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "\u00e2\u2030\u00a5T2,N1: PTV is a recommended dose."
    },
    {
        "id": 1528,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "High risk: Primary tumor and involved lymph nodes require a specific fractionation."
    },
    {
        "id": 1529,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday\u00e2\u20ac\u201cFriday in 6\u00e2\u20ac\u201c7 weeks is a recommended schedule."
    },
    {
        "id": 1530,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Concomitant boost accelerated RT: 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days) is a recommended schedule."
    },
    {
        "id": 1531,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Concomitant boost accelerated RT: 66\u00e2\u20ac\u201c70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) is a recommended schedule."
    },
    {
        "id": 1532,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Hyperfractionation: 79.2\u00e2\u20ac\u201c81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily) is a recommended schedule."
    },
    {
        "id": 1533,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Low to intermediate risk: Sites of suspected subclinical spread require a specific dose."
    },
    {
        "id": 1534,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Either IMRT (preferred) or 3D-CRT is recommended for low to intermediate risk."
    },
    {
        "id": 1535,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "CONCURRENT SYSTEMIC THERAPY/RT is discussed."
    },
    {
        "id": 1536,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "PTV is a recommended dose for high risk."
    },
    {
        "id": 1537,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "PTV is a recommended dose for low to intermediate risk."
    },
    {
        "id": 1538,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m2."
    },
    {
        "id": 1539,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "2\u00e2\u20ac\u201c3 cycles of chemotherapy are used depending on the radiation fractionation scheme."
    },
    {
        "id": 1540,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "When carboplatin and 5-FU are used, then the recommended regimen is standard fractionation plus 3 cycles of chemotherapy."
    },
    {
        "id": 1541,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Other fraction sizes (eg, 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy are efficacious."
    },
    {
        "id": 1542,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "There is no consensus on the optimal approach for concurrent systemic therapy/RT."
    },
    {
        "id": 1543,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "The use of concurrent systemic therapy/RT carries a high toxicity burden."
    },
    {
        "id": 1544,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Multiagent chemotherapy will likely further increase the toxicity burden."
    },
    {
        "id": 1545,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration."
    },
    {
        "id": 1546,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 45,
        "content": "Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care."
    },
    {
        "id": 1563,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 46,
        "content": "Bernier J, Domenge C, Ozsahin M, et al. wrote an article about Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer."
    },
    {
        "id": 1565,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 46,
        "content": "Cooper JS, Pajak TF, Forastiere AA, et al. wrote an article about Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck."
    },
    {
        "id": 1567,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 46,
        "content": "Bernier J, Cooper JS, Pajak TF, et al. wrote an article about Defining risk levels in locally advanced head and neck cancers."
    },
    {
        "id": 1569,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 46,
        "content": "Cooper JS, Zhang Q, Pajak TF, et al. wrote an article about Long-term follow-up of the RTOG 9501/intergroup phase III trial."
    },
    {
        "id": 1571,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 46,
        "content": "POSTOPERATIVE RT or Concurrent Systemic Therapy/RT is a treatment option."
    },
    {
        "id": 1572,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 46,
        "content": "The preferred interval between resection and postoperative RT is \u00e2\u2030\u00a46 weeks."
    },
    {
        "id": 1573,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 46,
        "content": "PTV is used in postoperative RT."
    },
    {
        "id": 1574,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 46,
        "content": "High risk patients have adverse pathologic features such as positive margins."
    },
    {
        "id": 1575,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 46,
        "content": "High risk patients receive \u00e2\u0178\u00a660\u00e2\u20ac\u201c66 Gy (2.0 Gy/fraction) in 6\u00e2\u20ac\u201c6.5 weeks."
    },
    {
        "id": 1576,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 46,
        "content": "Low to intermediate risk patients receive \u00e2\u0178\u00a644\u00e2\u20ac\u201c50 Gy (2.0 Gy/fraction) to 54\u00e2\u20ac\u201c63 Gy (1.6\u00e2\u20ac\u201c1.8 Gy/fraction)."
    },
    {
        "id": 1577,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 46,
        "content": "Either IMRT (preferred) or 3D-CRT is recommended for postoperative RT."
    },
    {
        "id": 1584,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "A H&P should include documentation and quantification of tobacco use history, as well as alcohol use and counseling."
    },
    {
        "id": 1585,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "All patients who currently smoke should be advised to quit smoking, and those who formerly smoked should be advised to remain abstinent from smoking."
    },
    {
        "id": 1586,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Refer to the Patient/Provider Smoking Cessation and Treatment Resources in the NCCN Guidelines for Smoking Cessation for additional cessation support."
    },
    {
        "id": 1587,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Screen for depression according to the NCCN Guidelines for Distress Management."
    },
    {
        "id": 1588,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Image-guided needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis in this setting."
    },
    {
        "id": 1589,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "A core biopsy would allow for ancillary immune-genomic testing for unresectable or metastatic disease where there is a plan for systemic therapy."
    },
    {
        "id": 1590,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "A complete head and neck exam is part of the H&P."
    },
    {
        "id": 1591,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "A mirror and/or fiberoptic examination is clinically indicated as part of the H&P."
    },
    {
        "id": 1592,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Biopsy of primary site or FNA of the neck is part of the workup."
    },
    {
        "id": 1593,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Chest CT with or without contrast is clinically indicated as part of the workup."
    },
    {
        "id": 1594,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "CT with contrast and thin angled cuts through larynx and/or MRI with and without contrast of primary and neck is part of the workup."
    },
    {
        "id": 1595,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Consider FDG-PET/CT as part of the workup."
    },
    {
        "id": 1596,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "EUA with endoscopy is part of the workup."
    },
    {
        "id": 1597,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Preanesthesia studies are clinically indicated as part of the workup."
    },
    {
        "id": 1598,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Consider PFTs for conservation surgery candidates as part of the workup."
    },
    {
        "id": 1599,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Consider videostrobe for select patients as part of the workup."
    },
    {
        "id": 1600,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Dental evaluation is part of the workup."
    },
    {
        "id": 1602,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Audiogram is part of the workup."
    },
    {
        "id": 1603,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 47,
        "content": "Smoking cessation counseling is part of the workup."
    },
    {
        "id": 1635,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "T1\u20132,N0 patients and selected T3 patients are amenable to larynx-preserving surgery."
    },
    {
        "id": 1636,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "Endoscopic resection + neck dissection is a treatment option for T1\u20132,N0 patients and selected T3 patients."
    },
    {
        "id": 1637,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "Endoscopic or open partial laryngectomy + neck dissection is a treatment option for T1\u20132,N0 patients and selected T3 patients."
    },
    {
        "id": 1638,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "Definitive RT is a treatment option for T1\u20132,N0 patients and selected T3 patients."
    },
    {
        "id": 1639,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "Node negative patients with T1\u2013T2,N0 have one positive node without other adverse pathologic features."
    },
    {
        "id": 1640,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "Positive node patients with positive margin have extranodal extension."
    },
    {
        "id": 1641,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "Node negative patients with T3\u2013T4a,N0 may consider RT."
    },
    {
        "id": 1642,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "Re-resection is an option for highly selected patients if feasible."
    },
    {
        "id": 1643,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "RT is an option for highly selected patients."
    },
    {
        "id": 1644,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "Systemic therapy/RT is an option for highly selected patients."
    },
    {
        "id": 1645,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "Adjuvant Treatment is discussed in SUPRA-3 and SUPRA-8."
    },
    {
        "id": 1646,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "Positive node patients with other adverse pathologic features may consider systemic therapy/RT."
    },
    {
        "id": 1647,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "Post Systemic Therapy/RT or RT Neck Evaluation is discussed in FOLL-A, 2 of 2."
    },
    {
        "id": 1623,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 48,
        "content": "There are adverse pathologic features including extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 1662,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Requiring total laryngectomy is an option for T3,N0 patients."
    },
    {
        "id": 1663,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Concurrent systemic therapy/RT is an option for T3,N0 patients."
    },
    {
        "id": 1664,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "RT is an option for T3,N0 patients if the patient is not a medical candidate for concurrent systemic therapy/RT."
    },
    {
        "id": 1665,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Laryngectomy, thyroidectomy, and ipsilateral, central, or bilateral neck dissection are options for T3,N0 patients."
    },
    {
        "id": 1666,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Induction chemotherapy is an option for T3,N0 patients."
    },
    {
        "id": 1667,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Clinical trials are an option for T3,N0 patients."
    },
    {
        "id": 1668,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Follow-up is necessary for patients with Recurrent or persistent disease."
    },
    {
        "id": 1669,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "pN1 without other risk features is a consideration for Follow-up."
    },
    {
        "id": 1670,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Adverse pathologic features are a consideration for Follow-up."
    },
    {
        "id": 1671,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Extranodal extension and/or positive margin are adverse pathologic features."
    },
    {
        "id": 1672,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Other risk features are a consideration for Follow-up."
    },
    {
        "id": 1673,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Systemic therapy/RT is an option for patients with adverse pathologic features."
    },
    {
        "id": 1674,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "RT is an option for patients with adverse pathologic features."
    },
    {
        "id": 1675,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Consider systemic therapy/RT is an option for patients with adverse pathologic features."
    },
    {
        "id": 1676,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Response Assessment is necessary for patients with Recurrent or persistent disease."
    },
    {
        "id": 1683,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "CT or MRI is necessary for evaluation of primary and neck."
    },
    {
        "id": 1684,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Recurrent or persistent disease requires evaluation."
    },
    {
        "id": 1685,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "Post Systemic Therapy/RT or RT Neck Evaluation is necessary for Follow-up."
    },
    {
        "id": 1686,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 49,
        "content": "pN0 with no adverse pathologic features is a consideration for Follow-up."
    },
    {
        "id": 1702,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 50,
        "content": "T4a,N1\u2013N3 is a type of node-positive disease."
    },
    {
        "id": 1703,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 50,
        "content": "T4b,N1\u2013N3 is a type of node-positive disease."
    },
    {
        "id": 1704,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 50,
        "content": "Unresectable nodal disease is a type of node-positive disease."
    },
    {
        "id": 1706,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 50,
        "content": "There is a treatment for Primary and Neck in SUPRA-5."
    },
    {
        "id": 1707,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 50,
        "content": "There is a treatment for Primary and Neck in SUPRA-6."
    },
    {
        "id": 1708,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 50,
        "content": "There is a treatment for Primary and Neck in SUPRA-8."
    },
    {
        "id": 1709,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 50,
        "content": "There is a treatment for Head and Neck Cancer in ADV-1."
    },
    {
        "id": 1719,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "The NCCN Guidelines Version 2.2024 is about Cancer of the Supraglottic Larynx."
    },
    {
        "id": 1797,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "The NCCN Guidelines Version 2.2024 is about Cancer of the Supraglottic Larynx."
    },
    {
        "id": 1720,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "There are principles of Imaging (IMG-A) in the NCCN Guidelines."
    },
    {
        "id": 1721,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "There are principles of Surgery (SURG-A) in the NCCN Guidelines."
    },
    {
        "id": 1722,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "There are principles of Radiation Therapy (SUPRA-A) in the NCCN Guidelines."
    },
    {
        "id": 1723,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 1773,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 1724,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "There are principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A) in the NCCN Guidelines."
    },
    {
        "id": 1725,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Clinical staging is part of the treatment of primary and neck."
    },
    {
        "id": 1726,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Adjuvant treatment is part of the treatment of primary and neck."
    },
    {
        "id": 1727,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Follow-up is part of the treatment of primary and neck."
    },
    {
        "id": 1728,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Recurrent or persistent disease is addressed in ADV-3."
    },
    {
        "id": 1747,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Recurrent or persistent disease is addressed in ADV-3."
    },
    {
        "id": 1730,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Concurrent systemic therapy/RT is an option for treatment."
    },
    {
        "id": 1731,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Clinical trials are an option for treatment."
    },
    {
        "id": 1733,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Endoscopic or open partial laryngectomy and neck dissection(s) is an option for treatment."
    },
    {
        "id": 1734,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Induction chemotherapy is an option for treatment."
    },
    {
        "id": 1735,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "No adverse pathologic features are considered in treatment."
    },
    {
        "id": 1736,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Adverse pathologic features are considered in treatment."
    },
    {
        "id": 1737,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Extranodal extension and/or positive margin are considered in treatment."
    },
    {
        "id": 1738,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Other risk features are considered in treatment."
    },
    {
        "id": 1739,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Systemic therapy/RT is an option for treatment (category 1)."
    },
    {
        "id": 1740,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "RT is an option for treatment."
    },
    {
        "id": 1741,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Consider systemic therapy/RT is an option for treatment."
    },
    {
        "id": 1742,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Response Assessment is addressed in SUPRA-7."
    },
    {
        "id": 1743,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Cisplatin is the preferred agent when using concurrent systemic therapy/RT (category 1)."
    },
    {
        "id": 1744,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Induction chemotherapy is discussed in the Discussion section."
    },
    {
        "id": 1785,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Induction chemotherapy is discussed in the Discussion section."
    },
    {
        "id": 1745,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "In highly select patients, re-resection is an option where it would potentially change the subsequent indication for chemotherapy."
    },
    {
        "id": 1746,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "CT (with contrast) or MRI (with and without contrast) of primary and neck is part of the treatment."
    },
    {
        "id": 1748,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 51,
        "content": "Post Systemic Therapy/RT or RT Neck Evaluation is part of the follow-up."
    },
    {
        "id": 1765,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Recurrent or persistent disease may require total laryngectomy."
    },
    {
        "id": 1766,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Total laryngectomy is amenable to most T3,N1\u2013N3 cases."
    },
    {
        "id": 1767,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Concurrent systemic therapy/RT is an option for recurrent or persistent disease."
    },
    {
        "id": 1768,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Clinical trials are an option for recurrent or persistent disease."
    },
    {
        "id": 1769,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Laryngectomy, ipsilateral thyroidectomy with neck dissection is an option for recurrent or persistent disease."
    },
    {
        "id": 1770,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Induction chemotherapy is an option for recurrent or persistent disease."
    },
    {
        "id": 1771,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "No adverse pathologic features are present in some cases."
    },
    {
        "id": 1772,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "RT is an option for cases with no adverse pathologic features."
    },
    {
        "id": 1774,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Systemic therapy/RT is an option for cases with adverse pathologic features."
    },
    {
        "id": 1775,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "RT is an option for cases with adverse pathologic features."
    },
    {
        "id": 1776,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Consider systemic therapy/RT is an option for cases with adverse pathologic features."
    },
    {
        "id": 1777,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Response Assessment is a part of NCCN Guidelines Version 2.2024."
    },
    {
        "id": 1778,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "CT with contrast or MRI with and without contrast is used for Response Assessment."
    },
    {
        "id": 1779,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 52,
        "content": "Recurrent or persistent disease is assessed using CT with contrast or MRI with and without contrast."
    },
    {
        "id": 1845,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 54,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 1806,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Response assessment is done after induction chemotherapy."
    },
    {
        "id": 1807,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Primary site CR is a type of response."
    },
    {
        "id": 1808,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Primary site PR is a type of response."
    },
    {
        "id": 1809,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Primary site < PR is a type of response."
    },
    {
        "id": 1810,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Definitive RT is a type of radiation therapy."
    },
    {
        "id": 1812,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Systemic therapy/RT is a type of treatment."
    },
    {
        "id": 1823,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Systemic therapy/RT is a type of treatment."
    },
    {
        "id": 1813,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Surgery is a type of treatment."
    },
    {
        "id": 1814,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Unresectable nodal disease is a type of disease."
    },
    {
        "id": 1815,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Follow-up is a type of care."
    },
    {
        "id": 1817,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Recurrent or persistent disease is a type of disease."
    },
    {
        "id": 1818,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "ADV-3 is a type of disease."
    },
    {
        "id": 1819,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "No adverse pathologic features is a type of disease."
    },
    {
        "id": 1820,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Other risk features is a type of disease."
    },
    {
        "id": 1821,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Adverse pathologic features include extranodal extension and/or positive margin."
    },
    {
        "id": 1825,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Post Systemic Therapy/RT or RT is a type of treatment."
    },
    {
        "id": 1826,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 53,
        "content": "Neck Evaluation is a type of evaluation."
    },
    {
        "id": 1848,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 54,
        "content": "T4a,N0\u2013N3 patients who decline surgery should undergo Laryngectomy, thyroidectomy as indicated with ipsilateral or bilateral neck dissection."
    },
    {
        "id": 1849,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 54,
        "content": "T4a,N0\u2013N3 patients who decline surgery may consider concurrent systemic therapy/RT or clinical trial or induction chemotherapy."
    },
    {
        "id": 1850,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 54,
        "content": "Extranodal extension and/or positive margin are risk features."
    },
    {
        "id": 1851,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 54,
        "content": "Other risk features include pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 1852,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 54,
        "content": "Systemic therapy/RT is recommended for patients with extranodal extension and/or positive margin."
    },
    {
        "id": 1853,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 54,
        "content": "RT is recommended for patients with other risk features."
    },
    {
        "id": 1854,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 54,
        "content": "Follow-up is recommended for patients after treatment."
    },
    {
        "id": 1855,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 54,
        "content": "Response Assessment is described in SUPRA-7."
    },
    {
        "id": 1856,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 54,
        "content": "CT with contrast or MRI with and without contrast of primary and neck is recommended for recurrent or persistent disease."
    },
    {
        "id": 1857,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 54,
        "content": "Neck Evaluation is described in FOLL-A."
    },
    {
        "id": 1869,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "For select T1\u20132,N0 tumors, accelerated fractionation may be used according to NCCN Guidelines."
    },
    {
        "id": 1870,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "For doses >70 Gy, some clinicians feel that the fractionation should be slightly modified to minimize toxicity."
    },
    {
        "id": 1871,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "An additional 2\u20133 doses can be added depending on clinical circumstances according to NCCN Guidelines."
    },
    {
        "id": 1872,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "NCCN suggests 44\u201350 Gy in 3D-CRT and sequentially planned IMRT or 54\u201363 Gy with IMRT dose painting technique."
    },
    {
        "id": 1874,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m2."
    },
    {
        "id": 1875,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "2\u20133 cycles of chemotherapy are used depending on the radiation fractionation scheme according to RTOG."
    },
    {
        "id": 1876,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "When carboplatin and 5-FU are used, the recommended regimen is standard fractionation plus 3 cycles of chemotherapy."
    },
    {
        "id": 1877,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Other fraction sizes, multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy are efficacious."
    },
    {
        "id": 1878,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "There is no consensus on the optimal approach for concurrent systemic therapy/RT."
    },
    {
        "id": 1879,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "The use of concurrent systemic therapy/RT carries a high toxicity burden."
    },
    {
        "id": 1880,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Multiagent chemotherapy will likely further increase the toxicity burden."
    },
    {
        "id": 1881,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration."
    },
    {
        "id": 1882,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care."
    },
    {
        "id": 1883,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "RT Alone is a principle of radiation therapy for definitive treatment."
    },
    {
        "id": 1884,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "T1\u20133,N0\u20131 tumors can be treated with 66\u201370 Gy conventional RT."
    },
    {
        "id": 1885,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "PTV high-risk areas include primary tumor and involved lymph nodes."
    },
    {
        "id": 1886,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Fractionation for high-risk areas can be 66 Gy to 70 Gy."
    },
    {
        "id": 1887,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Concomitant boost accelerated RT can be used for high-risk areas."
    },
    {
        "id": 1888,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Hyperfractionation can be used for high-risk areas."
    },
    {
        "id": 1889,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Low to intermediate risk areas can be treated with 44\u201350 Gy to 54\u201363 Gy."
    },
    {
        "id": 1890,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Concurrent systemic therapy/RT can be used for high-risk areas."
    },
    {
        "id": 1891,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "PTV high-risk areas can be treated with 70 Gy."
    },
    {
        "id": 1892,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "PTV low to intermediate and low risk areas can be treated with 44\u201350 Gy to 54\u201363 Gy."
    },
    {
        "id": 1893,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Either IMRT or 3D-CRT is recommended for concurrent systemic therapy/RT."
    },
    {
        "id": 1894,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Proton therapy is an area of active investigation."
    },
    {
        "id": 1895,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Proton therapy may be considered when normal tissue constraints cannot be met by photon-based therapy."
    },
    {
        "id": 1896,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 55,
        "content": "Proton therapy may be considered when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes."
    },
    {
        "id": 1930,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "A health and physical (H&P) examination should include documentation and quantification of tobacco use history."
    },
    {
        "id": 1931,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "A health and physical (H&P) examination should include documentation and quantification of alcohol use and counseling."
    },
    {
        "id": 1932,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "All patients who currently smoke should be advised to quit smoking."
    },
    {
        "id": 1933,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Those who formerly smoked should be advised to remain abstinent from smoking."
    },
    {
        "id": 1934,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Additional cessation support can be found in the Patient/Provider Smoking Cessation and Treatment Resources in the NCCN Guidelines for Smoking Cessation."
    },
    {
        "id": 1935,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Screening for depression should be done according to the NCCN Guidelines for Distress Management."
    },
    {
        "id": 1940,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "A complete head and neck exam should be performed as part of the workup."
    },
    {
        "id": 1941,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Nasal endoscopy should be performed as clinically indicated."
    },
    {
        "id": 1942,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "A CT with contrast or MRI with and without contrast of skull base and neck should be performed."
    },
    {
        "id": 1943,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "A chest CT with or without contrast should be performed as clinically indicated."
    },
    {
        "id": 1944,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "FDG-PET/CT should be considered as clinically indicated."
    },
    {
        "id": 1945,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Dental evaluation should be performed as clinically indicated."
    },
    {
        "id": 1946,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Nutrition, speech, and swallowing evaluation/therapy should be performed as clinically indicated."
    },
    {
        "id": 1947,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Smoking cessation counseling should be performed as clinically indicated."
    },
    {
        "id": 1948,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Fertility/reproductive counseling should be performed as clinically indicated."
    },
    {
        "id": 1949,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Screening for hepatitis B should be performed."
    },
    {
        "id": 1950,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Multidisciplinary consultation should be performed as clinically indicated."
    },
    {
        "id": 1951,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Biopsy is necessary for diagnosis."
    },
    {
        "id": 1952,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Squamous cell carcinoma is a possible diagnosis."
    },
    {
        "id": 1953,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Adenocarcinoma is a possible diagnosis."
    },
    {
        "id": 1954,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Minor salivary gland tumor is a possible diagnosis."
    },
    {
        "id": 1955,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Esthesioneuroblastoma is a possible diagnosis."
    },
    {
        "id": 1956,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Undifferentiated carcinoma is a possible diagnosis."
    },
    {
        "id": 1957,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Image-guided (US or CT) needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis."
    },
    {
        "id": 1958,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "A core biopsy would allow for ancillary immune-genomic testing for unresectable or metastatic disease where there is a plan for systemic therapy."
    },
    {
        "id": 1959,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "The salivary gland algorithm should be consulted for management after resection."
    },
    {
        "id": 1960,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Ethmoid sinus tumors are rare and histopathologically diverse."
    },
    {
        "id": 1961,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Correct pathologic diagnosis is paramount to treatment decisions."
    },
    {
        "id": 1962,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 57,
        "content": "Consider referral to a major medical center that specializes in these tumors for confirmation of diagnosis."
    },
    {
        "id": 1978,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "For recurrent or persistent disease, RTm or Observep for T1 only is recommended."
    },
    {
        "id": 1979,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "For recurrent or persistent disease, Consider systemic therapy/RTm is recommended if adverse pathologic features are present."
    },
    {
        "id": 1980,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "Resection is the preferred treatment for newly diagnosed T1 and T2."
    },
    {
        "id": 1981,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "Definitive RTm is an option for newly diagnosed T1 and T2."
    },
    {
        "id": 1982,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "For newly diagnosed T1 and T2, Consider systemic therapy/RTm is recommended if adverse pathologic features are present."
    },
    {
        "id": 1983,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "Resection is an option for newly diagnosed T3 and T4a."
    },
    {
        "id": 1984,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "Induction chemotherapyn is an option for newly diagnosed T3 and T4a."
    },
    {
        "id": 1985,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "Concurrent systemic therapy/RTm is an option for newly diagnosed T3 and T4a."
    },
    {
        "id": 1986,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "For newly diagnosed T4b or patient declines surgery, Consider systemic therapy/RTm is recommended."
    },
    {
        "id": 1987,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "NCCN recommends referring to the salivary gland algorithm for management after resection."
    },
    {
        "id": 1988,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "NCCN recommends referring to NCCN Guidelines for Salivary Gland Tumors for SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies."
    },
    {
        "id": 1989,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "NCCN recommends considering a clinical trial and referral to a major medical center that specializes in these diseases for SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies."
    },
    {
        "id": 1990,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "N+ neck disease is uncommon in ethmoid cancers, but, if present, requires neck dissection and appropriate risk-based adjuvant therapy."
    },
    {
        "id": 1991,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "NCCN recommends referring to Principles of Surgery for surgical management."
    },
    {
        "id": 1992,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "NCCN recommends referring to Principles of Radiation Therapy for radiation therapy management."
    },
    {
        "id": 1993,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "NCCN recommends referring to Principles of Systemic Therapy for Non-Nasopharyngeal Cancers for systemic therapy management."
    },
    {
        "id": 1994,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "Nonsurgical RT-based treatment is an option in selected patients with disease that has a major response to induction therapy short of a CR."
    },
    {
        "id": 1995,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "Pathologic features include negative margins, favorable histology, not located along the cribriform plate or medial wall of the orbit, no perineural invasion, and lymphovascular space invasion."
    },
    {
        "id": 1996,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 58,
        "content": "Adverse pathologic features include positive margins, close margins, unfavorable histology, intracranial and/or intraorbital extension, cribriform plate location, medial wall of orbit location, perineural invasion, and lymphovascular space invasion."
    },
    {
        "id": 2008,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 59,
        "content": "For management after resection, see the salivary gland algorithm."
    },
    {
        "id": 2010,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 59,
        "content": "For SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies, systemic therapy should be a part of the overall treatment."
    },
    {
        "id": 2011,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 59,
        "content": "A clinical trial should be considered for SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies."
    },
    {
        "id": 2012,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 59,
        "content": "Referral to a major medical center that specializes in these diseases should be considered for SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies."
    },
    {
        "id": 2015,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 59,
        "content": "If N+ neck disease is present, neck dissection and appropriate risk-based adjuvant therapy are required."
    },
    {
        "id": 2027,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 59,
        "content": "Surgery is a preferred treatment option if feasible."
    },
    {
        "id": 2028,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 59,
        "content": "RT is a treatment option."
    },
    {
        "id": 2029,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 59,
        "content": "Concurrent systemic therapy/RT is a treatment option."
    },
    {
        "id": 2030,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 59,
        "content": "Systemic therapy/RT is a treatment option."
    },
    {
        "id": 2034,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 59,
        "content": "Primary RT is an option for minimal residual squamous cell carcinoma."
    },
    {
        "id": 2043,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "In the paranasal sinus area, care should be taken to avoid critical neural structures."
    },
    {
        "id": 2044,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "Therefore, 1.8 Gy/fraction can be considered in the paranasal sinus area."
    },
    {
        "id": 2045,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "For doses >70 Gy, some clinicians feel that the fractionation should be slightly modified to minimize toxicity."
    },
    {
        "id": 2046,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "An additional 2\u20133 doses can be added depending on clinical circumstances."
    },
    {
        "id": 2047,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "Suggest 44\u201350 Gy in sequentially planned IMRT or 54\u201363 Gy with IMRT dose painting technique."
    },
    {
        "id": 2048,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "RT Alone is a type of radiation therapy."
    },
    {
        "id": 2049,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "PTV is a type of radiation therapy."
    },
    {
        "id": 2050,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "High risk primary tumor and involved lymph nodes should be treated with RT Alone."
    },
    {
        "id": 2051,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "Fractionation for RT Alone can be 66 Gy (2.2 Gy/fraction) to 70\u201370.2 Gy (1.8\u20132.0 Gy/fraction)."
    },
    {
        "id": 2052,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "Concomitant boost accelerated RT can be used for RT Alone."
    },
    {
        "id": 2053,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "Hyperfractionation can be used for RT Alone."
    },
    {
        "id": 2054,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "Low to intermediate risk sites of suspected subclinical spread should be treated with RT Alone."
    },
    {
        "id": 2055,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "CONCURRENT SYSTEMIC THERAPY/RT is a type of radiation therapy."
    },
    {
        "id": 2056,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "High risk sites should be treated with CONCURRENT SYSTEMIC THERAPY/RT."
    },
    {
        "id": 2057,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "Low to intermediate risk sites should be treated with CONCURRENT SYSTEMIC THERAPY/RT."
    },
    {
        "id": 2058,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "POSTOPERATIVE RT or Concurrent Systemic Therapy/RT is a type of radiation therapy."
    },
    {
        "id": 2059,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "The preferred interval between resection and postoperative RT is \u22646 weeks."
    },
    {
        "id": 2060,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "High risk adverse pathologic features should be treated with POSTOPERATIVE RT or Concurrent Systemic Therapy/RT."
    },
    {
        "id": 2061,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "Low to intermediate risk sites of suspected subclinical spread should be treated with POSTOPERATIVE RT or Concurrent Systemic Therapy/RT."
    },
    {
        "id": 2062,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "Either IMRT or proton therapy is recommended for maxillary sinus or paranasal/ethmoid sinus tumors."
    },
    {
        "id": 2063,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 60,
        "content": "IMRT or proton therapy can minimize dose to critical structures."
    },
    {
        "id": 2075,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "A H&P should include documentation and quantification of tobacco use history."
    },
    {
        "id": 2076,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "A H&P should include documentation and quantification of alcohol use and counseling."
    },
    {
        "id": 2077,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "All patients who currently smoke should be advised to quit smoking."
    },
    {
        "id": 2078,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Those who formerly smoked should be advised to remain abstinent from smoking."
    },
    {
        "id": 2079,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Additional cessation support can be found in the Patient/Provider Smoking Cessation and Treatment Resources in the NCCN Guidelines for Smoking Cessation."
    },
    {
        "id": 2080,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Screening for depression should be done according to the NCCN Guidelines for Distress Management."
    },
    {
        "id": 2085,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "A complete head and neck exam is part of the H&P."
    },
    {
        "id": 2086,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Nasal endoscopy is clinically indicated as part of the H&P."
    },
    {
        "id": 2087,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "A complete head and neck CT with contrast and/or MRI with and without contrast is part of the workup."
    },
    {
        "id": 2088,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Chest CT with or without contrast is clinically indicated as part of the workup."
    },
    {
        "id": 2089,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "FDG-PET/CT is clinically indicated as part of the workup."
    },
    {
        "id": 2090,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Dental/prosthodontic evaluation is part of the workup."
    },
    {
        "id": 2091,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Nutrition, speech and swallowing evaluation/therapy is part of the workup."
    },
    {
        "id": 2092,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Smoking cessation counseling is part of the workup."
    },
    {
        "id": 2093,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Fertility/reproductive counseling is part of the workup."
    },
    {
        "id": 2094,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Screening for hepatitis B is part of the workup."
    },
    {
        "id": 2095,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Multidisciplinary consultation is clinically indicated as part of the workup."
    },
    {
        "id": 2096,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Squamous cell carcinoma is a type of maxillary sinus tumor."
    },
    {
        "id": 2102,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "The preferred route for biopsy is transnasal."
    },
    {
        "id": 2103,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Needle biopsy may be acceptable for maxillary sinus tumors."
    },
    {
        "id": 2104,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Canine fossa puncture or Caldwell-Luc approach should be avoided for biopsy."
    },
    {
        "id": 2106,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Correct pathologic diagnosis is paramount to treatment decisions for maxillary sinus tumors."
    },
    {
        "id": 2107,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 61,
        "content": "Consider referral to a major medical center that specializes in maxillary sinus tumors for confirmation of diagnosis."
    },
    {
        "id": 2120,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "For SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies, systemic therapy should be part of the overall treatment."
    },
    {
        "id": 2121,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "A clinical trial should be considered for SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies."
    },
    {
        "id": 2160,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 63,
        "content": "A clinical trial should be considered for SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies."
    },
    {
        "id": 2122,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "Referral to a major medical center that specializes in these diseases should be considered for SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies."
    },
    {
        "id": 2161,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 63,
        "content": "Referral to a major medical center that specializes in these diseases should be considered for SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies."
    },
    {
        "id": 2128,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "T1\u20132,N0 is a stage of Maxillary Sinus Tumors."
    },
    {
        "id": 2129,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "All histologies except adenoid cystic are considered in the T1\u20132,N0 stage."
    },
    {
        "id": 2130,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "Resection is a treatment option for T1\u20132,N0 Maxillary Sinus Tumors."
    },
    {
        "id": 2131,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "Margin negative is a characteristic of resection for T1\u20132,N0 Maxillary Sinus Tumors."
    },
    {
        "id": 2132,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "Perineural, vascular, or lymphatic invasion is a characteristic of resection for T1\u20132,N0 Maxillary Sinus Tumors."
    },
    {
        "id": 2133,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "Close or positive margin is a characteristic of resection for T1\u20132,N0 Maxillary Sinus Tumors."
    },
    {
        "id": 2134,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "RT or systemic therapy/RT should be considered for T1\u20132,N0 Maxillary Sinus Tumors with close or positive margin."
    },
    {
        "id": 2139,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "Re-resection is a treatment option for Recurrent or Persistent Disease."
    },
    {
        "id": 2140,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "RT is a treatment option for Recurrent or Persistent Disease."
    },
    {
        "id": 2141,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "Systemic therapy/RT should be considered for Recurrent or Persistent Disease."
    },
    {
        "id": 2142,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "Principles of Surgery are outlined in SURG-A."
    },
    {
        "id": 2143,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "Principles of Radiation Therapy are outlined in MAXI-A."
    },
    {
        "id": 2144,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 62,
        "content": "Principles of Systemic Therapy for Non-Nasopharyngeal Cancers are outlined in SYST-A."
    },
    {
        "id": 2171,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 63,
        "content": "T3\u2013T4a,N0 tumors can be treated with complete resection."
    },
    {
        "id": 2172,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 63,
        "content": "T4b,N0\u20133 tumors can be treated with resection and neck dissection."
    },
    {
        "id": 2173,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 63,
        "content": "T1\u2013T4a,N+ tumors can be treated with resection and neck dissection."
    },
    {
        "id": 2174,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 63,
        "content": "Adverse pathologic features include positive margins, close margins, or extranodal extension."
    },
    {
        "id": 2175,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 63,
        "content": "RT is a treatment option for Maxillary Sinus Tumors."
    },
    {
        "id": 2176,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 63,
        "content": "Systemic therapy can be considered for Maxillary Sinus Tumors."
    },
    {
        "id": 2177,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 63,
        "content": "RT can be used to treat the primary tumor and neck."
    },
    {
        "id": 2193,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "In the paranasal sinus area, care should be taken to avoid critical neural structures."
    },
    {
        "id": 2194,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "In the paranasal sinus area, 1.8 Gy/fraction can be considered."
    },
    {
        "id": 2195,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "For doses >70 Gy, some clinicians feel that the fractionation should be slightly modified to minimize toxicity."
    },
    {
        "id": 2197,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Radiation therapy can be definitive."
    },
    {
        "id": 2198,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Radiation therapy can be RT Alone."
    },
    {
        "id": 2199,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "PTV is part of radiation therapy."
    },
    {
        "id": 2200,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "High risk includes primary tumor and involved lymph nodes."
    },
    {
        "id": 2202,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Fractionation can be concomitant boost accelerated RT."
    },
    {
        "id": 2203,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Fractionation can be hyperfractionation: 81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)."
    },
    {
        "id": 2204,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Low to intermediate risk includes sites of suspected subclinical spread."
    },
    {
        "id": 2205,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Fractionation for low to intermediate risk can be 44\u00e2\u20ac\u201c50 Gy (2.0 Gy/fraction) to 54\u00e2\u20ac\u201c63 Gy (1.6\u00e2\u20ac\u201c1.8 Gy/fraction)."
    },
    {
        "id": 2206,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Concurrent systemic therapy/RT is an option."
    },
    {
        "id": 2207,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "High risk in concurrent systemic therapy/RT typically involves 70\u00e2\u20ac\u201c70.2 Gy (1.8\u00e2\u20ac\u201c2.0 Gy/fraction)."
    },
    {
        "id": 2208,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Low to intermediate risk in concurrent systemic therapy/RT involves 44\u00e2\u20ac\u201c50 Gy (2.0 Gy/fraction) to 54\u00e2\u20ac\u201c63 Gy (1.6\u00e2\u20ac\u201c1.8 Gy/fraction)."
    },
    {
        "id": 2209,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Postoperative radiation therapy or concurrent systemic therapy/RT is an option."
    },
    {
        "id": 2210,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "The preferred interval between resection and postoperative RT is \u00e2\u2030\u00a46 weeks."
    },
    {
        "id": 2211,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "High risk in postoperative radiation therapy involves adverse pathologic features such as positive margins."
    },
    {
        "id": 2212,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Fractionation for high risk in postoperative radiation therapy can be 60\u00e2\u20ac\u201c66 Gy (1.8\u00e2\u20ac\u201c2.0 Gy/fraction)."
    },
    {
        "id": 2213,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Low to intermediate risk in postoperative radiation therapy involves sites of suspected subclinical spread."
    },
    {
        "id": 2214,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "Fractionation for low to intermediate risk in postoperative radiation therapy can be 44\u00e2\u20ac\u201c50 Gy (2.0 Gy/fraction) to 54\u00e2\u20ac\u201c63 Gy (1.6\u00e2\u20ac\u201c1.8 Gy/fraction)."
    },
    {
        "id": 2215,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 64,
        "content": "IMRT or proton therapy is recommended for maxillary sinus or paranasal/ethmoid sinus tumors to minimize dose to critical structures."
    },
    {
        "id": 2231,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "When using concurrent systemic therapy/RT, the preferred agent is cisplatin."
    },
    {
        "id": 2232,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "Cisplatin is a category 1 agent."
    },
    {
        "id": 2235,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "Newly diagnosed patients with T4b,N0\u20133 or unresectable nodal disease or unfit for surgery are considered for treatment."
    },
    {
        "id": 2236,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "Newly diagnosed patients with M1 disease at initial presentation are considered for treatment."
    },
    {
        "id": 2237,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "Clinical trial is preferred for newly diagnosed patients."
    },
    {
        "id": 2240,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "Concurrent systemic therapy/RT or induction systemic therapy followed by RT or systemic therapy/RT are treatment options."
    },
    {
        "id": 2241,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "Recurrent or persistent disease is referred to as ADV-3."
    },
    {
        "id": 2242,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "Concurrent systemic therapy/RT is a preferred treatment option for recurrent or persistent disease."
    },
    {
        "id": 2243,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "RT is a treatment option for recurrent or persistent disease."
    },
    {
        "id": 2244,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "Palliative RT is a treatment option for recurrent or persistent disease."
    },
    {
        "id": 2245,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "Single-agent systemic therapy is a treatment option for recurrent or persistent disease."
    },
    {
        "id": 2246,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 65,
        "content": "Best supportive care is a treatment option for recurrent or persistent disease."
    },
    {
        "id": 2270,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Metastatic disease at initial presentation is considered M1 disease."
    },
    {
        "id": 2271,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Clinical trial is preferred for Metastatic disease at initial presentation."
    },
    {
        "id": 2272,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Distant metastases may be considered for locoregional treatment based on primary site algorithms."
    },
    {
        "id": 2274,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Combination systemic therapy or Single-agent systemic therapy or Surgery or RT or systemic therapy/RT may be considered for selected patients with limited metastases."
    },
    {
        "id": 2275,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Best supportive care is an option for patients."
    },
    {
        "id": 2276,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Single-agent systemic therapy or Best supportive care may be considered for patients."
    },
    {
        "id": 2281,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Single-agent systemic therapy or Best supportive care may be considered for patients."
    },
    {
        "id": 2277,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Palliative RT or Palliative surgery may be added to treatment options."
    },
    {
        "id": 2282,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Palliative RT or Palliative surgery may be added to treatment options."
    },
    {
        "id": 2278,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Systemic therapy is preferred, and clinical trial is preferred."
    },
    {
        "id": 2279,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Or, Palliative RT or Best supportive care may be considered."
    },
    {
        "id": 2280,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 66,
        "content": "Best supportive care or Alternate single-agent systemic therapy or Palliative RT may be considered."
    },
    {
        "id": 2293,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 67,
        "content": "The treatment of recurrent or persistent disease is locoregional recurrence or persistent disease without prior RT."
    },
    {
        "id": 2294,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 67,
        "content": "The treatment of locoregional recurrence or persistent disease with prior RT is reirradiation \u00c2\u00b1 systemic therapy/j clinical trial preferred or ADV-4 for systemic therapy/j."
    },
    {
        "id": 2295,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 67,
        "content": "The treatment of distant metastases is resectable or unresectable."
    },
    {
        "id": 2296,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 67,
        "content": "Surgery \u00c2\u00b1 postoperative reirradiation/b,i or systemic therapy/RT/a,b is a treatment option."
    },
    {
        "id": 2297,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 67,
        "content": "Reirradiation/b \u00c2\u00b1 systemic therapy/j clinical trial preferred or ADV-4 for systemic therapy/j is a treatment option."
    },
    {
        "id": 2298,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 67,
        "content": "Best supportive care is a treatment option."
    },
    {
        "id": 2302,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 67,
        "content": "Adverse pathologic features include extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, and lymphatic invasion."
    },
    {
        "id": 2306,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 67,
        "content": "Cisplatin is the preferred agent when using concurrent systemic therapy/RT."
    },
    {
        "id": 2307,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 67,
        "content": "Next-generation sequencing genomic profiling for biomarker identification should be considered."
    },
    {
        "id": 2308,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 67,
        "content": "Palliative RT as clinically indicated should be considered."
    },
    {
        "id": 2328,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 68,
        "content": "Recurrent or persistent disease with distant metastases is a type of cancer."
    },
    {
        "id": 2330,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 68,
        "content": "Combination systemic therapy or Single-agent systemic therapy or Surgery or RT or concurrent systemic therapy/RT are treatment options for patients with PS 0\u20131 and recurrent or persistent disease with distant metastases."
    },
    {
        "id": 2331,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 68,
        "content": "Single-agent systemic therapy or Best supportive care are treatment options for patients with PS 2 and recurrent or persistent disease with distant metastases."
    },
    {
        "id": 2332,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 68,
        "content": "Single-agent systemic therapy or Best supportive care or Palliative RT or Palliative surgery are treatment options for patients with PS 3 and recurrent or persistent disease with distant metastases."
    },
    {
        "id": 2333,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 68,
        "content": "Systemic therapy is a preferred treatment option for patients with recurrent or persistent disease with distant metastases, and clinical trial is preferred."
    },
    {
        "id": 2334,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 68,
        "content": "Palliative RT or Best supportive care are treatment options for patients with distant metastases only."
    },
    {
        "id": 2335,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 68,
        "content": "If locoregional failure occurs, consider locoregional treatment based on disease extent and symptoms, according to ADV-3."
    },
    {
        "id": 2344,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "The reirradiated population of patients with head and neck cancer described in current literature represents a diverse but highly selected group of patients treated in centers where there is a high level of expertise and systems in place for managing acute and long-term toxicities."
    },
    {
        "id": 2369,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "The reirradiated population of patients with head and neck cancer described in current literature represents a diverse but highly selected group of patients treated in centers where there is a high level of expertise and systems in place for managing acute and long-term toxicities."
    },
    {
        "id": 2345,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "When the goal of treatment is curative and surgery is not an option, reirradiation strategies can be considered for patients who develop locoregional failures or second primaries at \u22656 months after the initial radiotherapy."
    },
    {
        "id": 2346,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "Reirradiation strategies can be considered for patients who can receive additional doses of radiotherapy of at least 60 Gy."
    },
    {
        "id": 2371,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Reirradiation strategies can be considered for patients who can receive additional doses of radiotherapy of at least 60 Gy."
    },
    {
        "id": 2347,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "Reirradiation strategies can be considered for patients who can tolerate concurrent chemotherapy."
    },
    {
        "id": 2372,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Reirradiation strategies can be considered for patients who can tolerate concurrent chemotherapy."
    },
    {
        "id": 2348,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "Organs at risk (OARs) for toxicity should be carefully analyzed through review of dose-volume histograms."
    },
    {
        "id": 2349,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "Consideration for acceptable doses should be made on the basis of time interval since original radiotherapy, anticipated volumes to be included, and patient's life expectancy."
    },
    {
        "id": 2374,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Consideration for acceptable doses should be made on the basis of time interval since original radiotherapy, anticipated volumes to be included, and patient's life expectancy."
    },
    {
        "id": 2350,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "Proton therapy can be considered when normal tissue constraints cannot be met by photon-based therapy."
    },
    {
        "id": 2375,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Proton therapy can be considered when normal tissue constraints cannot be met by photon-based therapy."
    },
    {
        "id": 2351,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "Proton therapy can be considered when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes."
    },
    {
        "id": 2376,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Proton therapy can be considered when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes."
    },
    {
        "id": 2356,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "Concurrent systemic therapy/RT typically uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m2."
    },
    {
        "id": 2357,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "2-3 cycles of chemotherapy are used depending on the radiation fractionation scheme."
    },
    {
        "id": 2358,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "When carboplatin and 5-FU are used, then the recommended regimen is standard fractionation plus 3 cycles of chemotherapy."
    },
    {
        "id": 2359,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "Other fraction sizes, multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy are efficacious, and there is no consensus on the optimal approach."
    },
    {
        "id": 2360,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "Accelerated fractionation does not offer improved efficacy over conventional fractionation."
    },
    {
        "id": 2361,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "Multiagent chemotherapy will likely further increase the toxicity burden."
    },
    {
        "id": 2362,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 69,
        "content": "Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care."
    },
    {
        "id": 2377,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Bernier J, Domenge C, Ozsahin M, et al. published a study on postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer in 2004."
    },
    {
        "id": 2378,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Cooper JS, Pajak TF, Forastiere AA, et al. published a study on postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck in 2004."
    },
    {
        "id": 2379,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Bernier J, Cooper JS, Pajak TF, et al. published a study on defining risk levels in locally advanced head and neck cancers in 2005."
    },
    {
        "id": 2380,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "PTV for high-risk primary tumor and involved lymph nodes includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s)."
    },
    {
        "id": 2381,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Fractionation for high-risk primary tumor and involved lymph nodes can be 70-72 Gy (2.0 Gy/fraction) daily Monday-Friday in 7-7.5 weeks."
    },
    {
        "id": 2382,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Concomitant boost accelerated RT can be 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days)."
    },
    {
        "id": 2383,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Concomitant boost accelerated RT can be 66-70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated)."
    },
    {
        "id": 2384,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Hyperfractionation can be 81.6 Gy/7 weeks (1.2 Gy/fraction, twice daily)."
    },
    {
        "id": 2385,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Modified fractionation can be total dose >70 Gy and treatment course <7 weeks."
    },
    {
        "id": 2386,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "PTV for low to intermediate risk sites of suspected subclinical spread can be 44-50 Gy (2.0 Gy/fraction) to 54-63 Gy (1.6-1.8 Gy/fraction)."
    },
    {
        "id": 2387,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "Either IMRT (preferred) or 3D-CRT is recommended for PTV for low to intermediate risk sites of suspected subclinical spread."
    },
    {
        "id": 2389,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 70,
        "content": "PTV for high-risk adverse pathologic features such as positive margins can be 60-66 Gy (2.0 Gy/fraction); daily Monday-Friday in 6-6.5 weeks."
    },
    {
        "id": 2395,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "A H&P should include documentation and quantification of tobacco use history."
    },
    {
        "id": 2396,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "A H&P should include documentation and quantification of alcohol use and counseling."
    },
    {
        "id": 2397,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "All patients who currently smoke should be advised to quit smoking."
    },
    {
        "id": 2398,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Those who formerly smoked should be advised to remain abstinent from smoking."
    },
    {
        "id": 2399,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Additional cessation support can be found in the Patient/Provider Smoking Cessation and Treatment Resources in the NCCN Guidelines for Smoking Cessation."
    },
    {
        "id": 2400,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Screening for depression should be done according to the NCCN Guidelines for Distress Management."
    },
    {
        "id": 2402,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "A patient should be prepared for neck dissection at the time of open biopsy if indicated."
    },
    {
        "id": 2403,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "A complete head and neck exam should be performed with attention to skin."
    },
    {
        "id": 2404,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Palpation of the oropharynx should be performed."
    },
    {
        "id": 2405,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Mirror and fiberoptic examination should be performed as clinically indicated to examine nasopharynx, oropharynx, hypopharynx, and larynx."
    },
    {
        "id": 2406,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "FNA should be performed."
    },
    {
        "id": 2407,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Squamous cell carcinoma, adenocarcinoma, and anaplastic/undifferentiated epithelial tumors can be diagnosed with FNA."
    },
    {
        "id": 2411,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "CT with contrast or MRI with and without contrast should be performed from the skull base through the thoracic inlet."
    },
    {
        "id": 2412,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "FDG-PET/CT should be performed as indicated before EUA."
    },
    {
        "id": 2413,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Chest CT with contrast should be performed if PET/CT is not done."
    },
    {
        "id": 2414,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "HPV, EBV testing should be performed for squamous cell or undifferentiated histology."
    },
    {
        "id": 2415,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Thyroglobulin, calcitonin, PAX8, and/or thyroid transcription factor (TTF) staining should be performed for adenocarcinoma and anaplastic/undifferentiated tumors."
    },
    {
        "id": 2416,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Dental evaluation should be performed as clinically indicated."
    },
    {
        "id": 2417,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Nutrition, speech, and swallowing evaluation/therapy should be performed as clinically indicated."
    },
    {
        "id": 2418,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Smoking cessation counseling should be performed as clinically indicated."
    },
    {
        "id": 2419,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Fertility/reproductive counseling should be performed as clinically indicated."
    },
    {
        "id": 2420,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 71,
        "content": "Screening for hepatitis B should be performed as clinically indicated."
    },
    {
        "id": 2436,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "Image-guided (US or CT) needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis in this setting."
    },
    {
        "id": 2437,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "A core biopsy would allow for ancillary immune-genomic testing for unresectable or metastatic disease where there is a plan for systemic therapy."
    },
    {
        "id": 2440,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "Node level I, II, III, upper V requires EUA, palpation and inspection, biopsy of areas of clinical concern and tonsillectomy \u00c2\u00b1 lingual tonsillectomy, direct laryngoscopy and nasopharynx survey."
    },
    {
        "id": 2441,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "Node level IV, lower V requires EUA including direct laryngoscopy, esophagoscopy, bronchoscopy, and chest/abdomen/pelvis CT with contrast (or FDG-PET/CT if not previously performed)."
    },
    {
        "id": 2446,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "Definitive Treatment (OCC-3) for Levels I-III involves neck dissection + parotidectomy, if indicated."
    },
    {
        "id": 2447,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "Definitive Treatment (OCC-3) for Levels IV, V involves evaluating for infraclavicular primary and RT to neck \u00c2\u00b1 parotid bed."
    },
    {
        "id": 2448,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "Neck dissection is indicated if necessary \u00c2\u00b1 adjuvant treatment if indicated (OCC-4)."
    },
    {
        "id": 2449,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "Follow-up (FOLL-A, 1 of 2) involves post systemic therapy/RT or RT neck evaluation."
    },
    {
        "id": 2450,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "Follow-up (FOLL-A, 2 of 2) involves primary not found."
    },
    {
        "id": 2451,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "M1 disease at initial presentation is a type of cancer."
    },
    {
        "id": 2452,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "Unresectable nodal disease or unfit for surgery is a type of cancer (ADV-2)."
    },
    {
        "id": 2453,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "HPV and EBV testing are suggested if not yet done."
    },
    {
        "id": 2454,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "Principles of Surgery (SURG-A) are relevant."
    },
    {
        "id": 2455,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 72,
        "content": "Principles of Radiation Therapy (OCC-A) are relevant."
    },
    {
        "id": 2485,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 74,
        "content": "It is being investigated whether HPV or EBV positive status may help to define the radiation fields."
    },
    {
        "id": 2491,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 74,
        "content": "Post neck dissection, treatment options for N1 without extranodal extension include RT or observation."
    },
    {
        "id": 2492,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 74,
        "content": "The target volume for RT is determined by tumor size, nodal station, and HPV and EBV status."
    },
    {
        "id": 2493,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 74,
        "content": "Treatment options for N2,N3 without extranodal extension include RT or systemic therapy/RT."
    },
    {
        "id": 2494,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 74,
        "content": "Treatment options for extranodal extension include systemic therapy/RT."
    },
    {
        "id": 2511,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Squamous cell carcinoma, adenocarcinoma, and poorly differentiated carcinoma are types of cancer."
    },
    {
        "id": 2551,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 76,
        "content": "Squamous cell carcinoma, adenocarcinoma, and poorly differentiated carcinoma are types of cancer."
    },
    {
        "id": 2514,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "For doses greater than 70 Gy, some clinicians feel that the fractionation should be slightly modified to minimize toxicity."
    },
    {
        "id": 2516,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "A dose of 44\u201350 Gy in 3D-CRT and sequentially planned IMRT or 54\u201363 Gy with IMRT dose painting technique is suggested."
    },
    {
        "id": 2517,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks."
    },
    {
        "id": 2518,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Single-agent cisplatin is given every 3 weeks at 100 mg/m2."
    },
    {
        "id": 2519,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "2\u20133 cycles of chemotherapy are used depending on the radiation fractionation scheme."
    },
    {
        "id": 2528,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Principles of Radiation Therapy are outlined."
    },
    {
        "id": 2529,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Definitive RT alone is an option."
    },
    {
        "id": 2530,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "PTV is used for high-risk involved lymph nodes."
    },
    {
        "id": 2531,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Fractionation is 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction) daily Monday\u2013Friday in 6\u20137 weeks."
    },
    {
        "id": 2532,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Mucosal dosing is 50\u201366 Gy (2.0 Gy/fraction) to putative mucosal sites, depending on field size."
    },
    {
        "id": 2533,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Higher dose to 60\u201366 Gy can be considered for particularly suspicious areas."
    },
    {
        "id": 2538,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Higher dose to 60\u201366 Gy can be considered for particularly suspicious areas."
    },
    {
        "id": 2534,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Low to intermediate risk sites of suspected subclinical spread are treated with 44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)."
    },
    {
        "id": 2535,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Concurrent systemic therapy/RT is an option."
    },
    {
        "id": 2536,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "PTV is used for high-risk sites, typically 70 Gy (2.0 Gy/fraction)."
    },
    {
        "id": 2537,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Mucosal dosing is 50\u201360 Gy (2.0 Gy/fraction) to putative mucosal primary sites, depending on field size and use of chemotherapy."
    },
    {
        "id": 2539,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Low to intermediate risk sites are treated with 44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)."
    },
    {
        "id": 2540,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "IMRT (preferred) or 3D-CRT is recommended when targeting the pharyngeal axis to minimize the dose to critical structures."
    },
    {
        "id": 2541,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Proton therapy is an area of active investigation."
    },
    {
        "id": 2569,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 76,
        "content": "Proton therapy is an area of active investigation."
    },
    {
        "id": 2542,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 75,
        "content": "Proton therapy may be considered when normal tissue constraints cannot be met by photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes."
    },
    {
        "id": 2556,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 76,
        "content": "Bernier J, Domenge C, Ozsahin M, et al. wrote an article about postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer."
    },
    {
        "id": 2558,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 76,
        "content": "Cooper JS, Pajak TF, Forastiere AA, et al. wrote an article about postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck."
    },
    {
        "id": 2561,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 76,
        "content": "PTV is a relevant concept in radiation therapy."
    },
    {
        "id": 2562,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 76,
        "content": "High-risk patients have adverse pathologic features such as extranodal extension (OCC-4)."
    },
    {
        "id": 2565,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 76,
        "content": "Low to intermediate risk patients have sites of suspected subclinical spread."
    },
    {
        "id": 2567,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 76,
        "content": "IMRT is preferred when targeting the pharyngeal axis to minimize the dose to critical structures."
    },
    {
        "id": 2568,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 76,
        "content": "3D-CRT is an alternative to IMRT when targeting the pharyngeal axis."
    },
    {
        "id": 2570,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 76,
        "content": "Proton therapy may be considered when normal tissue constraints cannot be met by photon-based therapy."
    },
    {
        "id": 2571,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 76,
        "content": "Proton therapy may be considered when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes."
    },
    {
        "id": 2583,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "H&P should include documentation and quantification of tobacco use history."
    },
    {
        "id": 2584,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Tobacco use history should include pack years smoked."
    },
    {
        "id": 2585,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "H&P should include documentation of alcohol use and counseling."
    },
    {
        "id": 2586,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "All patients who currently smoke should be advised to quit smoking."
    },
    {
        "id": 2587,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Those who formerly smoked should be advised to remain abstinent from smoking."
    },
    {
        "id": 2588,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Additional cessation support can be found in the Patient/Provider Smoking Cessation and Treatment Resources in the NCCN Guidelines for Smoking Cessation."
    },
    {
        "id": 2589,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Screening for depression should be done according to the NCCN Guidelines for Distress Management."
    },
    {
        "id": 2590,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "A complete head and neck exam should be performed as part of the H&P."
    },
    {
        "id": 2591,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "A mirror and fiberoptic examination should be performed as clinically indicated."
    },
    {
        "id": 2592,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "FNA biopsy should be performed as part of the workup."
    },
    {
        "id": 2593,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "CT/MRI with and without contrast of skull base to clavicle should be performed as clinically indicated."
    },
    {
        "id": 2594,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Chest CT with or without contrast should be performed as clinically indicated."
    },
    {
        "id": 2595,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Preanesthesia studies should be performed as clinically indicated."
    },
    {
        "id": 2596,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Dental evaluation should be performed as clinically indicated."
    },
    {
        "id": 2597,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Nutrition and speech and swallowing evaluation should be performed as clinically indicated."
    },
    {
        "id": 2598,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Smoking cessation counseling should be performed as part of the workup."
    },
    {
        "id": 2599,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Fertility/reproductive counseling should be performed as clinically indicated."
    },
    {
        "id": 2600,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Screening for hepatitis B should be performed as clinically indicated."
    },
    {
        "id": 2602,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Image-guided needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis."
    },
    {
        "id": 2603,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "A core biopsy would allow for ancillary immune-genomic testing for unresectable or metastatic disease where there is a plan for systemic therapy."
    },
    {
        "id": 2608,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 77,
        "content": "Characteristics of a benign tumor include mobile superficial lobe, slow growth, painless, V and/or VII intact, and no neck nodes."
    },
    {
        "id": 2617,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 78,
        "content": "A clinically benign tumor or T1, T2 tumor can undergo complete resection."
    },
    {
        "id": 2618,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 78,
        "content": "T3, T4a, or T4b tumors require surgical evaluation."
    },
    {
        "id": 2619,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 78,
        "content": "A benign or low-grade tumor may not require resection."
    },
    {
        "id": 2620,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 78,
        "content": "Adenoid cystic, intermediate, or high-grade tumors may require radiation therapy if there is tumor spillage or perineural invasion."
    },
    {
        "id": 2621,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 78,
        "content": "Radiation therapy is considered for tumors with tumor spillage or perineural invasion."
    },
    {
        "id": 2622,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 78,
        "content": "Follow-up is clinically indicated for patients who have undergone treatment."
    },
    {
        "id": 2623,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 78,
        "content": "Recurrent or persistent disease is addressed in SALI-4."
    },
    {
        "id": 2624,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 78,
        "content": "Parotid gland and other salivary glands are cancer sites."
    },
    {
        "id": 2625,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 78,
        "content": "Definitive radiation therapy or concurrent systemic therapy/RT is a treatment option for cancer."
    },
    {
        "id": 2626,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 78,
        "content": "Follow-up is necessary for patients with recurrent or persistent disease."
    },
    {
        "id": 2627,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 78,
        "content": "Resection of a clinically benign tumor includes no enucleation of lateral lobe and intraoperative communication with a pathologist if indicated."
    },
    {
        "id": 2636,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Complete gland and tumor resection is recommended for submandibular and sublingual gland tumors."
    },
    {
        "id": 2637,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "The facial nerve should be preserved if possible during surgery for submandibular and sublingual gland tumors."
    },
    {
        "id": 2638,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Referral to a specialized center with reconstructive expertise should be strongly considered for submandibular and sublingual gland tumors."
    },
    {
        "id": 2641,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Major salivary gland tumors include parotid, submandibular, and sublingual gland tumors."
    },
    {
        "id": 2642,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Minor salivary gland tumors are a type of salivary gland tumor."
    },
    {
        "id": 2643,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Surgery with complete resection of tumor is recommended for clinical N0 major salivary gland tumors."
    },
    {
        "id": 2644,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Surgery with neck dissection is recommended for clinical N+ major salivary gland tumors."
    },
    {
        "id": 2645,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Complete tumor resection is recommended for clinical N0 minor salivary gland tumors."
    },
    {
        "id": 2646,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Complete tumor resection and lymph node dissection are recommended for clinical N+ minor salivary gland tumors."
    },
    {
        "id": 2647,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Tumors that are completely resected have no adverse pathologic features."
    },
    {
        "id": 2648,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Tumors that are incompletely resected have gross residual disease."
    },
    {
        "id": 2649,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Adenoid cystic tumors have adverse pathologic features."
    },
    {
        "id": 2650,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Adverse pathologic features include intermediate or high grade, close or positive margins, neural/perineural invasion, lymph node metastases, lymphatic/vascular invasion, and T3\u20134a tumors."
    },
    {
        "id": 2671,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 80,
        "content": "NGS profiling and other appropriate biomarker testing should be used to check the status of androgen receptor, HER2, NTRK, HRAS, PIK3CA, and tumor mutational burden prior to treatment."
    },
    {
        "id": 2653,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Adjuvant RT is preferred for recurrent or persistent disease."
    },
    {
        "id": 2654,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Systemic therapy/RT is an option for recurrent or persistent disease."
    },
    {
        "id": 2658,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Systemic therapy/RT is an option for recurrent or persistent disease."
    },
    {
        "id": 2655,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Resection is recommended if possible for recurrent or persistent disease."
    },
    {
        "id": 2656,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "No further resection is possible for some recurrent or persistent diseases."
    },
    {
        "id": 2657,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 79,
        "content": "Definitive RT is an option for recurrent or persistent disease."
    },
    {
        "id": 2707,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Reirradiation strategies can be considered for patients who develop locoregional failures or second primaries at \u22656 months after the initial radiotherapy."
    },
    {
        "id": 2708,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Reirradiation strategies can be considered for patients who can receive additional doses of radiotherapy of at least 60 Gy."
    },
    {
        "id": 2709,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Reirradiation strategies can be considered for patients who can tolerate concurrent chemotherapy."
    },
    {
        "id": 2710,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "OARs for toxicity should be carefully analyzed through review of dose-volume histograms."
    },
    {
        "id": 2711,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Consideration for acceptable doses should be made on the basis of time interval since original radiotherapy, anticipated volumes to be included, and patient's life expectancy."
    },
    {
        "id": 2712,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Proton therapy can be considered when normal tissue constraints cannot be met by photon-based therapy."
    },
    {
        "id": 2730,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Proton therapy can be considered when normal tissue constraints cannot be met by photon-based therapy."
    },
    {
        "id": 2713,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Proton therapy can be considered when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes."
    },
    {
        "id": 2731,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Proton therapy can be considered when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes."
    },
    {
        "id": 2714,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Reirradiation dosing can be found in Principles of Radiation Techniques (RAD-A)."
    },
    {
        "id": 2715,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "For doses >70 Gy, some clinicians feel that the fractionation should be slightly modified to minimize toxicity."
    },
    {
        "id": 2716,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "An additional 2\u20133 doses can be added depending on clinical circumstances."
    },
    {
        "id": 2717,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Suggest 44\u201350 Gy in 3D-CRT and sequentially planned IMRT or 54\u201363 Gy with IMRT dose painting technique."
    },
    {
        "id": 2718,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Photon or photon/electron therapy or highly conformal RT techniques are used for definitive RT alone or concurrent systemic therapy/RT."
    },
    {
        "id": 2719,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "PTV includes high risk: Primary tumor and involved lymph nodes."
    },
    {
        "id": 2720,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Fractionation for high risk is 66 Gy (2.0 Gy/fraction) to 70\u201370.2 Gy (1.8\u20132.0 Gy/fraction); daily Monday\u2013Friday in 6\u20138 weeks."
    },
    {
        "id": 2721,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "PTV includes low to intermediate risk: Sites of suspected subclinical spread."
    },
    {
        "id": 2722,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Fractionation for low to intermediate risk is 44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)."
    },
    {
        "id": 2723,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Postoperative RT is recommended with an interval between resection and postoperative RT of \u22646 weeks."
    },
    {
        "id": 2724,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Photon or photon/electron therapy is used for postoperative RT."
    },
    {
        "id": 2725,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "PTV for high risk in postoperative RT includes adverse pathologic features such as positive margins."
    },
    {
        "id": 2726,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Fractionation for high risk in postoperative RT is 60\u201366 Gy (2.0 Gy/fraction); daily Monday\u2013Friday in 6\u20137 weeks."
    },
    {
        "id": 2727,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "PTV for low to intermediate risk in postoperative RT includes sites of suspected subclinical spread."
    },
    {
        "id": 2728,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Fractionation for low to intermediate risk in postoperative RT is 44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction)."
    },
    {
        "id": 2729,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 81,
        "content": "Either IMRT (preferred) or 3D-CRT is recommended for postoperative RT."
    },
    {
        "id": 2741,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "The choice of systemic therapy for salivary gland tumors should be individualized based on patient characteristics."
    },
    {
        "id": 2742,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Patient characteristics that influence the choice of systemic therapy include PS and goals of therapy."
    },
    {
        "id": 2743,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "There are no preferred regimens for systemic therapy for salivary gland tumors."
    },
    {
        "id": 2744,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Cisplatin/vinorelbine is an other recommended regimen for systemic therapy for salivary gland tumors."
    },
    {
        "id": 2745,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Cisplatin/doxorubicin/cyclophosphamide is an other recommended regimen for systemic therapy for salivary gland tumors with a category 2B rating."
    },
    {
        "id": 2746,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Paclitaxel is an other recommended regimen for systemic therapy for non-adenoid cystic carcinoma salivary gland tumors with a category 2A rating."
    },
    {
        "id": 2747,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Paclitaxel is an other recommended regimen for systemic therapy for adenoid cystic carcinoma salivary gland tumors with a category 2B rating."
    },
    {
        "id": 2748,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Carboplatin/paclitaxel is an other recommended regimen for systemic therapy for salivary gland tumors."
    },
    {
        "id": 2749,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Carboplatin/gemcitabine is an other recommended regimen for systemic therapy for salivary gland tumors."
    },
    {
        "id": 2750,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Androgen receptor therapy is useful in certain circumstances for AR+ salivary gland tumors."
    },
    {
        "id": 2751,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Leuprolide is an androgen receptor therapy for AR+ salivary gland tumors."
    },
    {
        "id": 2752,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Bicalutamide is an androgen receptor therapy for AR+ salivary gland tumors."
    },
    {
        "id": 2753,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Abiraterone is an androgen receptor therapy for AR+ salivary gland tumors."
    },
    {
        "id": 2754,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Goserelin is an androgen receptor therapy for AR+ salivary gland tumors with a category 2B rating."
    },
    {
        "id": 2755,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "NTRK therapy is useful in certain circumstances for NTRK gene fusion-positive salivary gland tumors."
    },
    {
        "id": 2756,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Larotrectinib is an NTRK therapy for NTRK gene fusion-positive salivary gland tumors."
    },
    {
        "id": 2757,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Entrectinib is an NTRK therapy for NTRK gene fusion-positive salivary gland tumors."
    },
    {
        "id": 2758,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "HER2-targeted therapy is useful in certain circumstances for HER2+ salivary gland tumors."
    },
    {
        "id": 2759,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Trastuzumab is a HER2-targeted therapy for HER2+ salivary gland tumors."
    },
    {
        "id": 2760,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Ado-trastuzumab emtansine is a HER2-targeted therapy for HER2+ salivary gland tumors."
    },
    {
        "id": 2761,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Trastuzumab/pertuzumab is a HER2-targeted therapy for HER2+ salivary gland tumors."
    },
    {
        "id": 2762,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Docetaxel/trastuzumab is a HER2-targeted therapy for HER2+ salivary gland tumors."
    },
    {
        "id": 2763,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Fam-trastuzumab deruxtecan-nxki is a HER2-targeted therapy for HER2+ salivary gland tumors."
    },
    {
        "id": 2764,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Sorafenib is a useful therapy in certain circumstances for salivary gland tumors with a category 2B rating."
    },
    {
        "id": 2765,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Axitinib is a useful therapy in certain circumstances for salivary gland tumors with a category 2B rating."
    },
    {
        "id": 2766,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Axitinib + avelumab is a useful therapy in certain circumstances for adenoid cystic carcinoma salivary gland tumors with a category 2B rating."
    },
    {
        "id": 2767,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Lenvatinib is a useful therapy in certain circumstances for adenoid cystic carcinoma salivary gland tumors with a category 2B rating."
    },
    {
        "id": 2768,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Pembrolizumab is a useful therapy in certain circumstances for microsatellite instability-high, mismatch repair deficient, TMB-H salivary gland tumors."
    },
    {
        "id": 2769,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Dabrafenib/trametinib is a useful therapy in certain circumstances for BRAF V600E-positive salivary gland tumors."
    },
    {
        "id": 2770,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 82,
        "content": "Selpercatinib is a useful therapy in certain circumstances for RET gene fusion-positive salivary gland tumors."
    },
    {
        "id": 2832,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Image-guided needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis in this setting."
    },
    {
        "id": 2833,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "A core biopsy would allow for ancillary immune-genomic testing for unresectable or metastatic disease where there is a plan for systemic therapy."
    },
    {
        "id": 2834,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "A biopsy confirms the diagnosis of mucosal malignant melanoma."
    },
    {
        "id": 2835,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "H&P including complete head and neck exam is part of the workup for mucosal melanoma."
    },
    {
        "id": 2836,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Mirror and fiberoptic examination are clinically indicated as part of the workup for mucosal melanoma."
    },
    {
        "id": 2837,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Verification of pathology using appropriate staining is part of the workup for mucosal melanoma."
    },
    {
        "id": 2838,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "CT with contrast and/or MRI with and without contrast are used to determine anatomic extent of disease, particularly for sinus disease."
    },
    {
        "id": 2839,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Chest CT with or without contrast is considered as part of the workup for mucosal melanoma."
    },
    {
        "id": 2840,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "FDG-PET/CT or chest/abdomen/pelvis CT with contrast, and brain MRI with and without contrast are considered to rule out metastatic disease."
    },
    {
        "id": 2841,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Dental/prosthodontic evaluation is part of the workup for mucosal melanoma."
    },
    {
        "id": 2842,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Nutrition, speech and swallowing evaluation/therapy are part of the workup for mucosal melanoma."
    },
    {
        "id": 2843,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Smoking cessation counseling is part of the workup for mucosal melanoma."
    },
    {
        "id": 2844,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Fertility/reproductive counseling is part of the workup for mucosal melanoma."
    },
    {
        "id": 2845,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Screening for hepatitis B is part of the workup for mucosal melanoma."
    },
    {
        "id": 2846,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Multidisciplinary consultation is clinically indicated as part of the workup for mucosal melanoma."
    },
    {
        "id": 2847,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Sinus or nasal cavity mucosal melanoma is a type of mucosal melanoma."
    },
    {
        "id": 2848,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "Oral cavity, oropharynx, larynx, or hypopharynx mucosal melanoma is a type of mucosal melanoma."
    },
    {
        "id": 2849,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "H&P should include documentation and quantification of tobacco use history, as well as alcohol use and counseling."
    },
    {
        "id": 2850,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 84,
        "content": "All patients who currently smoke should be advised to quit smoking, and those who formerly smoked should be advised to remain abstinent from smoking."
    },
    {
        "id": 2865,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Postoperative RT is strongly considered for primary site treatment of T3,N0 mucosal melanoma."
    },
    {
        "id": 2866,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Systemic therapy is an option for T3,N0 mucosal melanoma with a category 2B recommendation."
    },
    {
        "id": 2867,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Resection of primary is an option for T3,N0 mucosal melanoma."
    },
    {
        "id": 2868,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Clinical trial is an option for T3,N0 mucosal melanoma."
    },
    {
        "id": 2869,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Resection + neck dissection of positive neck is an option for T3\u2013T4a,N1 mucosal melanoma."
    },
    {
        "id": 2870,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Postoperative RT to primary site and neck is an option for T3\u2013T4a,N1 mucosal melanoma."
    },
    {
        "id": 2871,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Systemic therapy is an option for T3\u2013T4a,N1 mucosal melanoma with a category 2B recommendation."
    },
    {
        "id": 2872,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Resection is an option for T4a,N0 and T4b,N0 mucosal melanoma."
    },
    {
        "id": 2873,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Clinical trial is an option for T4a,N0 and T4b,N0 mucosal melanoma."
    },
    {
        "id": 2874,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Postoperative RT to primary site is an option for T4a,N0 and T4b,N0 mucosal melanoma."
    },
    {
        "id": 2875,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Systemic therapy is an option for T4a,N0 and T4b,N0 mucosal melanoma with a category 2B recommendation."
    },
    {
        "id": 2876,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Clinical trial is the preferred option for T4b,N1 mucosal melanoma."
    },
    {
        "id": 2877,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Primary RT is an option for T4b,N1 mucosal melanoma."
    },
    {
        "id": 2878,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Systemic therapy is an option for T4b,N1 mucosal melanoma."
    },
    {
        "id": 2879,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Follow-up is recommended for mucosal melanoma patients."
    },
    {
        "id": 2880,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Recurrent or persistent disease is managed according to the NCCN Guidelines for Melanoma: Cutaneous."
    },
    {
        "id": 2881,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 85,
        "content": "Neck Evaluation is part of follow-up for mucosal melanoma patients."
    },
    {
        "id": 2902,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 86,
        "content": "Postoperative RT is strongly considered for T3,N0 mucosal melanoma."
    },
    {
        "id": 2903,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 86,
        "content": "Systemic therapy is an option for T3,N0 mucosal melanoma, with a category 2B recommendation."
    },
    {
        "id": 2905,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 86,
        "content": "Resection with or without neck dissection is an option for T3,N1 or T4a,N0-1 mucosal melanoma."
    },
    {
        "id": 2906,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 86,
        "content": "Postoperative RT is an option for T3,N1 or T4a,N0-1 mucosal melanoma."
    },
    {
        "id": 2907,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 86,
        "content": "Systemic therapy is an option for T3,N1 or T4a,N0-1 mucosal melanoma, with a category 2B recommendation."
    },
    {
        "id": 2909,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 86,
        "content": "Primary RT is an option for T4b,N0 mucosal melanoma."
    },
    {
        "id": 2910,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 86,
        "content": "Systemic therapy is an option for T4b,N0 mucosal melanoma."
    },
    {
        "id": 2915,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 86,
        "content": "Follow-up is necessary for mucosal melanoma."
    },
    {
        "id": 2920,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 86,
        "content": "Adjuvant systemic therapy may be used for mucosal melanoma, but data to support its use are limited."
    },
    {
        "id": 2921,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 86,
        "content": "Nivolumab is an option for adjuvant systemic therapy, with a category 2B recommendation."
    },
    {
        "id": 2922,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 86,
        "content": "Cisplatin/temozolomide is an option for adjuvant systemic therapy, with a category 2B recommendation."
    },
    {
        "id": 2939,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 87,
        "content": "High-risk features include >2 nodes, single node >3 cm, extranodal extension, and recurrence in nodal basin after previous surgery."
    },
    {
        "id": 2943,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 87,
        "content": "RT to nodal basin is considered for high-risk features."
    },
    {
        "id": 2944,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 87,
        "content": "Adjuvant systemic therapy is considered per NCCN Guidelines for Melanoma: Cutaneous."
    },
    {
        "id": 2961,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "Radiation therapy can be used alone for unresectable locally advanced melanoma."
    },
    {
        "id": 2962,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "The primary tumor and involved lymph nodes should be included in the PTV for high-risk patients."
    },
    {
        "id": 2963,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "The PTV should receive 66 Gy to 70 Gy in 6-7 weeks for high-risk patients."
    },
    {
        "id": 2964,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "The PTV should receive 44-50 Gy to 54-63 Gy for low to intermediate risk patients."
    },
    {
        "id": 2965,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "Palliative RT doses and schedules may be considered."
    },
    {
        "id": 2966,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "Optional dosing schedules may be considered."
    },
    {
        "id": 2967,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "Postoperative RT should be given within 6 weeks of resection."
    },
    {
        "id": 2968,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "The PTV should receive 60-66 Gy in 6-6.5 weeks for high-risk patients after resection."
    },
    {
        "id": 2969,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "The PTV should receive 44-50 Gy to 54-63 Gy for low to intermediate risk patients after resection."
    },
    {
        "id": 2970,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "IMRT is the preferred radiation therapy technique."
    },
    {
        "id": 2971,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "3D-CRT can be used if IMRT is not possible."
    },
    {
        "id": 2972,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "Proton therapy can be used when normal tissue constraints cannot be met by photon-based therapy."
    },
    {
        "id": 2973,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "Proton therapy can be used when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes."
    },
    {
        "id": 2974,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 88,
        "content": "Optional dose schedules include 48-50 Gy and 30-36 Gy."
    },
    {
        "id": 2988,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "A physical exam for mucosal melanoma and paranasal sinus cancers should include endoscopic inspection for paranasal sinus disease."
    },
    {
        "id": 2987,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "Most recurrences are reported by the patient."
    },
    {
        "id": 3002,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "The H&P exam should be performed every 2-6 months in the second year."
    },
    {
        "id": 3003,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "The H&P exam should be performed every 4-8 months in years 3-5."
    },
    {
        "id": 3005,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "AM cortisol, growth hormone (GH), free T4, prolactin, insulin-like growth factor 2 (IGF-2), luteinizing hormone (LH), follicle-stimulating hormone (FSH), serum adrenocorticotropic hormone (ACTH), TSH, and total and bioavailable testosterone levels should be evaluated annually."
    },
    {
        "id": 3006,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "Imaging should be performed according to the Principles of Imaging (IMG-A)."
    },
    {
        "id": 3007,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "Thyroid-stimulating hormone (TSH) should be evaluated every 6-12 months if the neck was irradiated."
    },
    {
        "id": 3008,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "Dental evaluation should be performed for oral cavity and sites exposed to significant intraoral radiation treatment."
    },
    {
        "id": 3010,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "Supportive care and rehabilitation should include speech/hearing and swallowing evaluation and rehabilitation as clinically indicated."
    },
    {
        "id": 3011,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "Supportive care and rehabilitation should include nutritional evaluation and rehabilitation as clinically indicated until nutritional status is stabilized."
    },
    {
        "id": 3012,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "Supportive care and rehabilitation should include ongoing surveillance for depression."
    },
    {
        "id": 3013,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "Supportive care and rehabilitation should include smoking cessation and alcohol counseling as clinically indicated."
    },
    {
        "id": 3014,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 89,
        "content": "Supportive care and rehabilitation should include lymphedema evaluation and rehabilitation as clinically indicated."
    },
    {
        "id": 3028,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "Systemic therapy or RT or RT should be followed by a clinical assessment 4-8 weeks later."
    },
    {
        "id": 3029,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "A residual primary, persistent disease, or progression should be assessed through imaging."
    },
    {
        "id": 3030,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "Imaging should assess the extent of disease or distant metastases."
    },
    {
        "id": 3031,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "CT with contrast or MRI with and without contrast can be used for imaging."
    },
    {
        "id": 3032,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "FDG-PET/CT can also be used for imaging."
    },
    {
        "id": 3033,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "Imaging should be performed at a minimum of 12 weeks."
    },
    {
        "id": 3034,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "CT with contrast of primary and neck and/or MRI with and without contrast can be used for imaging at 8-12 weeks."
    },
    {
        "id": 3035,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "A confirmed residual or persistent disease or progression should be treated with resection of residual primary and/or neck dissection."
    },
    {
        "id": 3036,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "Imaging positive results should be treated with resection of residual primary and/or neck dissection."
    },
    {
        "id": 3037,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "Imaging negative results should be observed."
    },
    {
        "id": 3038,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "FDG-PET/CT imaging at 12 weeks or later can be used to assess the response to treatment."
    },
    {
        "id": 3039,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "Neck dissection can be performed after confirming residual or persistent disease or progression."
    },
    {
        "id": 3040,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "FDG-PET/CT negative results indicate no or low-grade uptake, felt not suspicious for disease."
    },
    {
        "id": 3041,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "FDG-PET/CT equivocal results require further evaluation."
    },
    {
        "id": 3042,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "FDG-PET/CT strongly positive results indicate PET suspicious for disease."
    },
    {
        "id": 3043,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "Biopsy can be performed if FDG-PET/CT is equivocal."
    },
    {
        "id": 3044,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "CT with contrast or MRI with and without contrast can be used for further evaluation."
    },
    {
        "id": 3045,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "Observation or repeat FDG-PET/CT at 3-6 months can be used for follow-up."
    },
    {
        "id": 3047,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 90,
        "content": "Unresectable disease should be treated with resection of primary if feasible and/or neck dissection if nodal disease in neck is feasible."
    },
    {
        "id": 3054,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "Imaging plays an essential role in the clinical care of patients with head and neck cancer."
    },
    {
        "id": 3055,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "The proper selection and utilization of imaging studies is critical in caring for patients with head and neck cancer."
    },
    {
        "id": 3056,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "CT is performed with contrast."
    },
    {
        "id": 3057,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "CT imaging of the chest can be performed with or without contrast, as clinically indicated."
    },
    {
        "id": 3058,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "MRI is performed with and without contrast, unless contraindicated."
    },
    {
        "id": 3059,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "Imaging assessment of primary site can be performed with CT of the soft tissues of the neck or MRI of the neck."
    },
    {
        "id": 3060,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "CT is complementary to MRI for head and neck cancers."
    },
    {
        "id": 3061,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "CT is used to evaluate cortical bone erosion or periosteal invasion."
    },
    {
        "id": 3062,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "CT is used to evaluate cartilage invasion."
    },
    {
        "id": 3063,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "CT is used to evaluate bony erosion/destruction."
    },
    {
        "id": 3064,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "MRI is preferred over CT for evaluating the extent of bone marrow invasion."
    },
    {
        "id": 3065,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "MRI is preferred over CT for patients with extensive dental amalgam that may obscure the anatomy on CT."
    },
    {
        "id": 3066,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "MRI is preferred over CT for assessing skull base invasion and cranial nerve involvement."
    },
    {
        "id": 3067,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "MRI is preferred over CT for evaluating skull base or intracranial or orbital invasion, and to differentiate tumor from obstructed sinuses."
    },
    {
        "id": 3068,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "MRI is preferred over CT if there are cranial nerve symptoms or if radiographic perineural tumor spread is a possibility."
    },
    {
        "id": 3069,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "CT or MRI of the neck should image the anatomy from the skull base to the thoracic inlet to achieve complete evaluation of the primary and any nodal disease."
    },
    {
        "id": 3070,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "For certain conditions, such as involved lymph nodes in the low neck or cancers that frequently involve the upper mediastinum (such as thyroid cancer), the imaging should extend to the carina."
    },
    {
        "id": 3071,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "If imaging does not reveal an obvious primary, PET/CT should be ordered before EUA, biopsies, and tonsillectomy, to help identify potential primary sites before any intervention occurs."
    },
    {
        "id": 3072,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "FNA biopsy of metastatic nodes may be pathologically informative."
    },
    {
        "id": 3073,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "Image-guided (ultrasound [US] or CT) needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis in this setting."
    },
    {
        "id": 3074,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "Panoramic dental x-ray is recommended for oral cavity cancers requiring mandibulotomy and/or mandibulectomy."
    },
    {
        "id": 3075,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 91,
        "content": "When postoperative RT is anticipated (including such sites as the lip, other oral cavity subsites, or the oropharynx), panoramic x-ray is part of a comprehensive pre-radiation dental evaluation to assess the health of the affected dentition and determine if pre-radiation dental procedures or extractions are needed."
    },
    {
        "id": 3082,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "NCCN provides guidelines for the initial workup of head and neck cancers."
    },
    {
        "id": 3083,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "Evaluation of lymph node metastases should be conducted with CT or MRI of the neck."
    },
    {
        "id": 3084,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "CT or MRI should be used for primary site evaluation."
    },
    {
        "id": 3085,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "For patients with multistation or lower neck nodal involvement or high-grade tumor histology, CT of the chest should be considered to assess for mediastinal lymph node metastases."
    },
    {
        "id": 3086,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "FDG-PET/CT is associated with higher sensitivity for both nodal and distant metastases."
    },
    {
        "id": 3087,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "For patients who are under consideration for a surgical primary approach, FDG-PET/CT is warranted for tumors approaching the midline."
    },
    {
        "id": 3088,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "FDG-PET/CT is beneficial for determining the surgical approach to the contralateral neck."
    },
    {
        "id": 3089,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "Patients who are scheduled for a definitive RT approach may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes."
    },
    {
        "id": 3090,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "For patients with locoregionally advanced cancer, FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases."
    },
    {
        "id": 3091,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "FDG-PET/CT cannot rule out brain metastasis."
    },
    {
        "id": 3092,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "For cancers where brain metastasis is a concern, contrast-enhanced brain MRI should be additionally obtained."
    },
    {
        "id": 3093,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "If FDG-PET/CT is not performed, CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement."
    },
    {
        "id": 3094,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases."
    },
    {
        "id": 3095,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "Non-contrast CT of the chest is not adequate for assessment of mediastinal adenopathy."
    },
    {
        "id": 3096,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "Annual CT screening for lung metastasis is controversial following primary definitive treatment."
    },
    {
        "id": 3097,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "Annual chest CT can be considered for patients with a substantial smoking history or who are at high risk for lung metastases."
    },
    {
        "id": 3098,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "Historically, annual chest x-ray has been obtained but this is a much less sensitive test than CT."
    },
    {
        "id": 3099,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "If clinical concern for metastatic disease is confined to a specific anatomical area, the assessment of distant disease can be performed with directed CT or MRI examination."
    },
    {
        "id": 3100,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "The frequency of imaging tests depends on the planned treatment regimen and type of cancer."
    },
    {
        "id": 3102,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "FDG-PET/CT can explore distant disease or second primaries that may significantly impact choice of therapy."
    },
    {
        "id": 3103,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "PET/CT is preferred over PET scan alone."
    },
    {
        "id": 3104,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 92,
        "content": "PET/CT provides more accurate anatomical localization of abnormalities."
    },
    {
        "id": 3112,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 93,
        "content": "Short-term post-treatment imaging is recommended for patients who show signs of early recurrence or who are at high risk of early recurrence prior to starting adjuvant postoperative therapy."
    },
    {
        "id": 3113,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 93,
        "content": "CT and/or MRI should be obtained within 3\u20134 months after surgical treatment for patients with locoregionally advanced disease or with altered anatomy causing challenging physical exam assessment."
    },
    {
        "id": 3114,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 93,
        "content": "A CT or MRI scan may be obtained earlier, such as 4\u20138 weeks post-treatment or even immediately, in cases of concern for incomplete response."
    },
    {
        "id": 3115,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 93,
        "content": "US of the neck for targeted sampling of any suspicious tissues may also be helpful."
    },
    {
        "id": 3116,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 93,
        "content": "FDG-PET/CT should be performed within 3\u20136 months of definitive radiation or systemic therapy/RT for assessment of treatment response and to identify any residual tumor."
    },
    {
        "id": 3117,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 93,
        "content": "Early FDG-PET/CT scans before 12 weeks are associated with significant false-positive rates and should be avoided in the absence of signs of recurrence or progression."
    },
    {
        "id": 3118,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 93,
        "content": "The optimal timing of PET scans after radiation treatment appears to be at the 3- to 6-month window."
    },
    {
        "id": 3119,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 93,
        "content": "A negative PET at this time point predicts improved overall survival at 2 years."
    },
    {
        "id": 3120,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 93,
        "content": "FDG-PET/CT surveillance approach led to fewer neck dissections and considerable cost savings compared to a routine approach of planned post-treatment neck dissection in patients receiving definitive RT-based treatment of mucosal squamous cell carcinoma with AJCC 7th edition N2\u2013N3 nodal disease."
    },
    {
        "id": 3131,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "The majority of recurrences after treatment of head and neck cancer occur in the first 2 years."
    },
    {
        "id": 3132,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "Surveillance can be challenging because of altered anatomy and/or fibrosis from surgery, radiation, and/or chemotherapy."
    },
    {
        "id": 3135,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "US, CT, MRI, and PET/CT all have unique advantages and disadvantages when used as surveillance imaging."
    },
    {
        "id": 3136,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "FDG-PET/CT may be the most sensitive of these modalities for surveillance imaging."
    },
    {
        "id": 3137,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "A 12-month PET has been shown to reveal recurrent or second primary cancers in approximately 10% of treated patients."
    },
    {
        "id": 3138,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "A 24-month FDG-PET/CT imaging revealed these findings in approximately 5% of treated cases."
    },
    {
        "id": 3139,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "Most cases of asymptomatic FDG-PET/CT lesion localization occur at distant sites."
    },
    {
        "id": 3145,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "A tailored approach to surveillance with attention to tumor type, stage, prognostic factors, symptomatology, and physical exam changes or restrictions is appropriate."
    },
    {
        "id": 3146,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "US of the neck is a well-established tool for nodal surveillance."
    },
    {
        "id": 3147,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "US is generally widely available, safe, fast, inexpensive, and an accurate modality for examination of the neck for any suspicious nodal disease."
    },
    {
        "id": 3148,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "Additional post-treatment imaging is indicated for worrisome or equivocal signs/symptoms."
    },
    {
        "id": 3149,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 94,
        "content": "Routine annual imaging may be indicated to visualize areas inaccessible to routine clinical examination."
    },
    {
        "id": 3160,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "All patients should be evaluated by a head and neck surgical oncologist prior to treatment."
    },
    {
        "id": 3161,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "The evaluation should review the adequacy of biopsy material, review staging and imaging to determine the extent of disease, exclude the presence of a synchronous primary tumor, assess current functional status, and evaluate for potential surgical options."
    },
    {
        "id": 3162,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "Pre-treatment evaluation should include consultations with a medical oncologist, radiation oncologist, dentist or oral maxillofacial surgeon, speech-language pathologist, dietitian, and reconstructive surgeon as appropriate."
    },
    {
        "id": 3163,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "Tumor staging for untreated patients is essential based on review of the head and neck diagnostic imaging studies and chest imaging as appropriate."
    },
    {
        "id": 3164,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "An office-based head and neck examination to include fiberoptic nasopharyngolaryngoscopy is indicated."
    },
    {
        "id": 3165,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "EUA is indicated to assess the tumor extent and to obtain a biopsy."
    },
    {
        "id": 3166,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "In the setting of metastatic carcinoma to the neck, an EUA is important to search for the putative primary site for diagnosis and treatment planning."
    },
    {
        "id": 3167,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "Participation in multidisciplinary team discussions regarding patient treatment options is important to maximize survival with preservation of form and function."
    },
    {
        "id": 3168,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "A prospective surveillance plan that includes adequate dental, nutritional, and health behavioral evaluation and intervention and any other ancillary evaluations is necessary for comprehensive rehabilitation."
    },
    {
        "id": 3169,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "Multidisciplinary evaluation and treatment should be coordinated and integrated prospectively by all disciplines involved in patient care before the initiation of any treatment."
    },
    {
        "id": 3170,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "For patients undergoing an operation, the surgical procedure, margins, and reconstructive plan should be developed and designed to resect all gross tumors with adequate tumor-free surgical margins."
    },
    {
        "id": 3171,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "The surgical procedure should rarely be modified based on any response observed as a result of prior therapy except in instances of tumor progression that mandate a more extensive procedure in order to encompass the tumor at the time of definitive resection."
    },
    {
        "id": 3172,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "Once the multidisciplinary team has established a proposed treatment regimen, the responsible physician and a member of the team should discuss the recommendations in detail with the patient to include the risks, benefits, and potential outcomes."
    },
    {
        "id": 3173,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 95,
        "content": "The patient should be offered the opportunity to participate in the final decision (shared decision-making)."
    },
    {
        "id": 3180,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Often, the patient\u2019s first presenting sign of oropharyngeal squamous cell carcinoma (OPSCC) is a neck mass."
    },
    {
        "id": 3181,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "The primary tumor is commonly small and asymptomatic and may not be detectable on inspection, palpation, fiberoptic examination, or imaging of the oropharynx."
    },
    {
        "id": 3182,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "It is incumbent upon the treating physician or surgeon to diligently search for and pathologically confirm the primary site."
    },
    {
        "id": 3183,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "The primary site is usually located in the base of tongue or tonsil."
    },
    {
        "id": 3184,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Information obtained from a thorough workup evaluation is vital to enable the multidisciplinary team to develop a comprehensive and focused treatment plan individualized to the patient."
    },
    {
        "id": 3185,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Identification of the primary site will either permit definitive transoral surgery to remove the primary disease or permit focused radiation, thus sparing adjacent sites in the oropharynx."
    },
    {
        "id": 3186,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "As therapy becomes more personalized, biomarker assessment of the primary tumor may be instrumental in determining a patient\u2019s eligibility for a clinical trial or adjuvant therapy."
    },
    {
        "id": 3187,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Cross-sectional imaging should be performed to facilitate identification of the primary site, followed by direct examination and confirmatory biopsies."
    },
    {
        "id": 3188,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "EUA and confirmatory biopsies for patients with suspected OPSCC should be performed before beginning therapy."
    },
    {
        "id": 3189,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "EUA may entail unilateral or bilateral biopsies of suspicious areas in the oropharynx."
    },
    {
        "id": 3190,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Palatine tonsillectomies may reveal a small primary tumor."
    },
    {
        "id": 3191,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Lingual tonsillectomy may be considered if biopsies and palatine tonsils are negative for tumor."
    },
    {
        "id": 3193,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "FNA biopsy of the neck mass, often performed under US guidance, will usually establish the diagnosis of metastatic carcinoma."
    },
    {
        "id": 3194,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "A definitive cytologic diagnosis of squamous cell carcinoma is highly accurate."
    },
    {
        "id": 3195,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Further assessment of immunostaining for p16 can support the diagnosis of HPV-associated OPSCC in the presence of an oropharyngeal primary tumor."
    },
    {
        "id": 3202,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Tumor involvement of the pterygoid muscles, particularly when associated with severe trismus or pterygopalatine fossa involvement with cranial neuropathy, is associated with poor prognosis or function or with T4b cancer."
    },
    {
        "id": 3203,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Gross extension of the tumor to the skull base is associated with poor prognosis or function or with T4b cancer."
    },
    {
        "id": 3205,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Invasion of the common or internal carotid artery is associated with poor prognosis or function or with T4b cancer."
    },
    {
        "id": 3206,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Direct extension of neck disease to involve the external skin is associated with poor prognosis or function or with T4b cancer."
    },
    {
        "id": 3207,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Direct extension to mediastinal structures, prevertebral fascia, or cervical vertebrae is associated with poor prognosis or function or with T4b cancer."
    },
    {
        "id": 3208,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 96,
        "content": "Presence of subdermal metastases is associated with poor prognosis or function or with T4b cancer."
    },
    {
        "id": 3217,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "The resection of advanced tumors of the oral cavity, oropharynx, hypopharynx, larynx, or paranasal sinus will vary in extent depending on the structures involved."
    },
    {
        "id": 3218,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "The primary tumor should be considered surgically curable by appropriate resection using accepted criteria for adequate excision, depending on the region involved."
    },
    {
        "id": 3219,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "En bloc resection of the primary tumor should be attempted whenever feasible."
    },
    {
        "id": 3220,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "In-continuity neck dissection is necessary when there is direct extension of the primary tumor into the neck."
    },
    {
        "id": 3221,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Resection should be planned based on the extent of the primary tumor as ascertained by clinical examination and careful interpretation of appropriate radiographic images."
    },
    {
        "id": 3222,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "For oral cavity cancers, as depth of invasion increases, the risk of regional metastases and the need for adjuvant elective neck dissection also increases."
    },
    {
        "id": 3223,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Perineural invasion should be suspected when tumors are adjacent to motor or sensory nerves."
    },
    {
        "id": 3224,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "The goal is total cancer resection."
    },
    {
        "id": 3225,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "When gross invasion is present and the nerve can be resected without significant morbidity, the nerve should be dissected both proximally and distally and should be resected to obtain clearance of disease."
    },
    {
        "id": 3226,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Frozen section determination of the proximal and distal nerve margins may prove helpful to facilitate tumor clearance."
    },
    {
        "id": 3227,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Partial or segmental resection of the mandible may be necessary to adequately encompass the cancer with adequate tumor-free margins."
    },
    {
        "id": 3228,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Adequate resection may require partial, horizontal, or sagittal resection of the mandible for tumors involving or adherent to mandibular periosteum."
    },
    {
        "id": 3229,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Segmental or marginal resection should be considered in tumors that grossly involve mandibular periosteum or show evidence of direct tumor involvement of the bone at the time of operation or through preoperative imaging."
    },
    {
        "id": 3230,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "A Panorex may be useful for assessing mandibular height when a marginal or coronal mandibulectomy is a consideration."
    },
    {
        "id": 3231,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "In the edentulous patient due to mandibular atrophy that occurs over time, a partial mandibulectomy may not be possible."
    },
    {
        "id": 3232,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "The extent of mandibular resection will depend on the degree of involvement accessed clinically and in the operating room."
    },
    {
        "id": 3233,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Medullary space invasion is an indication for segmental resection."
    },
    {
        "id": 3234,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Frozen section examination of available marrow may be considered to guide resection."
    },
    {
        "id": 3235,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "For tumors of the larynx, the decision to perform either total laryngectomy or conservation laryngeal surgery will be decided by the surgeon and the patient."
    },
    {
        "id": 3236,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "The decision to perform either total laryngectomy or conservation laryngeal surgery should adhere to the principles of complete tumor extirpation with curative intent and function preservation."
    },
    {
        "id": 3237,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Partial laryngeal surgery should be avoided if adjuvant RT is likely following surgery."
    },
    {
        "id": 3238,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "For T4 or N2\u20133 laryngeal cancers treated with surgery, consideration should be given to thyroidectomy for tumor clearance and clearance of central compartment pretracheal or paratracheal nodes."
    },
    {
        "id": 3239,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Transoral robotic surgery (TORS) or laser-assisted resections of primary cancers of the larynx and pharynx are increasingly used approaches for cancer resection in selected patients with accessible tumors."
    },
    {
        "id": 3240,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Oncologic principles are similar to open procedures."
    },
    {
        "id": 3241,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Successful application of these techniques requires specialized skills and experience."
    },
    {
        "id": 3242,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Postoperative hemorrhage can be a major and rarely life-threatening complication."
    },
    {
        "id": 3243,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "It is incumbent upon the TORS surgeon to use appropriate surgical strategies to diminish the risk of postoperative hemorrhage."
    },
    {
        "id": 3244,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "In oropharyngeal cancer cases, treatment selection should favor usage of fewest modalities necessary in order to minimize treatment-related toxicity and preserve function."
    },
    {
        "id": 3245,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Avoid triple modality treatment when possible."
    },
    {
        "id": 3246,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 97,
        "content": "Patients with fixed nodes are not appropriate candidates for upfront definitive surgery."
    },
    {
        "id": 3253,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "An overarching goal of oncologic surgery is complete tumor resection with histologic verification of tumor-free margins."
    },
    {
        "id": 3254,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Margin assessment may be done in real time by frozen section or by assessment of formalin-fixed tissues."
    },
    {
        "id": 3255,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Tumor-free margins are an essential surgical strategy for diminishing the risk for local tumor recurrence."
    },
    {
        "id": 3256,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Positive margins increase the risk for local relapse and are an indication for postoperative adjuvant therapy."
    },
    {
        "id": 3257,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Clinical pathologic studies have demonstrated the significance of close or positive margins and their relationship with local tumor recurrence."
    },
    {
        "id": 3258,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "When there is an initial cut-through with an invasive tumor at the surgical margin, obtaining additional adjacent margins from the patient may also be associated with a higher risk for local relapse."
    },
    {
        "id": 3259,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Obtaining additional margins from the patient is subject to ambiguity regarding whether the tissue taken from the surgical bed corresponds to the actual site of margin positivity."
    },
    {
        "id": 3260,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "If positive surgical margins are reported, re-resection and/or adjuvant therapy should be considered in selected patients."
    },
    {
        "id": 3261,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Frozen section margin assessment is always at the discretion of the surgeon and should be considered when it will facilitate complete tumor removal."
    },
    {
        "id": 3262,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "The achievement of adequate wide margins may require resection of an adjacent structure in the oral cavity or laryngopharynx."
    },
    {
        "id": 3263,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Adequate resection is defined as clear resection margins with at least enough clearance from the gross tumor to obtain clear frozen section and permanent margins."
    },
    {
        "id": 3264,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "For glottic cancers, a 1- to 2-mm margin is considered adequate."
    },
    {
        "id": 3265,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "In transoral endoscopic and robotic approaches for oropharynx cancers, margins of 1.5\u20132.0 mm may be acceptable."
    },
    {
        "id": 3266,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "The details of resection margins should be included in the operative dictation."
    },
    {
        "id": 3267,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "The margins may be assessed on the resected specimen or alternatively from the surgical bed with proper orientation."
    },
    {
        "id": 3268,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Adequacy of the margins may vary by site."
    },
    {
        "id": 3269,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "For a glottic cancer 1- to 2-mm margins are sufficient but inadequate for an invasive carcinoma of the oral tongue."
    },
    {
        "id": 3270,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "There is no universal definition for what constitutes a clear/close margin."
    },
    {
        "id": 3271,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Distance in mm to achieve clinically acceptable margins is influenced by tumor primary site, histology, and HPV status in oropharyngeal cancer and following neoadjuvant therapy."
    },
    {
        "id": 3272,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "The previous universally followed definition of adequate margin (5 mm in final histopathology) has been disputed."
    },
    {
        "id": 3273,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "A positive margin is defined as carcinoma in situ or as invasive carcinoma at the margin of resection."
    },
    {
        "id": 3274,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "If carcinoma in situ is present and if additional margins can be obtained that is the favored approach."
    },
    {
        "id": 3275,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Carcinoma in situ should not be considered an indication for concurrent postoperative systemic therapy/RT."
    },
    {
        "id": 3276,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "The primary tumor should be marked in a fashion adequate for orientation by the surgical pathologist."
    },
    {
        "id": 3277,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "The primary tumor should be assessed histologically for depth of invasion and for distance from the invasive portion of the tumor to the margin of resection."
    },
    {
        "id": 3278,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "The pathology report should be template-driven and describe how the margins were assessed."
    },
    {
        "id": 3279,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "The report should provide information regarding the primary specimen to include the distance from the invasive portion of the tumor to the peripheral and deep margin."
    },
    {
        "id": 3280,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "If the surgeon obtains additional margins from the patient, the new margins should refer back to the geometric orientation of the resected tumor specimen with a statement by the pathologist that this is the final margin of resection and its histologic status."
    },
    {
        "id": 3281,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "The neck dissection should be oriented or sectioned in order to identify levels of lymph nodes encompassed in the dissection."
    },
    {
        "id": 3282,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Reconstruction of surgical defects should be performed using conventional techniques at the discretion of the surgeon."
    },
    {
        "id": 3283,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Primary closure is recommended when appropriate but should not be pursued at the expense of obtaining wide, tumor-free margins."
    },
    {
        "id": 3284,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "Reconstructive closure with locoregional flaps, free-tissue transfer, or split-thickness skin or other grafts with or without mandibular reconstruction is performed at the discretion of the surgeon."
    },
    {
        "id": 3285,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 98,
        "content": "A two-team approach is advisable to improve efficiency and address both oncologic and reconstructive goals."
    },
    {
        "id": 3291,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 99,
        "content": "The surgical management of cranial nerves VII, X, XI, and XII is influenced by the preoperative clinical function of the nerve."
    },
    {
        "id": 3292,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 99,
        "content": "When the nerve is functioning, thorough efforts should be made to preserve the structure and function of the nerve."
    },
    {
        "id": 3293,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 99,
        "content": "The surgeon should leave no gross residual disease when preserving the nerve."
    },
    {
        "id": 3294,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 99,
        "content": "Adjuvant postoperative radiation or systemic therapy/RT is generally prescribed when a microscopic residual or gross residual tumor is suspected."
    },
    {
        "id": 3295,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 99,
        "content": "Direct nerve invasion by a tumor and/or preoperative paralysis of the nerve may warrant segmental resection at the discretion of the surgeon."
    },
    {
        "id": 3296,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 99,
        "content": "Tumor-free margins should be ensured throughout the remainder of the procedure during segmental resection."
    },
    {
        "id": 3297,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 99,
        "content": "Nerve grafting may be performed at the discretion of the surgeon during segmental resection."
    },
    {
        "id": 3304,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "The surgical management of regional lymphatics is dictated by the extent of the tumor at initial tumor staging."
    },
    {
        "id": 3305,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "Patients undergoing surgery for resection of the primary tumor will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases."
    },
    {
        "id": 3306,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "Tumor sites that frequently have bilateral lymphatic drainage often should have both sides of the neck dissected."
    },
    {
        "id": 3307,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "For patients with tumors at or approaching the midline, both sides of the neck are at risk for metastases, and bilateral neck dissections should be performed."
    },
    {
        "id": 3308,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline should undergo contralateral selective/modified neck dissection as necessary to achieve adequate tumor resection."
    },
    {
        "id": 3309,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "Elective neck dissection should be based on risk of occult metastasis in the appropriate nodal basin."
    },
    {
        "id": 3310,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "For oral cavity squamous cell carcinoma, SLN biopsy or the primary tumor depth of invasion is currently the best predictor of occult metastatic disease and should be used to guide decision-making."
    },
    {
        "id": 3311,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "For tumors with a depth greater than 3 mm, elective dissection should be strongly considered if RT is not already planned."
    },
    {
        "id": 3312,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion."
    },
    {
        "id": 3313,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "For a depth less than 2 mm, elective dissection is only indicated in highly selective situations."
    },
    {
        "id": 3314,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "For a depth of 2\u20134 mm, clinical judgment must be utilized to determine appropriateness of elective dissection."
    },
    {
        "id": 3315,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise."
    },
    {
        "id": 3316,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "The type of neck dissection is defined according to preoperative clinical staging and is determined at the discretion of the surgeon."
    },
    {
        "id": 3317,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "The type of neck dissection is based on the initial preoperative staging."
    },
    {
        "id": 3318,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "For N0, selective neck dissection is performed."
    },
    {
        "id": 3319,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "For N1\u2013N2a\u2013c, selective or comprehensive neck dissection is performed."
    },
    {
        "id": 3320,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "For N3, comprehensive neck dissection is performed."
    },
    {
        "id": 3321,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "Level VI neck dissections are performed for certain primary sites as required to resect the primary tumor and any clinically evident neck nodes."
    },
    {
        "id": 3322,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "Elective dissection depends on primary tumor extent and site."
    },
    {
        "id": 3323,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "For advanced glottic and hypopharyngeal cancers treated with primary surgery, a level VI dissection and hemithyroidectomy to total thyroidectomy are appropriate."
    },
    {
        "id": 3324,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "For primary subglottic tumors or glottic cancers with significant subglottic extension, a level VI dissection with unilateral or total thyroidectomy is considered appropriate based on the extent of the primary tumor."
    },
    {
        "id": 3325,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 100,
        "content": "Parathyroid glands should be preserved in situ or auto transplanted as indicated."
    },
    {
        "id": 3332,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Sentinel Lymph Node Biopsy (SLN biopsy) is an alternative to elective neck dissection for identifying occult cervical metastasis in patients with early oral cavity carcinoma."
    },
    {
        "id": 3333,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "SLN biopsy requires technical experience and judgment for successful execution of lymphatic mapping and SLN."
    },
    {
        "id": 3334,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "SLN biopsy has advantages including reduced morbidity and an improved cosmetic outcome."
    },
    {
        "id": 3335,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Rates of detection of sentinel nodes in excess of 95% have been widely reported."
    },
    {
        "id": 3336,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Patients with metastatic disease in their sentinel nodes must undergo a completion neck dissection."
    },
    {
        "id": 3337,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Patients without metastatic disease in their sentinel nodes may be observed."
    },
    {
        "id": 3338,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Accuracy of sentinel node biopsy for nodal staging of early oral carcinoma has been tested extensively in multiple single-center studies and two multi-institutional trials."
    },
    {
        "id": 3339,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "The pooled estimate of sensitivity of sentinel node biopsy is 0.93."
    },
    {
        "id": 3340,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "The negative predictive values of sentinel node biopsy range from 0.88 to 1.6."
    },
    {
        "id": 3341,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Available evidence points towards comparable survival outcomes between sentinel node biopsy and elective neck dissection."
    },
    {
        "id": 3342,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Sentinel node biopsy is a technically demanding procedure."
    },
    {
        "id": 3343,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Procedural success rates for sentinel node identification depend on technical expertise and experience."
    },
    {
        "id": 3344,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Accuracy of detecting occult lymphatic metastasis depends on technical expertise and experience."
    },
    {
        "id": 3345,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Sufficient caution must be exercised when offering sentinel node biopsy as an alternative to elective neck dissection."
    },
    {
        "id": 3346,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Accuracy of sentinel node biopsy has been found to be lower for floor-of-mouth cancer than for other locations such as the tongue."
    },
    {
        "id": 3347,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Cancers of certain locations such as upper gingiva and hard palate may not lend themselves well technically to sentinel node biopsy."
    },
    {
        "id": 3348,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Occult cervical metastases are uncommon in early lip cancer."
    },
    {
        "id": 3349,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "SLN biopsy has been shown to be feasible and effective in patients with lip cancers deemed to be at high risk of metastases generally based on tumor size or depth."
    },
    {
        "id": 3350,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Resectable primary cancers should be re-resected with curative intent if feasible."
    },
    {
        "id": 3351,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Recurrences in a previously treated neck should undergo surgery as well."
    },
    {
        "id": 3352,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Neck disease in an untreated neck should be addressed by formal neck dissection or modification depending on the clinical situation."
    },
    {
        "id": 3353,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Non-surgical therapy may also be utilized as clinically appropriate."
    },
    {
        "id": 3354,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "All patients should have regular follow-up visits to assess for symptoms and possible tumor recurrence, health behaviors, nutrition, dental health, and speech and swallowing function."
    },
    {
        "id": 3355,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "Tumor evaluations must be performed by specialists skilled in head and neck clinical examination."
    },
    {
        "id": 3356,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 101,
        "content": "The frequency of evaluation is summarized elsewhere in the NCCN Guidelines for Head and Neck Cancers."
    },
    {
        "id": 3386,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "All patients should be evaluated by a radiation oncologist prior to treatment."
    },
    {
        "id": 3387,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "The evaluation should review staging and imaging to determine the extent of disease."
    },
    {
        "id": 3388,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "The evaluation should exclude the presence of a synchronous primary tumor."
    },
    {
        "id": 3389,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "The evaluation should assess functional status."
    },
    {
        "id": 3390,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "The evaluation should evaluate for potential RT options."
    },
    {
        "id": 3391,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "Radiation oncologists should participate in multidisciplinary team discussions regarding patient treatment options."
    },
    {
        "id": 3392,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "The goal of the discussions is to maximize survival with preservation of form and function."
    },
    {
        "id": 3393,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "A prospective surveillance plan should be developed for patients."
    },
    {
        "id": 3394,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "The plan should include adequate dental, swallowing, nutritional, and health behavior evaluation and intervention."
    },
    {
        "id": 3395,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "The plan may include other ancillary evaluations that would provide for comprehensive rehabilitation."
    },
    {
        "id": 3396,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "Target delineation and optimal dose distribution require experience in head and neck imaging."
    },
    {
        "id": 3397,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "Target delineation and optimal dose distribution require a thorough understanding of patterns of disease spread."
    },
    {
        "id": 3398,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "Standards for target definition, dose specification, fractionation, and normal tissue constraints are still evolving."
    },
    {
        "id": 3399,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "Published contouring guidelines are referenced for patients who have not been operated upon."
    },
    {
        "id": 3400,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "IMRT or other conformal techniques may be used as appropriate depending on the stage, tumor location, physician training, and available physics support."
    },
    {
        "id": 3403,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "FDG-PET/CT or MRI with contrast can be used for fusion in treatment planning."
    },
    {
        "id": 3404,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "Advanced RT technologies such as IMRT, tomotherapy, VMAT, IGRT, and PBT may offer clinically relevant advantages in specific instances."
    },
    {
        "id": 3405,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "These technologies can spare important organs at risk, such as the brain, brain stem, cochlea, and others."
    },
    {
        "id": 3406,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "These technologies can decrease the risk for late, normal tissue damage while still achieving the primary goal of local tumor control."
    },
    {
        "id": 3407,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "The demonstration of clinically significant dose-sparing of these organs at risk reflects best clinical practice."
    },
    {
        "id": 3408,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "Target definition and delineation and treatment delivery verification require careful monitoring to avoid the risk of tumor geographic miss."
    },
    {
        "id": 3409,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "Initial diagnostic imaging with contrast-enhanced CT, MRI, FDG-PET/CT, and other imaging modalities facilitate target definition."
    },
    {
        "id": 3410,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "Image guidance is required to provide assurance of accurate daily delivery."
    },
    {
        "id": 3411,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 103,
        "content": "Anatomical changes may necessitate repeat diagnostic imaging and replanning."
    },
    {
        "id": 3420,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "IMRT is preferred in reducing long-term toxicity in oropharyngeal, nasal cavity, paranasal sinus, salivary gland, and nasopharyngeal cancers."
    },
    {
        "id": 3421,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "IMRT reduces the dose to salivary glands, temporal lobes, auditory structures, and optic structures."
    },
    {
        "id": 3422,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "IMRT is preferred for thyroid cancers because of its ability to spare the larynx, brachial plexus, and esophagus."
    },
    {
        "id": 3423,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "Helical tomotherapy and VMAT are advanced forms of IMRT."
    },
    {
        "id": 3425,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "PBT is especially important for patients whose primary tumors are periocular in location and/or invade the orbit, skull base, and/or cavernous sinus."
    },
    {
        "id": 3426,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "PBT is especially important for patients who are being treated with curative intent and/or who have long life expectancies following treatment."
    },
    {
        "id": 3427,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "Proton therapy can be considered when normal tissue constraints cannot be met by photon-based therapy."
    },
    {
        "id": 3428,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "Proton therapy can be considered when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes."
    },
    {
        "id": 3429,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "A number of ways exist to integrate IMRT or PBT, target volume dosing, and fractionation."
    },
    {
        "id": 3430,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "The SIB technique uses differential \u201cdose painting\u201d for each fraction of treatment throughout the entire course of radiation."
    },
    {
        "id": 3431,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "The SIB technique is commonly used in the conventional and the \u201c6 fractions/wk accelerated\u201d schedule."
    },
    {
        "id": 3432,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "The sequential technique typically delivers the initial phase followed by the high-dose boost volume phase using 2\u20133 separate dose plans."
    },
    {
        "id": 3433,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 104,
        "content": "The sequential technique is commonly applied in standard fractionation and hyperfractionation."
    },
    {
        "id": 3445,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 105,
        "content": "Palliative radiation should be considered in the advanced cancer setting when curative-intent treatment is not appropriate."
    },
    {
        "id": 3446,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 105,
        "content": "There is no general consensus for appropriate palliative RT regimens in head and neck cancer."
    },
    {
        "id": 3447,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 105,
        "content": "Palliative RT should be considered for relief or prevention of locoregional symptoms if the RT toxicities are acceptable."
    },
    {
        "id": 3448,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 105,
        "content": "RT regimens should be tailored individually."
    },
    {
        "id": 3449,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 105,
        "content": "Severe RT toxicities should be avoided when treatment is for palliation."
    },
    {
        "id": 3450,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 105,
        "content": "One recommended RT regimen is 50 Gy in 20 fractions."
    },
    {
        "id": 3451,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 105,
        "content": "Another recommended RT regimen is 37.5 Gy in 15 fractions."
    },
    {
        "id": 3452,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 105,
        "content": "Yet another recommended RT regimen is 30 Gy in 10 fractions."
    },
    {
        "id": 3453,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 105,
        "content": "Another recommended RT regimen is 30 Gy in 5 fractions with 2 fractions/week with \u22653 days between the 2 treatments."
    },
    {
        "id": 3454,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 105,
        "content": "Another recommended RT regimen is 44.4 Gy in 12 fractions, in 3 cycles."
    },
    {
        "id": 3469,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 106,
        "content": "Reirradiation with 3D-CRT, SBRT, PBT, or IMRT may be considered for patients with head and neck cancers."
    },
    {
        "id": 3470,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 106,
        "content": "The area in consideration for reirradiation should not overlap with the previously radiated volume, or the prior radiotherapy should have been more than 6 months from the appearance of new disease."
    },
    {
        "id": 3471,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 106,
        "content": "In certain rare circumstances, reirradiation with intraoperative RT (IORT) or brachytherapy may be considered in high-volume centers with expertise in these techniques."
    },
    {
        "id": 3528,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 107,
        "content": "There are dose constraints for the Larynx."
    },
    {
        "id": 3529,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 107,
        "content": "The mean dose for the Larynx is less than 35 Gy."
    },
    {
        "id": 3526,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 107,
        "content": "There are dose constraints for the Glottis."
    },
    {
        "id": 3527,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 107,
        "content": "The mean dose for the Glottis is less than 45 Gy."
    },
    {
        "id": 3643,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "The categories of evidence and consensus for induction therapy vary depending on the site of the cancer."
    },
    {
        "id": 3644,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Adverse pathologic features include extranodal extension and/or positive margins or close margins."
    },
    {
        "id": 3645,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Cisplatin is a preferred regimen for postoperative systemic therapy and radiotherapy."
    },
    {
        "id": 3646,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Cisplatin is category 1 for high-risk non-oropharyngeal cancers."
    },
    {
        "id": 3647,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Docetaxel is a useful regimen in certain circumstances, especially if cisplatin is ineligible."
    },
    {
        "id": 3661,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Docetaxel is a useful regimen in certain circumstances, especially if cisplatin is ineligible."
    },
    {
        "id": 3648,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Docetaxel/cetuximab is a useful regimen in certain circumstances, especially if cisplatin is ineligible and there is extranodal extension and/or positive margins."
    },
    {
        "id": 3649,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Weekly carboplatin plus concurrent radiotherapy is a preferred regimen for systemic therapy and radiotherapy following induction therapy or for recurrent/persistent disease."
    },
    {
        "id": 3650,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Weekly cisplatin plus concurrent radiotherapy is a preferred regimen for systemic therapy and radiotherapy following induction therapy or for recurrent/persistent disease."
    },
    {
        "id": 3651,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Weekly cetuximab plus concurrent radiotherapy is a useful regimen in certain circumstances."
    },
    {
        "id": 3652,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Docetaxel/cisplatin/5-FU is a preferred regimen for induction/sequential systemic therapy."
    },
    {
        "id": 3653,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Paclitaxel/cisplatin/infusional 5-FU is an other recommended regimen for induction/sequential systemic therapy."
    },
    {
        "id": 3654,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Carboplatin/paclitaxel/cetuximab is a useful regimen in certain circumstances."
    },
    {
        "id": 3655,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Etoposide/cisplatin is a useful regimen for newly diagnosed T3, T4a ethmoid sinus tumor."
    },
    {
        "id": 3656,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Docetaxel/cisplatin/fluorouracil is a useful regimen for newly diagnosed T3, T4a ethmoid sinus tumor."
    },
    {
        "id": 3657,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "High-dose cisplatin is a preferred regimen for primary systemic therapy plus concurrent radiotherapy."
    },
    {
        "id": 3658,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Carboplatin/infusional 5-FU is a preferred regimen for primary systemic therapy plus concurrent radiotherapy."
    },
    {
        "id": 3659,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Weekly cisplatin is an other recommended regimen for primary systemic therapy plus concurrent radiotherapy."
    },
    {
        "id": 3660,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Carboplatin/paclitaxel is a useful regimen in certain circumstances."
    },
    {
        "id": 3662,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "5-FU/hydroxyurea is a useful regimen in certain circumstances."
    },
    {
        "id": 3663,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Cetuximab is a useful regimen in certain circumstances."
    },
    {
        "id": 3664,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Cisplatin/infusional 5-FU is a useful regimen in certain circumstances."
    },
    {
        "id": 3665,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Cisplatin/paclitaxel is a useful regimen in certain circumstances."
    },
    {
        "id": 3666,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Carboplatin/etoposide plus concurrent radiotherapy is a useful regimen for select ethmoid/maxillary sinus cancers."
    },
    {
        "id": 3667,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Cisplatin/etoposide plus concurrent radiotherapy is a useful regimen for select ethmoid/maxillary sinus cancers."
    },
    {
        "id": 3668,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Cyclophosphamide/doxorubicin/vincristine followed by radiotherapy-based treatment is a useful regimen for select ethmoid/maxillary sinus cancers."
    },
    {
        "id": 3669,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "The choice of systemic therapy should be individualized based on patient characteristics."
    },
    {
        "id": 3670,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Next-generation sequencing genomic profiling, including testing for combined positive score, may be considered to guide patient treatment options."
    },
    {
        "id": 3671,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "The preferred chemoradiotherapy approach for fit patients with locally advanced disease remains concurrent cisplatin and radiotherapy."
    },
    {
        "id": 3672,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Cisplatin-based induction chemotherapy can be used, followed by radiation-based locoregional treatment."
    },
    {
        "id": 3673,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "Cisplatin-based induction chemotherapy followed by high-dose, every-3-week cisplatin chemoradiotherapy is associated with toxicity concerns."
    },
    {
        "id": 3674,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 110,
        "content": "After induction chemotherapy, multiple options can be used for the radiation-based portion of therapy."
    },
    {
        "id": 3684,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Pembrolizumab/platinum (cisplatin or carboplatin)/5-FU is a preferred regimen for first-line therapy."
    },
    {
        "id": 3685,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Pembrolizumab is a preferred regimen for first-line therapy for tumors that express PD-L1 with CPS \u22651."
    },
    {
        "id": 3686,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Nivolumab is a recommended regimen for subsequent-line therapy if disease progression occurs on or after platinum therapy."
    },
    {
        "id": 3687,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Pembrolizumab is a recommended regimen for subsequent-line therapy if disease progression occurs on or after platinum therapy."
    },
    {
        "id": 3688,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Cetuximab/platinum (cisplatin or carboplatin)/5-FU is a combination regimen."
    },
    {
        "id": 3689,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Cisplatin/cetuximab is a combination regimen."
    },
    {
        "id": 3690,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Cisplatin or carboplatin/docetaxel is a combination regimen."
    },
    {
        "id": 3691,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Cisplatin/5-FU is a combination regimen."
    },
    {
        "id": 3692,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Cisplatin or carboplatin/docetaxel/cetuximab is a combination regimen."
    },
    {
        "id": 3693,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Cisplatin or carboplatin/paclitaxel/cetuximab is a combination regimen."
    },
    {
        "id": 3694,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Pembrolizumab/platinum (cisplatin or carboplatin)/docetaxel is a combination regimen."
    },
    {
        "id": 3695,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Pembrolizumab/platinum (cisplatin or carboplatin)/paclitaxel is a combination regimen."
    },
    {
        "id": 3696,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Cisplatin is a single agent."
    },
    {
        "id": 3697,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Carboplatin is a single agent."
    },
    {
        "id": 3698,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Paclitaxel is a single agent."
    },
    {
        "id": 3699,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Docetaxel is a single agent."
    },
    {
        "id": 3700,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "5-FU is a single agent."
    },
    {
        "id": 3705,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Cetuximab/nivolumab is a regimen for squamous cell carcinoma."
    },
    {
        "id": 3706,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Cetuximab/pembrolizumab is a regimen for squamous cell carcinoma."
    },
    {
        "id": 3707,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Cisplatin/etoposide or carboplatin/etoposide is a regimen for select ethmoid/maxillary sinus cancers."
    },
    {
        "id": 3709,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Paclitaxel/cetuximab is a regimen."
    },
    {
        "id": 3710,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Docetaxel/cetuximab is a regimen."
    },
    {
        "id": 3711,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Pembrolizumab is a regimen for MSI-H, dMMR, or TMB-H tumors."
    },
    {
        "id": 3712,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Cisplatin/pemetrexed is a regimen for PS 0\u20131."
    },
    {
        "id": 3713,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Gemcitabine/paclitaxel is a regimen."
    },
    {
        "id": 3714,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "Nivolumab/ipilimumab is a regimen for CPS \u226520 and first-line therapy only."
    },
    {
        "id": 3715,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 111,
        "content": "The choice of systemic therapy should be individualized based on patient characteristics."
    },
    {
        "id": 3723,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Adelstein DJ, Moon J, Hanna E, et al. conducted a Southwest Oncology Group phase II trial (S0216) on docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer."
    },
    {
        "id": 3724,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Lefebvre JL, Pointreau Y, Rolland F, et al. conducted the TREMPLIN randomized phase II study on induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation."
    },
    {
        "id": 3725,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Adelstein DJ, Li Y, Adams GL, et al. conducted an intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer."
    },
    {
        "id": 3726,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Forastiere AA, Zhang Q, Weber RS, et al. conducted a study on long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer."
    },
    {
        "id": 3727,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Bourhis J, Sire C, Graff P, et al. conducted a GORTEC 99-02 randomized phase 3 trial on concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma."
    },
    {
        "id": 3728,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Denis F, Garaud P, Bardet E, et al. conducted a French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma."
    },
    {
        "id": 3729,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Beckmann GK, Hoppe F, Pfreundner L, Flentje MP conducted a study on hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer."
    },
    {
        "id": 3730,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Medina JA, Rueda A, de Pasos AS, et al. conducted a phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas."
    },
    {
        "id": 3731,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Suntharalingam M, Haas ML, Conley BA, et al. conducted a study on the use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck."
    },
    {
        "id": 3732,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Patil VM, Noronha V, Menon N, et al. conducted a phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation."
    },
    {
        "id": 3733,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Garden AS, Harris J, Vokes EE, et al. conducted a Radiation Therapy Oncology Group 97-03 randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck."
    },
    {
        "id": 3734,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Bonner JA, Harari PM, Giralt J, et al. conducted a phase 3 randomized trial of radiotherapy plus cetuximab for locoregionally advanced head and neck cancer."
    },
    {
        "id": 3735,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Taylor SG, Murthy AK, Vannetzel JM, et al. conducted a randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer."
    },
    {
        "id": 3736,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Patil VM, Joshi A, Noronha V, et al. conducted a study on neoadjuvant chemotherapy in locally advanced and borderline resectable nonsquamous sinonasal tumors (esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation)."
    },
    {
        "id": 3737,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Resto VA, Eisele DW, Forastiere A, et al. conducted a study on esthesioneuroblastoma at Johns Hopkins."
    },
    {
        "id": 3738,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Rastogi M, Bhatt M, Chufal K, et al. conducted a study on esthesioneuroblastoma treated with non-craniofacial resection surgery followed by combined chemotherapy and radiotherapy."
    },
    {
        "id": 3739,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Janoray G, Pointreau Y, Garaud P, et al. conducted a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, +/- docetaxel for larynx preservation."
    },
    {
        "id": 3740,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Pointreau Y, Garaud P, Chapet S, et al. conducted a randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation."
    },
    {
        "id": 3741,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Posner MR, Hershock DM, Blajman CR, et al. conducted a study on cisplatin and fluorouracil alone or with docetaxel in head and neck cancer."
    },
    {
        "id": 3742,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Vermorken JB, Remenar E, van Herpen C, et al. conducted a study on cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer."
    },
    {
        "id": 3743,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. conducted a phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer."
    },
    {
        "id": 3744,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Kies MS, Holsinger FC, Lee JJ, et al. conducted a phase II prospective trial of induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3745,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. conducted a randomized, non-inferiority, open trial of systemic therapy/RT comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer."
    },
    {
        "id": 3746,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Haddad R, O'Neill A, Rabinowits G, et al. conducted a randomized phase 3 trial of induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer."
    },
    {
        "id": 3747,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. conducted a study on combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma."
    },
    {
        "id": 3748,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Bernier J, Cooper JS, Pajak TF, et al. conducted a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)."
    },
    {
        "id": 3749,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Bernier J, Domenge C, Ozsahin M, et al. conducted a study on postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer."
    },
    {
        "id": 3750,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Cooper JS, Pajak TF, Forastiere AA, et al. conducted a study on postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck."
    },
    {
        "id": 3751,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Cooper JS, Zhang Q, Pajak TF, et al. conducted a study on long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3752,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Noronha V, Joshi A, Patil VM, et al. conducted a phase III randomized noninferiority trial of once-a-week versus once-every-3-weeks cisplatin systemic therapy/RT for locally advanced head and neck cancer."
    },
    {
        "id": 3753,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 112,
        "content": "Harari PM, Harris J, Kies MS, et al. conducted a study on postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3760,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Burtness B, Harrington KJ, Greil R, et al. published a study on pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3762,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Ferris RL, Blumenschein G, Jr., Fayette J, et al. published a study on nivolumab for recurrent squamous-cell carcinoma of the head and neck."
    },
    {
        "id": 3763,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Chow LQ, Haddad R, Gupta S, et al. published a study on antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma."
    },
    {
        "id": 3764,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Cohen EEW, Soulieres D, Le Tourneau C, et al. published a study on pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma."
    },
    {
        "id": 3765,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Seiwert TY, Burtness B, Mehra R, et al. published a study on safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3766,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Vermorken JB, Mesia R, Rivera F, et al. published a study on platinum-based chemotherapy plus cetuximab in head and neck cancer."
    },
    {
        "id": 3767,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Burtness B, Goldwasser MA, Flood W, et al. published a study on phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer."
    },
    {
        "id": 3768,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Samlowski WE, Moon J, Kuebler JP, et al. published a study on evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3769,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Gibson MK, Li Y, Murphy B, et al. published a study on randomised phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer."
    },
    {
        "id": 3770,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Forastiere AA, Metch B, Schuller DE, et al. published a study on randomised comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck."
    },
    {
        "id": 3771,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Guigay J, Fayette J, Dillies A-F, et al. published a study on cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3772,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Herbst RS, Arquette M, Shin DM, et al. published a study on phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3773,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Dzienis M, Cundom J, Fuentes CS, et al. published a study on pembrolizumab + carboplatin + paclitaxel as first-line therapy in recurrent/metastatic head and neck squamous cell carcinoma."
    },
    {
        "id": 3774,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Jacobs C, Lyman G, Velez-Garcia E, et al. published a study on a phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3775,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Al-Sarraf M, Metch B, Kish J, et al. published a study on platinum analogs in recurrent and advanced head and neck cancer."
    },
    {
        "id": 3776,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Grau JJ, Caballero M, Verger E, et al. published a study on weekly paclitaxel for platin-resistant stage IV head and neck cancer patients."
    },
    {
        "id": 3777,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Catimel G, Verweij J, Mattijssen V, et al. published a study on docetaxel for the treatment of patients with advanced squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3778,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Guardiola E, Peyrade F, Chaigneau L, et al. published a study on results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer."
    },
    {
        "id": 3779,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Stewart JS, Cohen EE, Licitra L, et al. published a study on phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3780,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Vermorken JB, Trigo J, Hitt R, et al. published a study on open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3781,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Fury MG, Sherman E, Lisa D, et al. published a study on a randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer."
    },
    {
        "id": 3782,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Martinez-Trufero J, Isla D, Adansa JC, et al. published a study on phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment."
    },
    {
        "id": 3783,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Machiels JP, Haddad RI, Fayette J, et al. published a study on afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy."
    },
    {
        "id": 3784,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Chung CH, Li J, Steuer CE, et al. published a study on phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma."
    },
    {
        "id": 3785,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Sacco AG, Chen R, Worden FP, et al. published a study on pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma."
    },
    {
        "id": 3786,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Bossi P, Miceli R, Locati LD, et al. published a study on a randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3787,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Marabelle A, Le DT, Ascierto PA, et al. published a study on efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer."
    },
    {
        "id": 3788,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Urba S, van Herpen CML, Sahoo TP, et al. published a study on pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer."
    },
    {
        "id": 3789,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Malhotra B, Moon J, Kucuk O, et al. published a study on phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3790,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 113,
        "content": "Haddad RI, Harrington K, Tahara M, et al. published a study on nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 3802,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Lefebvre T, Tack L, Lycke M, et al published a systematic review on the effectiveness of adjunctive analgesics in head and neck cancer patients receiving curative (chemo-) radiotherapy in 2021."
    },
    {
        "id": 3803,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Most patients with head and neck cancer lose weight and are nutritionally compromised."
    },
    {
        "id": 3804,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Nutritional management is important in patients with head and neck cancer to improve outcomes and minimize treatment-related complications."
    },
    {
        "id": 3805,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "A registered dietitian and a speech language/swallowing therapist should be part of the multidisciplinary team for treating patients with head and neck cancer."
    },
    {
        "id": 3806,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Bar Ad V, Weinstein G, Dutta PR, et al published a study on gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer in 2010."
    },
    {
        "id": 3807,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Leenstra JL, Miller RC, Qin R, et al published a phase III, randomized, double-blind trial on doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy in 2014."
    },
    {
        "id": 3808,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Sio TT, Le-Rademacher JG, Leenstra JL, et al published a randomized clinical trial on the effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo on radiotherapy-related oral mucositis pain in 2019."
    },
    {
        "id": 3809,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Close monitoring of nutritional status is recommended in patients who have significant weight loss or difficulty swallowing."
    },
    {
        "id": 3810,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "All patients should be evaluated for nutritional risks and receive nutrition counseling by a registered dietitian."
    },
    {
        "id": 3811,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Nutrition interventions, such as feeding tubes or intravenous nutrition support, may be indicated for patients with nutritional risks."
    },
    {
        "id": 3812,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Pre- and post-treatment functional evaluation, including nutritional status, should be undertaken using subjective and objective assessment tools."
    },
    {
        "id": 3813,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "All patients should receive dietary counseling with the initiation of treatment, especially with radiotherapy-based treatments."
    },
    {
        "id": 3814,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Regular follow-up with the registered dietitian should continue at least until the patient has achieved a nutritionally stable baseline following treatment."
    },
    {
        "id": 3815,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "A formal speech and swallowing evaluation at baseline is recommended for patients with speech and/or swallowing dysfunction or patients whose treatment is likely to affect speech and/or swallowing."
    },
    {
        "id": 3816,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Patients with ongoing abnormal function should be seen regularly by speech-language pathologists."
    },
    {
        "id": 3817,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Dysphagia and swallowing function can be measured by clinical swallowing assessments or by videofluoroscopic swallowing studies."
    },
    {
        "id": 3818,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Patient evaluations should also include assessment for any changes in speech and communication; changes in taste; and assessment for xerostomia, pain, trismus, lymphedema, and fibrosis."
    },
    {
        "id": 3819,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Follow-up with the speech-language pathologist should continue at least until the patient has achieved a stable baseline following treatment."
    },
    {
        "id": 3820,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 114,
        "content": "Pain from oral mucositis should be assessed and pregabalin, gabapentin, doxepin, or diphenhydramine/lidocaine/antacid mouthwash may be prescribed as clinically indicated."
    },
    {
        "id": 3827,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "Ehrsson YT, Langius-Ekl\u00f6f A, and Laurell G wrote about nutritional surveillance and weight loss in head and neck cancer patients."
    },
    {
        "id": 3828,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "Locher JL, Bonner JA, Carroll WR, et al wrote a comprehensive review of prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer."
    },
    {
        "id": 3829,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "Langius JA, van Dijk AM, Doornaert P, et al found that more than 10% weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life."
    },
    {
        "id": 3830,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "The panel does not recommend prophylactic PEG or NG tube placement in patients with very good PS and without significant pretreatment weight loss, significant airway obstruction, or severe dysphagia."
    },
    {
        "id": 3831,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "Prophylactic feeding tube placement should be strongly considered for patients with severe weight loss prior to treatment, ongoing dehydration or dysphagia, anorexia, or pain interfering with the ability to eat/drink adequately, significant comorbidities, severe aspiration, or mild aspiration in patients who are older or have compromised cardiopulmonary function, or patients for whom long-term swallowing disorders are likely."
    },
    {
        "id": 3832,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "Caloric intake, treatment-related side effects, and change in body weight should be monitored weekly during treatment for those who did not warrant prophylactic PEG or NG tube placement pre-treatment."
    },
    {
        "id": 3833,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "Reactive feeding tube placement should be considered if two or more of the following criteria apply: inadequate food intake, weight loss of 5% or more in 1 month, severe mucositis, odynophagia, dysphagia, or aspiration, or age >60 years."
    },
    {
        "id": 3834,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "Patients who may have feeding tube placement should be encouraged to intake orally if they can swallow without aspiration or any other compromises."
    },
    {
        "id": 3835,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "Alterations in swallowing function can occur long after treatment and should be monitored for the lifetime of the patient."
    },
    {
        "id": 3836,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "Bossola M wrote a narrative review of nutritional intervention in head and neck cancer patients undergoing chemoradiotherapy."
    },
    {
        "id": 3837,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "Talwar B, Donnelly R, Skelly R, et al wrote about nutritional management in head and neck cancer."
    },
    {
        "id": 3838,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 115,
        "content": "Sachdev S, Refaat T, Bacchus ID, et al found that age is the most significant predictor of requiring enteral feeding in head-and-neck cancer patients."
    },
    {
        "id": 3846,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Radiation therapy (RT) to the head and neck causes xerostomia and salivary gland dysfunction."
    },
    {
        "id": 3847,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Xerostomia and salivary gland dysfunction dramatically increase the risk of dental caries and its sequelae."
    },
    {
        "id": 3848,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Dental caries and its sequelae include dentoalveolar infection and osteoradionecrosis."
    },
    {
        "id": 3849,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "RT also affects the dental hard tissues, which increases their susceptibility to demineralization."
    },
    {
        "id": 3850,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Demineralization occurs in the presence of xerostomia, microbial changes following RT, and changes to a more cariogenic diet."
    },
    {
        "id": 3851,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "IMRT and salivary gland-sparing techniques are associated with dose-dependent recovery of salivary function over time."
    },
    {
        "id": 3852,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "IMRT and salivary gland-sparing techniques are associated with reduced risk for dental caries long term for some patients."
    },
    {
        "id": 3853,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Radiation-related caries and other dental hard tissue changes can appear within the first 3 months following RT."
    },
    {
        "id": 3854,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "The goal of Pre-RT Oral/Dental Evaluation is patient education regarding oral and dental complications of RT and need for adherence with preventive protocols."
    },
    {
        "id": 3855,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Patient education includes both oral and written information."
    },
    {
        "id": 3856,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "One principle of oral/dental evaluation and management is the effect on salivary glands."
    },
    {
        "id": 3857,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Dry mouth strategies include increased hydration, minimizing ingestion of caffeinated products and alcohol, and using salivary substitutes."
    },
    {
        "id": 3858,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Salivary substitutes include gels containing lysozyme, lactoferrin, peroxidase, and supersaturated calcium phosphate solutions."
    },
    {
        "id": 3859,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Another dry mouth strategy is using an alcohol-free mouthwash, such as stabilized 0.1% chlorine dioxide oral rinse."
    },
    {
        "id": 3860,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Salivary stimulation can be achieved through gustatory stimulants or cholinergic agonists."
    },
    {
        "id": 3861,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Gustatory stimulants include xylitol chewing gum, sorbitol/malic acid lozenges, and xylitol lozenges."
    },
    {
        "id": 3862,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Cholinergic agonists include pilocarpine and cevimeline."
    },
    {
        "id": 3863,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "One principle of oral/dental evaluation and management is dental caries prevention."
    },
    {
        "id": 3864,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Diet counseling is part of dental caries prevention."
    },
    {
        "id": 3865,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Meticulous oral hygiene is part of dental caries prevention."
    },
    {
        "id": 3866,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Meticulous oral hygiene includes brushing teeth twice daily, flossing or using an interdental cleaner daily, and using an alcohol-free mouthwash twice daily."
    },
    {
        "id": 3867,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "High potency topical fluoride is part of dental caries prevention."
    },
    {
        "id": 3868,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "High potency topical fluoride can be applied through daily 1.1% NaF gel or SNF2 gel, brush on or in custom dental trays, or daily 1.1% NaF dentifrice."
    },
    {
        "id": 3869,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Fluoride varnish application three times per year is also part of dental caries prevention."
    },
    {
        "id": 3870,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Calcium phosphate artificial saliva rinse is part of dental caries prevention."
    },
    {
        "id": 3871,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Regular frequent dental evaluations are necessary to detect dental disease."
    },
    {
        "id": 3872,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Candidiasis prevention and control is part of oral/dental evaluation and management."
    },
    {
        "id": 3873,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Candidiasis prevention and control includes topical therapy with anti-fungal lozenges or suspensions."
    },
    {
        "id": 3874,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Systemic antifungal therapy may be necessary if candidiasis is refractory to topicals."
    },
    {
        "id": 3875,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "An infectious disease consult may be necessary for systemic antifungal therapy."
    },
    {
        "id": 3876,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "One principle of oral/dental evaluation and management is the effect on bone in irradiated field."
    },
    {
        "id": 3877,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "A pre-RT dental evaluation is necessary to determine the need for dental extractions."
    },
    {
        "id": 3878,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Dental extractions should be completed at least 2 weeks prior to the start of RT."
    },
    {
        "id": 3879,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "The long-term prognosis of teeth and patient motivation should be considered in determining the need for dental extractions."
    },
    {
        "id": 3880,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "The oncology team should be contacted if any future extractions or surgery in irradiated field are necessary."
    },
    {
        "id": 3881,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "One principle of oral/dental evaluation and management is the effect on masticatory muscles, which can lead to trismus."
    },
    {
        "id": 3882,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Maintaining range of motion is necessary to prevent trismus."
    },
    {
        "id": 3883,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Tongue blades and gentle stretching can help maintain range of motion."
    },
    {
        "id": 3884,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 116,
        "content": "Custom mouth-opening devices can be used for rehabilitation of trismus and jaw motion."
    },
    {
        "id": 3902,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The treatment plan includes eliminating potential sources of infection."
    },
    {
        "id": 3903,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The treatment plan includes performing extractions at least 2 weeks before the start of RT."
    },
    {
        "id": 3904,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The treatment plan includes treating active dental caries and periodontal disease."
    },
    {
        "id": 3905,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The treatment plan includes using silicone guards to minimize radiation backscatter if patients have metal restorations."
    },
    {
        "id": 3906,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The treatment plan includes prescribing potent topical fluoride for daily use."
    },
    {
        "id": 3907,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The duration of use of potent topical fluoride is to be determined by periodic caries risk assessment over time."
    },
    {
        "id": 3908,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The treatment plan includes scheduling a return visit for re-evaluation and reinforcement of the preventive protocol for 6\u201312 weeks after completion of RT."
    },
    {
        "id": 3909,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The treatment plan includes evaluating for oral candidiasis and treating appropriately with antifungal agents."
    },
    {
        "id": 3910,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The principles of oral/dental evaluation and management include managing xerostomia during cancer therapy."
    },
    {
        "id": 3911,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The principles of oral/dental evaluation and management include preventing trismus of masticatory muscles during cancer therapy."
    },
    {
        "id": 3912,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The principles of oral/dental evaluation and management include evaluating for oral candidiasis and treating as clinically indicated during cancer therapy."
    },
    {
        "id": 3913,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The goals of oral/dental management post-treatment include managing xerostomia."
    },
    {
        "id": 3914,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The goals of oral/dental management post-treatment include preventing and minimizing trismus."
    },
    {
        "id": 3915,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The goals of oral/dental management post-treatment include preventing and treating dental caries."
    },
    {
        "id": 3916,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The goals of oral/dental management post-treatment include preventing and managing post-radiation osteonecrosis."
    },
    {
        "id": 3918,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "Stabilized 0.1% chlorine dioxide oral rinse is recommended in the guidelines."
    },
    {
        "id": 3919,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "The goals of oral/dental management post-treatment include preventing and managing oral candidiasis."
    },
    {
        "id": 3920,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "Consultation with the treating radiation oncologist is recommended before considering implants or extraction."
    },
    {
        "id": 3921,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "Dental recall visit interval is based on risk and is at least once every 6 months."
    },
    {
        "id": 3922,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 117,
        "content": "Dental recall visit interval may be more frequent for those with xerostomia or for those with new caries or lesions following radiotherapy."
    },
    {
        "id": 3929,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Epstein JB and Barasch A wrote about oral and dental health in head and neck cancer patients in Cancer Treat Res 2018."
    },
    {
        "id": 3930,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Sroussi HY, Epstein JB, Bensadoun RJ, et al wrote about common oral complications of head and neck cancer radiation therapy in Cancer Med 2017."
    },
    {
        "id": 3931,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Walker MP, Wichman B, Cheng AL, et al wrote about the impact of radiotherapy dose on dentition breakdown in head and neck cancer patients in Pract Radiat Oncol 2011."
    },
    {
        "id": 3932,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Little M, Schipper M, Feng FY, et al wrote about reducing xerostomia after chemo-IMRT for head-and-neck cancer in Int J Radiat Oncol Biol Phys 2012."
    },
    {
        "id": 3933,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Studer G, Glanzmann C, Studer SP, et al wrote about risk-adapted dental care prior to intensity-modulated radiotherapy in Schweiz Monatsschr Zahnmed 2011."
    },
    {
        "id": 3934,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Murdoch-Kinch CA, Zwetchkenbaum S wrote about dental management of the head and neck cancer patient treated with radiation therapy in J Mich Dent Assoc 2011."
    },
    {
        "id": 3935,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Epstein JB, Thariat J, Bensadoun RJ, et al wrote about oral complications of cancer and cancer therapy in CA Cancer J Clin 2012."
    },
    {
        "id": 3936,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Singh ML, Papas AS wrote about long-term clinical observation of dental caries in salivary hypofunction patients in J Clin Dent 2009."
    },
    {
        "id": 3937,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Gorsky M, Epstein JB, Parry J, et al wrote about the efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy in Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004."
    },
    {
        "id": 3938,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Jensen SB, Pedersen AM, Vissink A, et al wrote about salivary gland hypofunction and xerostomia induced by cancer therapies in Support Care Cancer 2010."
    },
    {
        "id": 3939,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Gomez DR, Estilo CL, Wolden SL, et al wrote about correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer in Int J Radiat Oncol Biol Phys 2011."
    },
    {
        "id": 3940,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Lee IJ, Koom WS, Lee CG, et al wrote about risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients in Int J Radiat Oncol Biol Phys 2009."
    },
    {
        "id": 3941,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Lalla RV, Treister N, Sollecito T, et al wrote about oral complications at 6 months after radiation therapy for head and neck cancer in Oral Dis 2017."
    },
    {
        "id": 3942,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Elad S, Cheng KKF, Lalla RV, et al wrote about MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy in Cancer 2020."
    },
    {
        "id": 3943,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 118,
        "content": "Myneni Venkatasatya SR, Wang HH, Alluri S, Ciancio SG wrote about phosphate buffer-stabilized 0.1% chlorine dioxide oral rinse for managing medication-related osteonecrosis of the jaw in Am J Dent 2017."
    },
    {
        "id": 3952,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "T1 is a classification for tumors \u22642 cm with depth of invasion (DOI) \u22645 mm."
    },
    {
        "id": 3953,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "T2 is a classification for tumors \u22642 cm, with DOI >5 mm or tumors >2 cm and \u22644 cm, with DOI \u226410 mm."
    },
    {
        "id": 3954,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "T3 is a classification for tumors >2 cm and \u22644 cm, with DOI >10 mm or tumors >4 cm, with DOI \u226410 mm."
    },
    {
        "id": 3955,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "T4 is a classification for moderately advanced or very advanced local disease."
    },
    {
        "id": 3956,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "T4a is a classification for moderately advanced local disease."
    },
    {
        "id": 3957,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "Tumor >4 cm, with DOI >10 mm or tumor invades adjacent structures only is classified as T4a."
    },
    {
        "id": 3958,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "T4b is a classification for very advanced local disease."
    },
    {
        "id": 3959,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery is classified as T4b."
    },
    {
        "id": 3960,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "DOI is depth of invasion and not tumor thickness."
    },
    {
        "id": 3961,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "NX is a classification for regional lymph nodes that cannot be assessed."
    },
    {
        "id": 3962,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N0 is a classification for no regional lymph node metastasis."
    },
    {
        "id": 3963,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N1 is a classification for metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013)."
    },
    {
        "id": 3964,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N2 is a classification for metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 3965,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N2 is a classification for metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 3966,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N2 is a classification for metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(\u2013)."
    },
    {
        "id": 3967,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N2a is a classification for metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension, and ENE(\u2013)."
    },
    {
        "id": 3968,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N2b is a classification for metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(\u2013)."
    },
    {
        "id": 3969,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N2c is a classification for metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(\u2013)."
    },
    {
        "id": 3970,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N3 is a classification for metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(\u2212)."
    },
    {
        "id": 3971,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N3 is a classification for metastasis in any node(s) and clinically overt ENE(+)."
    },
    {
        "id": 3972,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N3a is a classification for metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(\u2212)."
    },
    {
        "id": 3973,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "N3b is a classification for metastasis in any node(s) and clinically overt ENE(+)."
    },
    {
        "id": 3974,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L)."
    },
    {
        "id": 4000,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L)."
    },
    {
        "id": 3975,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 119,
        "content": "Clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+)."
    },
    {
        "id": 4002,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "The American College of Surgeons published the AJCC Cancer Staging Manual, Eighth Edition in 2017."
    },
    {
        "id": 4003,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "The AJCC Cancer Staging Manual, Eighth Edition is the original source for the TNM Staging Classification for the Oral Cavity."
    },
    {
        "id": 4004,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "Distant Metastasis is classified as M in the TNM Staging Classification for the Oral Cavity."
    },
    {
        "id": 4005,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "M0 means that there is no distant metastasis."
    },
    {
        "id": 4006,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "M1 means that there is distant metastasis."
    },
    {
        "id": 4007,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "Histologic Grade is classified as G in the TNM Staging Classification for the Oral Cavity."
    },
    {
        "id": 4008,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "GX means that the histologic grade cannot be assessed."
    },
    {
        "id": 4009,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "G1 means that the histologic grade is well differentiated."
    },
    {
        "id": 4010,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "G2 means that the histologic grade is moderately differentiated."
    },
    {
        "id": 4011,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "G3 means that the histologic grade is poorly differentiated."
    },
    {
        "id": 4012,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "Prognostic Stage Groups are classified in the TNM Staging Classification for the Oral Cavity."
    },
    {
        "id": 4013,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "Stage 0 means that the tumor is Tis, N0, and M0."
    },
    {
        "id": 4014,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "Stage I means that the tumor is T1, N0, and M0."
    },
    {
        "id": 4015,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "Stage II means that the tumor is T2, N0, and M0."
    },
    {
        "id": 4016,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "Stage III means that the tumor is T1 or T2, N1, and M0; or T3, N0 or N1, and M0."
    },
    {
        "id": 4017,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "Stage IVA means that the tumor is T1, N2, and M0; or T2, N2, and M0; or T3, N2, and M0; or T4a, N0, N1, or N2, and M0."
    },
    {
        "id": 4018,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "Stage IVB means that the tumor is any T, N3, and M0; or T4b, any N, and M0."
    },
    {
        "id": 4019,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 120,
        "content": "Stage IVC means that the tumor is any T, any N, and M1."
    },
    {
        "id": 4022,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "TX is a classification for primary tumor that cannot be assessed."
    },
    {
        "id": 4024,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "T0 means no tumor is identified, but EBV-positive cervical node(s) involvement is present."
    },
    {
        "id": 4026,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "Tis is a classification for carcinoma in situ."
    },
    {
        "id": 4027,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "T1 is a classification for tumor confined to nasopharynx, or extension to oropharynx and/or nasal cavity without parapharyngeal involvement."
    },
    {
        "id": 4028,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "T2 is a classification for tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles)."
    },
    {
        "id": 4029,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "T3 is a classification for tumor with infiltration of bony structures at skull base, cervical vertebra, pterygoid structures, and/or paranasal sinuses."
    },
    {
        "id": 4030,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "T4 is a classification for tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/ or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle."
    },
    {
        "id": 4031,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "NX is a classification for regional lymph nodes that cannot be assessed."
    },
    {
        "id": 4032,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "N0 is a classification for no regional lymph node metastasis."
    },
    {
        "id": 4033,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "N1 is a classification for unilateral metastasis in cervical lymph node(s) and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage."
    },
    {
        "id": 4034,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "N2 is a classification for bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage."
    },
    {
        "id": 4035,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "N3 is a classification for unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage."
    },
    {
        "id": 4036,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "M0 is a classification for no distant metastasis."
    },
    {
        "id": 4037,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "M1 is a classification for distant metastasis."
    },
    {
        "id": 4045,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "The American College of Surgeons granted permission for the use of this information."
    },
    {
        "id": 4095,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "The American College of Surgeons granted permission for the use of this information."
    },
    {
        "id": 4046,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing."
    },
    {
        "id": 4096,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing."
    },
    {
        "id": 4048,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "The NCCN Guidelines Version 2.2024 is for Head and Neck Cancers."
    },
    {
        "id": 4049,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 121,
        "content": "The NCCN Guidelines Version 2.2024 was last updated on 12/08/2023."
    },
    {
        "id": 4055,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "The American Joint Committee on Cancer (AJCC) published the TNM Staging System for the Oropharynx (p16-) and Hypopharynx in 2017."
    },
    {
        "id": 4080,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "The American Joint Committee on Cancer (AJCC) published the TNM Staging System for the Oropharynx (p16-) and Hypopharynx in 2017."
    },
    {
        "id": 4056,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "The TNM Staging System does not include P16-positive (p16+) oropharyngeal cancers and nasopharyngeal cancer."
    },
    {
        "id": 4081,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "The TNM Staging System does not include P16-positive (p16+) oropharyngeal cancers and nasopharyngeal cancer."
    },
    {
        "id": 4057,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "The Oropharynx (p16-) has a staging system that includes TX, Tis, T1, T2, T3, and T4."
    },
    {
        "id": 4058,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "TX means the primary tumor cannot be assessed."
    },
    {
        "id": 4069,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "TX means the primary tumor cannot be assessed."
    },
    {
        "id": 4059,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "Tis means carcinoma in situ."
    },
    {
        "id": 4070,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "Tis means carcinoma in situ."
    },
    {
        "id": 4060,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T1 means the tumor is 2 cm or smaller in greatest dimension."
    },
    {
        "id": 4061,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T2 means the tumor is larger than 2 cm but not larger than 4 cm in greatest dimension."
    },
    {
        "id": 4062,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T3 means the tumor is larger than 4 cm in greatest dimension or has extension to lingual surface of epiglottis."
    },
    {
        "id": 4063,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T4 means moderately advanced or very advanced local disease."
    },
    {
        "id": 4074,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T4 means moderately advanced or very advanced local disease."
    },
    {
        "id": 4064,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T4a means moderately advanced local disease, and the tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible."
    },
    {
        "id": 4065,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T4b means very advanced local disease, and the tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery."
    },
    {
        "id": 4068,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "The Hypopharynx has a staging system that includes TX, Tis, T1, T2, T3, and T4."
    },
    {
        "id": 4071,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T1 means the tumor is limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension."
    },
    {
        "id": 4072,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T2 means the tumor invades more than one subsite of hypopharynx or an adjacent site, or measures larger than 2 cm but not larger than 4 cm in greatest dimension without fixation of hemilarynx."
    },
    {
        "id": 4073,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T3 means the tumor is larger than 4 cm in greatest dimension or has fixation of hemilarynx or extension to esophageal mucosa."
    },
    {
        "id": 4075,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T4a means moderately advanced local disease, and the tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, esophageal muscle or central compartment soft tissue."
    },
    {
        "id": 4076,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 122,
        "content": "T4b means very advanced local disease, and the tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures."
    },
    {
        "id": 4082,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "The Regional Lymph Nodes (N) category is part of the TNM Staging System."
    },
    {
        "id": 4083,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "NX means that regional lymph nodes cannot be assessed."
    },
    {
        "id": 4084,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "N0 means that there is no regional lymph node metastasis."
    },
    {
        "id": 4085,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "N1 means that there is metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)."
    },
    {
        "id": 4086,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "N2 means that there is metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4087,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "N2a means that there is metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4088,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "N2b means that there are metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4089,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "N2c means that there are metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4090,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "N3 means that there is metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) and clinically overt ENE(+)."
    },
    {
        "id": 4091,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "N3a means that there is metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4092,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 123,
        "content": "N3b means that there is metastasis in any node(s) and clinically overt ENE(+)."
    },
    {
        "id": 4102,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "M0 means no distant metastasis."
    },
    {
        "id": 4103,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "M1 means distant metastasis."
    },
    {
        "id": 4104,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "GX means the grade cannot be assessed."
    },
    {
        "id": 4105,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "G1 means the tumor is well differentiated."
    },
    {
        "id": 4106,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "G2 means the tumor is moderately differentiated."
    },
    {
        "id": 4107,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "G3 means the tumor is poorly differentiated."
    },
    {
        "id": 4108,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "G4 means the tumor is undifferentiated."
    },
    {
        "id": 4109,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "Stage 0 is characterized by Tis, N0, and M0."
    },
    {
        "id": 4110,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "Stage I is characterized by T1, N0, and M0."
    },
    {
        "id": 4111,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "Stage II is characterized by T2, N0, and M0."
    },
    {
        "id": 4112,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "Stage III is characterized by T3, N0, and M0, or T1, N1, and M0, or T2, N1, and M0, or T3, N1, and M0."
    },
    {
        "id": 4113,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "Stage IVA is characterized by T1, N2, and M0, or T2, N2, and M0, or T3, N2, and M0, or T4a, N0, N1, N2, and M0."
    },
    {
        "id": 4114,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "Stage IVB is characterized by T4b, any N, and M0, or any T, N3, and M0."
    },
    {
        "id": 4115,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "Stage IVC is characterized by any T, any N, and M1."
    },
    {
        "id": 4116,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "The American Joint Committee on Cancer (AJCC) published the TNM Staging System for the Oropharynx (p16-) and Hypopharynx in 2017."
    },
    {
        "id": 4117,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "The TNM Staging System is used for oropharyngeal cancers and hypopharyngeal cancers."
    },
    {
        "id": 4118,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "NX means regional lymph nodes cannot be assessed."
    },
    {
        "id": 4119,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "N0 means no regional lymph node metastasis."
    },
    {
        "id": 4120,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "N1 means metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension, and ENE(-)."
    },
    {
        "id": 4121,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "N2 means metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension, and ENE(+), or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-), or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-), or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4122,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "N2a means metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension, and ENE(+)."
    },
    {
        "id": 4123,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "N2b means metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4124,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "N2c means metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4125,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "N3 means metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-), or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+), or multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+), or a single contralateral node of any size and ENE(+)."
    },
    {
        "id": 4126,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "N3a means metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4127,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 124,
        "content": "N3b means metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+), or multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+), or a single contralateral node of any size and ENE(+)."
    },
    {
        "id": 4128,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "The American Joint Committee on Cancer (AJCC) published the TNM Staging System for HPV-Mediated (p16+) Oropharyngeal Cancer in 2017."
    },
    {
        "id": 4129,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "The TNM Staging System does not include P16-negative (p16-) cancers of the oropharynx."
    },
    {
        "id": 4130,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "The AJCC defined Prognostic Stage Groups for HPV-Mediated (p16+) Oropharyngeal Cancer."
    },
    {
        "id": 4131,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "The Clinical Stage I includes T0, T1, T2, N0, N1, and M0."
    },
    {
        "id": 4132,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "The Clinical Stage II includes T0, T1, T2, N2, M0, and T3, N0, N1, N2, M0."
    },
    {
        "id": 4133,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "The Clinical Stage III includes T0, T1, T2, T3, N3, M0, and T4, N0, N1, N2, N3, M0."
    },
    {
        "id": 4134,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "The Clinical Stage IV includes Any T, Any N, and M1."
    },
    {
        "id": 4135,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "The Pathological Stage I includes T0, T1, T2, N0, N1, M0."
    },
    {
        "id": 4136,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "The Pathological Stage II includes T0, T1, T2, N2, M0, and T3, T4, N0, N1, M0."
    },
    {
        "id": 4137,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "The Pathological Stage III includes T3, T4, N2, M0."
    },
    {
        "id": 4138,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "The Pathological Stage IV includes Any T, Any N, and M1."
    },
    {
        "id": 4139,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "T0 means No primary tumor is identified."
    },
    {
        "id": 4140,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "T1 means the tumor is 2 cm or smaller in greatest dimension."
    },
    {
        "id": 4141,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "T2 means the tumor is larger than 2 cm but not larger than 4 cm in greatest dimension."
    },
    {
        "id": 4142,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "T3 means the tumor is larger than 4 cm in greatest dimension or has extension to the lingual surface of the epiglottis."
    },
    {
        "id": 4143,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "T4 means the tumor has moderately advanced local disease."
    },
    {
        "id": 4144,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "T4 means the tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond."
    },
    {
        "id": 4145,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "Mucosal extension to the lingual surface of the epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx."
    },
    {
        "id": 4146,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "NX means Regional lymph nodes cannot be assessed."
    },
    {
        "id": 4147,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "N0 means No regional lymph node metastasis."
    },
    {
        "id": 4148,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "N1 means One or more ipsilateral lymph nodes, none larger than 6 cm."
    },
    {
        "id": 4149,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "N2 means Contralateral or bilateral lymph nodes, none larger than 6 cm."
    },
    {
        "id": 4150,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "N3 means Lymph node(s) larger than 6 cm."
    },
    {
        "id": 4151,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "pN0 means No regional lymph node metastasis."
    },
    {
        "id": 4152,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "pN1 means Metastasis in 4 or fewer lymph nodes."
    },
    {
        "id": 4153,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "pN2 means Metastasis in more than 4 lymph nodes."
    },
    {
        "id": 4154,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "M0 means No distant metastasis."
    },
    {
        "id": 4155,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 125,
        "content": "M1 means Distant metastasis."
    },
    {
        "id": 4163,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "The American Joint Committee on Cancer (AJCC) published the TNM Staging System for the Larynx in 2017."
    },
    {
        "id": 4195,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 127,
        "content": "The American Joint Committee on Cancer (AJCC) published the TNM Staging System for the Larynx in 2017."
    },
    {
        "id": 4164,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "The 8th edition of the TNM Staging System for the Larynx was published in 2017."
    },
    {
        "id": 4165,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "The TNM Staging System for the Larynx does not include nonepithelial tumors such as those of lymphoid tissue, soft tissue, bone and cartilage, and mucosal melanoma of the lip and oral cavity."
    },
    {
        "id": 4166,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "The Primary Tumor (T) category in the TNM Staging System for the Larynx has several subcategories."
    },
    {
        "id": 4167,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "TX means the primary tumor cannot be assessed."
    },
    {
        "id": 4168,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "Tis means carcinoma in situ."
    },
    {
        "id": 4169,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T1 in the supraglottis category means the tumor is limited to one subsite of supraglottis with normal vocal cord mobility."
    },
    {
        "id": 4170,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T2 in the supraglottis category means the tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis."
    },
    {
        "id": 4171,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T3 in the supraglottis category means the tumor is limited to the larynx with vocal cord fixation and/or invades any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage."
    },
    {
        "id": 4172,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T4 in the supraglottis category means the tumor is moderately advanced or very advanced."
    },
    {
        "id": 4173,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T4a in the supraglottis category means the tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx."
    },
    {
        "id": 4174,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T4b in the supraglottis category means the tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures."
    },
    {
        "id": 4175,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T1 in the glottis category means the tumor is limited to the vocal cord(s) with normal mobility."
    },
    {
        "id": 4176,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T1a in the glottis category means the tumor is limited to one vocal cord."
    },
    {
        "id": 4177,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T1b in the glottis category means the tumor involves both vocal cords."
    },
    {
        "id": 4178,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T2 in the glottis category means the tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility."
    },
    {
        "id": 4179,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T3 in the glottis category means the tumor is limited to the larynx with vocal cord fixation and/or invasion of paraglottic space and/or inner cortex of the thyroid cartilage."
    },
    {
        "id": 4180,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T4 in the glottis category means the tumor is moderately advanced or very advanced."
    },
    {
        "id": 4181,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T4a in the glottis category means the tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx."
    },
    {
        "id": 4182,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T4b in the glottis category means the tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures."
    },
    {
        "id": 4183,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T1 in the subglottis category means the tumor is limited to the subglottis."
    },
    {
        "id": 4184,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T2 in the subglottis category means the tumor extends to vocal cord(s) with normal or impaired mobility."
    },
    {
        "id": 4185,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T3 in the subglottis category means the tumor is limited to the larynx with vocal cord fixation and/or inner cortex of the thyroid cartilage."
    },
    {
        "id": 4186,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T4 in the subglottis category means the tumor is moderately advanced or very advanced."
    },
    {
        "id": 4187,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T4a in the subglottis category means the tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx."
    },
    {
        "id": 4188,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 126,
        "content": "T4b in the subglottis category means the tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures."
    },
    {
        "id": 4202,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 127,
        "content": "N2a means that there is metastasis in a single ipsilateral lymph node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4203,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 127,
        "content": "N2b means that there are metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4204,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 127,
        "content": "N2c means that there are metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4205,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 127,
        "content": "N3 means that there is metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2013), or metastasis in any lymph node(s) with clinically overt ENE(+)."
    },
    {
        "id": 4206,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 127,
        "content": "N3a means that there is metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4207,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 127,
        "content": "N3b means that there is metastasis in any lymph node(s) with clinically overt ENE(+)."
    },
    {
        "id": 4208,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 127,
        "content": "A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L)."
    },
    {
        "id": 4228,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L)."
    },
    {
        "id": 4287,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L)."
    },
    {
        "id": 4209,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 127,
        "content": "Clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+)."
    },
    {
        "id": 4217,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "Pathological N (pN) is a classification system for lymph nodes."
    },
    {
        "id": 4218,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "NX means regional lymph nodes cannot be assessed."
    },
    {
        "id": 4276,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "NX means regional lymph nodes cannot be assessed."
    },
    {
        "id": 4219,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "N0 means no regional lymph node metastasis."
    },
    {
        "id": 4277,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "N0 means no regional lymph node metastasis."
    },
    {
        "id": 4220,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "N1 means metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4221,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "N2 means metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2013); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2013); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4230,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "M0 means no distant metastasis."
    },
    {
        "id": 4231,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "M1 means distant metastasis."
    },
    {
        "id": 4232,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "GX means grade cannot be assessed."
    },
    {
        "id": 4233,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "G1 means well differentiated."
    },
    {
        "id": 4234,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "G2 means moderately differentiated."
    },
    {
        "id": 4235,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "G3 means poorly differentiated."
    },
    {
        "id": 4236,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "Stage 0 means Tis, N0, M0."
    },
    {
        "id": 4237,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "Stage I means T1, N0, M0."
    },
    {
        "id": 4238,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "Stage II means T2, N0, M0."
    },
    {
        "id": 4239,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "Stage III means T3, N0, M0 or T1, N1, M0 or T2, N1, M0 or T3, N1, M0."
    },
    {
        "id": 4240,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "Stage IVA means T1, N2, M0 or T2, N2, M0 or T3, N2, M0 or T4a, N0, N1, N2, M0."
    },
    {
        "id": 4241,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "Stage IVB means Any T, N3, M0 or T4b, Any N, M0."
    },
    {
        "id": 4242,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 128,
        "content": "Stage IVC means Any T, Any N, M1."
    },
    {
        "id": 4254,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "TX means the primary tumor cannot be assessed."
    },
    {
        "id": 4255,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "Tis means carcinoma in situ."
    },
    {
        "id": 4256,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T1 of the Maxillary Sinus means the tumor is limited to maxillary sinus mucosa with no erosion or destruction of bone."
    },
    {
        "id": 4257,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T2 of the Maxillary Sinus means the tumor causes bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates."
    },
    {
        "id": 4258,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T3 of the Maxillary Sinus means the tumor invades any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, ethmoid sinuses."
    },
    {
        "id": 4259,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T4 of the Maxillary Sinus means moderately advanced or very advanced local disease."
    },
    {
        "id": 4260,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T4a of the Maxillary Sinus means moderately advanced local disease, and the tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses."
    },
    {
        "id": 4261,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T4b of the Maxillary Sinus means very advanced local disease, and the tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus."
    },
    {
        "id": 4262,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T1 of the Nasal Cavity and Ethmoid Sinus means the tumor is restricted to any one subsite, with or without bony invasion."
    },
    {
        "id": 4263,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T2 of the Nasal Cavity and Ethmoid Sinus means the tumor invades two subsites in a single region or extends to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion."
    },
    {
        "id": 4264,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T3 of the Nasal Cavity and Ethmoid Sinus means the tumor extends to invade the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate."
    },
    {
        "id": 4265,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T4 of the Nasal Cavity and Ethmoid Sinus means moderately advanced or very advanced local disease."
    },
    {
        "id": 4266,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T4a of the Nasal Cavity and Ethmoid Sinus means moderately advanced local disease, and the tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses."
    },
    {
        "id": 4267,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 129,
        "content": "T4b of the Nasal Cavity and Ethmoid Sinus means very advanced local disease, and the tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than (V2), nasopharynx, or clivus."
    },
    {
        "id": 4275,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "Regional lymph nodes are classified as Clinical N (cN)."
    },
    {
        "id": 4278,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "N1 means metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)."
    },
    {
        "id": 4280,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "N2 means metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4281,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "N2a means metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4282,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "N2b means metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4283,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "N2c means metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4284,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "N3 means metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) with clinically overt ENE(+)."
    },
    {
        "id": 4285,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "N3a means metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4286,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 130,
        "content": "N3b means metastasis in any node(s) with clinically overt ENE(+)."
    },
    {
        "id": 4302,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N1 is 3 cm or smaller in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4303,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N2 is a classification of regional lymph nodes with metastasis in a single ipsilateral lymph node."
    },
    {
        "id": 4304,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N2 is 3 cm or smaller in greatest dimension and ENE(+)."
    },
    {
        "id": 4305,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N2 can also be larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4306,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N2 can also be in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4307,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N2 can also be in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4308,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N2a is a subclassification of N2."
    },
    {
        "id": 4309,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N2a is a classification of regional lymph nodes with metastasis in a single ipsilateral node."
    },
    {
        "id": 4310,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N2a is 3 cm or less in greatest dimension and ENE(+)."
    },
    {
        "id": 4311,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N2a can also be in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4312,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N2b is a subclassification of N2."
    },
    {
        "id": 4313,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N2b is a classification of regional lymph nodes with metastases in multiple ipsilateral nodes."
    },
    {
        "id": 4314,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastases in N2b are none larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4315,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N2c is a subclassification of N2."
    },
    {
        "id": 4316,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N2c is a classification of regional lymph nodes with metastases in bilateral or contralateral lymph node(s)."
    },
    {
        "id": 4317,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastases in N2c are none larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4318,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N3 is a classification of regional lymph nodes with metastasis in a lymph node."
    },
    {
        "id": 4319,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N3 is larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4320,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N3 can also be in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+)."
    },
    {
        "id": 4321,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N3 can also be in multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+)."
    },
    {
        "id": 4322,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N3 can also be in a single contralateral node of any size and ENE(+)."
    },
    {
        "id": 4323,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N3a is a subclassification of N3."
    },
    {
        "id": 4324,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N3a is a classification of regional lymph nodes with metastasis in a lymph node."
    },
    {
        "id": 4325,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N3a is larger than 6 cm in greatest dimension and ENE(\u2013)."
    },
    {
        "id": 4326,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N3b is a subclassification of N3."
    },
    {
        "id": 4327,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "N3b is a classification of regional lymph nodes with metastasis in a single ipsilateral node."
    },
    {
        "id": 4328,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N3b is larger than 3 cm in greatest dimension and ENE(+)."
    },
    {
        "id": 4329,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N3b can also be in multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+)."
    },
    {
        "id": 4330,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "The metastasis in N3b can also be in a single contralateral node of any size and ENE(+)."
    },
    {
        "id": 4331,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "A designation of 'U' or 'L' may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L)."
    },
    {
        "id": 4332,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 131,
        "content": "Clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+)."
    },
    {
        "id": 4380,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "Clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+)."
    },
    {
        "id": 4395,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 134,
        "content": "Clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+)."
    },
    {
        "id": 4366,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "Regional lymph nodes are classified as Clinical N (cN) for patients who are treated with primary nonsurgical treatment without a cervical lymph node dissection."
    },
    {
        "id": 4367,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "The classification NX means that regional lymph nodes cannot be assessed."
    },
    {
        "id": 4368,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "The classification N0 means that there is no regional lymph node metastasis."
    },
    {
        "id": 4369,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "The classification N1 means that there is metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)."
    },
    {
        "id": 4370,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "The classification N2 means that there is metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-)."
    },
    {
        "id": 4371,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "The classification N2a means that there is metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4372,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "The classification N2b means that there are metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4373,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "The classification N2c means that there are metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4374,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "The classification N3 means that there is metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) with clinically overt ENE(+)."
    },
    {
        "id": 4375,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "The classification N3a means that there is metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4376,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "The classification N3b means that there is metastasis in any node(s) with clinically overt ENE(+)."
    },
    {
        "id": 4377,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "Midline nodes are considered ipsilateral nodes."
    },
    {
        "id": 4391,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 134,
        "content": "Midline nodes are considered ipsilateral nodes."
    },
    {
        "id": 4378,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "ENEc is defined as invasion of skin, infiltration of musculature, dense tethering or fixation to adjacent structures, or cranial nerve, brachial plexus, sympathetic trunk, or phrenic nerve invasion with dysfunction."
    },
    {
        "id": 4379,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 133,
        "content": "A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L)."
    },
    {
        "id": 4394,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 134,
        "content": "A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L)."
    },
    {
        "id": 4386,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 134,
        "content": "Pathological N (pN) is for patients who are treated surgically with a cervical lymph node dissection."
    },
    {
        "id": 4387,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 134,
        "content": "NX means regional lymph nodes cannot be assessed."
    },
    {
        "id": 4388,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 134,
        "content": "N0 means no regional lymph node metastasis."
    },
    {
        "id": 4389,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 134,
        "content": "N1 means metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)."
    },
    {
        "id": 4392,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 134,
        "content": "ENE detected on histopathologic examination is designated as ENEmi (microscopic ENE \u2264 2 mm) or ENEma (major ENE > 2 mm)."
    },
    {
        "id": 4393,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 134,
        "content": "Both ENEmi and ENEma qualify as ENE(+) for definition of pN."
    },
    {
        "id": 4346,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "Stage 0 of the TNM Staging System is defined as Tis, N0, and M0."
    },
    {
        "id": 4347,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "Stage I of the TNM Staging System is defined as T1, N0, and M0."
    },
    {
        "id": 4348,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "Stage II of the TNM Staging System is defined as T2, N0, and M0."
    },
    {
        "id": 4349,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "Stage III of the TNM Staging System is defined as T1, N1, and M0, or T2, N1, and M0, or T3, N0, N1, and M0."
    },
    {
        "id": 4350,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "Stage IVA of the TNM Staging System is defined as T1, N2, and M0, or T2, N2, and M0, or T3, N2, and M0, or T4a, N0, N1, N2, and M0."
    },
    {
        "id": 4351,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "Stage IVB of the TNM Staging System is defined as Any T, N3, and M0, or T4b, Any N, and M0."
    },
    {
        "id": 4352,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "Stage IVC of the TNM Staging System is defined as Any T, Any N, and M1."
    },
    {
        "id": 4353,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "M0 is defined as no distant metastasis."
    },
    {
        "id": 4354,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "M1 is defined as distant metastasis."
    },
    {
        "id": 4355,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "GX is a histologic grade that means the grade cannot be assessed."
    },
    {
        "id": 4356,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "G1 is a histologic grade that means well differentiated."
    },
    {
        "id": 4357,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "G2 is a histologic grade that means moderately differentiated."
    },
    {
        "id": 4358,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 132,
        "content": "G3 is a histologic grade that means poorly differentiated."
    },
    {
        "id": 4402,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 134,
        "content": "Stage IVB is T0, N3, M0."
    },
    {
        "id": 4403,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 134,
        "content": "Stage IVC is T0, Any N, M1."
    },
    {
        "id": 4407,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The Primary Tumor (T) classification includes TX, which means the primary tumor cannot be assessed."
    },
    {
        "id": 4409,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The T0 classification means No evidence of primary tumor."
    },
    {
        "id": 4410,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The Tis classification means Carcinoma in situ."
    },
    {
        "id": 4411,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The T1 classification means Tumor 2 cm or smaller in greatest dimension without extraparenchymal extension."
    },
    {
        "id": 4412,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The T2 classification means Tumor larger than 2 cm but not larger than 4 cm in greatest dimension without extraparenchymal extension."
    },
    {
        "id": 4413,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The T3 classification means Tumor larger than 4 cm and/or tumor having extraparenchymal extension."
    },
    {
        "id": 4414,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The T4 classification means Moderately advanced or very advanced disease."
    },
    {
        "id": 4415,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The T4a classification means Moderately advanced disease, with tumor invading skin, mandible, ear canal, and/or facial nerve."
    },
    {
        "id": 4416,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The T4b classification means Very advanced disease, with tumor invading skull base and/or pterygoid plates and/or encasing carotid artery."
    },
    {
        "id": 4417,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues."
    },
    {
        "id": 4418,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes."
    },
    {
        "id": 4419,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The Regional Lymph Nodes (N) classification includes NX, which means Regional lymph nodes cannot be assessed."
    },
    {
        "id": 4420,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The N0 classification means No regional lymph node metastasis."
    },
    {
        "id": 4421,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The N1 classification means Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)."
    },
    {
        "id": 4422,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The N2 classification means Metastasis in a single ipsilateral lymph node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4423,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The N2a classification means Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4424,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The N2b classification means Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4425,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The N2c classification means Metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4426,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The N3 classification means Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) with clinically overt ENE(+)."
    },
    {
        "id": 4427,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The N3a classification means Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4428,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The N3b classification means Metastases in any node(s) with clinically overt ENE(+)."
    },
    {
        "id": 4429,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L)."
    },
    {
        "id": 4430,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "Clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+)."
    },
    {
        "id": 4432,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 135,
        "content": "The TNM Staging System is used for the Parotid, submandibular, and sublingual glands."
    },
    {
        "id": 4442,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "M0 means no distant metastasis."
    },
    {
        "id": 4443,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "M1 means distant metastasis."
    },
    {
        "id": 4445,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "Stage 0 is Tis, N0, M0."
    },
    {
        "id": 4446,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "Stage I is T1, N0, M0."
    },
    {
        "id": 4447,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "Stage II is T2, N0, M0."
    },
    {
        "id": 4448,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "Stage III is T3, N0, M0 or T0, T1, T2, T3, N1, M0."
    },
    {
        "id": 4449,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "Stage IVA is T0, N2, M0 or T1, N2, M0 or T2, N2, M0 or T3, N2, M0 or T4a, N0, N1, N2, M0."
    },
    {
        "id": 4450,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "Stage IVB is Any T, N3, M0 or T4b, Any N, M0."
    },
    {
        "id": 4451,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "Stage IVC is Any T, Any N, M1."
    },
    {
        "id": 4452,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "The TNM Staging System for the Major Salivary Glands has a category for Regional Lymph Nodes (N)."
    },
    {
        "id": 4453,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "Pathological N (pN) is a category in the TNM Staging System for the Major Salivary Glands."
    },
    {
        "id": 4454,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "NX means regional lymph nodes cannot be assessed."
    },
    {
        "id": 4480,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "NX means regional lymph nodes cannot be assessed."
    },
    {
        "id": 4455,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "N0 means no regional lymph node metastasis."
    },
    {
        "id": 4456,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "N1 means metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-)."
    },
    {
        "id": 4457,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "N2 means metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4458,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "N2a means metastasis in a single ipsilateral lymph node 3 cm or smaller in greatest dimension and ENE(+)."
    },
    {
        "id": 4459,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "N2b means metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4460,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "N2c means metastases in bilateral or contralateral lymph node(s), none more than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4461,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "N3 means metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)."
    },
    {
        "id": 4462,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "N3a means metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)."
    },
    {
        "id": 4463,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 136,
        "content": "N3b means metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)."
    },
    {
        "id": 4474,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "T3 tumors are limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension."
    },
    {
        "id": 4475,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "T3 tumors can be polypoid nasal disease, pigmented or nonpigmented lesions of the oral cavity, pharynx, or larynx."
    },
    {
        "id": 4476,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "T4 tumors are moderately advanced or very advanced."
    },
    {
        "id": 4477,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "T4a tumors are moderately advanced disease and involve deep soft tissue, cartilage, bone, or overlying skin."
    },
    {
        "id": 4478,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "T4b tumors are very advanced disease and involve brain, dura, skull base, lower cranial nerves, masticator space, carotid artery, prevertebral space, or mediastinal structures."
    },
    {
        "id": 4479,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "The Regional Lymph Nodes (N) classification includes NX, N0, and N1."
    },
    {
        "id": 4481,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "N0 means no regional lymph node metastases are present."
    },
    {
        "id": 4482,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "N1 means regional lymph node metastases are present."
    },
    {
        "id": 4483,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "The Distant Metastasis (M) classification includes M0 and M1."
    },
    {
        "id": 4484,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "M0 means no distant metastasis is present."
    },
    {
        "id": 4485,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 137,
        "content": "M1 means distant metastasis is present."
    },
    {
        "id": 4587,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers address tumors arising from the oral cavity, pharynx, larynx, and paranasal sinuses."
    },
    {
        "id": 4588,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "The NCCN Guidelines for Head and Neck Cancers also address occult primary cancers, salivary gland cancers, and mucosal melanoma (MM)."
    },
    {
        "id": 4589,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "In 2023, it is estimated that about 66,920 new cases of oral cavity, pharyngeal, and laryngeal cancers will occur in the United States."
    },
    {
        "id": 4590,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "These new cases account for approximately 3.4% of new cancer cases in the United States."
    },
    {
        "id": 4591,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "An estimated 15,400 deaths from head and neck (H&N) cancers will occur in the United States in 2023."
    },
    {
        "id": 4592,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "Squamous cell carcinomas account for more than 90% of these tumors."
    },
    {
        "id": 4593,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "Tobacco and alcohol use disorders are the most common etiologies for oral cavity, hypopharynx, larynx, and human papillomavirus (HPV)-unrelated oropharynx cancers."
    },
    {
        "id": 4594,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "Patients with H&N cancers due to tobacco and alcohol are at risk for harboring synchronous primary tumors and developing second primary neoplasms of the H&N, lung, esophagus, bladder, and other potential sites that are exposed to these carcinogens."
    },
    {
        "id": 4595,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "Stage at diagnosis predicts survival rates and guides care of patients with H&N cancers."
    },
    {
        "id": 4596,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "In general, stage I or II disease defines a relatively small primary tumor with no nodal involvement amongst HPV-unrelated cancers."
    },
    {
        "id": 4597,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "Stage III or IV HPV-unrelated cancers and stages I, II, and III HPV-related cancers may include larger primary tumors, which may invade underlying structures and/or spread to regional nodes."
    },
    {
        "id": 4598,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "Distant metastases are less common at presentation as compared to lung and esophagus cancers."
    },
    {
        "id": 4599,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 141,
        "content": "More advanced TNM (tumor, node, metastasis) stages are associated with worse survival."
    },
    {
        "id": 4617,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "HPV infection is a predominant cause of squamous cell carcinomas of the oropharynx."
    },
    {
        "id": 4618,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "HPV infection is particularly prevalent in cancers of the tonsils and tongue base."
    },
    {
        "id": 4619,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "Small subsets of squamous cell carcinomas of the oral cavity, larynx, nasopharynx, and paranasal sinuses are HPV positive."
    },
    {
        "id": 4620,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "50% of patients with squamous cell carcinoma of unknown primary in the H&N are HPV positive."
    },
    {
        "id": 4621,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "The overall incidence of HPV-positive oropharynx cancers is increasing in the United States, particularly in men."
    },
    {
        "id": 4622,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "The incidence of HPV-negative (primarily tobacco- and alcohol-related) cancer is decreasing."
    },
    {
        "id": 4623,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "The attributable fraction for HPV in newly diagnosed oropharyngeal cancer is estimated as 60% to 70% in the United States and parts of the European Union."
    },
    {
        "id": 4624,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "Patients with HPV-positive cancer have tended to be younger."
    },
    {
        "id": 4625,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "HPV-positive oropharynx cancer rates are rising among older adults as the exposed cohorts age."
    },
    {
        "id": 4626,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "Oral HPV16 infection increases the risk of oropharynx cancer."
    },
    {
        "id": 4627,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "A strong causal relationship has been established between oral HPV16 infection and oropharynx cancer."
    },
    {
        "id": 4628,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "HPV16 accounts for ~90% of cases, and HPV18, 33, and 35 are responsible for the vast majority of the small remaining fraction."
    },
    {
        "id": 4629,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "The prevalence of HPV16 is higher in oropharyngeal cancer than in cervical cancer (~50%), in which HPV18 is also highly prevalent."
    },
    {
        "id": 4630,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "Expression of the HPV E6 and E7 oncogenes inactivates the tumor suppressor proteins p53 and pRb, respectively."
    },
    {
        "id": 4631,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "Inactivation of p53 and pRb promotes genomic instability and the development of cancer and is responsible for the upregulation of p16 protein expression."
    },
    {
        "id": 4632,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "p16 protein expression is a reliable surrogate marker of the presence of HPV DNA in these tumors."
    },
    {
        "id": 4633,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "Genetic profiling of HPV-positive cancer has demonstrated it to be genetically distinct from HPV-negative squamous cell carcinoma of the head and neck (SCCHN)."
    },
    {
        "id": 4641,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "Patients with locally advanced HPV-positive SCCHN have improved response to treatment and survival (overall survival [OS] and progression-free survival [PFS]) when compared with HPV-negative tumors."
    },
    {
        "id": 4642,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 142,
        "content": "Patients receiving radiation therapy (RT) or chemoradiation have improved treatment response."
    },
    {
        "id": 4646,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "18 studies with 4424 patients with SCCHN showed that patients with tumors that are both HPV-positive and p16-positive had better 5-year OS and 5-year disease-free survival (DFS)."
    },
    {
        "id": 4647,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "Patients with tumors that are HPV-negative/p16-negative, HPV-positive/p16-negative, and HPV-negative/p16-positive had worse 5-year OS and 5-year disease-free survival (DFS) compared to patients with tumors that are both HPV-positive and p16-positive."
    },
    {
        "id": 4648,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "Patients with tumors that are HPV-negative/p16-positive had greater 5-year OS compared to patients with tumors that are p16-negative (regardless of HPV status)."
    },
    {
        "id": 4650,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "The impact of smoking and cancer stage on survival of patients with HPV-positive SCCHN has been investigated in numerous studies."
    },
    {
        "id": 4651,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "Analyses of patients with oropharyngeal cancer who were enrolled in RTOG 9003 or 0129 showed that smoking was associated with decreased OS and PFS, regardless of p16 status."
    },
    {
        "id": 4652,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "An analysis of data compiled from four cooperative group trials estimated that those who never smoked had a 51% reduction in risk of cancer progression when compared to those who formerly or currently smoked and had HPV-positive SCCHN."
    },
    {
        "id": 4653,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "A retrospective analysis from a clinical trial (RTOG 0129) showed no difference in the rate of distant metastasis in patients with p16-positive versus p16-negative disease."
    },
    {
        "id": 4654,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "Individuals with T4 or N3 disease or radiographically detectable matted lymph nodes may have a worse prognosis, and therefore should be excluded from deintensification trials."
    },
    {
        "id": 4656,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "The striking difference in prognosis for HPV-positive versus HPV-negative SCCHN led to the creation of new AJCC staging criteria in 2018."
    },
    {
        "id": 4657,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "The specific site of disease, histology, stage, and baseline comorbid conditions guide treatment decisions."
    },
    {
        "id": 4658,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "Single-modality treatment with surgery or RT is generally recommended for the approximately 30% to 40% of patients who present with early-stage disease (stage I or II) HPV-unrelated cancers."
    },
    {
        "id": 4660,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "RT with or without chemotherapy is nearly always preferred for all stages of nasopharyngeal carcinoma (NPC) and more advanced stages of HPV-associated oropharyngeal cancer."
    },
    {
        "id": 4661,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "The choice of surgery or RT as the primary treatment modality is often based on local institutional expertise and/or perceived relative morbidity of these treatment options."
    },
    {
        "id": 4662,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "Combined modality therapy is generally recommended for the approximately 60% of patients with locally or regionally advanced disease at diagnosis."
    },
    {
        "id": 4663,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "Participation in clinical trials is a preferred or recommended treatment option in many situations."
    },
    {
        "id": 4664,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "In formulating these NCCN Guidelines, panel members have tried to make them evidence-based while providing a statement of consensus as to the acceptable range of treatment options."
    },
    {
        "id": 4665,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "In numerous population-based studies, patients treated at high-volume centers appear to have better outcomes relative to patients treated at low-volume centers."
    },
    {
        "id": 4666,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 143,
        "content": "The initial evaluation and treatment planning for patients with H&N cancers requires a multidisciplinary team of health care providers with expertise in head and neck oncology."
    },
    {
        "id": 4674,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Sequelae following surgery, RT, and systemic therapy include trismus, pain, lymphedema and muscle spasm of the neck, xerostomia, dysphagia, speech and swallowing problems, dental and jaw decay, depression, peripheral neuropathy, hearing loss, and renal failure."
    },
    {
        "id": 4675,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Follow-up for sequelae should include a comprehensive H&N examination, supportive care, and rehabilitation."
    },
    {
        "id": 4676,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Adequate nutritional support can help to prevent severe weight loss in patients receiving treatment for head and neck cancers and shorten post-treatment recovery times."
    },
    {
        "id": 4677,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Patients should be encouraged to consult with a registered dietitian at diagnosis, during, and after treatment as needed."
    },
    {
        "id": 4678,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Dental care to prevent and treat radiation-related effects should be provided."
    },
    {
        "id": 4679,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Evaluation by a speech-language/swallowing therapist before and after treatment is highly recommended."
    },
    {
        "id": 4680,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Evaluation and management of lymphedema and trismus should be conducted as clinically indicated with appropriate referrals to occupational and physical therapy."
    },
    {
        "id": 4681,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Patients are at risk for depression from head and neck cancer and its sequelae, so screening for depression is advised."
    },
    {
        "id": 4682,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Fertility/reproductive counseling should be offered to patients who have these concerns."
    },
    {
        "id": 4686,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Cigarette smoking is associated with at least 30% of cancer deaths."
    },
    {
        "id": 4687,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Patients\u2019 history of tobacco use must be assessed."
    },
    {
        "id": 4688,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Patients should be encouraged to stop smoking and to modify excessive alcohol consumption."
    },
    {
        "id": 4689,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 144,
        "content": "Smoking cessation resources and support can be found in the NCCN Guidelines for Smoking Cessation."
    },
    {
        "id": 4703,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Examples of functionally unresectable disease include total pharyngectomy when reconstitution of the alimentary tract is not feasible."
    },
    {
        "id": 4704,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "The impact on quality of life and the need for continual supportive care are significant and open-ended in cases of functionally unresectable disease."
    },
    {
        "id": 4705,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Local and regional disease may be surgically treatable, but patients with distant metastases may not benefit from surgery."
    },
    {
        "id": 4706,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Disease with distant metastases is deemed inoperable."
    },
    {
        "id": 4707,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Surgery may still be considered for symptom palliation in select cases of incurable disease."
    },
    {
        "id": 4713,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Comorbidity refers to the presence of concomitant disease(s) in addition to Head and Neck cancers."
    },
    {
        "id": 4714,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Comorbidity may affect diagnosis, treatment, and prognosis."
    },
    {
        "id": 4715,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Documentation of comorbidity is important to facilitate optimal treatment selection."
    },
    {
        "id": 4716,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Comorbidity is a strong independent predictor for mortality in patients with Head and Neck cancers."
    },
    {
        "id": 4717,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Comorbidity also influences quality of life and health care costs and utilization."
    },
    {
        "id": 4718,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "The Adult Comorbidity Evaluation-27 is a validated instrument for assessing comorbidity in numerous cancer types including Head and Neck cancers."
    },
    {
        "id": 4720,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Health-related quality of life issues are important in patients with Head and Neck cancers."
    },
    {
        "id": 4725,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Patient-completed scales should be used to measure quality of life."
    },
    {
        "id": 4726,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "The University of Washington Quality of Life Questionnaire is a validated and accepted measure for Head and Neck cancer-specific issues."
    },
    {
        "id": 4727,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module is a validated and accepted measure for Head and Neck cancer-specific issues."
    },
    {
        "id": 4728,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "The Functional Assessment of Cancer Therapy Head and Neck scale is a validated and accepted measure for Head and Neck cancer-specific issues."
    },
    {
        "id": 4731,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Appropriate selection and utilization of imaging studies is crucial for proper care of patients with Head and Neck cancers."
    },
    {
        "id": 4732,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 145,
        "content": "Initial imaging of the primary site is performed with CT and/or MRI."
    },
    {
        "id": 4739,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "CT is complementary to MRI for evaluation of bony erosion or cartilage invasion in Head and Neck tumors."
    },
    {
        "id": 4740,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "MRI is needed to evaluate the extent of bone marrow invasion in patients with oral cavity cancers that involve the bone."
    },
    {
        "id": 4741,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "CT may be appropriate to evaluate cortical bone erosion or periosteal invasion in patients with oral cavity cancers that involve the bone."
    },
    {
        "id": 4745,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "FDG PET/CT has a higher accuracy than CT or MRI for detecting locoregional nodal and distant metastases in patients with Head and Neck cancers."
    },
    {
        "id": 4746,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "A meta-analysis showed that the positive predictive value of FDG PET/CT for detection of cervical lymph node involvement in patients with clinically node-negative SCCHN was 0.62."
    },
    {
        "id": 4747,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "A meta-analysis showed that the negative predictive value of FDG PET/CT for detection of cervical lymph node involvement in patients with clinically node-negative SCCHN was 0.83."
    },
    {
        "id": 4752,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "Contrast-enhanced chest CT can be used to evaluate pulmonary metastases and/or mediastinal lymph node involvement."
    },
    {
        "id": 4753,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "Contrast-enhanced brain MRI can be used to evaluate brain metastases or skull base invasion."
    },
    {
        "id": 4758,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "Imaging is often part of response assessment following definitive therapy."
    },
    {
        "id": 4759,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "Careful consideration should be given as to the type of imaging performed in response assessment."
    },
    {
        "id": 4763,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "Postoperative imaging is recommended if there are signs of early recurrence or for patients considered high risk of early recurrence."
    },
    {
        "id": 4765,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 146,
        "content": "Patients with positive margins, advanced T or N stage, or oral cavity cancers are at particular risk for rapid recurrence after surgery."
    },
    {
        "id": 4769,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "The panel generally recommends imaging 3 to 4 months after the end of treatment."
    },
    {
        "id": 4775,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "Careful and regular follow-up examinations are recommended."
    },
    {
        "id": 4776,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "Follow-up examinations are recommended to detect local or regional recurrence early."
    },
    {
        "id": 4777,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "After RT-based treatment, evaluation with imaging guides the use of neck dissection."
    },
    {
        "id": 4778,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "Imaging modalities used for evaluation include CT and/or MRI with contrast or FDG PET/CT."
    },
    {
        "id": 4779,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "A meta-analysis of 27 studies showed that the PPV and NPV for PET or PET/CT to detect local residual or recurrent disease were 52.7% and 96.3%, respectively."
    },
    {
        "id": 4780,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "A meta-analysis of 27 studies showed that the PPV and NPV for PET or PET/CT to detect nodal residual or recurrent disease were 72.3% and 88.3%, respectively."
    },
    {
        "id": 4781,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "If PET/CT is used for follow-up, the first scan should be performed at a minimum of 12 weeks after treatment."
    },
    {
        "id": 4782,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "Performing PET/CT at a minimum of 12 weeks after treatment reduces the false-positive rate."
    },
    {
        "id": 4787,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "A complete clinical response is defined as no visible or palpable evidence of residual disease and no concerning findings on CT or MRI."
    },
    {
        "id": 4788,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "A complete pathologic response requires pathologic confirmation."
    },
    {
        "id": 4789,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "If a complete clinical response to RT-based treatment has been achieved, then the panel recommends observing the patient."
    },
    {
        "id": 4790,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "In patients who have a clinically negative neck, PET/CT is associated with NPVs ranging from 97% to 100%."
    },
    {
        "id": 4791,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "Panel members concur that any patient with residual disease after RT-based treatment should be considered for surgical resection for refractory disease."
    },
    {
        "id": 4792,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "Surgical resection for refractory disease may include a neck dissection if indicated."
    },
    {
        "id": 4793,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "If the residual, persistent, or progressing disease is unresectable, then these patients should receive systemic therapy and/or RT."
    },
    {
        "id": 4794,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "Systemic therapy and/or RT should be given to patients with unresectable residual, persistent, or progressing disease."
    },
    {
        "id": 4795,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "For patients with equivocal PET/CT scan results in the neck, a repeat PET/CT scan 4 to 6 weeks later may help identify those patients who can be safely observed without surgery to the neck."
    },
    {
        "id": 4797,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "Recurrences in patients with H&N cancer tend to occur in the first 3 years following treatment."
    },
    {
        "id": 4798,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "More recurrences occur earlier rather than later in the 3-year interval."
    },
    {
        "id": 4801,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 147,
        "content": "A meta-analysis including seven studies with 577 scans showed that FDG PET/CT showed high sensitivity and specificity values for detection of H&N cancer recurrence 12 months after treatment."
    },
    {
        "id": 4807,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "H&N cancer treatment can result in fibrosis and altered anatomy."
    },
    {
        "id": 4808,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Fibrosis and altered anatomy frequently lead to challenges in physical examination."
    },
    {
        "id": 4809,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Follow-up imaging may assist in physical examination."
    },
    {
        "id": 4810,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "The plan for long-term surveillance should consider tumor site, stage, prognostic factors, presence of symptoms, and changes based on clinical examination."
    },
    {
        "id": 4811,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Neck ultrasound is widely available, inexpensive, safe, and accurate."
    },
    {
        "id": 4812,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Neck ultrasound may be used to evaluate suspected nodal disease."
    },
    {
        "id": 4813,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Routine annual imaging using the pretreatment imaging modality may be indicated for areas difficult to visualize by clinical examination."
    },
    {
        "id": 4814,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "The pretreatment imaging modality is usually CT or MRI."
    },
    {
        "id": 4815,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "The impact of annual screening for lung metastasis or synchronous lung cancer in patients with a heavy smoking history is an area in need of investigation."
    },
    {
        "id": 4816,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Annual low-resolution chest CT should be considered for patients with a heavy smoking history."
    },
    {
        "id": 4818,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "There is limited sensitivity of chest x-ray for lung screening."
    },
    {
        "id": 4819,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "RT treatment is associated with development of carotid artery stenosis."
    },
    {
        "id": 4820,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "RT dose to the carotid artery is associated with increased stroke risk."
    },
    {
        "id": 4822,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "All patients should be evaluated by an H&N surgical oncologist before treatment."
    },
    {
        "id": 4823,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Multidisciplinary evaluation and treatment should be well coordinated."
    },
    {
        "id": 4824,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Minimally invasive surgery may be useful for decreasing morbidity."
    },
    {
        "id": 4825,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Transoral resection using robotic, endoscopic, or direct access surgery may offer advantages over conventional methods for H&N cancer surgery."
    },
    {
        "id": 4827,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Postoperative hemorrhage is reported in 13% to 16% of patients who are treated with transoral robotic surgery."
    },
    {
        "id": 4828,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "The risk of postoperative hemorrhage can be reduced through use of appropriate surgical strategies."
    },
    {
        "id": 4829,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "TORS is associated with favorable QOL and swallowing outcomes."
    },
    {
        "id": 4830,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Outcome may vary depending on baseline function, T stage, and adjuvant treatment."
    },
    {
        "id": 4832,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Cervical lymph node dissections have been classified as radical or modified radical procedures historically."
    },
    {
        "id": 4833,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "The NCCN Panel prefers to classify cervical lymphadenectomy using contemporary nomenclature."
    },
    {
        "id": 4834,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Cervical lymph node dissections are classified as either comprehensive or selective."
    },
    {
        "id": 4835,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "A comprehensive neck dissection removes all lymph node groups that would be included in a classic radical neck dissection."
    },
    {
        "id": 4837,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Comprehensive neck dissection is often recommended for N3 disease."
    },
    {
        "id": 4838,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Selective neck dissections have been developed based on the common pathways for spread of H&N cancers to regional nodes."
    },
    {
        "id": 4839,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 148,
        "content": "Selective neck dissection is often recommended for N0 disease."
    },
    {
        "id": 4843,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "A selective neck dissection is recommended to remove the nodes most commonly involved with metastases from the oral cavity."
    },
    {
        "id": 4845,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "A selective neck dissection is recommended to remove the nodes most commonly involved with metastases from the pharynx and larynx."
    },
    {
        "id": 4847,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "SCCHN with no clinical nodal involvement rarely presents with nodal metastasis beyond the confines of an appropriate selective neck dissection (<10% of the time)."
    },
    {
        "id": 4849,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "Selective neck dissections may be used as treatment when neck tumor burden is low."
    },
    {
        "id": 4850,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "Patients undergoing selective neck dissection should not have clinical nodal disease."
    },
    {
        "id": 4851,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "Selective neck dissection may prevent morbidity as opposed to comprehensive neck dissection in patients with low-volume nodal disease."
    },
    {
        "id": 4852,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "Selective neck dissection may be used in certain patients with N1\u2013N2 disease."
    },
    {
        "id": 4853,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "In patients with pathologically positive lymph nodes, radiation with or without chemotherapy should be considered."
    },
    {
        "id": 4854,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "A decision should be made following multidisciplinary evaluation in patients with pathologically positive lymph nodes."
    },
    {
        "id": 4855,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "In the NCCN Guidelines, patients with cervical node metastases who undergo operations with therapeutic intent are generally treated with cervical lymphadenectomy."
    },
    {
        "id": 4856,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "Cervical lymphadenectomy removes all clinically positive nodes, other levels of the neck that may be at high risk for harboring metastasis, and non-lymphatic structures that are directly involved with cancer."
    },
    {
        "id": 4857,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "Determining whether an ipsilateral or bilateral neck dissection is needed depends on location and the extent of the tumor."
    },
    {
        "id": 4858,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "Bilateral lymphatic drainage is likely for tumors that approach or involve the midline."
    },
    {
        "id": 4859,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "When anatomic imaging and/or fine-needle aspiration (FNA) identify pathologic adenopathy bilaterally, both sides of the neck should be dissected."
    },
    {
        "id": 4861,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "Many factors influence survival and locoregional tumor control in patients with H&N cancers."
    },
    {
        "id": 4862,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "The role of systemic therapy/RT in the postoperative care of the patient with adverse prognostic risk factors has been clarified by two separate multicenter randomized trials for patients with high-risk cancers of the oral cavity, oropharynx, larynx, or hypopharynx."
    },
    {
        "id": 4868,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "Patients in both trials with extranodal extension of tumor and/or positive resection margins benefited from the addition of cisplatin to postoperative RT."
    },
    {
        "id": 4869,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 149,
        "content": "For those with multiple involved regional nodes without extranodal extension, there was no survival advantage."
    },
    {
        "id": 4878,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 150,
        "content": "Performance status and physiologic reserve should be taken into consideration before recommending postoperative concurrent chemoradiotherapy in patients with high-risk pathology."
    },
    {
        "id": 4879,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 150,
        "content": "A randomized phase III trial from a single institution in India compared cisplatin 30 mg/m2 weekly to cisplatin 100 mg/m2 every 3 weeks, when given concurrently with RT, in 300 patients with locally advanced SCCHN."
    },
    {
        "id": 4883,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 150,
        "content": "A schedule using cisplatin at 50 mg intravenously weekly has also been shown to improve survival in the adjuvant setting in a randomized trial."
    },
    {
        "id": 4884,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 150,
        "content": "In the randomized phase II RTOG-0234 trial, two regimens in patients with stage III and IV SCCHN were compared."
    },
    {
        "id": 4885,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 150,
        "content": "Patients randomized to receive docetaxel experienced a 31% reduction in DFS failure rate."
    },
    {
        "id": 4886,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 150,
        "content": "Patients randomized to receive docetaxel experienced a 44% reduction in mortality."
    },
    {
        "id": 4888,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 150,
        "content": "For patients with high-risk adverse pathologic features following surgery who are ineligible for platinum therapy, docetaxel/cetuximab is a category 2B option for postoperative systemic therapy/RT."
    },
    {
        "id": 4889,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 150,
        "content": "Patients with advanced carcinoma who undergo nonsurgical treatment need very close follow-up both to evaluate for local recurrence and to assess for ipsilateral or contralateral neck recurrence."
    },
    {
        "id": 4890,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 150,
        "content": "Surgery is recommended as indicated for patients who do not have a complete clinical response to systemic therapy/RT."
    },
    {
        "id": 4891,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 150,
        "content": "Panel members emphasized that it may be difficult to detect local or regional recurrence due to radiation-related tissue changes, and this may result in a delayed diagnosis of persistent or recurrent disease."
    },
    {
        "id": 4892,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 150,
        "content": "Panel members also emphasized the increased risk of complications when surgery in patients with relapsed/refractory disease is attempted."
    },
    {
        "id": 4897,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "Patients may require microvascular free tissue transfer to reconstruct the surgical defect at the primary site."
    },
    {
        "id": 4898,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "Patients undergoing neck dissection may develop complications related to delayed wound healing, skin necrosis, or carotid exposure."
    },
    {
        "id": 4899,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "Laryngectomy may be indicated to obtain clear surgical margins or to prevent aspiration in patients with advanced oropharyngeal cancer."
    },
    {
        "id": 4900,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "After laryngectomy for relapsed/refractory disease, patients may have a higher incidence of pharyngocutaneous fistula, pharyngeal and stomal stenosis, and other wound complications."
    },
    {
        "id": 4901,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "Flaps may be advantageous for reconstructing the laryngopharyngeal defect or buttressing the suture line if the pharynx can be closed primarily."
    },
    {
        "id": 4904,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "A thorough understanding of the natural history, anatomy, clinical circumstances, and imaging of specific disease conditions continues to guide the use of radiation as primary or adjuvant treatment."
    },
    {
        "id": 4909,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "When radiation is given with definitive intent, the dosages prescribed for gross disease are fairly standard, usually in the range of 70 Gy."
    },
    {
        "id": 4910,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "The dosages prescribed for gross disease are usually in the range of 70 Gy (at approximately 2 Gy/fraction/day) for the following sites: lip, oral cavity, nasopharynx, oropharynx, hypopharynx, glottic larynx, supraglottic larynx, occult primary, salivary gland tumors, and MM."
    },
    {
        "id": 4911,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "A second dose (often approximately 60 Gy, but varies) may be used to cover volumes considered at the highest risk for microscopic spread."
    },
    {
        "id": 4912,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "A lower dose (often approximately 50 Gy, but varies) is used for volumes treated electively with low risk for microscopic spread."
    },
    {
        "id": 4918,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "Selection of an exact radiation dose prescription and schedule of delivery depends on the primary tumor and neck node size."
    },
    {
        "id": 4919,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "Selection of an exact radiation dose prescription and schedule of delivery depends on whether altered fractionation is used."
    },
    {
        "id": 4920,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "Selection of an exact radiation dose prescription and schedule of delivery depends on clinical circumstances, including whether concurrent systemic therapy will be used."
    },
    {
        "id": 4921,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "The dose may need to be decreased if it is prescribed very close to adjacent organ at risk (eg, brain, cochlea, optic chiasm and nerves, spinal cord)."
    },
    {
        "id": 4922,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 151,
        "content": "Precise target definition and delineation is crucial, and on-treatment imaging should be used to ensure accurate radiation delivery."
    },
    {
        "id": 4926,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Significant weight loss may necessitate repeat imaging and treatment replanning."
    },
    {
        "id": 4927,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "When treating definitively using conventional fractionation, the primary tumor and involved lymph nodes generally require a total of 66 Gy (2.0\u20132.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction)."
    },
    {
        "id": 4928,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Some clinicians feel that the fractionation should be slightly modified for areas considered highly sensitive to radiation, such as neural structures."
    },
    {
        "id": 4929,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "In these cases, additional fractions can be added depending on clinical circumstances to increase the total physical dose."
    },
    {
        "id": 4930,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "A hyperfractionated schedule allows gross disease to be prescribed a dose up to 81.6 Gy (at 1.2 Gy/fraction)."
    },
    {
        "id": 4931,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Hyperfractionation has been used for situations when tumor is abutting brain or optic structures."
    },
    {
        "id": 4932,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Care must be taken if prescribed doses exceed 72 Gy using conventional fractionation (2.0 Gy/fraction), as this may lead to unacceptable rates of normal tissue injury."
    },
    {
        "id": 4940,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Postoperative irradiation is recommended based on stage, histology, and surgical-pathologic findings."
    },
    {
        "id": 4941,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Postoperative RT is recommended for selected risk factors, including advanced T stage, close surgical margins, depth or extent of invasion, multiple positive nodes, or perineural/lymphovascular invasion."
    },
    {
        "id": 4942,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "High doses of postoperative RT alone (eg, 66 Gy) and/or systemic therapy/RT are recommended for high-risk features of extranodal extension and/or positive margins."
    },
    {
        "id": 4943,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "The preferred maximum elapsed time interval between surgical resection and the start of postoperative RT is 6 weeks or less."
    },
    {
        "id": 4944,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Postoperative radiation fractionation schedules tend to be similar (60\u201366 Gy at 2 Gy/fraction) whether or not systemic therapy is administered concurrently with postoperative RT."
    },
    {
        "id": 4945,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Hypofractionation may be considered for patients who are not good candidates for an extended course of several weeks of RT due to comorbidities."
    },
    {
        "id": 4946,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "No single fractionation schedule has proven to be best for all tumors."
    },
    {
        "id": 4947,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Data strongly indicate that SCCHN can grow rapidly and may compensate for RT-induced cell loss through the mechanism of accelerated repopulation."
    },
    {
        "id": 4948,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Schedules delivering at least 1000 cGy per week to gross disease are recommended in the RT-alone setting."
    },
    {
        "id": 4949,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Some tumors, such as those of the salivary gland, may have slower cell kinetics."
    },
    {
        "id": 4950,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 152,
        "content": "Trials in early-stage laryngeal glottic cancer have shown higher recurrence rates with daily fraction sizes less than 200 cGy where the cumulative weekly dose is less than 1000 cGy."
    },
    {
        "id": 4954,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "Two large randomized trials from Europe have reported improved locoregional control using altered fractionation as compared to conventional fractionation, when concurrent chemotherapy is not given."
    },
    {
        "id": 4955,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "The EORTC protocol 22791 compared hyperfractionation with conventional fractionation in the treatment of T2, T3, N0\u20131 oropharyngeal carcinoma excluding base of tongue primaries."
    },
    {
        "id": 4960,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "A long-term follow-up analysis has also shown a small survival advantage for hyperfractionation (P = .05) in the EORTC protocol 22791."
    },
    {
        "id": 4961,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "The EORTC protocol 22851 compared accelerated fractionation with conventional fractionation in various intermediate to advanced H&N cancers (excluding cancers of the hypopharynx)."
    },
    {
        "id": 4964,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "Patients in the accelerated fractionation arm had significantly better locoregional control at 5 years (P = .02) in the EORTC protocol 22851."
    },
    {
        "id": 4965,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "Disease-specific survival (DSS) showed a trend in favor of the accelerated fractionation arm (P = .06) in the EORTC protocol 22851."
    },
    {
        "id": 4967,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "The RTOG reported the results of a four-arm, phase III, randomized clinical trial (RTOG 90-03) comparing hyperfractionation and two variants of accelerated fractionation versus standard fractionation."
    },
    {
        "id": 4968,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "Hyperfractionation was associated with improved locoregional control and DFS compared with standard fractionation in the RTOG 90-03 trial."
    },
    {
        "id": 4969,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "Accelerated fractionation using a concomitant boost (AFX-C) was associated with improved locoregional control and DFS compared with standard fractionation in the RTOG 90-03 trial."
    },
    {
        "id": 4972,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "Long-term follow-up confirmed a statistically significant improvement in locoregional control and OS with hyperfractionation compared to standard fractionation in the RTOG 90-03 trial."
    },
    {
        "id": 4973,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "The MARCH meta-analysis, including individual patient data from 15 randomized trials, analyzed the effect of hyperfractionated or accelerated RT on survival of patients with H&N cancers."
    },
    {
        "id": 4975,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "An absolute survival benefit for altered fractionation of 3.4% at 5 years (HR, 0.92; 95% CI, 0.86\u20130.97; P = .003) was reported in the MARCH meta-analysis."
    },
    {
        "id": 4979,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "Consensus on the optimal use of altered fractionation schedules using either concomitant boost or hyperfractionation for stage III or IV oral cavity, oropharynx, supraglottic larynx, and hypopharyngeal squamous cell cancers has not yet emerged among NCCN Member Institutions."
    },
    {
        "id": 4980,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "Panel members generally agree on conventionally fractionated radiation in combination with most concurrent systemic therapies in the definitive treatment setting."
    },
    {
        "id": 4981,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 153,
        "content": "Most published studies have used conventional fractionation (at 2.0 Gy/fraction to a typical dose of 70 Gy in 7 weeks) with single-agent high-dose cisplatin (given every 3 weeks at 100 mg/m2)."
    },
    {
        "id": 4987,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "Chemotherapy is more efficacious than altered fractionation alone in some cases."
    },
    {
        "id": 4988,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "The GORTEC 99-02 trial reported that altered fractionation did not improve outcomes when compared with conventional fractionation given with concurrent chemotherapy."
    },
    {
        "id": 4989,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "The RTOG 0129 trial assessed accelerated fractionation with two cycles of concurrent cisplatin versus standard fractionation with three cycles of concurrent cisplatin."
    },
    {
        "id": 4990,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "There was no significant difference in overall survival between the two arms in the RTOG 0129 trial."
    },
    {
        "id": 4991,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "Accelerated fractionation is not clearly more efficacious than conventional fractionation in the setting of concurrent chemotherapy."
    },
    {
        "id": 4992,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "Concurrent chemoradiation increases acute toxicity compared to radiation alone."
    },
    {
        "id": 4993,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "An increase in late toxicity beyond that caused by RT alone is less clearly established."
    },
    {
        "id": 4994,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "Altered fractionation and/or multiagent systemic therapy may further increase the toxicity burden."
    },
    {
        "id": 4995,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "For any chemotherapeutic approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration."
    },
    {
        "id": 4996,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "Chemoradiation should be performed by an experienced team and should include state-of-the-art supportive care."
    },
    {
        "id": 4997,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "IMRT is a highly advanced form of CRT permitting more precise cancer targeting while reducing dose to normal tissues."
    },
    {
        "id": 4998,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "IMRT has displaced older techniques in the treatment of most H&N malignancies over the last 15 years."
    },
    {
        "id": 4999,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "IMRT dose painting, also known as SIB, refers to the method of assigning different dose levels to different anatomic areas."
    },
    {
        "id": 5000,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "Dose painting has been used to improve the specificity of radiation delivery to tumors and thereby reduce unwanted radiation of uninvolved areas."
    },
    {
        "id": 5003,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "A meta-analysis including seven studies showed no significant difference in survival outcomes or grade 3 or higher adverse events between SIB-IMRT and sequential boost-IMRT."
    },
    {
        "id": 5007,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "IMRT has been clearly proven to reduce long-term toxicities."
    },
    {
        "id": 5008,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 154,
        "content": "Xerostomia is a common long-term side effect of RT, which can be ameliorated with use of IMRT, drug therapy, salivary substitutes, and other novel approaches."
    },
    {
        "id": 5012,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 155,
        "content": "Radiotherapy techniques have evolved to IMRT."
    },
    {
        "id": 5013,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 155,
        "content": "Numerous phase II and III studies show that IMRT decreases late toxicity (xerostomia) without compromising tumor control for nasopharyngeal, oropharyngeal, sinonasal, and other sites."
    },
    {
        "id": 5014,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 155,
        "content": "Pow et al evaluated treatment of early-stage NPC with conventional RT techniques versus with IMRT."
    },
    {
        "id": 5015,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 155,
        "content": "The results showed a statistical improvement in salivary flow and in patient-reported QOL parameters."
    },
    {
        "id": 5016,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 155,
        "content": "Kam et al randomly assigned patients with NPC to either IMRT or conventional 2D-RT."
    },
    {
        "id": 5017,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 155,
        "content": "At 1 year after treatment, patients in the IMRT arm had significantly lower rates of clinician-rated severe xerostomia than patients in the 2D-RT arm."
    },
    {
        "id": 5018,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 155,
        "content": "Salivary flow rates were also higher with IMRT."
    },
    {
        "id": 5027,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 155,
        "content": "IMRT likely reduces other long-term toxicities due to decreased radiation doses to structures such as pharyngeal constrictors, larynx, temporal lobes, mandible, auditory structures (including cochlea), and optic structures."
    },
    {
        "id": 5028,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 155,
        "content": "IMRT is particularly useful in avoiding excess radiation of the optic pathway in patients with sinonasal malignancies."
    },
    {
        "id": 5029,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 155,
        "content": "Retrospective analyses including 2993 patients who received RT for treatment of H&N cancer showed that patients who received IMRT had a shorter duration of feeding tube placement, compared to those who received 3D-RT."
    },
    {
        "id": 5058,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 156,
        "content": "Brachytherapy is a uniquely conformal modality that is considered to be effective and safe when delivered by an experienced team of practitioners."
    },
    {
        "id": 5064,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 157,
        "content": "Brachytherapy may have a role in other select clinical scenarios such as reirradiation, as a boost for highly refractory disease or a positive surgical margin, or when extremely conformal radiation delivery is needed to a very well-defined tumor location."
    },
    {
        "id": 5066,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 157,
        "content": "Stereotactic body RT (SBRT) is an advanced technique of external beam RT (EBRT) that delivers large ablative doses of radiation in a limited number of fractions."
    },
    {
        "id": 5078,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 157,
        "content": "Systemic therapy for locally advanced squamous cell carcinoma of the head and neck is recommended for locoregionally advanced and metastatic disease."
    },
    {
        "id": 5080,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 157,
        "content": "Primary systemic therapy with concurrent RT is a treatment option for locally advanced squamous cell carcinoma of the head and neck."
    },
    {
        "id": 5081,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 157,
        "content": "Randomized trials and meta-analyses showed significantly improved OS, DFS, and locoregional control when a systemic therapy and RT regimen was compared with RT alone for locally advanced disease."
    },
    {
        "id": 5082,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 157,
        "content": "High-dose cisplatin plus RT is the most studied effective systemic therapy/RT regimen."
    },
    {
        "id": 5101,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "Epidermal growth factor receptor overexpression is common in SCCHN and is associated with poor survival outcomes."
    },
    {
        "id": 5103,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "Locoregional control and median OS were significantly improved in patients treated with RT and cetuximab compared to RT alone."
    },
    {
        "id": 5104,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "The five-year OS was 45.6% in patients treated with RT and cetuximab and 36.4% in patients who received RT alone."
    },
    {
        "id": 5105,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "The randomized phase III RTOG 0522 trial showed that the addition of cetuximab to cisplatin and RT did not significantly improve OS, compared to cisplatin and RT, in patients with stage III or IV SCCHN."
    },
    {
        "id": 5106,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "The phase III GORTEC 2007-01 trial compared cetuximab combined with carboplatin/5-FU and RT to cetuximab and RT."
    },
    {
        "id": 5107,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "Three-year PFS and locoregional failure rates were better with the combination regimen, but OS and distant metastases rates were not significantly improved."
    },
    {
        "id": 5108,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "Grade 3 or 4 mucositis and hospitalization for toxicity were more prevalent in patients who received cetuximab combined with carboplatin/5-FU and RT."
    },
    {
        "id": 5109,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "Cetuximab combined with chemoradiation is not recommended as treatment for SCCHN."
    },
    {
        "id": 5110,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "In three randomized phase III trials, cetuximab and RT was compared to cisplatin and RT as a deintensification treatment strategy for HPV-positive locally advanced oropharyngeal cancer, but cetuximab and RT proved to be inferior to cisplatin."
    },
    {
        "id": 5111,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "In the RTOG 1016 non-inferiority trial, 849 patients with locally advanced HPV-positive oropharyngeal cancer were randomized to receive accelerated IMRT with either cetuximab or cisplatin."
    },
    {
        "id": 5112,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "After a median follow-up of 4.5 years, the cetuximab arm did not meet the criterion for noninferiority."
    },
    {
        "id": 5113,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "Five-year OS was 77.9% for the cetuximab arm and 84.6% for the cisplatin arm."
    },
    {
        "id": 5114,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "PFS and risk of locoregional failure were significantly worse in the cetuximab arm compared to the cisplatin arm."
    },
    {
        "id": 5115,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "In the randomized phase III De-ESCALaTE HPV trial, cetuximab and RT was compared to cisplatin and RT in 334 patients with locally advanced p16-positive oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 5116,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 158,
        "content": "Patients given cisplatin and RT had significantly better 2-year OS and a lower recurrence rate compared to patients given cetuximab and RT."
    },
    {
        "id": 5121,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "A trial, MS-20, involved 189 patients with intermediate-risk HPV-positive oropharyngeal cancer."
    },
    {
        "id": 5122,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "The patients in the trial were randomized to receive 70 Gy RT with either weekly cisplatin or cetuximab."
    },
    {
        "id": 5123,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "The 3-year failure-free survival was 93% in the RT/cisplatin arm and 80% in the RT/cetuximab arm."
    },
    {
        "id": 5124,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "There was a significant difference in the 3-year failure-free survival between the RT/cisplatin arm and the RT/cetuximab arm (P = .015)."
    },
    {
        "id": 5125,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "Three phase III trials demonstrated that cetuximab and RT was inferior to cisplatin and RT in patients with HPV-positive locally advanced oropharyngeal cancer."
    },
    {
        "id": 5126,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "The panel recommends high-dose cisplatin as the preferred systemic agent for treatment of locoregionally advanced HPV-positive oropharyngeal cancer."
    },
    {
        "id": 5127,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "Weekly cisplatin is also an option for treatment of locoregionally advanced HPV-positive oropharyngeal cancer."
    },
    {
        "id": 5128,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "An NRG trial is currently in progress for comparing high-dose cisplatin to weekly cisplatin in locally advanced SCCHN (NCT05050162)."
    },
    {
        "id": 5129,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "There is a lack of consensus among NCCN Member Institutions regarding the role of induction chemotherapy in the management of locally advanced SCCHN."
    },
    {
        "id": 5130,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "The NCCN Panel has a category 3 recommendation for induction chemotherapy for the management of locoregionally advanced p16-negative and p16-positive oropharyngeal cancer."
    },
    {
        "id": 5132,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "Induction chemotherapy is listed as a category 2A designation for selected patients with hypopharyngeal and laryngeal cancers (with less than T4a in extent, for which total laryngectomy is indicated)."
    },
    {
        "id": 5133,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "Panel members feel that induction chemotherapy should only be administered at sites with expertise in these regimens."
    },
    {
        "id": 5134,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "Induction chemotherapy may complicate the subsequent delivery of definitive RT or systemic therapy/RT."
    },
    {
        "id": 5135,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "Most randomized trials comparing induction chemotherapy followed by RT and/or surgery to locoregional treatment alone did not show an improvement in OS with the incorporation of induction chemotherapy."
    },
    {
        "id": 5136,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "In some studies, a lower rate of distant metastases was noted with induction chemotherapy."
    },
    {
        "id": 5137,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "A correlation was noted between favorable tumor response to induction chemotherapy and durable disease control with subsequent RT."
    },
    {
        "id": 5138,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "The hypothesis was developed that induction chemotherapy could facilitate organ preservation, avoid morbid surgery, and improve QOL of patients although OS was not improved."
    },
    {
        "id": 5139,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "Total laryngectomy is among the procedures most feared by patients."
    },
    {
        "id": 5140,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "Larynx preservation was the focus of initial studies of induction chemotherapy."
    },
    {
        "id": 5141,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "Two randomized studies established the role of induction cisplatin/5-FU followed by definitive RT in responding patients as an alternative treatment to total laryngectomy and postoperative RT, offering potential larynx preservation without compromise in OS."
    },
    {
        "id": 5142,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "The utilization of induction chemotherapy has decreased with time."
    },
    {
        "id": 5143,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "Randomized trials and related meta-analyses indicated that concurrent systemic therapy/RT offered superior locoregional tumor control and OS compared to RT alone."
    },
    {
        "id": 5144,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 159,
        "content": "Meta-analyses reported that concurrent systemic therapy/RT was more efficacious than an induction chemotherapy followed by definitive RT strategy."
    },
    {
        "id": 5148,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "The Intergroup 91-11 trial compared RT alone, concurrent cisplatin/RT, and induction cisplatin/5-FU followed by RT."
    },
    {
        "id": 5149,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "All arms of the Intergroup 91-11 trial offered surgery for locally relapsed/refractory disease."
    },
    {
        "id": 5150,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "The concurrent cisplatin/RT arm had the highest larynx preservation rate."
    },
    {
        "id": 5151,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Long-term follow-up of the 91-11 trial confirmed that concomitant systemic therapy/RT improved the larynx preservation rate."
    },
    {
        "id": 5152,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Long-term follow-up of the 91-11 trial confirmed that induction chemotherapy was not superior to RT alone."
    },
    {
        "id": 5153,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "OS did not differ among the three treatment arms of the 91-11 trial."
    },
    {
        "id": 5154,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "There is interest in the role of induction chemotherapy for several reasons."
    },
    {
        "id": 5155,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Advances in surgery, RT, and concurrent systemic therapy/RT have yielded improvements in locoregional control."
    },
    {
        "id": 5156,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Distant metastases have increased as a source of treatment failure."
    },
    {
        "id": 5157,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Induction chemotherapy allows greater drug delivery as a strategy to prevent distant metastases."
    },
    {
        "id": 5158,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Clinicians have increasing concern regarding the long-term morbidity of concurrent systemic therapy/RT."
    },
    {
        "id": 5159,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Clinicians are interested in exploring alternative approaches that might have a more favorable long-term side effect profile."
    },
    {
        "id": 5160,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "A more effective triplet induction chemotherapy regimen was identified compared to the standard cisplatin/5-FU used in the induction trials of the 1980s and 1990s."
    },
    {
        "id": 5161,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Three phase III trials compared induction cisplatin plus 5-FU with or without the addition of a taxane (docetaxel or paclitaxel) followed by the same locoregional treatment in both groups."
    },
    {
        "id": 5162,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Results showed significantly improved outcomes for patients in the three-drug induction group compared to those receiving two drugs (cisplatin plus 5-FU)."
    },
    {
        "id": 5163,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "A randomized phase III trial in the larynx preservation setting similarly showed superior larynx preservation outcome with induction docetaxel/cisplatin/5-FU (TPF) compared to cisplatin/5-FU."
    },
    {
        "id": 5164,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "A meta-analysis including five randomized controlled trials (RCTs) showed that the TPF induction chemotherapy regimen, compared to cisplatin plus 5-FU, was associated with reduced risk of death."
    },
    {
        "id": 5165,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "The TPF induction chemotherapy regimen, compared to cisplatin plus 5-FU, was associated with greater reductions in progression."
    },
    {
        "id": 5166,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "The TPF induction chemotherapy regimen, compared to cisplatin plus 5-FU, was associated with greater reductions in locoregional failure."
    },
    {
        "id": 5167,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "The TPF induction chemotherapy regimen, compared to cisplatin plus 5-FU, was associated with greater reductions in distant failure."
    },
    {
        "id": 5168,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Whether adding induction chemotherapy to concurrent chemoradiation results in a clear advantage in OS continues to be unclear."
    },
    {
        "id": 5169,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "The DeCIDE and the PARADIGM trials did not convincingly show a survival advantage with the incorporation of induction chemotherapy."
    },
    {
        "id": 5170,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "A randomized phase II study compared induction TPF followed by concurrent cisplatin/5-FU with RT versus concurrent cisplatin/5-FU with RT alone."
    },
    {
        "id": 5171,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "A higher radiologic complete response rate was reported with the incorporation of induction chemotherapy."
    },
    {
        "id": 5172,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Results from a larger follow-up study suggest a survival advantage."
    },
    {
        "id": 5173,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Other induction chemotherapy regimens have been evaluated in phase II trials."
    },
    {
        "id": 5174,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "The ECOG-ACRIN trial (E2303) showed promising results in terms of primary site response and survival for cetuximab, paclitaxel, and carboplatin as induction chemotherapy."
    },
    {
        "id": 5175,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "The incremental benefit of induction chemotherapy requires validation using randomized design."
    },
    {
        "id": 5176,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "Two phase II studies evaluated the feasibility of TPF with cetuximab followed by systemic therapy/RT or RT alone."
    },
    {
        "id": 5177,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "The DeLOS-II trial showed that TPF followed by RT, with cetuximab administered throughout, was feasible but not superior to TPF and subsequent RT without cetuximab."
    },
    {
        "id": 5178,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "An EORTC trial evaluating this induction regimen followed by systemic therapy/RT was stopped prematurely due to numerous serious adverse events."
    },
    {
        "id": 5179,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 160,
        "content": "There is a lack of consensus regarding the most appropriate systemic therapy/RT regimen to be administered following induction chemotherapy."
    },
    {
        "id": 5183,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "Panel members agree that weekly carboplatin is a reasonable agent to use with concurrent RT."
    },
    {
        "id": 5184,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "The TREMPLIN study showed no significant difference in larynx preservation rate at 3 months in patients with locally advanced larynx or hypopharynx cancers who received either cisplatin or cetuximab with concurrent RT following induction TPF."
    },
    {
        "id": 5185,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "Surgery for persistent disease was feasible only in patients who received cetuximab with RT following TPF."
    },
    {
        "id": 5186,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "The rate of treatment failure was lower in patients who received cisplatin with RT."
    },
    {
        "id": 5187,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "There were no significant differences in toxicities between the cisplatin and cetuximab arms."
    },
    {
        "id": 5188,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "Late toxicities tended to be more common in the cetuximab arm compared to the cisplatin arm."
    },
    {
        "id": 5189,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "The phase III GORTEC 2007-02 trial showed no significant differences between the study arms for survival outcomes and local control."
    },
    {
        "id": 5190,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "There was a trend towards a lower rate of distant metastases in the TPF arm."
    },
    {
        "id": 5191,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "The panel recommends cetuximab with concurrent RT following induction chemotherapy may also be used, but only in select circumstances such as in patients who are cisplatin-ineligible."
    },
    {
        "id": 5192,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "Weekly cisplatin with RT following induction chemotherapy is a category 2B option, based on extrapolation."
    },
    {
        "id": 5193,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "High-dose cisplatin (100 mg/m2 every 21 days \u00d7 3 doses) is not recommended with RT after induction cisplatin-based chemotherapy."
    },
    {
        "id": 5194,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "The data summarized in this section highlights overarching concerns that any efficacy gains of an induction chemotherapy followed by RT strategy may be offset by the poorer patient adherence with the RT-based part of treatment."
    },
    {
        "id": 5195,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "Enrollment of patients in appropriate clinical trials of induction chemotherapy is encouraged."
    },
    {
        "id": 5196,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "Outside of a clinical trial, concurrent systemic therapy/RT\u2014with high-dose cisplatin preferred\u2014is considered the gold standard by many NCCN Panel Members."
    },
    {
        "id": 5197,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "When induction chemotherapy is used, data show that the addition of a taxane to cisplatin/5-FU (of which TPF is the most extensively studied) is more efficacious than cisplatin/5-FU."
    },
    {
        "id": 5198,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "Docetaxel with cisplatin/5-FU is a category 1 preferred recommendation for induction chemotherapy for SCCHN."
    },
    {
        "id": 5199,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "Paclitaxel, cisplatin, and 5-FU is also an option for induction chemotherapy."
    },
    {
        "id": 5203,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "The multidisciplinary expertise of a registered dietitian and a speech-language/swallowing therapist should be utilized throughout the continuum of care."
    },
    {
        "id": 5204,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "Patients who have had significant weight loss need nutritional evaluation and close monitoring of their weight to prevent further weight loss."
    },
    {
        "id": 5205,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "All patients should receive nutritional evaluation before and after treatment to assess the need for interventions."
    },
    {
        "id": 5206,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 161,
        "content": "Lymphedema of the head and neck commonly occurs in patients and is associated with increased symptom burden."
    },
    {
        "id": 5210,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Fibrosis can occur in addition to dysfunction and pain."
    },
    {
        "id": 5211,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Fibrosis and lymphedema negatively impact function and quality of life."
    },
    {
        "id": 5212,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Evaluation and management of fibrosis and lymphedema are warranted."
    },
    {
        "id": 5213,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Patient referrals to occupational therapy may be warranted to learn massage techniques or to be fitted for custom-made compression devices."
    },
    {
        "id": 5214,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Patients are at risk for problems with speech and/or swallowing."
    },
    {
        "id": 5215,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Treatment and/or the progression of their disease may cause deterioration in their ability to speak and/or swallow."
    },
    {
        "id": 5216,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Evaluation by a speech-language/swallowing therapist is needed before and after treatment to help mitigate potential problems."
    },
    {
        "id": 5217,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Patients are at risk for dental problems."
    },
    {
        "id": 5218,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Long-term swallowing and dental dysfunction are particular risks that are worsened by multimodality therapy and require long-term specialized attention."
    },
    {
        "id": 5219,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Oral mucositis, or tissue damage, is common in patients treated with RT for H&N cancers."
    },
    {
        "id": 5220,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Use of advanced RT techniques may decrease the incidence and duration of oral mucositis."
    },
    {
        "id": 5221,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Oral mucositis causes pain in the mouth and when swallowing, which may affect the ability to eat and drink."
    },
    {
        "id": 5222,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Oral mucositis may be associated with breaks and/or delays in treatment, as well as hospitalization."
    },
    {
        "id": 5223,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Oral mucositis is more severe in patients receiving concurrent systemic therapy/RT."
    },
    {
        "id": 5224,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "The Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology have published clinical practice guidelines for treatment of oral mucositis."
    },
    {
        "id": 5226,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "In the Alliance A221304 trial, patients with H&N cancer who were treated with RT were randomized to receive a diphenhydramine-lidocaine-antacid mouthwash, doxepin mouthwash, or a placebo."
    },
    {
        "id": 5227,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "The reduction in mucositis pain during the first 4 hours of treatment was significantly greater in the patients who received the diphenhydramine-lidocaine-antacid mouthwash or the doxepin mouthwash, compared to the placebo."
    },
    {
        "id": 5229,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "Gabapentin is under investigation for treatment of pain from oral mucositis."
    },
    {
        "id": 5232,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "A small retrospective study including patients with H&N cancer treated with RT or systemic therapy/RT showed that treatment with gabapentin for pain from oral mucositis is associated with a reduced need for narcotic pain medication and high doses of opioids."
    },
    {
        "id": 5238,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "The panel recommends consideration of doxepin, diphenhydramine-lidocaine-antacid mouthwash, pregabalin, or gabapentin for pain related to oral mucositis, as clinically indicated and as tolerated."
    },
    {
        "id": 5239,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 162,
        "content": "NCCN Panel Members agree that reactive feeding tube placement, in which patients are first given oral nutrition supplements, followed by enteral feeding, when maintenance of nutritional requirements is no longer possible, is recommended."
    },
    {
        "id": 5243,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 163,
        "content": "Reactive feeding tube placement is appropriate in selected patients with Head and Neck cancers."
    },
    {
        "id": 5244,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 163,
        "content": "Reactive feeding tube placement should be considered if at least two of the following criteria are met: inability to maintain adequate intake, greater than 5% weight loss in a single month, severe mucositis, odynophagia, dysphagia, or aspiration, or older age."
    },
    {
        "id": 5245,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 163,
        "content": "Age >60 years was the most significant risk factor predicting need for enteral feeding in a retrospective analysis of 100 patients treated with chemoradiation for advanced SCCHN."
    },
    {
        "id": 5255,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 163,
        "content": "Patients with H&N cancers are at risk of oral and dental complications after surgery or RT."
    },
    {
        "id": 5256,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 163,
        "content": "Treatment-induced xerostomia and salivary gland dysfunction are associated with increased dental caries."
    },
    {
        "id": 5257,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 163,
        "content": "RT to the salivary and oral soft tissues is also associated with bone demineralization and trismus of the masticatory muscles."
    },
    {
        "id": 5258,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 163,
        "content": "Using IMRT and limiting the RT dose to the salivary glands and oral cavity can decrease xerostomia and damage to the teeth."
    },
    {
        "id": 5259,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 163,
        "content": "Dental/oral evaluation and management can help decrease dental caries and associated problems such as dentoalveolar infection and osteoradionecrosis."
    },
    {
        "id": 5260,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 163,
        "content": "A dental/oral treatment plan needs to be implemented before RT and should include eliminating potential sources of infection, allowing adequate time for healing before RT, treating active dental caries and periodontal disease, treating oral candidiasis, and educating patients about preventive strategies."
    },
    {
        "id": 5261,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 163,
        "content": "General strategies to decrease oral and dental complications include decreasing dry mouth, reducing risk of dental caries, decreasing dentoalveolar infection, preventing and addressing osteoradionecrosis, decreasing trismus of the masticatory muscles, and having patient undergo evaluations during and after treatment to help minimize complications."
    },
    {
        "id": 5271,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "The oral cavity includes the following subsites: buccal mucosa, upper and lower alveolar ridge, retromolar trigone, floor of the mouth, hard palate, and anterior two thirds of the tongue."
    },
    {
        "id": 5272,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "The area has a rich lymphatic supply, and initial regional node dissemination to nodal groups at levels I to III."
    },
    {
        "id": 5273,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "The risk of occult metastasis to level IV and V from squamous cell carcinoma of the oral cavity is low."
    },
    {
        "id": 5274,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "The results of numerous studies on the role of surgical resection with an extended supraomohyoid neck dissection are mixed and inconclusive."
    },
    {
        "id": 5275,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "Regional node involvement at presentation is evident in approximately 30% of patients."
    },
    {
        "id": 5276,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "The risk of lymph node metastases in these cancers is related to the location, size, and grade of the primary tumor."
    },
    {
        "id": 5277,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "Primaries of the alveolar ridge and hard palate infrequently involve the neck."
    },
    {
        "id": 5278,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "Occult neck metastasis is common (50%\u201360%) in patients with anterior tongue cancers."
    },
    {
        "id": 5279,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "The incidence of lymph node metastases in cancer of the mucosal lip is historically low."
    },
    {
        "id": 5280,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "The incidence of lymph node metastases in early-stage lower lip cancer is historically low."
    },
    {
        "id": 5281,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "The incidence of lymph node metastases in T3/4 disease or those with oral commissure involvement is higher."
    },
    {
        "id": 5282,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "Cancers of the lip mucosa are now staged as cancers of the oral cavity."
    },
    {
        "id": 5283,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "The AJCC TNM staging system reflects tumor size, extension, and nodal disease."
    },
    {
        "id": 5284,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "For the 8th edition of the AJCC Cancer Staging Manual, cancers of the external vermilion lip are staged as cutaneous carcinomas of the H&N."
    },
    {
        "id": 5285,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "Imaging studies to evaluate mandibular involvement and regional lymph node disease are particularly important for staging and planning therapy for oral cavity cancers."
    },
    {
        "id": 5286,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "A careful dental evaluation is particularly important for staging and planning therapy for oral cavity cancers."
    },
    {
        "id": 5287,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "A complete H&N examination, biopsy, and other appropriate studies are necessary for staging and planning therapy for oral cavity cancers."
    },
    {
        "id": 5288,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "Pretreatment dental evaluation and care are critical to minimize the risk of subsequent osteoradionecrosis in patients likely to receive RT."
    },
    {
        "id": 5289,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "Nutrition, speech, and swallowing evaluations are recommended for selected at-risk patients."
    },
    {
        "id": 5290,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "Treatment recommendations are based on clinical stage, medical status of the patient, anticipated functional and cosmetic results, and patient preference."
    },
    {
        "id": 5291,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "Surgery remains the preferred modality for the majority of oral cancers."
    },
    {
        "id": 5292,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 164,
        "content": "RT is the preferred modality for early-stage mucosal lip cancer."
    },
    {
        "id": 5296,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "A non-surgical approach should be considered when surgical morbidity will be high."
    },
    {
        "id": 5297,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "A non-surgical approach should be considered when the patient favors an organ preservation approach based on systemic therapy with radiation."
    },
    {
        "id": 5298,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Postoperative adjuvant radiation is recommended based on stage of disease and pathologic findings following surgery."
    },
    {
        "id": 5299,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "The specific treatment is dictated by the TN stage and, if N0 at diagnosis, by the risk of nodal involvement."
    },
    {
        "id": 5300,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Multidisciplinary team involvement is particularly important for head and neck cancers."
    },
    {
        "id": 5301,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Most panel members prefer surgical therapy for resectable oral cavity tumors."
    },
    {
        "id": 5303,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Some very small or superficial cancers are managed more expeditiously with a surgical resection without resultant functional deformity or an undesired cosmetic result."
    },
    {
        "id": 5304,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Organ preservation using systemic therapy has received less attention and is generally less effective in obtaining locoregional control than upfront surgery for the initial care of patients with oral cavity cancers."
    },
    {
        "id": 5307,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "For patients with early-stage oral cavity cancers, the recommended initial options are resection of the primary tumor."
    },
    {
        "id": 5308,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Many patients undergo either ipsilateral or bilateral neck dissection, which is guided by depth of invasion, proximity to the midline, and other factors."
    },
    {
        "id": 5309,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "It is debatable whether or not patients with early-stage node-negative oral cavity cancers should receive elective neck dissection."
    },
    {
        "id": 5310,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "The decision for neck dissection is determined by the relative risk of occult metastasis from the oral cavity subsite."
    },
    {
        "id": 5311,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Elective neck dissection reduces the risk of disease-specific mortality."
    },
    {
        "id": 5312,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Elective neck dissection was not associated with a statistically significant OS and DFS benefit, compared to delayed/therapeutic neck dissection."
    },
    {
        "id": 5313,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Elective neck dissection may be considered in patients with T2 tumors, given their risk of occult nodal metastasis."
    },
    {
        "id": 5314,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Disease recurrence rates were greater in patients with cT1\u20132, N0 disease who were observed, compared to those who underwent elective neck dissection."
    },
    {
        "id": 5315,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Depth of invasion is a risk factor for nodal metastasis in lip cancer."
    },
    {
        "id": 5316,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Depth of invasion should be used to determine treatment of the neck in early-stage mucosal lip cancer."
    },
    {
        "id": 5317,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 165,
        "content": "Sentinel lymph node biopsy may be used to identify occult cervical metastases."
    },
    {
        "id": 5320,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Metastases are not common in patients with early-stage lip cancer."
    },
    {
        "id": 5321,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Sentinel lymph node biopsy (SLNB) has been shown to be feasible and effective in patients who may be at high risk of metastases based on tumor size and depth."
    },
    {
        "id": 5322,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "A systematic review including 98 observational or retrospective studies showed sensitivity and specificity values of 82.7% and 98.1%, respectively, for detection of cervical metastases in patients with cT1\u20132 N0 oral cavity cancer."
    },
    {
        "id": 5323,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "SLNB and neck dissection were compared in one randomized phase III multicenter equivalence trial, which included 307 patients with cT1\u20132 N0 oral cavity cancer."
    },
    {
        "id": 5324,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "There were no statistically significant differences between the study arms for recurrence-free survival, DSS, and OS."
    },
    {
        "id": 5330,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Postsurgical adjuvant treatment options depend on whether adverse pathologic features are present."
    },
    {
        "id": 5331,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Close or positive margins on the primary specimen and the presence of ENE in lymph nodes are indications for systemic therapy with radiation."
    },
    {
        "id": 5332,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "The role of perineural invasion, vascular invasion, and lymphatic invasion in directing adjuvant therapy are less established."
    },
    {
        "id": 5333,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Perineural invasion, vascular invasion, and lymphatic invasion are usually considered indications for adjuvant radiotherapy."
    },
    {
        "id": 5334,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "For patients with resected oral cavity cancers who have the adverse pathologic features of extranodal extension with or without a positive mucosal margin, postoperative systemic therapy/RT is the recommended treatment."
    },
    {
        "id": 5335,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "For patients with positive or close margins, re-resection is preferred if feasible."
    },
    {
        "id": 5336,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "If not, RT is an option for these patients, and systemic therapy/RT may be considered."
    },
    {
        "id": 5337,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "For patients with other risk features, options include RT or to consider systemic therapy/RT."
    },
    {
        "id": 5338,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Surgery is preferred for locally advanced disease."
    },
    {
        "id": 5339,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Select patients who decline surgery may be treated with concurrent systemic therapy/RT or RT alone."
    },
    {
        "id": 5340,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "For patients with advanced-stage, resected oral cavity cancers who have the adverse pathologic features of extranodal extension with or without a positive mucosal margin, the recommended postoperative adjuvant treatment is systemic therapy/RT."
    },
    {
        "id": 5341,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Adjuvant treatment options for positive or close margins are the same, but re-resection is an option if technically feasible, with consideration of subsequent RT."
    },
    {
        "id": 5342,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "For other risk features, RT alone is recommended, or systemic therapy/RT may be considered."
    },
    {
        "id": 5343,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Radiation therapy may be used as definitive treatment for T1\u20132, N0 disease."
    },
    {
        "id": 5344,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "The fraction size to the intermediate- and low-risk sites ranges from 44 Gy to 63 Gy."
    },
    {
        "id": 5345,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Doses of 44\u201350 Gy are suggested if 3D-CRT is used or 54\u201363 Gy if IMRT is used, depending on the dose/fraction."
    },
    {
        "id": 5346,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Doses of 66\u201370 Gy are adequate to control high-risk disease."
    },
    {
        "id": 5347,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "RT, when used as definitive treatment, may consist of EBRT with or without brachytherapy, depending on the size of the tumor."
    },
    {
        "id": 5348,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Brachytherapy should only be performed at centers with expertise."
    },
    {
        "id": 5349,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 166,
        "content": "Brachytherapy may be an option for select situations, such as close or positive margins after surgical resection with flap reconstruction."
    },
    {
        "id": 5357,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "The oropharynx includes the base of the tongue, tonsils, soft palate, and pharyngeal wall."
    },
    {
        "id": 5358,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "The oropharynx is extremely rich in lymphatics."
    },
    {
        "id": 5359,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "Depending on the subsite involved, 15% to 75% of patients present with lymph node involvement."
    },
    {
        "id": 5360,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "Oropharyngeal cancer that is p16-positive is a different disease than p16-negative cancer."
    },
    {
        "id": 5361,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "Separate staging criteria were published for p16-negative and p16-positive oropharyngeal cancer in the 8th edition of the AJCC Cancer Staging Manual."
    },
    {
        "id": 5363,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "A multidisciplinary consultation is encouraged for patients with oropharyngeal cancer."
    },
    {
        "id": 5364,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "A registered dietitian and a speech-language/swallowing therapist should be included in the consultation as clinically indicated."
    },
    {
        "id": 5365,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "Accurate staging of oropharyngeal cancer depends on a complete H&N examination and appropriate imaging studies."
    },
    {
        "id": 5366,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "The NCCN Guidelines provide staging criteria for p16-negative oropharyngeal cancer in Table 3."
    },
    {
        "id": 5367,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "The NCCN Guidelines provide staging criteria for p16-positive oropharyngeal cancer in Table 4."
    },
    {
        "id": 5368,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "The panel recommends examination under anesthesia with biopsy confirmation for patients presenting with a p16-positive cervical lymph node prior to treatment decision-making."
    },
    {
        "id": 5369,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "There may be situations in which the examination under anesthesia is undesirable or could be bypassed."
    },
    {
        "id": 5370,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 167,
        "content": "The NCCN Guidelines recommend tumor HPV testing by p16 IHC in all patients diagnosed with an oropharyngeal cancer."
    },
    {
        "id": 5384,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "The algorithms for Oropharyngeal Cancer in the NCCN Guidelines for Head and Neck Cancers reflect the staging criteria published in the 8th edition of the AJCC Cancer Staging Manual for p16-negative oropharyngeal cancer and p16-positive oropharyngeal cancer."
    },
    {
        "id": 5385,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "The staging criteria for p16-negative oropharyngeal cancer include separate pathologic criteria for involvement of regional lymph nodes."
    },
    {
        "id": 5386,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "Extranodal extension is difficult to accurately capture through the imaging workup that is routinely done for clinical staging."
    },
    {
        "id": 5387,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "The treatment algorithm for p16-negative disease is divided into three staging categories: 1) T1\u20132, N0\u20131; 2) T3\u20134a, N0\u20131; and 3) any T, N2\u20133."
    },
    {
        "id": 5388,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "T4b, any N; unresectable nodal disease; unfit for surgery; or M1 disease at initial presentation are treated as advanced cancer."
    },
    {
        "id": 5389,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "A clinical staging system for p16-positive oropharyngeal cancer was developed using data from 1907 patients with non-metastatic HPV-positive oropharyngeal cancer from seven cancer centers in Europe and the United States."
    },
    {
        "id": 5390,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "OS did not significantly differ between T4a and T4b disease."
    },
    {
        "id": 5391,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "Five-year OS rates did not significantly differ in patients with N1, N2a, or N2b disease."
    },
    {
        "id": 5392,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "The N-classification system for oropharyngeal cancer that was described in the 7th edition of the AJCC Cancer Staging Manual was not significantly associated with OS."
    },
    {
        "id": 5393,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "Patients with four or fewer pathologically confirmed metastatic nodes had a higher 5-year OS rate, compared to patients with five or more pathologically confirmed metastatic nodes."
    },
    {
        "id": 5394,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "The recommendations for p16 (HPV)-positive oropharyngeal cancer in the NCCN Guidelines for Head and Neck Cancers accommodate the AJCC 8th edition staging system for p16-positive oropharyngeal cancer."
    },
    {
        "id": 5395,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "Differences in recommendations between p16-negative disease and p16-positive disease are relatively modest."
    },
    {
        "id": 5396,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "The staging criteria for p16-positive oropharyngeal cancer differs from staging for p16-negative oropharyngeal cancer in the following ways."
    },
    {
        "id": 5397,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "T4b disease has been removed from the staging criteria for defining the primary tumor in p16-positive oropharyngeal cancer."
    },
    {
        "id": 5398,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "Criteria for defining nodal involvement have been simplified for p16-positive disease."
    },
    {
        "id": 5399,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "Clinical N staging for p16-positive oropharyngeal cancer is based on lymph node size and laterality."
    },
    {
        "id": 5400,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "Pathologic N staging is based on number of lymph nodes in p16-positive oropharyngeal cancer."
    },
    {
        "id": 5401,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 168,
        "content": "pN3 disease has been removed for pathologic N in p16-positive oropharyngeal cancer."
    },
    {
        "id": 5406,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "The algorithms for p16-positive oropharyngeal cancer in the NCCN Guidelines for Head and Neck Cancers incorporate the staging criteria presented in the 8th Edition of the AJCC Cancer Staging Manual."
    },
    {
        "id": 5407,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "The staging criteria presented in the 8th Edition of the AJCC Cancer Staging Manual are based on clinical staging criteria."
    },
    {
        "id": 5409,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "Expert consensus is that HPV status should be used as a stratification factor or should be addressed in separate trials for which patients with oropharyngeal cancer are eligible."
    },
    {
        "id": 5410,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "The treatment algorithms for p16-negative and p16-positive oropharyngeal cancer are identical with some exceptions."
    },
    {
        "id": 5411,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "There is currently no evidence that the staging criteria published in the 8th edition of the AJCC Cancer Staging Manual should drive clinical decision-making."
    },
    {
        "id": 5412,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "Panel members urge that patients with HPV-positive cancers be enrolled in clinical trials evaluating biological and treatment-related questions."
    },
    {
        "id": 5413,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "Some clinicians have suggested that less-intense treatment may be adequate for HPV-positive oropharyngeal cancers."
    },
    {
        "id": 5414,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "RT-based strategies that may be used to potentially minimize harm in patients with p16-positive oropharyngeal cancer include use of image-guided RT and consideration of unilateral neck irradiation in disease that is well-lateralized."
    },
    {
        "id": 5415,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "Available data supporting these assertions are limited by retrospective analyses, single-institution phase 3 trials, variability in HPV testing method used, and short follow-up periods."
    },
    {
        "id": 5416,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "Deintensification treatment protocols for HPV-positive locally advanced oropharyngeal cancer are being investigated in ongoing clinical trials."
    },
    {
        "id": 5417,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "Strategies under active investigation include reducing or using biomarker or response-stratified RT dose, using RT alone versus chemoradiation, using less invasive surgical procedures such as transoral laser microsurgery or TORS, using sequential systemic therapy/RT, and using immunotherapy."
    },
    {
        "id": 5418,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "Early-stage oropharyngeal cancers may be treated with definitive RT or resection of the primary with neck dissection."
    },
    {
        "id": 5419,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "Tumors at or approaching the midline are at risk of contralateral metastasis and warrant bilateral treatment."
    },
    {
        "id": 5420,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "A staged contralateral neck dissection can be performed in order to avoid RT in patients with cT1\u20132 p16-negative oropharyngeal cancer if the primary tumors is near the midline and resected to adequate margins with no adverse pathologic features."
    },
    {
        "id": 5421,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "The randomized phase II ORATOR trial aimed to compare swallow-related QOL outcomes in patients with early-stage T1\u2013T2, N0\u20132 oropharyngeal cancer treated with primary RT or systemic therapy/RT, versus those treated with TORS with neck dissection with or without adjuvant RT or systemic therapy/RT."
    },
    {
        "id": 5422,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "The study enrolled 68 patients from six hospitals in Canada and Australia, and compared MDADI scores between the two groups at 1 year."
    },
    {
        "id": 5423,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 169,
        "content": "Swallow-related QOL outcomes reached statistical significance favoring the primary RT cohort; however, this difference did not meet criteria for a clinically meaningful change and with long-term follow-up, the difference in scores became less pronounced with the passage of time."
    },
    {
        "id": 5428,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Clinicians and patients should be involved in shared decision-making, in a multidisciplinary context, to individualize treatment of OPSCC."
    },
    {
        "id": 5429,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "The randomized open-label phase II ORATOR2 trial aimed to evaluate long-term survival, disease outcomes, and toxicities."
    },
    {
        "id": 5430,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "The ORATOR2 trial randomized patients with early-stage p16-positive T1\u2013T2, N0\u20132 oropharyngeal cancer to receive primary RT or TORS with neck dissection."
    },
    {
        "id": 5431,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Study accrual was halted early due to unacceptable grade 5 toxicities in the TORS arm."
    },
    {
        "id": 5432,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Long-term data regarding survival and disease outcomes from the ORATOR2 trial are awaited."
    },
    {
        "id": 5433,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Additional randomized trials of minimally invasive transoral surgery or RT for oropharyngeal cancer are ongoing."
    },
    {
        "id": 5434,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Results from multiple phase II trials show that RT deintensification is associated with promising PFS rates in patients with p16-positive oropharyngeal cancer."
    },
    {
        "id": 5435,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "A phase II randomized trial of low-risk HPV-associated oropharyngeal cancer demonstrated that de-escalated RT to 60 Gy with concurrent cisplatin was associated with a 2-year PFS rate of 90.5%."
    },
    {
        "id": 5436,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Accelerated RT alone to 60 Gy was associated with a 2-year PFS rate of 87.6% in the same trial."
    },
    {
        "id": 5437,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "The former regimen met criteria for further study and is the subject of an ongoing cooperative group phase II/III randomized trial on dose de-escalation."
    },
    {
        "id": 5438,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "A nonrandomized phase II study of definitive RT to 60 Gy with or without concurrent cisplatin in patients with T0\u20133 N0\u20132 M0 p16-positive oropharyngeal cancer demonstrated a 2-year PFS of 86% and 2-year OS of 95%."
    },
    {
        "id": 5439,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Analyses of QOL outcomes from one of these trials showed that RT deintensification was associated with a quicker and more robust return to baseline-level functioning."
    },
    {
        "id": 5440,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "A prospective phase II trial of initial TORS followed by risk-adapted adjuvant treatment demonstrated a 2-year PFS rate of 96.9% for low-risk disease with TORS alone."
    },
    {
        "id": 5441,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "The same trial demonstrated a 2-year PFS rate of 94.9% for intermediate-risk disease with 50 Gy adjuvant RT, 96% for intermediate-risk disease with 60 Gy adjuvant RT, and 90.7% for high-risk disease with 66 Gy adjuvant RT with concurrent weekly cisplatin."
    },
    {
        "id": 5442,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Research on the impact of adverse pathologic features such as extranodal extension and number of involved nodes on outcomes in patients with p16-positive disease who have undergone resection is rapidly evolving."
    },
    {
        "id": 5443,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Analyses from the RTOG 9501131 and EORTC 22931 trials showed that extranodal extension is associated with poor prognosis and demonstrated benefit to adjuvant systemic therapy/RT in patients with locally advanced SCCHN who have undergone surgical resection."
    },
    {
        "id": 5444,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Data suggesting equivalent outcomes of adjuvant RT and systemic therapy/RT for p16-positive oropharyngeal cancer with extranodal extension are restricted to retrospective trials."
    },
    {
        "id": 5445,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Clinical trials are being conducted to validate the revised AJCC staging for clinical decision-making."
    },
    {
        "id": 5446,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Secondary to lack of high-quality, prospective clinical evidence in the modern era, systemic therapy/RT is a category 2A option for both patients with p16-positive disease and p16-negative disease and extranodal extension."
    },
    {
        "id": 5447,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Adjuvant systemic therapy/RT remains a category 1 recommendation for patients with non-oropharyngeal SCCHN who have extranodal extension."
    },
    {
        "id": 5448,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Patients with p16-positive oropharyngeal cancer have a generally favorable prognosis and may live longer, but toxicity and QOL are concerns for these patients."
    },
    {
        "id": 5449,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Patients with p16-positive oropharyngeal cancer are also younger, with fewer comorbidities, so they can probably tolerate combined adjuvant therapy better."
    },
    {
        "id": 5450,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "Omitting systemic therapy and administering radiotherapy alone is a category 2B option for patients with p16-positive cT0\u20132, cN0\u20131 disease who have extranodal extension following surgery."
    },
    {
        "id": 5451,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 170,
        "content": "For patients with positive or close margins, re-resection, RT, and systemic therapy/RT are options."
    },
    {
        "id": 5457,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "The treatment options for patients with pT3 or pT4 primary, one positive node greater than 3 cm or multiple positive nodes, nodal disease in levels IV or V, perineural invasion, vascular invasion, or lymphatic invasion include RT or systemic therapy/RT."
    },
    {
        "id": 5458,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Adjuvant treatment options for patients with p16-positive disease include systemic therapy/RT, which is a category 2B option."
    },
    {
        "id": 5459,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "RT may be considered for patients with p16-negative disease that is pN1 following resection with no other adverse pathologic features present."
    },
    {
        "id": 5460,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Systemic therapy/RT is a treatment option for patients with p16-negative N1 disease based on results from the phase III randomized GORTEC trial and retrospective analyses from the National Cancer Database (NCDB)."
    },
    {
        "id": 5461,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Systemic therapy/RT is a category 2B option for patients with p16-negative N1 disease."
    },
    {
        "id": 5462,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Systemic therapy/RT is also a category 2B option for patients with p16-positive disease and T0\u2013T2 disease and the involvement of a single node 3 cm or less."
    },
    {
        "id": 5463,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "For locally advanced resectable disease, treatment recommendations include concurrent systemic therapy/RT and resection of the primary and neck dissection."
    },
    {
        "id": 5464,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Enrollment in clinical trials is recommended for patients with locally advanced resectable disease."
    },
    {
        "id": 5465,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Tumors at or approaching the midline should be strongly considered for bilateral treatment of the neck."
    },
    {
        "id": 5466,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Concurrent systemic therapy/RT is preferred in patients with locoregionally advanced HPV-positive disease who have clinical evidence of fixed or matted nodes or obvious extranodal extension."
    },
    {
        "id": 5467,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Surgery is not recommended for patients with locoregionally advanced HPV-positive disease who have clinical evidence of fixed or matted nodes or obvious extranodal extension."
    },
    {
        "id": 5468,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Induction chemotherapy is listed as a treatment option for patients with locally advanced resectable oropharyngeal cancer regardless of p16 status."
    },
    {
        "id": 5469,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Induction chemotherapy is a category 3 option due to lack of consensus among NCCN Member Institutions."
    },
    {
        "id": 5470,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Panel concerns about induction chemotherapy are based on absence of consistent benefit in randomized clinical trials and concerns that use of better-tolerated\u2014but potentially less effective\u2014concurrent regimens or poorer patient adherence with RT may compromise outcomes."
    },
    {
        "id": 5471,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Patients with p16-positive cN2\u20133 disease who are treated with initial surgery have a high likelihood of extranodal extension, which warrants adjuvant systemic therapy/RT treatment."
    },
    {
        "id": 5472,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Triple modality management is associated with increased toxicity."
    },
    {
        "id": 5473,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Beginning treatment with concurrent systemic therapy/RT may help decrease the need for triple modality therapy and additional treatment-induced morbidity."
    },
    {
        "id": 5474,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Definitive concurrent systemic therapy/RT is preferred over upfront surgery for p16-positive cT4 or cN3 oropharyngeal cancer."
    },
    {
        "id": 5475,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Panel recommendations regarding adjuvant therapy for locally advanced disease do not differ between p16-positive and p16-negative oropharyngeal cancer."
    },
    {
        "id": 5476,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Concurrent systemic therapy/RT\u2014with high-dose cisplatin as the preferred systemic agent\u2014is recommended for treatment of locoregionally advanced p16-positive and p16-negative cancer of the oropharynx."
    },
    {
        "id": 5477,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "Evidence from multiple prospective trials in HPV-positive oropharyngeal cancer demonstrates that cetuximab and RT is inferior to cisplatin in terms of OS."
    },
    {
        "id": 5478,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "IMRT is preferred for radiation treatment of oropharynx cancer, as it is associated with decreased toxicity."
    },
    {
        "id": 5479,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "There is an ongoing randomized trial comparing IMRT with IMPT in oropharyngeal cancer (NCT01893307)."
    },
    {
        "id": 5480,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 171,
        "content": "A fractionation schedule of 66\u201370 Gy at 2 Gy/fraction daily is recommended for radiation treatment of oropharynx cancer."
    },
    {
        "id": 5486,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "For patients with gross disease, radiation therapy for 6 to 7 weeks is recommended."
    },
    {
        "id": 5487,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Hypofractionation, hyperfractionation, or accelerated fractionation is acceptable in patients with early-stage oropharyngeal cancer."
    },
    {
        "id": 5488,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Hypofractionation, hyperfractionation, or accelerated fractionation may be associated with improved locoregional control in patients with early-stage oropharyngeal cancer."
    },
    {
        "id": 5489,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "For elective nodal treatment, a biologically equivalent dose of approximately 40\u201350 Gy in 2 Gy/fraction is recommended."
    },
    {
        "id": 5490,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "The complete list of recommended schedules for radiation treatment of p16-positive oropharynx cancer are shown in the algorithm."
    },
    {
        "id": 5491,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "The algorithm is part of the NCCN Guidelines for Head and Neck Cancers."
    },
    {
        "id": 5492,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "The ECOG-ACRIN Cancer Research Group trial (E3311) is a prospective phase II trial."
    },
    {
        "id": 5493,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "De-escalation to 50 Gy may be considered in patients with p16-positive oropharynx cancer who have up to 4 positive lymph nodes, N1-2 disease with \u2264 1 mm ENE, or cT1-2 resected to negative or close margins (<3 mm)."
    },
    {
        "id": 5494,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "De-escalation to 50 Gy is a category 2B option based on less panel consensus."
    },
    {
        "id": 5495,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "RT dose deintensification may improve long-term function while preserving PFS in patients with p16-positive disease."
    },
    {
        "id": 5496,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "More studies are needed to confirm the benefits of RT dose deintensification in patients with p16-positive disease."
    },
    {
        "id": 5497,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "The majority of clinical trials in this space have been single-arm phase 2 and need to be compared to the standard of care in randomized trials."
    },
    {
        "id": 5498,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Enrollment of patients with low-risk HPV-positive oropharyngeal cancer is in progress for the randomized phase II/III NRG HN-005 trial."
    },
    {
        "id": 5499,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "The NRG HN-005 trial will compare deescalated 60 Gy with cisplatin, 60 Gy with nivolumab, and 70 Gy with cisplatin."
    },
    {
        "id": 5500,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "The NRG HN-005 trial is registered as NCT03952585."
    },
    {
        "id": 5501,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Recommendations for surveillance are provided in the algorithm."
    },
    {
        "id": 5504,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "The hypopharynx is essentially a muscular, lined tube extending from the oropharynx to the cervical esophagus."
    },
    {
        "id": 5505,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "For staging purposes, the hypopharynx is divided into three areas: 1) the pyriform sinus; 2) the posterior pharyngeal walls; and 3) the postcricoid area."
    },
    {
        "id": 5506,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "A multidisciplinary consultation is encouraged for patients with cancer of the hypopharynx."
    },
    {
        "id": 5507,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Accurate staging depends on a complete H&N examination coupled with appropriate studies."
    },
    {
        "id": 5508,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Table 3 shows the staging criteria for cancer of the hypopharynx."
    },
    {
        "id": 5509,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "For patients with cancer of the hypopharynx, the prognosis can be poor despite aggressive combined modality treatment."
    },
    {
        "id": 5510,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Patients with resectable disease are divided into two groups based on the indicated surgical options."
    },
    {
        "id": 5511,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Patients with early-stage cancer who are amenable to larynx-preserving (conservation) surgery have indicated surgical options."
    },
    {
        "id": 5512,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Patients with advanced resectable cancer who require pharyngectomy with total or partial laryngectomy have indicated surgical options."
    },
    {
        "id": 5513,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "The surgery and RT options for patients with early-stage cancer who are amenable to larynx-preserving (conservation) surgery represent a consensus among the panel members."
    },
    {
        "id": 5514,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Patients with T1\u20133, any N disease, for whom the indicated surgical option is partial or total laryngopharyngectomy, may be managed with three approaches."
    },
    {
        "id": 5515,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Induction chemotherapy followed by additional treatment, depending on the response, is an approach for patients with T1\u20133, any N disease."
    },
    {
        "id": 5516,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Surgery with neck dissection(s), and postoperative RT or chemoradiation as dictated by pathologic risk features, is an approach for patients with T1\u20133, any N disease."
    },
    {
        "id": 5517,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "Concurrent systemic therapy/RT is an approach for patients with T1\u20133, any N disease."
    },
    {
        "id": 5518,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 172,
        "content": "When using concurrent systemic therapy/RT, the preferred systemic agent is high-dose cisplatin."
    },
    {
        "id": 5524,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "The option of the induction chemotherapy/definitive RT is based on an EORTC randomized trial."
    },
    {
        "id": 5525,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "The EORTC trial enrolled 194 eligible patients with stage II\u2013IV resectable squamous cell carcinoma of the pyriform sinus and aryepiglottic fold."
    },
    {
        "id": 5533,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "For induction chemotherapy as part of a larynx preservation strategy, inclusion of only patients with the specified TNM stages is recommended."
    },
    {
        "id": 5534,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "Success on larynx preservation with an induction chemotherapy strategy is best established for patients who had a complete response to induction therapy at the primary site and stable or improved disease in the neck."
    },
    {
        "id": 5535,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "A randomized trial showed that an alternating regimen of cisplatin/5-FU with RT yielded larynx preservation, progression-free interval, and OS rates equivalent to those obtained with induction platinum/5-FU followed by RT."
    },
    {
        "id": 5537,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "Given available randomized data demonstrating the superiority of TPF compared with PF for induction chemoradiation, the triplet is now recommended as induction for this approach."
    },
    {
        "id": 5538,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "Surgery is recommended if a partial response or less occurs after induction chemotherapy."
    },
    {
        "id": 5539,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "The nature of the operation will depend on the stage and extent of the tumor at presentation."
    },
    {
        "id": 5540,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "Partial laryngeal surgery may still be considered, although most patients will require total laryngectomy, and at least a partial pharyngectomy."
    },
    {
        "id": 5541,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "Postoperative systemic therapy/RT is recommended for the adverse pathologic features of extranodal extension and/or positive or close mucosal margin."
    },
    {
        "id": 5542,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "For other risk features, clinical judgment should be used when deciding to use RT alone or when considering adding systemic therapy to RT."
    },
    {
        "id": 5543,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "Severe late toxicity appears to be associated with the amount of RT and treatment with radiosensitizing systemic therapy."
    },
    {
        "id": 5544,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "Options for patients with T4a, any N disease include total laryngopharyngectomy plus neck dissection(s) followed by adjuvant systemic therapy/RT or RT."
    },
    {
        "id": 5545,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "Options for patients with T4a, any N disease include enrollment in clinical trials."
    },
    {
        "id": 5546,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "Options for patients with T4a, any N disease include induction chemotherapy."
    },
    {
        "id": 5547,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 173,
        "content": "Options for patients with T4a, any N disease include systemic therapy/RT."
    },
    {
        "id": 5563,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "The NCCN Guidelines for Head and Neck Cancers provide recommendations for the evaluation and management of NPC."
    },
    {
        "id": 5564,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "The workup of nasopharyngeal cancer includes a complete Head and Neck examination and other studies."
    },
    {
        "id": 5566,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "Multidisciplinary consultation is encouraged."
    },
    {
        "id": 5567,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "The 2017 AJCC staging classification (8th edition) is used as the basis for treatment recommendations."
    },
    {
        "id": 5568,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "Epstein-Barr virus (EBV) DNA testing may also be considered."
    },
    {
        "id": 5573,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "Infection with EBV is an etiologic factor in the development of NPC."
    },
    {
        "id": 5574,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "Workup for NPC may include EBV testing of both the tumor itself and the blood, particularly in the presence of nonkeratinizing and undifferentiated histology."
    },
    {
        "id": 5575,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "Testing methods for detection of EBV in tumor include ISH for EBV-encoded RNA (EBER) and IHC staining for LMP1."
    },
    {
        "id": 5576,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "ISH for EBER tends to be a more sensitive testing method for carcinomas, relative to LMP1 IHC staining."
    },
    {
        "id": 5577,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "Real-time PCR may be used to evaluate EBV DNA load in serum or plasma."
    },
    {
        "id": 5578,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "Sensitivity and specificity values range from 53% to 96%, and 88% to 100%, respectively."
    },
    {
        "id": 5579,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "Testing for plasma EBV DNA has been shown to be independently prognostic at baseline."
    },
    {
        "id": 5580,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 174,
        "content": "Furthermore, after induction chemotherapy, and after radiation, EBV DNA levels are used in some centers as a means of outcome prognostication and residual disease monitoring."
    },
    {
        "id": 5584,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "Persistently elevated levels of plasma EBV DNA near or at the end of induction chemotherapy or definitive intent RT or chemoradiation are associated with a significantly poorer outcome."
    },
    {
        "id": 5585,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "A meta-analysis including 13 studies showed that plasma EBV DNA levels assessed pre-treatment were independent prognostic factors for mortality."
    },
    {
        "id": 5586,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "A meta-analysis including 13 studies showed that plasma EBV DNA levels assessed pre-treatment were independent prognostic factors for distant metastasis."
    },
    {
        "id": 5588,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "Plasma EBV DNA has been studied as an indicator of disease response to chemotherapy or chemoradiation prior to additional treatment."
    },
    {
        "id": 5589,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "Plasma EBV DNA has been studied in patients with distant metastases and with disease that is treatment-refractory."
    },
    {
        "id": 5590,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "Most studies on plasma EBV DNA have been based on real-time PCR assays amplifying the BamHI-W fragment."
    },
    {
        "id": 5591,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "Most recent clinical trial data regarding treatment of NPC are restricted to EBV-associated disease."
    },
    {
        "id": 5592,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "Prospective studies including patients with EBV-negative disease are largely absent or are represented only as non-prospectively defined subsets."
    },
    {
        "id": 5594,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "The Intergroup trial 0099 randomly assigned patients to EBRT with concurrent cisplatin plus adjuvant chemotherapy with cisplatin and 5-fluorouracil (PF) for three cycles versus EBRT alone."
    },
    {
        "id": 5595,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "The Intergroup trial 0099 closed early when an interim analysis disclosed a highly significant survival advantage favoring the combined chemotherapy and radiation group."
    },
    {
        "id": 5596,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "The addition of chemotherapy in the Intergroup trial 0099 also decreased local, regional, and distant recurrence rates."
    },
    {
        "id": 5597,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "Subsequent phase III randomized trials in Asia confirmed that concurrent chemoradiation without adjuvant PF similarly increased survival in endemic-area populations when compared with RT alone."
    },
    {
        "id": 5599,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "A randomized study conducted in Singapore confirmed the benefit of adding concurrent platinum to RT with adjuvant PF, using a multiday infusion of platinum instead of a single bolus high-dose approach."
    },
    {
        "id": 5600,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "One of the largest phase III randomized trials ever conducted in NPC comparing concurrent cisplatin/RT with (or without) adjuvant PF showed that adjuvant chemotherapy did not significantly improve survival following chemoradiation."
    },
    {
        "id": 5601,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 175,
        "content": "Advanced radiation techniques are needed for the appropriate treatment of NPC and to minimize the long-term side effects that are common in survivors."
    },
    {
        "id": 5612,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "Cancer invasion in the bones of the skull base has consequences of local failure in that region."
    },
    {
        "id": 5613,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "Blanchard et al conducted an individual patient data meta-analysis that included 19 trials and 4806 patients with non-metastatic NPC."
    },
    {
        "id": 5615,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "There were differences between the included studies assessing chemoradiation with and without adjuvant chemotherapy."
    },
    {
        "id": 5616,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "A network meta-analysis based on the individual patient data meta-analysis by Blanchard et al showed that the addition of adjuvant chemotherapy to chemoradiation was associated with better PFS."
    },
    {
        "id": 5617,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "The authors of the network meta-analysis argued that more chemotherapy, in addition to concurrent chemoradiation, could reduce recurrence rates."
    },
    {
        "id": 5620,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "There is evidence supporting the use of induction chemotherapy followed by concurrent systemic therapy/RT for treatment of locoregionally advanced nasopharyngeal cancer."
    },
    {
        "id": 5621,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "Two randomized phase III trials from China published in 2019 show a survival benefit for induction chemotherapy followed by concurrent systemic therapy/RT, compared to concurrent systemic therapy/RT alone."
    },
    {
        "id": 5622,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "Results from multiple systematic reviews suggest that induction chemotherapy prior to systemic therapy/RT in patients with locally advanced NPC may potentially impact tumor control, compared to systemic therapy/RT without additional chemotherapy."
    },
    {
        "id": 5623,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "Induction chemotherapy prior to systemic therapy/RT may be associated with superior OS and PFS rates, compared to systemic therapy/RT alone."
    },
    {
        "id": 5625,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "A meta-analysis including 27 trials with 7940 patients showed that induction chemotherapy prior to systemic therapy/IMRT ranked best for OS, PFS, and distant failure-free survival."
    },
    {
        "id": 5626,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "A randomized phase III trial from the Hong Kong Nasopharyngeal Cancer Study Group showed a survival benefit when comparing induction chemotherapy prior to systemic therapy/RT to systemic therapy/RT followed by adjuvant chemotherapy."
    },
    {
        "id": 5627,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "The induction chemotherapy sequence was also associated with better distant control, compared to the adjuvant chemotherapy arm."
    },
    {
        "id": 5628,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "The 2021 American Society of Clinical Oncology/Chinese Society of Clinical Oncology (ASCO/CSCO) consensus statement recommended that patients with locoregionally advanced disease receive treatment with induction chemotherapy followed by systemic therapy/RT."
    },
    {
        "id": 5629,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 176,
        "content": "Patients who do not receive induction chemotherapy should receive systemic therapy/RT according to the 2021 ASCO/CSCO consensus statement."
    },
    {
        "id": 5636,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Patients with locoregionally advanced NPC may be considered for adjuvant therapy."
    },
    {
        "id": 5637,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Currently available evidence generally favors the addition of chemotherapy to concurrent systemic therapy/RT in patients with locoregionally advanced NPC."
    },
    {
        "id": 5638,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "It remains unclear whether to administer chemotherapy to patients with locoregionally advanced NPC before or after systemic therapy/RT."
    },
    {
        "id": 5639,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Induction chemotherapy tends to perform better than adjuvant chemotherapy for some outcomes, such as in reduction of distant metastases."
    },
    {
        "id": 5640,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "In 2022, two trials reported on the adjuvant use of capecitabine following standard chemoradiation of locoregionally advanced NPC."
    },
    {
        "id": 5641,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "One of these trials demonstrated PFS and OS improvement from the use of 1 year of low-dose capecitabine following definitive treatment."
    },
    {
        "id": 5642,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "The vast majority of patients treated on this study had received both induction chemotherapy and concurrent chemoradiation."
    },
    {
        "id": 5643,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "This adjuvant approach is supported even in patients heavily pretreated with sequential chemoradiation."
    },
    {
        "id": 5644,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Patients with an unknown primary site after appropriate workup but harboring cervical lymph nodal squamous cell carcinoma that is EBV-positive may be treated in the same manner as locoregionally advanced NPC."
    },
    {
        "id": 5645,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "For other EBV-associated NPC, the principles of treatment can mostly be outlined according to stage."
    },
    {
        "id": 5646,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Patients with T1, N0, M0 nasopharyngeal tumors should be treated with definitive RT alone, including elective RT to the neck."
    },
    {
        "id": 5647,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "T2, N0 disease is less likely to progress to distant metastasis compared to T2, N1 disease."
    },
    {
        "id": 5648,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Definitive RT alone could be used for T2, N0 disease."
    },
    {
        "id": 5649,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Concurrent systemic therapy may be indicated in the presence of high-risk features such as bulky tumor volume or high serum EBV DNA copy number."
    },
    {
        "id": 5650,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Induction chemotherapy followed by systemic therapy/RT is preferred for advanced locoregional disease."
    },
    {
        "id": 5651,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "For patients who did not receive induction chemotherapy, adjuvant chemotherapy following treatment with concurrent systemic therapy/RT is recommended."
    },
    {
        "id": 5652,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "The use of capecitabine as adjuvant treatment following induction and concurrent chemoradiation is supported by one large randomized clinical trial."
    },
    {
        "id": 5653,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Concurrent systemic therapy/RT alone is generally not sufficient for treatment of patients with locoregionally advanced NPC."
    },
    {
        "id": 5654,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Concurrent systemic therapy/RT alone is recommended for patients with T0\u20132, N1 disease, as well as for patients with T3, N0 disease."
    },
    {
        "id": 5655,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Induction or adjuvant chemotherapy may be considered for patients with T0\u20132, N1 disease, as well as for patients with T3, N0 disease, in the presence of high-risk features."
    },
    {
        "id": 5656,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "For NPC that is not virally driven, similar principles are applied, although it may be a consideration that these tumors are generally more prone to local relapse and have low rates of regional persistence or distant metastases."
    },
    {
        "id": 5657,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "When induction chemotherapy is used, gemcitabine/cisplatin and modified TPF are the preferred options for patients with EBV-related NPC."
    },
    {
        "id": 5658,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Other induction/sequential chemotherapy regimens are included in the NCCN Guidelines for Head and Neck Cancers based on lower-level evidence."
    },
    {
        "id": 5659,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "The use of induction for patients with non\u2013EBV-related NPC is undefined, as all trials studying induction in NPC were in EBV-related NPC patient populations."
    },
    {
        "id": 5660,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "When using induction chemotherapy for non\u2013EBV-related NPC, it may be equally reasonable to use regimens established in other non\u2013EBV-related SCCHN sites, such as TPF."
    },
    {
        "id": 5661,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "The panel recommends concurrent systemic therapy/RT (cisplatin) with either induction or adjuvant chemotherapy for locoregionally advanced NPC, favoring induction over adjuvant in the clinical scenarios discussed above."
    },
    {
        "id": 5662,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 177,
        "content": "Concurrent cisplatin with RT is recommended for all patients who do not have a contraindication to the drug."
    },
    {
        "id": 5666,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Cisplatin is supported by randomized trials for use in this setting."
    },
    {
        "id": 5667,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Cisplatin/5-FU is the preferred option for adjuvant chemotherapy."
    },
    {
        "id": 5668,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Metronomic capecitabine is supported by a randomized phase III trial as an adjuvant chemotherapy option for treatment of stage III\u2013IVa disease."
    },
    {
        "id": 5669,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Most patients in the trial had received induction chemotherapy prior to chemoradiation."
    },
    {
        "id": 5670,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "The substitution of carboplatin for cisplatin should be limited to cisplatin-ineligible patients."
    },
    {
        "id": 5671,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Population-based data appear to support the role of earlier RT in the management of metastatic nasopharyngeal cancer."
    },
    {
        "id": 5672,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Earlier RT ultimately depends on whether the disease is localized or widespread and if it is symptomatic or posing a clinical risk to the patient."
    },
    {
        "id": 5673,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "For patients with oligometastatic disease, potentially curative therapy is indicated if the patient is fit and is often used following robust anti-tumor effects observed with systemic chemotherapy."
    },
    {
        "id": 5674,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "A multicenter randomized phase III trial showed that consolidative locoregional IMRT directed at the primary and nodal gross disease improved OS and PFS compared to chemotherapy alone."
    },
    {
        "id": 5675,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "RT at a definitive dose level to the primary site and involved regional nodes is recommended for patients with oligometastatic NPC if complete response is achieved with systemic therapy."
    },
    {
        "id": 5676,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Gemcitabine plus cisplatin is the preferred combination systemic therapy regimen for first-line therapy for patients with metastatic NPC."
    },
    {
        "id": 5677,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Category 1 level evidence demonstrates a survival advantage of GC over PF."
    },
    {
        "id": 5678,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "The data for GC demonstrating superiority to PF comes from an era when GC was not typically used for induction."
    },
    {
        "id": 5679,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "The superiority of GC over PF in patients with prior exposure to GC is unknown."
    },
    {
        "id": 5680,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Other combination regimens for these patients include cisplatin or carboplatin, plus a taxane; cisplatin/5-FU; gemcitabine/carboplatin; or carboplatin/cetuximab."
    },
    {
        "id": 5681,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Results from a comparison of five different cisplatin-based regimens for NPC showed that all had substantial anti-cancer activity."
    },
    {
        "id": 5682,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Active and more commonly used single agents are listed in the algorithm."
    },
    {
        "id": 5683,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "The anti-PD-1 antibodies camrelizumab, toripalimab, and tislelizumab were evaluated in three separate randomized phase III trials from China."
    },
    {
        "id": 5684,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "Interim analyses of these two trials showed longer PFS for the experimental arms for camrelizumab, toripalimab, and tislelizumab compared to the arms containing GC and placebo."
    },
    {
        "id": 5685,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "The immunotherapy agents tested in these studies are currently not available in the United States."
    },
    {
        "id": 5686,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 178,
        "content": "GC may be reasonably paired with an available anti-PD-1 antibody based on extrapolation."
    },
    {
        "id": 5691,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 179,
        "content": "Pembrolizumab was assessed in the nonrandomized multi-institutional phase IB KEYNOTE-028 trial."
    },
    {
        "id": 5692,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 179,
        "content": "The KEYNOTE-028 trial had 27 patients, all but two of whom had previously received systemic therapy for their recurrent or metastatic disease."
    },
    {
        "id": 5693,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 179,
        "content": "The objective response rate in the KEYNOTE-028 trial was 26%, with a median duration of response of 17.1 months."
    },
    {
        "id": 5694,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 179,
        "content": "The OS rate at 6 and 12 months in the KEYNOTE-028 trial was 85% and 63%, respectively."
    },
    {
        "id": 5695,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 179,
        "content": "The PFS rates at 6 and 12 months in the KEYNOTE-028 trial were 39% and 34%, respectively."
    },
    {
        "id": 5696,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 179,
        "content": "Approximately 30% of patients in the KEYNOTE-028 trial experienced a grade 3\u20135 drug-related adverse event."
    },
    {
        "id": 5697,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 179,
        "content": "The panel recommends pembrolizumab for patients with previously treated PD-L1\u2013positive recurrent or metastatic NPC."
    },
    {
        "id": 5698,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 179,
        "content": "Pembrolizumab is a category 2B option based on panel consensus."
    },
    {
        "id": 5699,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 179,
        "content": "Pembrolizumab is also an option for patients with previously treated tumor mutational burden-high disease."
    },
    {
        "id": 5739,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "The larynx is divided into three regions: supraglottis, glottis, and subglottis."
    },
    {
        "id": 5740,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "The distribution of cancers is as follows: 30% to 35% in the supraglottic region, 60% to 65% in the glottic region, and 5% in the subglottic region."
    },
    {
        "id": 5741,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "The incidence and pattern of metastatic spread to regional nodes vary with the primary region."
    },
    {
        "id": 5742,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "The lymphatic drainage of the glottis is sparse and early-stage primaries rarely spread to regional nodes."
    },
    {
        "id": 5743,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "Most glottic cancers are early stage at diagnosis because hoarseness is an early symptom."
    },
    {
        "id": 5744,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "Glottic cancer has an excellent cure rate of 80% to 90%."
    },
    {
        "id": 5745,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "Nodal involvement adversely affects survival rates and is rare in T1\u20132 disease."
    },
    {
        "id": 5746,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "More than 50% of patients with supraglottic primaries present with spread to regional nodes because of an abundant lymphatic network that crosses the midline."
    },
    {
        "id": 5747,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "Bilateral cervical metastases are not uncommon with early-stage supraglottic primaries."
    },
    {
        "id": 5748,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "Supraglottic cancer is often metastatic and higher stage at diagnosis."
    },
    {
        "id": 5750,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "The evaluation of the patient to determine tumor stage is similar for glottic and supraglottic primaries."
    },
    {
        "id": 5751,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "Multidisciplinary consultation is frequently indicated for both sites because of the potential impact on voice quality, speech, and swallowing functions."
    },
    {
        "id": 5752,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 180,
        "content": "The 2017 AJCC staging classification for laryngeal primary tumors is determined by the number of subsites involved, vocal cord mobility, the presence of metastases, extranodal extension, and invasion of thyroid/cricoid cartilage."
    },
    {
        "id": 5757,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "For patients with carcinoma in situ of the larynx, recommended treatment options include: 1) endoscopic resection, which is preferred; or 2) RT."
    },
    {
        "id": 5758,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Endoscopic resection is preferred for patients with carcinoma in situ of the larynx."
    },
    {
        "id": 5759,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "RT is a recommended treatment option for patients with carcinoma in situ of the larynx."
    },
    {
        "id": 5760,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "A systematic review published in 2009 showed that surgery or RT have similar effectiveness for early-stage glottic or supraglottic cancer."
    },
    {
        "id": 5761,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "The quality of studies comparing the effectiveness of RT and surgery in early laryngeal cancer is low."
    },
    {
        "id": 5762,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "A systematic review including 48 studies of patients with T2 glottic cancer specifically showed no difference in 5-year local control between transoral surgery and EBRT."
    },
    {
        "id": 5763,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Transoral surgery and EBRT have similar 5-year local control rates for patients with T2 glottic cancer."
    },
    {
        "id": 5764,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "A meta-analysis including 11 studies showed that OS and laryngeal preservation were both better in patients who were treated with transoral laser microsurgery, compared to patients treated with RT."
    },
    {
        "id": 5765,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Transoral laser microsurgery is associated with better OS and laryngeal preservation compared to RT."
    },
    {
        "id": 5766,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "The choice of treatment modality depends on anticipated functional outcome, the patient\u2019s wishes, reliability of follow-up, and general medical condition."
    },
    {
        "id": 5767,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Total laryngectomy may be preferable over endoscopic or open partial laryngectomy in patients with significant pulmonary comorbidity."
    },
    {
        "id": 5768,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Partial laryngeal surgery should be carefully considered if adjuvant RT is likely."
    },
    {
        "id": 5769,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Consideration should be given to any suspicious lymphadenopathy and risk of metastatic nodal disease."
    },
    {
        "id": 5770,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Neck dissection should be performed as indicated when the primary site is treated surgically."
    },
    {
        "id": 5771,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "In patients with T1\u20132 node-negative cancer of the supraglottic larynx, lymph node dissection is associated with greater OS."
    },
    {
        "id": 5772,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "T1\u20132 supraglottic cancers have a significant risk of occult nodal disease at presentation."
    },
    {
        "id": 5773,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Postoperative adjuvant treatment depends on the presence or absence of adverse pathologic features, such as margin status, nodal staging, and any extranodal extension."
    },
    {
        "id": 5774,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Subglottic extension is also considered an adverse pathologic feature for cancer of the glottic larynx."
    },
    {
        "id": 5775,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "In the event of close or positive margins in organ preservation surgery, re-resection to negative margins may be considered."
    },
    {
        "id": 5776,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Re-resection to negative margins may or may not require a total laryngectomy to achieve."
    },
    {
        "id": 5777,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Resectable, advanced-stage glottic and supraglottic primaries are usually managed with a combined modality approach."
    },
    {
        "id": 5778,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "If laryngeal preservation is desired, concurrent systemic therapy/RT is recommended, based on results from Intergroup trial RTOG 91-11."
    },
    {
        "id": 5785,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Concurrent RT and systemic therapy (cisplatin preferred [category 1]) is a treatment option for achieving laryngeal preservation for T3, any N glottic and supraglottic cancers."
    },
    {
        "id": 5786,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 181,
        "content": "Long-term follow-up (10 years) of R91-11 indicates that laryngeal preservation continues to be better."
    },
    {
        "id": 5794,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "Definitive RT is an option for patients with T3, N0\u20131 disease who are medically unfit or refuse systemic therapy."
    },
    {
        "id": 5795,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "Surgery is also an option for patients with T3, N0\u20131 disease who are medically unfit or refuse systemic therapy."
    },
    {
        "id": 5796,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "Surgical therapy is indicated for patients whose disease persists after systemic therapy/RT or RT."
    },
    {
        "id": 5797,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "Induction chemotherapy with management based on response is an option for all but T1\u20132, N0 glottic and supraglottic cancers."
    },
    {
        "id": 5800,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "RT alone is recommended after a complete or partial response with induction chemotherapy for patients with laryngeal cancer."
    },
    {
        "id": 5801,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "Systemic therapy/RT is a category 2B recommendation after a partial response."
    },
    {
        "id": 5803,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "For selected patients with T4a tumors who decline surgery, the NCCN Panel recommends considering concurrent systemic therapy/RT, clinical trials, or induction chemotherapy with additional management based on response."
    },
    {
        "id": 5804,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "Fractionation for RT is discussed in the algorithm."
    },
    {
        "id": 5805,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "An accelerated dosing schedule of 63 Gy (2.25 Gy/fraction) is preferred over conventional fractionation for patients with T1, N0 disease of the glottic larynx."
    },
    {
        "id": 5806,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "A dosing schedule of 50\u201352 Gy (3.12\u20133.28 Gy/fraction) may also be considered for patients with comorbidities or travel logistics or who are older adults."
    },
    {
        "id": 5807,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "Serial endoscopy is recommended during follow-up examinations."
    },
    {
        "id": 5808,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 182,
        "content": "High-resolution, advanced radiologic imaging may be supplemented with serial endoscopy during follow-up examinations."
    },
    {
        "id": 5817,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "The most common histology for Ethmoid Sinus Tumors and Maxillary Sinus Tumors is squamous cell carcinoma."
    },
    {
        "id": 5822,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "Locoregional control and incidence of distant metastasis are dependent on T stage, N stage, and tumor histology."
    },
    {
        "id": 5823,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "T stage remains the most reliable predictor of survival and locoregional control."
    },
    {
        "id": 5826,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "Patients with early-stage ethmoid sinus cancer are typically asymptomatic or have minor symptoms of nasal stuffiness, epistaxis, or anosmia."
    },
    {
        "id": 5828,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "For a patient with gross residual disease left behind after an initial endoscopic procedure, an oncologically complete resection of the residual tumor is required."
    },
    {
        "id": 5831,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "Nodal involvement is rare in ethmoid sinus tumors, and, when present, lymph node metastasis is associated with poor prognosis."
    },
    {
        "id": 5832,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "Patients with ethmoid sinus cancer who have N+ neck disease should undergo neck dissection with adjuvant therapy as appropriate based on the presence of adverse risk features."
    },
    {
        "id": 5833,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "Patients with high-grade tumors have worse survival outcomes compared to those with low-grade tumors."
    },
    {
        "id": 5834,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "Often patients with ethmoid sinus cancer present after having had an incomplete endoscopic resection."
    },
    {
        "id": 5835,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "The patient who is diagnosed after incomplete resection (eg, polypectomy with histologically positive margin)\u2014and has no documented residual disease on physical examination, imaging, and/or endoscopy\u2014should be treated with surgical resection to obtain oncologically appropriate margins if feasible."
    },
    {
        "id": 5836,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "If no adverse pathologic features are found, complete surgical resection may obviate the need for postoperative RT in T1 patients only."
    },
    {
        "id": 5837,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "In patients with high-risk pathologic features, such as positive or close margins adjacent to vital structures, high-grade lesions or other unfavorable histology, and/or intracranial and/or intraorbital extension, postoperative RT is recommended, and possibly systemic therapy/RT could be considered."
    },
    {
        "id": 5838,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "RT or concurrent systemic therapy/RT may be considered as definitive treatment in patients for whom an oncologically satisfactory surgical resection is not possible."
    },
    {
        "id": 5839,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "Radiation therapy fractionation for patients with ethmoid sinus tumors is described in Ethmoid Sinus Tumors: Principles of Radiation Therapy in the NCCN Guidelines for Head and Neck Cancers."
    },
    {
        "id": 5840,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "IMRT is preferred due to the proximity of this anatomic area to the optic structures."
    },
    {
        "id": 5841,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 183,
        "content": "Proton therapy should be considered if the normal tissue constraints cannot be met by IMRT."
    },
    {
        "id": 5846,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Systemic therapy and RT may be considered to preserve the orbital contents and avoid incomplete surgery in patients with T4 disease."
    },
    {
        "id": 5848,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "In patients with T4 disease, induction and concurrent chemotherapy may be given in combination with RT."
    },
    {
        "id": 5849,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "A retrospective study including 123 patients with stage III or IV sinonasal squamous cell carcinoma was conducted from 1988 to 2017 at an NCCN Member Institution."
    },
    {
        "id": 5850,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "The overall response rate (ORR) was 62.6% following treatment with induction chemotherapy using regimens typical for SCCHN."
    },
    {
        "id": 5851,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "There were 71 partial responses and 6 complete responses."
    },
    {
        "id": 5852,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "The 2-year OS was 61.4%."
    },
    {
        "id": 5853,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "The 2-year DFS was 67.9%."
    },
    {
        "id": 5854,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "The rate of orbital preservation was 81.5%."
    },
    {
        "id": 5855,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Distant metastasis occurred in only 6.5% of patients."
    },
    {
        "id": 5856,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "A single center retrospective study including 95 patients with SNUC was conducted."
    },
    {
        "id": 5857,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Concurrent systemic therapy/RT following complete or partial response to induction chemotherapy was associated with a 5-year DSS rate of 81%."
    },
    {
        "id": 5858,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "The 5-year DSS rate for the entire sample was 59%."
    },
    {
        "id": 5859,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "The DSS rate for patients who received surgery with adjuvant therapy following a less than partial response to induction chemotherapy was 39%."
    },
    {
        "id": 5860,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Definitive trials of induction chemotherapy prior to surgery are currently underway within the U.S. cooperative groups."
    },
    {
        "id": 5861,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Systemic therapy should routinely be part of the overall treatment for patients with SNUC with neuroendocrine features."
    },
    {
        "id": 5862,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Systemic therapy should routinely be part of the overall treatment for patients with small cell, high-grade olfactory esthesioneuroblastoma."
    },
    {
        "id": 5863,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Systemic therapy should routinely be part of the overall treatment for patients with SNEC histologies."
    },
    {
        "id": 5864,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "The optimal regimen for these patients is not well-defined."
    },
    {
        "id": 5865,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Regimens used for high-grade neuroendocrine carcinomas, such as etoposide plus platinum, cyclophosphamide/doxorubicin/vincristine, are typically used."
    },
    {
        "id": 5866,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Regimens used for advanced SCCHN, such as TPF, PF, or TP, are typically used."
    },
    {
        "id": 5867,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Long-term follow-up is necessary for esthesioneuroblastoma, since late recurrences can occur even after 15 years."
    },
    {
        "id": 5868,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "For patients with metastatic disease, options include platinum combined with etoposide, with or without concurrent RT."
    },
    {
        "id": 5869,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Cyclophosphamide/doxorubicin/vincristine is also an option for patients with metastatic disease."
    },
    {
        "id": 5870,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "The use of other systemic options, including immunotherapy, remains undefined due to a paucity of data."
    },
    {
        "id": 5871,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Surgical resection followed by postoperative radiotherapy remains a cornerstone of treatment for most maxillary sinus tumors."
    },
    {
        "id": 5872,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "This approach is not recommended for limited extent T1\u20132 tumors resected with negative margins."
    },
    {
        "id": 5873,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "The principles of treatment for maxillary sinus tumors are generally similar to those described for ethmoid sinus tumors."
    },
    {
        "id": 5874,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "For patients with SNUC with neuroendocrine features, small cell, high-grade olfactory esthesioneuroblastoma, or SNEC histologies, systemic therapy should be routinely included as part of the treatment plan."
    },
    {
        "id": 5875,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Participation in clinical trials is recommended for patients with malignant tumors of the paranasal sinuses with these histologies."
    },
    {
        "id": 5876,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "RT fractionation for patients with maxillary sinus tumors is described in the NCCN Guidelines for Head and Neck Cancers."
    },
    {
        "id": 5877,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Studies using IMRT have shown that it reduces the incidence of complications, such as radiation-induced ophthalmologic toxicity."
    },
    {
        "id": 5878,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "IMRT is preferred in this anatomic area due to proximity to the visual structures."
    },
    {
        "id": 5879,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 184,
        "content": "Proton therapy is preferred if the normal tissue constraints cannot be met by IMRT."
    },
    {
        "id": 5903,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 185,
        "content": "For patients with metastatic (M1) disease at initial presentation, palliative adjunctive measures include RT, surgery, analgesics, and other therapies to control manifestations of disease spread."
    },
    {
        "id": 5904,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 185,
        "content": "Locoregional treatment may be used for oligometastatic disease."
    },
    {
        "id": 5911,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Historically, single-agent and combination systemic therapy have both been used for Head and Neck Cancers."
    },
    {
        "id": 5912,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Response rates to single-agent therapies range from 15% to 35%."
    },
    {
        "id": 5913,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Randomized trials assessing a cisplatin-based combination regimen versus single-agent therapy with cisplatin, 5-FU, or methotrexate showed significantly higher response rates."
    },
    {
        "id": 5914,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "There was no difference in OS and greater toxicity for the combination regimen."
    },
    {
        "id": 5915,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Complete response is associated with longer survival and, although infrequent, has been reported more often with combination regimens."
    },
    {
        "id": 5916,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "A phase III randomized trial (EXTREME) of 442 patients found that cetuximab plus cisplatin/5-FU or carboplatin/5-FU improved response rate and median survival."
    },
    {
        "id": 5917,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "A randomized phase III trial found no significant difference in survival when comparing cisplatin/5-FU and cisplatin/paclitaxel."
    },
    {
        "id": 5918,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Trials evaluating immune checkpoint inhibitors demonstrated efficacy in patients with recurrent or metastatic SCCHN."
    },
    {
        "id": 5919,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Pembrolizumab, an anti-PD-1 antibody, was evaluated as a first-line option for recurrent or metastatic SCCHN in the KEYNOTE-048 trial."
    },
    {
        "id": 5920,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Patients were randomized to receive pembrolizumab, pembrolizumab with a platinum and 5-FU, or the EXTREME regimen."
    },
    {
        "id": 5921,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "In the total population, an OS benefit was observed in the pembrolizumab/platinum/5-FU arm, compared to the EXTREME arm."
    },
    {
        "id": 5922,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "PFS, however, did not significantly differ between these two study arms."
    },
    {
        "id": 5923,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "In patients with a PD-L1 combined positive score (CPS) of \u226520 or \u22651, median OS was better in patients who received pembrolizumab monotherapy."
    },
    {
        "id": 5924,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Median duration of response was greater in patients treated with pembrolizumab monotherapy or pembrolizumab with chemotherapy, compared to patients treated with the EXTREME regimen."
    },
    {
        "id": 5925,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Grade 3\u20135 toxicity was observed in 85% of patients receiving pembrolizumab/platinum/5-FU, and in 55% of patients receiving pembrolizumab monotherapy."
    },
    {
        "id": 5926,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "A post hoc analysis showed that the OS benefit of pembrolizumab with and without platinum/5-FU persisted at 4-year follow-up."
    },
    {
        "id": 5927,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "The panel considers immunotherapy as the preferred first-line systemic therapy option for all patients with recurrent, unresectable, or metastatic disease who have no surgical or radiotherapeutic option."
    },
    {
        "id": 5928,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Pembrolizumab alone or pembrolizumab/platinum/5-FU are both category 1 preferred first-line options based on the results of KEYNOTE-048."
    },
    {
        "id": 5929,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "The combination regimen may be particularly suitable in patients with a PS of 0 or 1 and either a large burden of disease or nearing a clinical crisis."
    },
    {
        "id": 5930,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Other combination regimens recommended by the panel for treatment of metastatic SCCHN include cisplatin or carboplatin, plus 5-FU with cetuximab."
    },
    {
        "id": 5931,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Cisplatin or carboplatin, plus a taxane, is also a recommended regimen."
    },
    {
        "id": 5932,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Cisplatin with cetuximab is another recommended regimen."
    },
    {
        "id": 5933,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Cisplatin with 5-FU is also a recommended regimen."
    },
    {
        "id": 5934,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Cetuximab with a platinum and a taxane is a recommended regimen."
    },
    {
        "id": 5935,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Pembrolizumab/platinum/paclitaxel is a category 2B option based on less panel consensus and less evidence than for use of docetaxel in this combination."
    },
    {
        "id": 5936,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Cetuximab combined with an anti-PD-1 antibody is also an option for recurrent or metastatic SCCHN based on results from non-randomized phase II trials."
    },
    {
        "id": 5937,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Cisplatin/pemetrexed is a category 2B option for patients with PS 0\u20131 only."
    },
    {
        "id": 5938,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 186,
        "content": "Gemcitabine/paclitaxel is also a category 2B option."
    },
    {
        "id": 5943,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "A multidisciplinary evaluation is critical in defining appropriate therapy for patients with local and/or regional disease recurrence or persistence without distant metastasis."
    },
    {
        "id": 5944,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "A subset of patients with local and/or regional disease recurrence or persistence without distant metastasis can be approached with curative intent local therapy."
    },
    {
        "id": 5945,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "The therapeutic options for patients with local and/or regional disease recurrence or persistence without distant metastasis depend on several factors."
    },
    {
        "id": 5946,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "The factors that determine the therapeutic options for patients with local and/or regional disease recurrence or persistence without distant metastasis include type of prior therapy, interval between prior therapy and recurrence, desire for functional preservation, and patient PS."
    },
    {
        "id": 5947,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Surgery is recommended for resectable recurrent or persistent locoregional disease in the absence of distant metastatic disease."
    },
    {
        "id": 5948,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Adjuvant therapy for resectable recurrent or persistent locoregional disease depends on pathologic risk factors."
    },
    {
        "id": 5949,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Patients with resectable recurrent or persistent locoregional disease who have not previously been treated with RT may also be treated with concurrent systemic therapy/RT."
    },
    {
        "id": 5950,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "High-dose cisplatin is the preferred systemic agent for concurrent systemic therapy/RT."
    },
    {
        "id": 5951,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Combination systemic therapy followed by RT or systemic therapy/RT may be considered for cytoreduction or symptom control, followed by local therapy such as surgery as clinically indicated."
    },
    {
        "id": 5952,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "RT with concurrent systemic therapy is recommended for patients with unresectable recurrence or persistence in a previously non-irradiated field."
    },
    {
        "id": 5953,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "The duration of RT and choice of systemic agent for patients with unresectable recurrence or persistence in a previously non-irradiated field depend on the PS."
    },
    {
        "id": 5954,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "No randomized data exist that define a preferred systemic therapy/RT combination for patients with unresectable recurrence or persistence in a previously non-irradiated field."
    },
    {
        "id": 5955,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Early-phase studies have explored carboplatin, PD-1 inhibitors, and cetuximab for patients with unresectable recurrence or persistence in a previously non-irradiated field."
    },
    {
        "id": 5956,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "In situations where patient or tumor factors render patients as poor candidates for curative-intent radiation or surgery, the treatment approach is the same as that for patients with metastatic disease."
    },
    {
        "id": 5957,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Reirradiation with systemic therapy is increasingly feasible for patients who are poor candidates for curative-intent radiation or surgery."
    },
    {
        "id": 5958,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Locoregional treatment such as palliative radiation may be considered in the presence of distant metastasis with locoregional failure to alleviate tumor burden-related symptoms."
    },
    {
        "id": 5959,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "RT fractionation for patients with recurrent or persistent disease is described in Very Advanced Head and Neck Cancers: Principles of Radiation Therapy in the NCCN Guidelines for Head and Neck Cancers."
    },
    {
        "id": 5960,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Reirradiation may be offered to patients with locally and/or regionally recurrent or persistent H&N cancer using IMRT, PBT, or SBRT."
    },
    {
        "id": 5961,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "A randomized phase III multicenter trial in France showed that reirradiation combined with systemic therapy in patients following a resected recurrence improves DFS, compared to patients receiving only surgery."
    },
    {
        "id": 5962,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "The toxicity of reirradiation combined with systemic therapy was considerable, with grade 3 of 4 acute toxicity in 28% of patients."
    },
    {
        "id": 5963,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "SBRT with or without cetuximab following surgery for relapsed or refractory disease has been investigated in an institutional report."
    },
    {
        "id": 5964,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Advanced RT techniques should be used for reirradiation."
    },
    {
        "id": 5965,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "A retrospective review of 227 patients showed that IMRT-based reirradiation of the H&N may be associated with local control and improved survival rates."
    },
    {
        "id": 5966,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Toxicity rates were considerable, with adverse events grade 3 or higher occurring in 16% of patients at 2 years."
    },
    {
        "id": 5967,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Use of concurrent systemic therapy may be associated with greater risk of toxicity."
    },
    {
        "id": 5968,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "Rates for 1-year local control, distant control, DFS, and OS were 51%, 90%, 49%, and 64%, respectively, and adverse events grade 3 or higher were rare."
    },
    {
        "id": 5969,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 187,
        "content": "The best outcomes for SBRT for reirradiation are in patients with smaller tumors."
    },
    {
        "id": 5986,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "Nivolumab was assessed in a phase III RCT including 361 patients with recurrent SCCHN whose disease had progressed within 6 months following platinum-based chemotherapy."
    },
    {
        "id": 5987,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "With a median follow-up of 5.1 months, the OS was significantly greater in patients given nivolumab, compared to patients given standard second-line single-agent systemic therapy."
    },
    {
        "id": 5988,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "One-year survival was also greater for patients who received nivolumab, relative to patients who received standard therapy."
    },
    {
        "id": 5989,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "Response rate was higher for patients who received nivolumab, relative to patients who received standard therapy."
    },
    {
        "id": 5990,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "Median PFS was not significantly different between the two groups."
    },
    {
        "id": 5991,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "In prespecified exploratory analyses, the OS benefit in patients treated with nivolumab appeared to be confined to those patients with a tumor PD-L1 expression level of 1% or more."
    },
    {
        "id": 5992,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "In patients with tumor PD-L1 expression level less than 1%, no OS advantage was demonstrated for the nivolumab-treated patients."
    },
    {
        "id": 5993,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "Grade 3 or 4 treatment-related adverse events occurred in 13.1% of patients who received nivolumab, compared to 35.1% of patients who received standard therapy."
    },
    {
        "id": 5994,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "Nivolumab prolongs survival in patients with recurrent or metastatic squamous cell H&N cancer that has progressed after platinum-based chemotherapy, relative to patients who receive standard single-agent systemic therapy."
    },
    {
        "id": 5995,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "There are two FDA-approved dosing regimens for nivolumab for treatment of SCCHN: 240 mg every 2 weeks or 480 mg every 4 weeks."
    },
    {
        "id": 5996,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "Pembrolizumab was initially studied at a dose of 10 mg/kg given every 2 weeks in the SCCHN cohort of the KEYNOTE-012 trial, and clinical activity was identified."
    },
    {
        "id": 5997,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 188,
        "content": "A lower, fixed-dose schedule using pembrolizumab 200 mg every 3 weeks was subsequently assessed in a phase 1b expansion cohort of 132 patients with recurrent or metastatic SCCHN."
    },
    {
        "id": 6001,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "The OS rate was 59% at 6 months."
    },
    {
        "id": 6003,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "The ORR was 18% at 6 months."
    },
    {
        "id": 6004,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "Observed responses appeared durable, although the follow-up was limited (median, 9 months)."
    },
    {
        "id": 6006,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "The 1-year OS rate was 38% after long-term follow-up of the initial and expansion cohorts (N = 192)."
    },
    {
        "id": 6007,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "Among the 34 patients with a disease response, 85% of the responses lasted 6 months or longer."
    },
    {
        "id": 6008,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "Among the 34 patients with a disease response, 71% of the responses lasted 12 months or longer."
    },
    {
        "id": 6012,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "Median OS was greater for the pembrolizumab arm compared to the standard-of-care arm (8.4 vs. 6.9 months; HR, 0.80; 95% CI, 0.65\u20130.98; P = .016)."
    },
    {
        "id": 6013,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "The results for OS were significantly better with pembrolizumab only for patients with tumors that have PD-L1 expression."
    },
    {
        "id": 6014,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "Patients treated with pembrolizumab had stable functioning and symptoms through 15 weeks."
    },
    {
        "id": 6015,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "Patients treated with standard of care had a decline in functioning and symptoms through 15 weeks."
    },
    {
        "id": 6016,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "Pembrolizumab monotherapy was also evaluated for previously treated tumors with high microsatellite instability (MSI-H)/mismatch repair deficiency (dMMR) in the phase II KEYNOTE-158 basket trial."
    },
    {
        "id": 6018,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "The ORR for the entire sample (N = 233) was 34.3% (95% CI, 28.3%\u201340.8%) in the KEYNOTE-158 basket trial."
    },
    {
        "id": 6019,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "The median PFS was 4.1 months (95% CI, 2.4\u20134.9) in the KEYNOTE-158 basket trial."
    },
    {
        "id": 6020,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "The median OS was 23.5 months (95% CI, 13.5 months\u2013not reached) in the KEYNOTE-158 basket trial."
    },
    {
        "id": 6021,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "Pembrolizumab was studied in 171 patients with SCCHN that progressed following treatment with both a platinum and cetuximab in the nonrandomized phase II KEYNOTE-055 trial."
    },
    {
        "id": 6022,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "The ORR was 16% (95% CI, 11%\u201323%) in the KEYNOTE-055 trial."
    },
    {
        "id": 6023,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "The mean duration of response was 8 months in the KEYNOTE-055 trial."
    },
    {
        "id": 6029,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "The panel recommends immunotherapy (nivolumab and pembrolizumab) as the category 1 preferred option for patients with recurrent or metastatic SCCHN who have progressed on or following platinum-based chemotherapy."
    },
    {
        "id": 6030,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "Pembrolizumab is also an option for treatment of MSI-H disease."
    },
    {
        "id": 6031,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "Pembrolizumab is FDA-approved for patients with previously treated TMB-H unresectable or metastatic disease that has progressed following prior treatment with no satisfactory treatment alternatives."
    },
    {
        "id": 6032,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 189,
        "content": "PD-L1 expression may be associated with better outcomes from treatment with immunotherapy for recurrent or metastatic SCCHN."
    },
    {
        "id": 6043,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 190,
        "content": "The most frequent histology of occult or unknown primary H&N cancer is squamous cell carcinoma."
    },
    {
        "id": 6047,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 190,
        "content": "H&N cancer of unknown primary site is a highly curable disease."
    },
    {
        "id": 6048,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 190,
        "content": "After appropriate evaluation and treatment, most patients experience low morbidity and long-term disease control."
    },
    {
        "id": 6061,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 190,
        "content": "High-risk HPV and EBV testing are recommended for squamous cell or undifferentiated histology."
    },
    {
        "id": 6062,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 190,
        "content": "High-risk HPV and EBV testing can be useful in workup and management of cancers of the neck of unknown primary."
    },
    {
        "id": 6063,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 190,
        "content": "Patients with EBV- or HPV-related cervical adenopathy are staged according to the classification for nasopharyngeal and HPV-positive oropharyngeal cancer, respectively."
    },
    {
        "id": 6064,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 190,
        "content": "A thorough operative examination of at-risk mucosal sites is an important component in the workup of a patient with an occult primary."
    },
    {
        "id": 6065,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 190,
        "content": "Directed biopsies of areas of mucosal abnormalities suspicious for the primary site are undertaken during the operative examination."
    },
    {
        "id": 6067,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 190,
        "content": "Many primary cancers are identified after tonsillectomy."
    },
    {
        "id": 6071,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 191,
        "content": "The treatment of head and neck cancers is uncertain because, when patients have been treated without tonsillectomy, only a few develop a clinically significant primary tumor."
    },
    {
        "id": 6072,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 191,
        "content": "Neck dissection is recommended for all patients with thyroglobulin-negative and calcitonin-negative adenocarcinoma."
    },
    {
        "id": 6073,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 191,
        "content": "If the metastatic adenocarcinoma presents high in the neck, parotidectomy may be included with the neck dissection."
    },
    {
        "id": 6074,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 191,
        "content": "After neck dissection, management depends on the findings (ie, N1 without extranodal extension, N2 or N3 without extranodal extension, or extranodal extension)."
    },
    {
        "id": 6078,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 191,
        "content": "RT is also an option for patients with N1 disease, as a retrospective single-institution study showed that IMRT in patients with cervical lymph node metastasis from an unknown primary was associated with good local control and survival outcomes."
    },
    {
        "id": 6080,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 191,
        "content": "A neck dissection may be recommended after treatment with RT and/or systemic therapy, depending on the clinical response."
    },
    {
        "id": 6081,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 191,
        "content": "Since HPV-positive occult primary is likely located in the tonsil or base of tongue regions, radiation targets may be limited to these mucosal regions."
    },
    {
        "id": 6082,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 191,
        "content": "Postoperative therapy among patients with occult primary squamous cell carcinoma is based on the amount of nodal disease and the presence or absence of extranodal extension."
    },
    {
        "id": 6083,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 191,
        "content": "For N1 disease without extranodal extension, NCCN Panel Members recommend either: 1) RT that encompasses the target volume; or 2) careful observation with regular H&N examinations."
    },
    {
        "id": 6084,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 191,
        "content": "Postoperative RT or consideration of concurrent chemoradiation (category 2B for chemoradiation) is recommended for N2 or N3 disease without extranodal extension."
    },
    {
        "id": 6085,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 191,
        "content": "For extranodal extension, concurrent chemoradiation is a category 1 recommendation; RT alone is an option."
    },
    {
        "id": 6106,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 192,
        "content": "The panel recommends highly conformal RT techniques such as IMRT, proton, or other heavy ions for definitive radiation treatment."
    },
    {
        "id": 6107,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 192,
        "content": "A retrospective cohort study showed better local control and survival outcomes with neutron therapy, relative to photon therapy."
    },
    {
        "id": 6111,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 192,
        "content": "Most malignant deep lobe parotid tumors will require postoperative RT because of adverse pathologic features."
    },
    {
        "id": 6112,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 192,
        "content": "RT is also used in an adjuvant setting for tumors with other adverse pathologic features."
    },
    {
        "id": 6113,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 192,
        "content": "Systemic therapy/RT can also be considered for patients with advanced salivary gland tumors."
    },
    {
        "id": 6118,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 192,
        "content": "NGS and other biomarker tests should be used to evaluate AR, NTRK, HRAS, PIK3CA, TMB, and HER2 status."
    },
    {
        "id": 6122,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 192,
        "content": "The panel recommends that patients with tumors that are AR+ receive androgen receptor therapy."
    },
    {
        "id": 6128,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "Larotrectinib is a TRK inhibitor that showed promising objective response rates of 75% to 100%."
    },
    {
        "id": 6129,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "A pooled analysis of a phase II trial and two phase I trials showed an objective response rate of 57.4% for entrectinib, another TRK inhibitor."
    },
    {
        "id": 6130,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "The FDA approved larotrectinib and entrectinib for treatment of patients with NTRK gene fusion-positive tumors."
    },
    {
        "id": 6131,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "The panel recommends NTRK therapy options such as larotrectinib and entrectinib for patients with recurrent NTRK gene fusion-positive salivary gland tumors and distant metastases."
    },
    {
        "id": 6132,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "HER2 positivity has been found in some advanced salivary gland tumors."
    },
    {
        "id": 6133,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "Trastuzumab is a HER2-targeted treatment option."
    },
    {
        "id": 6134,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "Ado-trastuzumab emtansine may be active in patients with previously treated metastatic HER2-positive salivary gland cancers."
    },
    {
        "id": 6143,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "Pembrolizumab is an option for patients with previously treated TMB-H or MSI-H/dMMR recurrent, unresectable, or metastatic salivary gland cancer."
    },
    {
        "id": 6146,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "Dabrafenib/trametinib is FDA-approved for all advanced BRAF V600E-mutated tumors."
    },
    {
        "id": 6148,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "Selpercatinib is FDA-approved for all locally advanced or metastatic RET gene fusion-positive solid tumors."
    },
    {
        "id": 6150,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "Other systemic therapy options may be used for palliation in advanced disease."
    },
    {
        "id": 6151,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "Various combinations of chemotherapy agents have been shown in small series to be active for some salivary gland malignant histologies."
    },
    {
        "id": 6152,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "ORRs ranging from 24% to 60% have been reported for various chemotherapy combinations."
    },
    {
        "id": 6153,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 193,
        "content": "Paclitaxel monotherapy has been shown to be active in patients with salivary gland cancer, with an RR of 26%."
    },
    {
        "id": 6160,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 194,
        "content": "Tyrosine kinase inhibitors such as axitinib and sorafenib have been evaluated in nonrandomized phase II trials."
    },
    {
        "id": 6161,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 194,
        "content": "The panel recommends axitinib and sorafenib as category 2B options for patients with unresectable, metastatic, or recurrent salivary gland tumors."
    },
    {
        "id": 6164,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 194,
        "content": "Lenvatinib has been evaluated in two phase II trials for recurrent or metastatic adenoid cystic carcinoma."
    },
    {
        "id": 6167,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 194,
        "content": "Mucosal Melanoma of the Head and Neck is a rare but highly aggressive neoplasm with a poor prognosis."
    },
    {
        "id": 6174,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 194,
        "content": "The AJCC Cancer Staging Manual includes a staging system for Mucosal Melanoma."
    },
    {
        "id": 6181,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 194,
        "content": "Primary treatment for Mucosal Melanoma should be surgical for T3, N0\u20131 and T4a, N0\u20131 disease."
    },
    {
        "id": 6183,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 194,
        "content": "Neck dissection with postoperative radiation is recommended for clinical nodal disease."
    },
    {
        "id": 6184,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 194,
        "content": "Postoperative radiation to the primary site is typically indicated in most cases of Mucosal Melanoma."
    },
    {
        "id": 6185,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 194,
        "content": "Postoperative radiation improves local control in Mucosal Melanoma, although this may depend on the extent of nodal involvement."
    },
    {
        "id": 6203,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Postoperative RT was associated with a significant reduction in relapse in the nodal basin."
    },
    {
        "id": 6204,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Postoperative RT was associated with a significant improvement in lymph node field control."
    },
    {
        "id": 6206,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "The NCCN Panel recommends postoperative RT for the following high-risk features: extranodal extension, involvement of two or more neck or intraparotid nodes, any node 3 cm or greater, or recurrence in the neck or soft tissue after initial surgical resection."
    },
    {
        "id": 6207,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Conventional fractionation is recommended at 2 Gy per fraction to a total postoperative dose of 60\u201366 Gy."
    },
    {
        "id": 6208,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "The Australian-New Zealand randomized trial used 48 Gy in 20 fractions to the neck, axilla, or groin."
    },
    {
        "id": 6209,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "The NCCN Panel prefers conventional fractionation to somewhat higher total doses in the neck."
    },
    {
        "id": 6210,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "The NCCN Panel has concerns about late effects from larger dose per fraction."
    },
    {
        "id": 6211,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "IMRT may be very useful in helping to achieve homogenous dose distributions and to spare critical organs, especially in paranasal sinus sites."
    },
    {
        "id": 6212,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "3D-CRT may also be used for RT."
    },
    {
        "id": 6213,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Reports suggest that the use of hypofractionation in cutaneous melanomas is associated with good outcomes but no clear advantage in cancer control."
    },
    {
        "id": 6214,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Little experience is available using large dose per fraction in mucosal sites."
    },
    {
        "id": 6215,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Hypofractionation must be carefully planned and delivered due to the close proximity of neural structures and risk of late effects."
    },
    {
        "id": 6216,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "RT should not be used concurrently with BRAF/MEK inhibitor therapy."
    },
    {
        "id": 6217,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Concurrent use of RT and BRAF/MEK inhibitor therapy has been found to be associated with grade \u22653 dermatologic reactions, and potentially lethal hemorrhaging in the liver, lung, and brain."
    },
    {
        "id": 6218,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "PBT should be considered for primary sites in the paranasal sinuses and nasal cavity due to the proximity of eye and other vital structures."
    },
    {
        "id": 6219,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Systemic therapy used for cutaneous melanoma is recommended for MM."
    },
    {
        "id": 6220,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Adjuvant systemic immunotherapy is an option for MM with nodal involvement."
    },
    {
        "id": 6221,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "While the majority of patients in melanoma adjuvant trials had cutaneous primaries, some patients with MM were included."
    },
    {
        "id": 6222,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Neoadjuvant checkpoint inhibitor for MM is not well-studied."
    },
    {
        "id": 6223,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Recent data suggest that neoadjuvant therapy for resectable MM is a feasible approach with signs of efficacy and an acceptable safety profile."
    },
    {
        "id": 6224,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 195,
        "content": "Further investigation is needed for neoadjuvant therapy for resectable MM."
    },
    {
        "id": 6230,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 196,
        "content": "Physical examination for MM should include endoscopic inspection for paranasal sinus disease."
    },
    {
        "id": 6355,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Ang KK, Harris J, Wheeler R, and others published an article about human papillomavirus and survival of patients with oropharyngeal cancer in the New England Journal of Medicine in 2010."
    },
    {
        "id": 6357,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Rischin D, Young RJ, Fisher R, and others published an article about the prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial in the Journal of Clinical Oncology in 2010."
    },
    {
        "id": 6359,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Fakhry C, Zhang Q, Nguyen-Tan PF, and others published an article about human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma in the Journal of Clinical Oncology in 2014."
    },
    {
        "id": 6361,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Posner MR, Lorch JH, Goloubeva O, and others published an article about survival and human papillomavirus in oropharynx cancer in TAX 324 in the Annals of Oncology in 2011."
    },
    {
        "id": 6363,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Fakhry C, Zhang Q, Nguyen-Tan PF, and others published an article about the development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer in the Journal of Clinical Oncology in 2017."
    },
    {
        "id": 6365,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Fullerton ZH, Butler SS, Mahal BA, and others published an article about short-term mortality risks among patients with oropharynx cancer by human papillomavirus status in Cancer in 2020."
    },
    {
        "id": 6367,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Fakhry C, Westra WH, Li S, and others published an article about improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial in the Journal of the National Cancer Institute in 2008."
    },
    {
        "id": 6369,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Lassen P, Eriksen JG, Hamilton-Dutoit S, and others published an article about the effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck in the Journal of Clinical Oncology in 2009."
    },
    {
        "id": 6371,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Coordes A, Lenz K, Qian X, and others published a meta-analysis about survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status in the European Archives of Otorhinolaryngology in 2016."
    },
    {
        "id": 6373,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Jordan RC, Lingen MW, Perez-Ordonez B, and others published an article about the validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials in the American Journal of Surgical Pathology in 2012."
    },
    {
        "id": 6375,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Gillison ML, Zhang Q, Jordan R, and others published an article about tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer in the Journal of Clinical Oncology in 2012."
    },
    {
        "id": 6377,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Sinha P, Lewis JS, Jr., Piccirillo JF, and others published an article about extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma in Cancer in 2012."
    },
    {
        "id": 6379,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Lassen P, Lacas B, Pignon JP, and others published an article about the prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer in the MARCH-HPV project in Radiotherapy and Oncology in 2018."
    },
    {
        "id": 6381,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Spector ME, Gallagher KK, Light E, and others published an article about matted nodes as a poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status in Head and Neck in 2012."
    },
    {
        "id": 6383,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "O'Sullivan B, Huang SH, Siu LL, and others published an article about deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis in the Journal of Clinical Oncology in 2013."
    },
    {
        "id": 6385,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 200,
        "content": "Vainshtein JM, Spector ME, Ibrahim M, and others published an article about matted nodes as a high distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer."
    },
    {
        "id": 6391,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Huang SH, O'Sullivan B, Su J, et al. wrote about the prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma."
    },
    {
        "id": 6394,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Wuthrick EJ, Zhang Q, Machtay M, et al. wrote about institutional clinical trial accrual volume and survival of patients with head and neck cancer."
    },
    {
        "id": 6397,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "David JM, Ho AS, Luu M, et al. wrote about treatment at high-volume facilities and academic centers being independently associated with improved survival in patients with locally advanced head and neck cancer."
    },
    {
        "id": 6400,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Gourin CG, Stewart CM, Frick KD, et al. wrote about the association of hospital volume with laryngectomy outcomes in patients with larynx cancer."
    },
    {
        "id": 6403,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Nocon CC, Ajmani GS, Bhayani MK wrote about the association of facility volume with positive margin rate in the surgical treatment of head and neck cancer."
    },
    {
        "id": 6406,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Lee NCJ, Kelly JR, An Y, et al. wrote about radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma."
    },
    {
        "id": 6409,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Cohen EE, LaMonte SJ, Erb NL, et al. wrote the American Cancer Society Head and Neck Cancer Survivorship Care Guideline."
    },
    {
        "id": 6412,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Jabbour J, Milross C, Sundaresan P, et al. wrote about education and support needs in patients with head and neck cancer."
    },
    {
        "id": 6415,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "So WK, Chan RJ, Chan DN, et al. wrote about quality-of-life among head and neck cancer survivors at one year after treatment."
    },
    {
        "id": 6418,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Smith BG, Hutcheson KA, Little LG, et al. wrote about lymphedema outcomes in patients with head and neck cancer."
    },
    {
        "id": 6421,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Colasanto JM, Prasad P, Nash MA, et al. wrote about nutritional support of patients undergoing radiation therapy for head and neck cancer."
    },
    {
        "id": 6424,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Lin BM, Starmer HM, Gourin CG wrote about the relationship between depressive symptoms, quality of life, and swallowing function in head and neck cancer patients 1 year after definitive therapy."
    },
    {
        "id": 6427,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Krebber AM, Leemans CR, de Bree R, et al. wrote about stepped care targeting psychological distress in head and neck and lung cancer patients."
    },
    {
        "id": 6430,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Verdonck-de Leeuw IM, de Bree R, Keizer AL, et al. wrote about computerized prospective screening for high levels of emotional distress in head and neck cancer patients and referral rate to psychosocial care."
    },
    {
        "id": 6433,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 201,
        "content": "Andersen BL, DeRubeis RJ, Berman BS, et al. wrote about screening, assessment, and care of anxiety and depressive symptoms in adults with cancer."
    },
    {
        "id": 6493,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Paleri V, Urbano TG, Mehanna H, et al. wrote about the Management of neck metastases in head and neck cancer."
    },
    {
        "id": 6495,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Kim SJ, Pak K, Kim K. wrote about the Diagnostic accuracy of F-18 FDG PET or PET/CT for detection of lymph node metastasis in clinically node negative head and neck cancer patients."
    },
    {
        "id": 6497,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Lowe VJ, Duan F, Subramaniam RM, et al. wrote about Multicenter trial of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography staging of head and neck cancer."
    },
    {
        "id": 6499,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Linz C, Brands RC, Herterich T, et al. wrote about Accuracy of 18-F fluorodeoxyglucose positron emission tomographic/computed tomographic imaging in primary staging of squamous cell carcinoma of the oral cavity."
    },
    {
        "id": 6501,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Hosni A, Huang SH, Chiu K, et al. wrote about Predictors of early recurrence prior to planned postoperative radiation therapy for oral cavity squamous cell carcinoma and outcomes following salvage intensified radiation therapy."
    },
    {
        "id": 6503,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Isles MG, McConkey C, Mehanna HM wrote about A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy."
    },
    {
        "id": 6507,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Cheung PK, Chin RY, Eslick GD wrote about Detecting residual/recurrent head neck squamous cell carcinomas using PET or PET/CT."
    },
    {
        "id": 6509,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Liauw SL, Mancuso AA, Amdur RJ, et al. wrote about Postradiotherapy neck dissection for lymph node-positive head and neck cancer."
    },
    {
        "id": 6511,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Porceddu SV, Jarmolowski E, Hicks RJ, et al. wrote about Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer."
    },
    {
        "id": 6513,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Yao M, Smith RB, Hoffman HT, et al. wrote about Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer."
    },
    {
        "id": 6515,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Lango MN, Myers JN, Garden AS wrote about Controversies in surgical management of the node-positive neck after chemoradiation."
    },
    {
        "id": 6517,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Kutler DI, Patel SG, Shah JP wrote about The role of neck dissection following definitive chemoradiation."
    },
    {
        "id": 6519,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 203,
        "content": "Mehanna H, Wong WL, McConkey CC, et al. wrote about PET-CT surveillance versus neck dissection in advanced head and neck cancer."
    },
    {
        "id": 6527,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 204,
        "content": "Mehanna H, McConkey CC, Rahman JK, et al. published a study on PET-NECK in 2017."
    },
    {
        "id": 6529,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 204,
        "content": "Corry J, Peters L, Fisher R, et al. published a study on N2-N3 neck nodal control in 2008."
    },
    {
        "id": 6531,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 204,
        "content": "Lau H, Phan T, Mackinnon J, Matthews TW published a study on absence of planned neck dissection in 2008."
    },
    {
        "id": 6533,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 204,
        "content": "Ong SC, Schoder H, Lee NY, et al. published a study on clinical utility of 18F-FDG PET/CT in 2008."
    },
    {
        "id": 6535,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 204,
        "content": "Nayak JV, Walvekar RR, Andrade RS, et al. published a study on deferring planned neck dissection in 2007."
    },
    {
        "id": 6537,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 204,
        "content": "Abgral R, Querellou S, Potard G, et al. published a study on 18F-FDG PET/CT in 2009."
    },
    {
        "id": 6539,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 204,
        "content": "Porceddu SV, Pryor DI, Burmeister E, et al. published a study on positron emission tomography-directed management in 2011."
    },
    {
        "id": 6541,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 204,
        "content": "Ho AS, Tsao GJ, Chen FW, et al. published a study on positron emission tomography/computed tomography surveillance in 2013."
    },
    {
        "id": 6543,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 204,
        "content": "Trosman SJ, Koyfman SA, Ward MC, et al. published a study on human papillomavirus in 2015."
    },
    {
        "id": 6545,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 204,
        "content": "Sheikhbahaei S, Taghipour M, Ahmad R, et al. published a study on diagnostic accuracy of follow-up FDG PET or PET/CT in 2015."
    },
    {
        "id": 6560,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "Carpenter DJ, Mowery YM, Broadwater G, et al. wrote an article about the risk of carotid stenosis in head and neck cancer patients after radiation therapy."
    },
    {
        "id": 6563,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "van Aken ESM, van der Laan HP, Bijl HP, et al. wrote an article about the risk of ischaemic cerebrovascular events in head and neck cancer patients."
    },
    {
        "id": 6566,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "Adelstein DJ, Ridge JA, Brizel DM, et al. wrote a summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting."
    },
    {
        "id": 6570,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "Arens C wrote an article about transoral treatment strategies for head and neck tumors."
    },
    {
        "id": 6573,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "Weinstein GS, O'Malley BW, Jr., Magnuson JS, et al. wrote an article about transoral robotic surgery."
    },
    {
        "id": 6576,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "Li RJ, Richmon JD wrote an article about transoral endoscopic surgery for oropharyngeal cancer."
    },
    {
        "id": 6579,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "Liu H, Wang Y, Wu C, et al. wrote a systematic review and meta-analysis about robotic compared with open operations for cancers of the head and neck."
    },
    {
        "id": 6582,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "Kubik M, Mandal R, Albergotti W, et al. wrote an article about the effect of transcervical arterial ligation on the severity of postoperative hemorrhage after transoral robotic surgery."
    },
    {
        "id": 6585,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "Hay A, Migliacci J, Karassawa Zanoni D, et al. wrote an article about haemorrhage following transoral robotic surgery."
    },
    {
        "id": 6588,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "Castellano A, Sharma A wrote a systematic review of validated quality of life and swallow outcomes after transoral robotic surgery."
    },
    {
        "id": 6591,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "De Virgilio A, Costantino A, Mercante G, et al. wrote a systematic review and meta-analysis about transoral robotic surgery and intensity-modulated radiotherapy in the treatment of oropharyngeal carcinoma."
    },
    {
        "id": 6606,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "Stringer SP wrote an article about current concepts in surgical management of neck metastases from head and neck cancer."
    },
    {
        "id": 6609,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "Robbins KT, Clayman G, Levine PA, et al. wrote an article about neck dissection classification update."
    },
    {
        "id": 6610,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 205,
        "content": "The article by Robbins KT, Clayman G, Levine PA, et al. proposed revisions to the American Head and Neck Society classification."
    },
    {
        "id": 6616,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The Society and the American Academy of Otolaryngology-Head and Neck Surgery published a study in Arch Otolaryngol Head Neck Surg in 2002."
    },
    {
        "id": 6617,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Candela FC, Kothari K, Shah JP was published in Head Neck in 1990."
    },
    {
        "id": 6618,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Candela FC, Shah J, Jaques DP, Shah JP was published in Arch Otolaryngol Head Neck Surg in 1990."
    },
    {
        "id": 6619,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Shah JP, Candela FC, Poddar AK was published in Cancer in 1990."
    },
    {
        "id": 6620,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Ferlito A, Rinaldo A, Silver CE, et al was published in Oral Oncol in 2006."
    },
    {
        "id": 6621,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Schmitz S, Machiels JP, Weynand B, et al was published in Eur Arch Otorhinolaryngol in 2009."
    },
    {
        "id": 6622,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Patel RS, Clark J, Wyten R, et al was published in Arch Otolaryngol Head Neck Surg in 2007."
    },
    {
        "id": 6623,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Sivanandan R, Kaplan MJ, Lee KJ, et al was published in Arch Otolaryngol Head Neck Surg in 2004."
    },
    {
        "id": 6624,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Bernier J, Domenge C, Ozsahin M, et al was published in N Engl J Med in 2004."
    },
    {
        "id": 6625,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Cooper JS, Pajak TF, Forastiere AA, et al was published in N Engl J Med in 2004."
    },
    {
        "id": 6626,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Bernier J, Cooper JS, Pajak TF, et al was published in Head Neck in 2005."
    },
    {
        "id": 6627,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Cooper JS, Zhang Q, Pajak TF, et al was published in Int J Radiat Oncol Biol Phys in 2012."
    },
    {
        "id": 6628,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Bachaud JM, Cohen-Jonathan E, Alzieu C, et al was published in Int J Radiat Oncol Biol Phys in 1996."
    },
    {
        "id": 6629,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Shah JP, Cendon RA, Farr HW, Strong EW was published in Am J Surg in 1976."
    },
    {
        "id": 6630,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 206,
        "content": "The study by Looser KG, Shah JP, Strong EW was published in Head Neck Surg in 1978."
    },
    {
        "id": 6637,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Johnson JT, Barnes EL, Myers EN, and others published a study on the extracapsular spread of tumors in cervical node metastasis in Arch Otolaryngol in 1981."
    },
    {
        "id": 6639,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Feldman M and Fletcher GH published a study on the analysis of the parameters relating to failures above the clavicles in patients treated by postoperative irradiation for squamous cell carcinomas of the oral cavity or oropharynx in Int J Radiat Oncol Biol Phys in 1982."
    },
    {
        "id": 6641,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Mirimanoff RO, Wang CC, and Doppke KP published a study on combined surgery and postoperative radiation therapy for advanced laryngeal and hypopharyngeal carcinomas in Int J Radiat Oncol Biol Phys in 1985."
    },
    {
        "id": 6643,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Peters LJ, Goepfert H, Ang KK, and others published a study on the evaluation of the dose for postoperative radiation therapy of head and neck cancer in Int J Radiat Oncol Biol Phys in 1993."
    },
    {
        "id": 6645,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Noronha V, Joshi A, Patil VM, and others published a study on once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer in J Clin Oncol in 2018."
    },
    {
        "id": 6647,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Harari PM, Harris J, Kies MS, and others published a study on postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck in J Clin Oncol in 2014."
    },
    {
        "id": 6649,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Hasan Z, Dwivedi RC, Gunaratne DA, and others published a systematic review and meta-analysis of the complications of salvage total laryngectomy in Eur J Surg Oncol in 2017."
    },
    {
        "id": 6651,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Gregoire V, Evans M, Le QT, and others published a study on the delineation of the primary tumour clinical target volumes in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma in Radiother Oncol in 2018."
    },
    {
        "id": 6653,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Lee AW, Ng WT, Pan JJ, and others published a study on the international guideline for the delineation of the clinical target volumes for nasopharyngeal carcinoma in Radiother Oncol in 2018."
    },
    {
        "id": 6655,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Stevens CM, Huang SH, Fung S, and others published a retrospective study of palliative radiotherapy in newly diagnosed head and neck carcinoma in Int J Radiat Oncol Biol Phys in 2011."
    },
    {
        "id": 6657,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Porceddu SV, Rosser B, Burmeister BH, and others published a study on hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment in Radiother Oncol in 2007."
    },
    {
        "id": 6659,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Corry J, Peters LJ, Costa ID, and others published a study on the 'QUAD SHOT'--a phase II study of palliative radiotherapy for incurable head and neck cancer in Radiother Oncol in 2005."
    },
    {
        "id": 6661,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Fu KK, Pajak TF, Trotti A, and others published a study on a Radiation Therapy Oncology Group phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas in Int J Radiat Oncol Biol Phys in 2000."
    },
    {
        "id": 6663,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 207,
        "content": "Beitler JJ, Zhang Q, Fu KK, and others published a study on the final results of local-regional control and late toxicity of RTOG 9003 in Int J Radiat Oncol Biol Phys in 2014."
    },
    {
        "id": 6673,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "Overgaard J, Hansen HS, Specht L, et al. published an article in Lancet in 2003."
    },
    {
        "id": 6676,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "Sher DJ, Adelstein DJ, Bajaj GK, et al. published an article in Pract Radiat Oncol in 2017."
    },
    {
        "id": 6679,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "Barkley HT, Fletcher GH published an article in Radiology in 1977."
    },
    {
        "id": 6682,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "ICRU Report 62 is titled 'Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50)'."
    },
    {
        "id": 6685,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "ICRU Report 83 is titled 'Prescribing, Recording, and Reporting Intensity Modulated Photon Beam Therapy (IMRT)'."
    },
    {
        "id": 6688,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "Garden AS, Dong L, Morrison WH, et al. published an article in Int J Radiat Oncol Biol Phys in 2013."
    },
    {
        "id": 6691,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "Daly ME, Le QT, Maxim PG, et al. published an article in Int J Radiat Oncol Biol Phys in 2010."
    },
    {
        "id": 6694,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "Eisbruch A, Harris J, Garden AS, et al. published an article in Int J Radiat Oncol Biol Phys in 2010."
    },
    {
        "id": 6697,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "Laursen M, Specht L, Kristensen CA, et al. published an article in Front Oncol in 2018."
    },
    {
        "id": 6700,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "Thames HD, Jr., Withers HR, Peters LJ, Fletcher GH published an article in Int J Radiat Oncol Biol Phys in 1982."
    },
    {
        "id": 6704,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "The article by Withers HR, Taylor JM, Maciejewski B is titled 'The hazard of accelerated tumor clonogen repopulation during radiotherapy'."
    },
    {
        "id": 6707,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "The article by Schwaibold F, Scariato A, Nunno M, et al. is titled 'The effect of fraction size on control of early glottic cancer'."
    },
    {
        "id": 6710,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "The article by Kim RY, Marks ME, Salter MM is titled 'Early-stage glottic cancer: importance of dose fractionation in radiation therapy'."
    },
    {
        "id": 6713,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "The chapter by Parson J is titled 'Time-dose-volume relationships in radiation therapy'."
    },
    {
        "id": 6715,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 208,
        "content": "The article by Yamazaki H, Nishiyama K, Tanaka E, et al. is titled 'Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time'."
    },
    {
        "id": 6752,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Bourhis J, Sire C, Graff P, et al. published a study on concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma in the Lancet Oncol in 2012."
    },
    {
        "id": 6755,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Haigentz M, Jr., Corry J, Strojan P, Ferlito A. published a study on easing acceleration of head and neck chemoradiotherapy in the Lancet Oncol in 2012."
    },
    {
        "id": 6757,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Ang K, Zhang Q, Wheeler RH, et al. published a study on a phase III trial of two radiation-cisplatin regimens for head and neck carcinomas in the J Clin Oncol in 2010."
    },
    {
        "id": 6759,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Nguyen-Tan PF, Zhang Q, Ang KK, et al. published a study on randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the J Clin Oncol in 2014."
    },
    {
        "id": 6761,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Denis F, Garaud P, Bardet E, et al. published a study on the final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma in the J Clin Oncol in 2004."
    },
    {
        "id": 6763,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Denis F, Garaud P, Bardet E, et al. published a study on late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma in the Int J Radiat Oncol Biol Phys in 2003."
    },
    {
        "id": 6765,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Bourhis J, Calais G, Lapeyre M, et al. published a study on concomitant radiochemotherapy or accelerated radiotherapy in the Semin Oncol in 2004."
    },
    {
        "id": 6767,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Machtay M, Moughan J, Trotti A, et al. published a study on factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer in the J Clin Oncol in 2008."
    },
    {
        "id": 6769,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Hartford AC, Palisca MG, Eichler TJ, et al. published a study on American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT) in the Int J Radiat Oncol Biol Phys in 2009."
    },
    {
        "id": 6771,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Holmes T, Das R, Low D, et al. published a study on American Society of Radiation Oncology recommendations for documenting intensity-modulated radiation therapy treatments in the Int J Radiat Oncol Biol Phys in 2009."
    },
    {
        "id": 6773,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Nutting CM, Morden JP, Harrington KJ, et al. published a study on parotid-sparing intensity-modulated versus conventional radiotherapy in head and neck cancer in the Lancet Oncol in 2011."
    },
    {
        "id": 6775,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Tribius S, Bergelt C. published a study on intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer in the Cancer Treat Rev in 2011."
    },
    {
        "id": 6777,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Ratko TA, Douglas GW, de Souza JA, et al. published a study on radiotherapy treatments for head and neck cancer update in Rockville (MD) in 2014."
    },
    {
        "id": 6778,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 210,
        "content": "Hunter KU, Schipper M, Feng FY, et al. published a study on toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer in the Int J Radiat Oncol Biol Phys."
    },
    {
        "id": 6789,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Lohia S, Rajapurkar M, Nguyen SA, et al. published a study on the comparison of outcomes using intensity-modulated radiation therapy and 3-dimensional conformal radiation therapy in treatment of oropharyngeal cancer."
    },
    {
        "id": 6792,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Kam MKM, Leung S-F, Zee B, et al. published a prospective randomized study on intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients."
    },
    {
        "id": 6795,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Baxi SS, Sher DJ, Pfister DG published a study on value considerations in the treatment of head and neck cancer."
    },
    {
        "id": 6798,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Schoenfeld JD, Sher DJ, Norris CM, Jr., et al. published a study on salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy."
    },
    {
        "id": 6801,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Gregoire V, Mackie TR published a report on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy."
    },
    {
        "id": 6804,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Chao KS, Majhail N, Huang CJ, et al. published a study on intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma."
    },
    {
        "id": 6807,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Dogan N, King S, Emami B, et al. published a study on assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing."
    },
    {
        "id": 6810,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Li Y, Taylor JMG, Ten Haken RK, Eisbruch A published a study on the impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy."
    },
    {
        "id": 6813,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Gregoire V, Jeraj R, Lee JA, O'Sullivan B published a review on radiotherapy for head and neck tumours in 2012 and beyond."
    },
    {
        "id": 6816,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Galvin JM, De Neve W published a review on intensity modulating and other radiation therapy devices for dose painting."
    },
    {
        "id": 6819,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Lauve A, Morris M, Schmidt-Ullrich R, et al. published a study on simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas."
    },
    {
        "id": 6822,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Schoenfeld GO, Amdur RJ, Morris CG, et al. published a study on patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer."
    },
    {
        "id": 6825,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Wu Q, Mohan R, Morris M, et al. published a study on simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas."
    },
    {
        "id": 6828,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Jiang L, Zhang Y, Yang Z, et al. published a meta-analysis on clinical outcomes between simultaneous integrated boost versus sequential boost intensity-modulated radiotherapy for head and neck cancer."
    },
    {
        "id": 6831,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 211,
        "content": "Ang KK, Chen A, Curran WJ, Jr., et al. published a report on head and neck carcinoma in the United States."
    },
    {
        "id": 6840,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 212,
        "content": "Lee NY and others compared intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma."
    },
    {
        "id": 6842,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 212,
        "content": "Hodge CW and others compared the outcome of oropharynx cancer with intensity-modulated radiotherapy."
    },
    {
        "id": 6844,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 212,
        "content": "Veldeman L and others conducted a systematic review of comparative clinical studies on the use of intensity-modulated radiotherapy."
    },
    {
        "id": 6846,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 212,
        "content": "Moon SH and others compared IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma."
    },
    {
        "id": 6848,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 212,
        "content": "Vergeer MR and others studied the effect of intensity-modulated radiotherapy on radiation-induced morbidity and health-related quality of life."
    },
    {
        "id": 6850,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 212,
        "content": "Pow EHN and others compared xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma."
    },
    {
        "id": 6858,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 212,
        "content": "Tao Y and others conducted a randomized phase III trial on concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC)."
    },
    {
        "id": 6860,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 212,
        "content": "Chi A and others focused on optic pathway preservation in intensity modulated radiotherapy for sinonasal malignancies."
    },
    {
        "id": 6862,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 212,
        "content": "Garden AS and others studied disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma."
    },
    {
        "id": 6871,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Eisbruch A, Levendag PC, Feng FY, et al. wrote an article titled 'Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer?'"
    },
    {
        "id": 6874,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Madani I, Bonte K, Vakaet L, et al. wrote an article titled 'Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update'."
    },
    {
        "id": 6877,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Eisbruch A wrote an article titled 'Reducing xerostomia by IMRT: what may, and may not, be achieved'."
    },
    {
        "id": 6880,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Nutting CM, Morden JP, Beasley M, et al. wrote an article titled 'Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer'."
    },
    {
        "id": 6883,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Beadle BM, Liao KP, Giordano SH, et al. wrote an article titled 'Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer'."
    },
    {
        "id": 6886,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Rosenthal DI, Chambers MS, Fuller CD, et al. wrote an article titled 'Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer'."
    },
    {
        "id": 6889,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Kocak-Uzel E, Gunn GB, Colen RR, et al. wrote an article titled 'Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy'."
    },
    {
        "id": 6892,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Hutcheson K, Lewin J, Garden A, et al. wrote an article titled 'Early experience with IMPT for the treatment of oropharyngeal tumors: Acute toxicities and swallowing-related outcomes'."
    },
    {
        "id": 6895,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Holliday EB, Frank SJ wrote an article titled 'Proton radiation therapy for head and neck cancer: a review of the clinical experience to date'."
    },
    {
        "id": 6898,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Frank SJ wrote an article titled 'Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT)'."
    },
    {
        "id": 6901,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Miller RC, Lodge M, Murad MH, Jones B wrote an article titled 'Controversies in clinical trials in proton radiotherapy: the present and the future'."
    },
    {
        "id": 6904,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Zenda S, Kawashima M, Nishio T, et al. wrote an article titled 'Proton beam therapy as a nonsurgical approach to mucosal melanoma of the head and neck: a pilot study'."
    },
    {
        "id": 6907,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Demizu Y, Fujii O, Terashima K, et al. wrote an article titled 'Particle therapy for mucosal melanoma of the head and neck'."
    },
    {
        "id": 6910,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 213,
        "content": "Fuji H, Yoshikawa S, Kasami M, et al. wrote an article titled 'High-dose proton beam therapy for sinonasal mucosal malignant melanoma'."
    },
    {
        "id": 6922,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Bhattasali O is the author of a study about definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma."
    },
    {
        "id": 6925,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Gunn GB is the author of a study about clinical outcomes and patterns of disease recurrence after intensity modulated proton therapy for oropharyngeal squamous carcinoma."
    },
    {
        "id": 6928,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Sio TT is the author of a study about intensity modulated proton therapy versus intensity modulated photon radiation therapy for oropharyngeal cancer."
    },
    {
        "id": 6931,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Holliday EB is the author of a study about dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation."
    },
    {
        "id": 6934,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Fan M is the author of a study about outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies."
    },
    {
        "id": 6937,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Fukumitsu N is the author of a study about the outcome of T4 (International Union Against Cancer Staging System, 7th edition) or recurrent nasal cavity and paranasal sinus carcinoma treated with proton beam."
    },
    {
        "id": 6940,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Patel S is the author of a study about recommendations for the referral of patients for proton-beam therapy, an Alberta Health Services report."
    },
    {
        "id": 6943,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Patel SH is the author of a study about charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases."
    },
    {
        "id": 6946,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Romesser PB is the author of a study about proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors."
    },
    {
        "id": 6949,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Russo AL is the author of a study about long-term outcomes after proton beam therapy for sinonasal squamous cell carcinoma."
    },
    {
        "id": 6952,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Dagan R is the author of a study about outcomes of sinonasal cancer treated with proton therapy."
    },
    {
        "id": 6955,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Blanchard P is the author of a study about intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer."
    },
    {
        "id": 6958,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Lee A is the author of a study about evaluation of proton therapy reirradiation for patients with recurrent head and neck squamous cell carcinoma."
    },
    {
        "id": 6961,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 214,
        "content": "Zenda S is the author of a study about proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses."
    },
    {
        "id": 6972,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 215,
        "content": "R. Santoni was an author of the study about Temporal lobe damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull."
    },
    {
        "id": 6977,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 215,
        "content": "J.E. Munzenrider was an author of the study about Proton therapy for tumors of the skull base."
    },
    {
        "id": 6981,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 215,
        "content": "M.M. Fitzek was an author of the study about Neuroendocrine tumors of the sinonasal tract."
    },
    {
        "id": 6986,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 215,
        "content": "A. Singh was an author of the study about Osteoradionecrosis of the jaw following proton radiation therapy for patients with head and neck cancer."
    },
    {
        "id": 6991,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 215,
        "content": "E.B. Holliday was an author of the study about A multidisciplinary orbit-sparing treatment approach that includes proton therapy for epithelial tumors of the orbit and ocular adnexa."
    },
    {
        "id": 6996,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 215,
        "content": "J. Pigneux was an author of the study about The place of interstitial therapy using 192 iridium in the management of carcinoma of the lip."
    },
    {
        "id": 7001,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 215,
        "content": "I. Karam was an author of the study about Stereotactic body radiotherapy for head and neck cancer: an addition to the armamentarium against head and neck cancer."
    },
    {
        "id": 7103,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 217,
        "content": "Rubin Grandis J, Melhem MF, Gooding WE, et al. wrote about levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival."
    },
    {
        "id": 7105,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 217,
        "content": "Zhu X, Zhang F, Zhang W, et al. wrote a meta-analysis about the prognostic role of epidermal growth factor receptor in head and neck cancer."
    },
    {
        "id": 7107,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 217,
        "content": "Bonner JA, Harari PM, Giralt J, et al. wrote about radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck."
    },
    {
        "id": 7111,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 217,
        "content": "Ang KK, Zhang Q, Rosenthal DI, et al. wrote about a randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma."
    },
    {
        "id": 7113,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 217,
        "content": "Tao Y, Auperin A, Sire C, et al. wrote about improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas."
    },
    {
        "id": 7115,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 217,
        "content": "Gillison ML, Trotti AM, Harris J, et al. wrote about radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer."
    },
    {
        "id": 7117,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 217,
        "content": "Mehanna H, Robinson M, Hartley A, et al. wrote about radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer."
    },
    {
        "id": 7119,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 217,
        "content": "Rischin D, King M, Kenny L, et al. wrote about a randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer."
    },
    {
        "id": 7121,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 217,
        "content": "Forastiere AA, Zhang Q, Weber RS, et al. wrote about long-term results of RTOG 91-11."
    },
    {
        "id": 7123,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 217,
        "content": "Ko EC, Genden EM, Misiukiewicz K, et al. wrote about toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation."
    },
    {
        "id": 7125,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 217,
        "content": "Lefebvre JL, Chevalier D, Luboinski B, et al. wrote about larynx preservation in pyriform sinus cancer."
    },
    {
        "id": 7132,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "The Department of Veterans Affairs Laryngeal Cancer Study Group published a study in the New England Journal of Medicine in 1991."
    },
    {
        "id": 7135,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "McNeil BJ, Weichselbaum R, and Pauker SG published a study in the New England Journal of Medicine in 1981."
    },
    {
        "id": 7138,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Pignon J-P, le Maitre A, Maillard E, and Bourhis J published a meta-analysis of chemotherapy in head and neck cancer in Radiother Oncol in 2009."
    },
    {
        "id": 7141,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Forastiere AA, Goepfert H, Maor M, et al published a study in the New England Journal of Medicine in 2003."
    },
    {
        "id": 7144,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Hanna GJ, Haddad RI, and Lorch JH published a review on induction chemotherapy for locoregionally advanced head and neck cancer in Oncologist in 2013."
    },
    {
        "id": 7147,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Argiris A, Haraf DJ, Kies MS, and Vokes EE published a study on intensive concurrent chemoradiotherapy for head and neck cancer in Oncologist in 2003."
    },
    {
        "id": 7150,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Machtay M, Moughan J, Farach A, et al published a study on hypopharyngeal dose and severe late toxicity in locally advanced head-and-neck cancer in Int J Radiat Oncol Biol Phys in 2012."
    },
    {
        "id": 7152,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Lorch JH, Goloubeva O, Haddad RI, et al published a study on induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck in Lancet Oncol in 2011."
    },
    {
        "id": 7154,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al published a phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer in J Clin Oncol in 2005."
    },
    {
        "id": 7156,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Posner MR, Hershock DM, Blajman CR, et al published a study on cisplatin and fluorouracil alone or with docetaxel in head and neck cancer in N Engl J Med in 2007."
    },
    {
        "id": 7158,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Vermorken JB, Remenar E, van Herpen C, et al published a study on cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer in N Engl J Med in 2007."
    },
    {
        "id": 7160,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Janoray G, Pointreau Y, Garaud P, et al published a long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, +/- docetaxel for larynx preservation in J Natl Cancer Inst in 2016."
    },
    {
        "id": 7162,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Pointreau Y, Garaud P, Chapet S, et al published a randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation in J Natl Cancer Inst in 2009."
    },
    {
        "id": 7164,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 218,
        "content": "Blanchard P, Bourhis J, Lacas B, et al published a meta-analysis of taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers in J Clin Oncol in 2013."
    },
    {
        "id": 7172,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Hitt R, Grau JJ, Lopez-Pousa A, et al. conducted a randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer."
    },
    {
        "id": 7174,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Haddad R, O'Neill A, Rabinowits G, et al. conducted a randomized phase 3 trial comparing induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer."
    },
    {
        "id": 7176,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Cohen EE, Karrison TG, Kocherginsky M, et al. conducted a phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer."
    },
    {
        "id": 7178,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Paccagnella A, Ghi MG, Loreggian L, et al. conducted a phase II randomized study comparing concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil followed by concomitant chemoradiotherapy in locally advanced head and neck cancer."
    },
    {
        "id": 7180,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Ghi MG, Paccagnella A, Ferrari D, et al. conducted a phase II-III trial comparing induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer."
    },
    {
        "id": 7182,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Wanebo HJ, Lee J, Burtness BA, et al. conducted a phase II ECOG-ACRIN trial comparing induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer."
    },
    {
        "id": 7184,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Dietz A, Wichmann G, Kuhnt T, et al. conducted a trial comparing induction chemotherapy followed by radiotherapy versus cetuximab plus induction chemotherapy and radiotherapy in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy."
    },
    {
        "id": 7186,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Specenier PM, Remenar E, Buter J, et al. conducted a randomized phase II EORTC trial comparing TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin."
    },
    {
        "id": 7188,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Haddad RI, Posner M, Hitt R, et al. discussed the role, controversy, and future directions of induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck."
    },
    {
        "id": 7190,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Lefebvre JL, Pointreau Y, Rolland F, et al. conducted a randomized phase II study comparing induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation."
    },
    {
        "id": 7192,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Janoray G, Pointreau Y, Alfonsi M, et al. conducted a randomized GORTEC trial comparing induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer."
    },
    {
        "id": 7194,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Geoffrois L, Martin L, De Raucourt D, et al. conducted a phase III randomized GORTEC trial comparing induction chemotherapy followed by cetuximab radiotherapy versus concurrent chemoradiotherapy for head and neck carcinomas."
    },
    {
        "id": 7196,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 219,
        "content": "Al-Sarraf M, LeBlanc M, Giri PG, et al. conducted a phase III randomized Intergroup study comparing chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer."
    },
    {
        "id": 7205,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Cousins N, MacAulay F, Lang H, et al. wrote a systematic review of interventions for eating and drinking problems following treatment for head and neck cancer."
    },
    {
        "id": 7209,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Locher JL, Bonner JA, Carroll WR, et al. wrote a comprehensive review of prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer."
    },
    {
        "id": 7212,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Langius JA, van Dijk AM, Doornaert P, et al. found that more than 10% weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life."
    },
    {
        "id": 7215,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "August DA, Huhmann MB, American Society for P, Enteral Nutrition Board of D. wrote A.S.P.E.N. clinical guidelines for nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation."
    },
    {
        "id": 7218,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Garg S, Yoo J, Winquist E. wrote a systematic review of nutritional support for head and neck cancer patients receiving radiotherapy."
    },
    {
        "id": 7221,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Alshadwi A, Nadershah M, Carlson ER, et al. wrote a review of nutritional considerations for head and neck cancer patients."
    },
    {
        "id": 7224,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Deng J, Murphy BA, Dietrich MS, et al. found differences of symptoms in head and neck cancer patients with and without lymphedema."
    },
    {
        "id": 7227,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Doersam JK, Dietrich MS, Adair MA, et al. compared symptoms among patients with head and neck or truncal lymphedema and normal controls."
    },
    {
        "id": 7230,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Jackson LK, Ridner SH, Deng J, et al. found that internal lymphedema correlates with subjective and objective measures of dysphagia in head and neck cancer patients."
    },
    {
        "id": 7233,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Ridner SH, Dietrich MS, Niermann K, et al. conducted a prospective study of the lymphedema and fibrosis continuum in patients with head and neck cancer."
    },
    {
        "id": 7236,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Dysphagia Section OCSGMAoSCiCISoOO, Raber-Durlacher JE, Brennan MT, et al. wrote about swallowing dysfunction in cancer patients."
    },
    {
        "id": 7239,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Wilson JA, Carding PN, Patterson JM. wrote about dysphagia after nonsurgical head and neck cancer treatment from patients' perspectives."
    },
    {
        "id": 7242,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Tschiesner U. wrote about preservation of organ function in head and neck cancer."
    },
    {
        "id": 7245,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Bressan V, Bagnasco A, Aleo G, et al. wrote a systematic review and meta-synthesis of the life experience of nutrition impact symptoms during treatment for head and neck cancer patients."
    },
    {
        "id": 7248,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 220,
        "content": "Roe JW, Carding PN, Rhys-Evans PH, et al. conducted a web-based survey of assessment and management of dysphagia in patients with head and neck cancer who receive radiotherapy in the United Kingdom."
    },
    {
        "id": 7256,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Russi EG, Corvo R, Merlotti A, et al. wrote an article about swallowing dysfunction in head and neck cancer patients treated by radiotherapy."
    },
    {
        "id": 7258,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Cnossen IC, de Bree R, Rinkel RN, et al. wrote an article about computerized monitoring of patient-reported speech and swallowing problems in head and neck cancer patients in clinical practice."
    },
    {
        "id": 7260,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Epstein JB, Thariat J, Bensadoun RJ, et al. wrote an article about oral complications of cancer and cancer therapy."
    },
    {
        "id": 7262,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Vera-Llonch M, Oster G, Hagiwara M, Sonis S wrote an article about oral mucositis in patients undergoing radiation treatment for head and neck carcinoma."
    },
    {
        "id": 7264,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Elting LS, Cooksley CD, Chambers MS, Garden AS wrote an article about risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies."
    },
    {
        "id": 7266,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Trotti A, Bellm LA, Epstein JB, et al. wrote a systematic literature review about mucositis incidence, severity, and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy."
    },
    {
        "id": 7268,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Bar Ad V, Weinstein G, Dutta PR, et al. wrote an article about gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy."
    },
    {
        "id": 7270,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Sroussi HY, Epstein JB, Bensadoun RJ, et al. wrote an article about common oral complications of head and neck cancer radiation therapy."
    },
    {
        "id": 7272,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Al-Ansari S, Zecha JA, Barasch A, et al. wrote an article about oral mucositis induced by anticancer therapies."
    },
    {
        "id": 7274,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Feng M, Eisbruch A wrote an article about future issues in highly conformal radiotherapy for head and neck cancer."
    },
    {
        "id": 7276,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Hong CHL, Gueiros LA, Fulton JS, et al. wrote a systematic review about basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines."
    },
    {
        "id": 7278,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Saunders DP, Rouleau T, Cheng K, et al. wrote a systematic review about antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines."
    },
    {
        "id": 7280,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Sio TT, Le-Rademacher JG, Leenstra JL, et al. wrote an article about the effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo on radiotherapy-related oral mucositis pain."
    },
    {
        "id": 7282,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 221,
        "content": "Smith DK, Cmelak A, Niermann K, et al. wrote an article about the preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation."
    },
    {
        "id": 7290,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 222,
        "content": "Hermann GM is an author of a study on the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer."
    },
    {
        "id": 7293,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 222,
        "content": "Ma SJ is an author of a study on the association of gabapentin use with pain control and feeding tube placement among patients with head and neck cancer receiving chemoradiotherapy."
    },
    {
        "id": 7296,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 222,
        "content": "Jiang J is an author of a study on the effect of pregabalin on radiotherapy-related neuropathic pain in patients with head and neck cancer."
    },
    {
        "id": 7299,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 222,
        "content": "Bossola M is an author of a narrative review on nutritional interventions in head and neck cancer patients undergoing chemoradiotherapy."
    },
    {
        "id": 7343,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "The head and neck cancer patient treated with radiation therapy requires dental management."
    },
    {
        "id": 7344,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Murdoch-Kinch CA and Zwetchkenbaum S wrote about dental management of the head and neck cancer patient treated with radiation therapy."
    },
    {
        "id": 7346,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Studer G, Glanzmann C, Studer SP, et al wrote about risk-adapted dental care prior to intensity-modulated radiotherapy."
    },
    {
        "id": 7348,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Ben-David MA, Diamante M, Radawski JD, et al wrote about the lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer."
    },
    {
        "id": 7350,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Thariat J, Ramus L, Darcourt V, et al wrote about compliance with fluoride custom trays in irradiated head and neck cancer patients."
    },
    {
        "id": 7352,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Chang DT, Sandow PR, Morris CG, et al wrote about pre-irradiation dental extractions reducing the risk of osteoradionecrosis of the mandible."
    },
    {
        "id": 7354,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Gevorgyan A, Wong K, Poon I, et al wrote about osteoradionecrosis of the mandible."
    },
    {
        "id": 7356,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Gomez DR, Estilo CL, Wolden SL, et al wrote about correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer."
    },
    {
        "id": 7358,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Jacobson AS, Buchbinder D, Hu K, Urken ML wrote about paradigm shifts in the management of osteoradionecrosis of the mandible."
    },
    {
        "id": 7360,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Lee IJ, Koom WS, Lee CG, et al wrote about risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients."
    },
    {
        "id": 7362,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "O'Dell K, Sinha U wrote about osteoradionecrosis."
    },
    {
        "id": 7364,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Oh HK, Chambers MS, Martin JW, et al wrote about osteoradionecrosis of the mandible."
    },
    {
        "id": 7366,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Sohn HO, Park EY, Jung YS, et al wrote about effects of professional oral hygiene care in patients with head-and-neck cancer during radiotherapy."
    },
    {
        "id": 7368,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Schiodt M, Hermund NU wrote about management of oral disease prior to radiation therapy."
    },
    {
        "id": 7370,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Rhodus NL, Bereuter J wrote about clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjogren's syndrome."
    },
    {
        "id": 7372,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 223,
        "content": "Singh ML, Papas AS wrote about long-term clinical observation of dental caries in salivary hypofunction patients using a supersaturated calcium-phosphate remineralizing rinse."
    },
    {
        "id": 7381,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Gorsky M, Epstein JB, Parry J, et al. wrote an article about the efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy."
    },
    {
        "id": 7384,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Dholam KP, Somani PP, Prabhu SD, Ambre SR wrote an article about the effectiveness of fluoride varnish application as cariostatic and desensitizing agent in irradiated head and neck cancer patients."
    },
    {
        "id": 7387,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Shulman DH, Shipman B, Willis FB wrote a case report about treating trismus with dynamic splinting."
    },
    {
        "id": 7390,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Teguh DN, Levendag PC, Voet P, et al. wrote an article about trismus in patients with oropharyngeal cancer."
    },
    {
        "id": 7393,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Papas A, Russell D, Singh M, et al. wrote an article about a caries clinical trial of a remineralising toothpaste in radiation patients."
    },
    {
        "id": 7396,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Wu F, Weng S, Li C, et al. wrote a systematic review and meta-analysis about submandibular gland transfer for the prevention of postradiation xerostomia in patients with head and neck cancer."
    },
    {
        "id": 7399,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Altuwaijri AA, Aldrees TM, Alessa MA wrote a systematic review about the prevalence of metastasis and involvement of level IV and V in oral squamous cell carcinoma."
    },
    {
        "id": 7403,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "The 7th edition of the AJCC Cancer Staging Manual was published in New York by Springer in 2010."
    },
    {
        "id": 7404,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Amin M, Edge S, Greene F, et al. edited the 8th edition of the AJCC Cancer Staging Manual."
    },
    {
        "id": 7406,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Hosni A, Chiu K, Huang SH, et al. wrote an article about non-operative management for oral cavity carcinoma."
    },
    {
        "id": 7409,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Fasunla AJ, Greene BH, Timmesfeld N, et al. wrote a meta-analysis about elective neck dissection versus therapeutic neck dissection in oral cavity cancers with clinically node-negative neck."
    },
    {
        "id": 7412,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Bulsara VM, Worthington HV, Glenny AM, et al. wrote a Cochrane review about interventions for the treatment of oral and oropharyngeal cancers."
    },
    {
        "id": 7415,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Massey C, Dharmarajan A, Bannuru RR, Rebeiz E wrote a systematic review and meta-analysis about the management of N0 neck in early oral squamous cell carcinoma."
    },
    {
        "id": 7421,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Alkureishi LW, Ross GL, Shoaib T, et al. wrote an article about sentinel node biopsy in head and neck squamous cell cancer."
    },
    {
        "id": 7424,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 224,
        "content": "Civantos FJ, Zitsch RP, Schuller DE, et al. wrote an article about sentinel lymph node biopsy accurately staging the regional lymph nodes for T1-T2 oral squamous cell carcinomas."
    },
    {
        "id": 7433,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Govers TM, Hannink G, Merkx MA, et al. published a diagnostic meta-analysis on sentinel node biopsy for squamous cell carcinoma of the oral cavity and oropharynx in Oral Oncol 2013."
    },
    {
        "id": 7435,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Samant S published a study on sentinel node biopsy as an alternative to elective neck dissection for staging of early oral carcinoma in Head Neck 2014."
    },
    {
        "id": 7437,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Broglie MA, Haerle SK, Huber GF, et al. published a study on occult metastases detected by sentinel node biopsy in patients with early oral and oropharyngeal squamous cell carcinomas in Head Neck 2013."
    },
    {
        "id": 7439,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Kovacs AF, Stefenelli U, Seitz O, et al. published a long-term study on positive sentinel lymph nodes as a negative prognostic factor for survival in T1-2 oral/oropharyngeal cancer in Ann Surg Oncol 2009."
    },
    {
        "id": 7441,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Pezier T, Nixon IJ, Gurney B, et al. published a prospective case series on sentinel lymph node biopsy for T1/T2 oral cavity squamous cell carcinoma in Ann Surg Oncol 2012."
    },
    {
        "id": 7443,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Chone CT, Magalhes RS, Etchehebere E, et al. published a study on the predictive value of sentinel node biopsy in head and neck cancer in Acta Otolaryngol 2008."
    },
    {
        "id": 7445,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Hokkam E, Gomaa A, Rifaat M, et al. published a study on the role of sentinel lymph-node biopsy in managing lip squamous cell carcinoma patients without clinical evidence of nodal metastasis in Gulf J Oncolog 2013."
    },
    {
        "id": 7447,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Sollamo EM, Ilmonen SK, Virolainen MS, Suominen SH published a retrospective study on sentinel lymph node biopsy in cN0 squamous cell carcinoma of the lip in Head Neck 2016."
    },
    {
        "id": 7449,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Kim DH, Kim Y, Kim SW, Hwang SH published a systematic review and meta-analysis on the usefulness of sentinel lymph node biopsy for oral cancer in Laryngoscope 2021."
    },
    {
        "id": 7451,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Garrel R, Poissonnet G, Moya Plana A, et al. published an equivalence randomized trial comparing treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1-T2N0 oral and oropharyngeal cancer in J Clin Oncol 2020."
    },
    {
        "id": 7453,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Agrawal A, Civantos FJ, Brumund KT, et al. published a phase III multi-institutional trial on [(99m)Tc]Tilmanocept accurately detecting sentinel lymph nodes and predicting node pathology status in patients with oral squamous cell carcinoma of the head and neck in Ann Surg Oncol 2015."
    },
    {
        "id": 7455,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Marcinow AM, Hall N, Byrum E, et al. published an initial institutional report on the use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma in JAMA Otolaryngol Head Neck Surg 2013."
    },
    {
        "id": 7457,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Nag S, Cano ER, Demanes DJ, et al. published the American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma in Int J Radiat Oncol Biol Phys 2001."
    },
    {
        "id": 7459,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Mazeron JJ, Ardiet JM, Haie-Meder C, et al. published the GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas in Radiother Oncol 2009."
    },
    {
        "id": 7461,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 225,
        "content": "Branstetter BF, Blodgett TM, Zimmer LA, et al. published a study on the accuracy of PET/CT, PET, and CT alone for head and neck malignancy in Radiology 2005."
    },
    {
        "id": 7471,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Weinberger PM, Yu Z, Haffty BG, et al. published an article titled 'Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis' in J Clin Oncol in 2006."
    },
    {
        "id": 7473,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Cantley RL, Gabrielli E, Montebelli F, et al. published an article titled 'Ancillary studies in determining human papillomavirus status of squamous cell carcinoma of the oropharynx: a review' in Patholog Res Int in 2011."
    },
    {
        "id": 7475,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Prigge ES, Arbyn M, von Knebel Doeberitz M, Reuschenbach M published an article titled 'Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis' in Int J Cancer in 2017."
    },
    {
        "id": 7477,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Lang Kuhs KA, Wood CB, Wiggleton J, et al. published an article titled 'Transcervical sonography and human papillomavirus 16 E6 antibodies are sensitive for the detection of oropharyngeal cancer' in Cancer in 2020."
    },
    {
        "id": 7479,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Singhi AD, Westra WH published an article titled 'Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience' in Cancer in 2010."
    },
    {
        "id": 7481,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Thavaraj S, Stokes A, Guerra E, et al. published an article titled 'Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice' in J Clin Pathol in 2011."
    },
    {
        "id": 7483,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Begum S, Gillison ML, Nicol TL, Westra WH published an article titled 'Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck' in Clin Cancer Res in 2007."
    },
    {
        "id": 7485,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Lewis JS, Jr., Beadle B, Bishop JA, et al. published an article titled 'Human papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists' in Arch Pathol Lab Med in 2018."
    },
    {
        "id": 7487,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Prabhu RS, Magliocca KR, Hanasoge S, et al. published an article titled 'Accuracy of computed tomography for predicting pathologic nodal extracapsular extension in patients with head-and-neck cancer undergoing initial surgical resection' in Int J Radiat Oncol Biol Phys in 2014."
    },
    {
        "id": 7489,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "O'Sullivan B, Huang SH, Su J, et al. published an article titled 'Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study' in Lancet Oncol in 2016."
    },
    {
        "id": 7491,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Haughey BH, Sinha P, Kallogjeri D, et al. published an article titled 'Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx' in Oral Oncol in 2016."
    },
    {
        "id": 7493,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Kaczmar JM, Tan KS, Heitjan DF, et al. published an article titled 'HPV-related oropharyngeal cancer: Risk factors for treatment failure in patients managed with primary transoral robotic surgery' in Head Neck in 2016."
    },
    {
        "id": 7495,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Dahlstrom KR, Garden AS, William WN, Jr., et al. published an article titled 'Proposed staging system for patients with HPV-related oropharyngeal cancer based on nasopharyngeal cancer N categories' in J Clin Oncol in 2016."
    },
    {
        "id": 7497,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Gillison ML published an article titled 'Human papillomavirus and oropharyngeal cancer stage' in J Clin Oncol in 2016."
    },
    {
        "id": 7499,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 226,
        "content": "Mehra R, Ang KK, Burtness B published an article titled 'Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer' in an unspecified publication."
    },
    {
        "id": 7505,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "The NCCN Guidelines Version 2.2024 is related to Head and Neck Cancers."
    },
    {
        "id": 7508,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Psyrri A, Rampias T, Vermorken JB wrote about the current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck."
    },
    {
        "id": 7510,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Mehanna H wrote about the update on de-intensification and intensification studies in HPV."
    },
    {
        "id": 7512,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Mehanna H, Rischin D, Wong SJ, et al wrote about de-escalation after DE-ESCALATE and RTOG 1016."
    },
    {
        "id": 7514,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Quon H, Forastiere AA wrote about controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas."
    },
    {
        "id": 7516,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Masterson L, Moualed D, Masood A, et al wrote about de-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 7518,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Kofler B, Laban S, Busch CJ, et al wrote about new treatment strategies for HPV-positive head and neck cancer."
    },
    {
        "id": 7520,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Hinni ML, Zarka MA, Hoxworth JM wrote about margin mapping in transoral surgery for head and neck cancer."
    },
    {
        "id": 7522,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Cracchiolo JR, Baxi SS, Morris LG, et al wrote about the increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features."
    },
    {
        "id": 7524,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Nichols AC, Theurer J, Prisman E, et al wrote about radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 7526,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Nichols AC, Theurer J, Prisman E, et al wrote about randomized trial of radiotherapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 7528,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Palma DA, Prisman E, Berthelet E, et al wrote about assessment of toxic effects and survival in treatment deescalation with radiotherapy vs transoral surgery for HPV-associated oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 7530,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Marur S, Li S, Cmelak AJ, et al wrote about E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx."
    },
    {
        "id": 7532,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Chen AM, Felix C, Wang PC, et al wrote about reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx."
    },
    {
        "id": 7534,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 227,
        "content": "Chera BS, Amdur RJ, Tepper JE, et al wrote about mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 7542,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Chera BS, Amdur RJ, Green R, et al. conducted a phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 7545,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Ma DJ, Price KA, Moore EJ, et al. conducted a phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma."
    },
    {
        "id": 7548,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Yom SS, Torres-Saavedra P, Caudell JJ, et al. conducted a study on reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma."
    },
    {
        "id": 7551,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Hegde JV, Shaverdian N, Daly ME, et al. conducted a study on patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma."
    },
    {
        "id": 7554,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Ferris RL, Flamand Y, Weinstein GS, et al. conducted a phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer."
    },
    {
        "id": 7557,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Iyer NG, Dogan S, Palmer F, et al. conducted a detailed analysis of clinicopathologic factors demonstrating distinct differences in outcome and prognostic factors between surgically treated HPV-positive and negative oropharyngeal cancer."
    },
    {
        "id": 7560,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Maxwell JH, Ferris RL, Gooding W, et al. conducted a study on extracapsular spread in head and neck carcinoma."
    },
    {
        "id": 7563,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Sinha P, Kallogjeri D, Gay H, et al. conducted a study on high metastatic node number, not extracapsular spread or N-classification, as a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer."
    },
    {
        "id": 7566,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "An Y, Park HS, Kelly JR, et al. conducted a study on the prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 7569,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Haughey BH, Sinha P. conducted a study on prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer."
    },
    {
        "id": 7572,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Freitag J, Wald T, Kuhnt T, et al. conducted a study on extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA as predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 7575,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Zumsteg ZS, Kim S, David JM, et al. conducted a study on the impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer."
    },
    {
        "id": 7578,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Yoshida EJ, Luu M, Mallen-St Clair J, et al. conducted a study on stage I HPV-positive oropharyngeal cancer."
    },
    {
        "id": 7581,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Haughey BH, Hinni ML, Salassa JR, et al. conducted a study on transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer."
    },
    {
        "id": 7584,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 228,
        "content": "Garden AS, Kies MS, Morrison WH, et al. conducted a study on outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the United States."
    },
    {
        "id": 7593,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 229,
        "content": "Al-Mamgani A is the author of a study on toxicity and outcome of intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy for oropharyngeal cancer."
    },
    {
        "id": 7596,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 229,
        "content": "Deschuymer S is the author of a randomized clinical trial on reduction of radiotherapy dose to the elective neck in head and neck squamous cell carcinoma."
    },
    {
        "id": 7599,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 229,
        "content": "Lefebvre JL is the author of a phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy."
    },
    {
        "id": 7633,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 229,
        "content": "The study by Pathmanathan R was published in N Engl J Med in 1995."
    },
    {
        "id": 7636,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 229,
        "content": "The study by Lewis JS Jr was published in Head Neck Pathol in 2014."
    },
    {
        "id": 7641,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 230,
        "content": "The head and neck cancers guidelines are part of the NCCN Guidelines Version 2.2024."
    },
    {
        "id": 7693,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "The section is about Head and Neck Cancers."
    },
    {
        "id": 7694,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "The reference MS-92 is about a study on pretherapy quantitative measurement of circulating Epstein-Barr virus DNA."
    },
    {
        "id": 7695,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Leung SF, Chan AT, Zee B, et al. conducted a study on pretherapy quantitative measurement of circulating Epstein-Barr virus DNA."
    },
    {
        "id": 7698,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Leung SF, Chan KC, Ma BB, et al. conducted a study on plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course."
    },
    {
        "id": 7701,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Zhang W, Chen Y, Chen L, et al. conducted a systematic review and meta-analysis on the clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma."
    },
    {
        "id": 7704,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Liu LT, Tang LQ, Chen QY, et al. conducted a study on the prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma."
    },
    {
        "id": 7707,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Chan ATC, Hui EP, Ngan RKC, et al. conducted a randomized controlled trial on analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation."
    },
    {
        "id": 7710,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Liang Y, Li J, Li Q, et al. conducted a study on plasma protein-based signature predicts distant metastasis and induction chemotherapy benefit in nasopharyngeal carcinoma."
    },
    {
        "id": 7713,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Wang WY, Twu CW, Chen HH, et al. conducted a study on plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma."
    },
    {
        "id": 7716,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Xu JY, Wei XL, Ren C, et al. conducted a study on association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy."
    },
    {
        "id": 7719,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "al-Sarraf M, Pajak TF, Cooper JS, et al. conducted a study on chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma."
    },
    {
        "id": 7722,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Chan AT, Leung SF, Ngan RK, et al. conducted a study on overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma."
    },
    {
        "id": 7725,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Lin JC, Jan JS, Hsu CY, et al. conducted a phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma."
    },
    {
        "id": 7728,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Wee J, Tan EH, Tai BC, et al. conducted a randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety."
    },
    {
        "id": 7731,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Lee AWM, Tung SY, Ng WT, et al. conducted a multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma."
    },
    {
        "id": 7734,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 231,
        "content": "Chen L, Hu CS, Chen XZ, et al. conducted a phase 3 randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma."
    },
    {
        "id": 7743,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Wang S, Li S, and Shen L wrote a meta-analysis of the published literature on combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma."
    },
    {
        "id": 7746,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Liu F, Jin T, Liu L, et al wrote a systematic review and meta-analysis on the role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era."
    },
    {
        "id": 7749,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Xu C, Zhang LH, Chen YP, et al wrote a systemic review and meta-analysis of 2138 patients on chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma."
    },
    {
        "id": 7752,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Huang X, Chen X, Zhao C, et al wrote a phase 2 multicenter clinical trial on adding concurrent chemotherapy to intensity-modulated radiotherapy for stage II nasopharyngeal carcinoma."
    },
    {
        "id": 7755,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Tang LL, Guo R, Zhang N, et al wrote a randomized clinical trial on the effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma."
    },
    {
        "id": 7758,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Blanchard P, Lee A, Marguet S, et al wrote an update of the MAC-NPC meta-analysis on chemotherapy and radiotherapy in nasopharyngeal carcinoma."
    },
    {
        "id": 7761,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Ribassin-Majed L, Marguet S, Lee AWM, et al wrote an individual patient data network meta-analysis on the best treatment of locally advanced nasopharyngeal carcinoma."
    },
    {
        "id": 7764,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Yang Q, Cao SM, Guo L, et al wrote a phase III multicentre randomised controlled trial on induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma."
    },
    {
        "id": 7767,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Zhang Y, Chen L, Hu GQ, et al wrote a study on gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma."
    },
    {
        "id": 7770,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Chen YP, Tang LL, Yang Q, et al wrote an individual patient data pooled analysis of four randomized trials on induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma."
    },
    {
        "id": 7773,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Tan TH, Soon YY, Cheo T, et al wrote a systematic review and meta-analysis on induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation."
    },
    {
        "id": 7776,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Wang P, Zhang M, Ke C, Cai C wrote a meta-analysis of randomized controlled trials on the efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma."
    },
    {
        "id": 7779,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 232,
        "content": "Tang M, Jia Z, Zhang J wrote a meta-analysis on the evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma."
    },
    {
        "id": 7788,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "You R, Cao YS, Huang PY, et al. wrote an article titled 'The changing therapeutic role of chemo-radiotherapy for loco-regionally advanced nasopharyngeal carcinoma from two/three-dimensional radiotherapy to intensity-modulated radiotherapy: a network meta-analysis' in Theranostics in 2017."
    },
    {
        "id": 7790,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Lee AWM, Ngan RKC, Ng WT, et al. wrote an article titled 'NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma' in Cancer in 2020."
    },
    {
        "id": 7792,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Chen YP, Ismaila N, Chua MLK, et al. wrote an article titled 'Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline' in J Clin Oncol in 2021."
    },
    {
        "id": 7794,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Chen YP, Liu X, Zhou Q, et al. wrote an article titled 'Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial' in Lancet in 2021."
    },
    {
        "id": 7796,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Tang LL, Chen YP, Mao YP, et al. wrote an article titled 'Validation of the 8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma from endemic areas in the intensity-modulated radiotherapy era' in J Natl Compr Canc Netw in 2017."
    },
    {
        "id": 7798,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Guo R, Tang LL, Mao YP, et al. wrote an article titled 'Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma' in Cancer in 2019."
    },
    {
        "id": 7800,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Sun Y, Li WF, Chen NY, et al. wrote an article titled 'Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial' in Lancet Oncol in 2016."
    },
    {
        "id": 7804,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Dechaphunkul T, Pruegsanusak K, Sangthawan D, Sunpaweravong P wrote an article titled 'Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma' in Head Neck Oncol in 2011."
    },
    {
        "id": 7806,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Songthong A, Chakkabat C, Kannarunimit D, Lertbutsayanukul C wrote an article titled 'Efficacy of intensity-modulated radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma' in Radiol Oncol in 2015."
    },
    {
        "id": 7808,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. wrote an article titled 'Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial' in Eur J Cancer in 2007."
    },
    {
        "id": 7810,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Rusthoven CG, Lanning RM, Jones BL, et al. wrote an article titled 'Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy' in Radiother Oncol in 2017."
    },
    {
        "id": 7812,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Chua GWY, Chua ET wrote an article titled 'Long-term disease-free survival of a patient with oligometastatic nasopharyngeal carcinoma treated with radiotherapy alone' in Case Rep Oncol in 2018."
    },
    {
        "id": 7814,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 233,
        "content": "Ma J, Wen ZS, Lin P, et al. wrote an article titled 'The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma'."
    },
    {
        "id": 7819,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "A retrospective study of 105 cases of nasopharyngeal carcinoma was published in Chin J Cancer 2010;29:787-795."
    },
    {
        "id": 7821,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "You R, Liu YP, Huang PY, et al. published a multicenter phase 3 randomized clinical trial in JAMA Oncol 2020;6:1345-1352."
    },
    {
        "id": 7823,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Zhang L, Huang Y, Hong S, et al. published a multicentre, randomised, open-label, phase 3 trial in Lancet 2016;388:1883-1892."
    },
    {
        "id": 7825,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Hong S, Zhang Y, Yu G, et al. published a phase III study in J Clin Oncol 2021;39:3273-3282."
    },
    {
        "id": 7827,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Samlowski WE, Moon J, Kuebler JP, et al. published a Southwest Oncology Group Phase II study in Cancer Invest 2007;25:182-188."
    },
    {
        "id": 7829,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Gibson MK, Li Y, Murphy B, et al. published a randomized phase III evaluation in J Clin Oncol 2005;23:3562-3567."
    },
    {
        "id": 7831,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Forastiere AA, Metch B, Schuller DE, et al. published a randomized comparison in J Clin Oncol 1992;10:1245-1251."
    },
    {
        "id": 7833,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Chan ATC, Hsu M-M, Goh BC, et al. published a multicenter, phase II study in J Clin Oncol 2005;23:3568-3576."
    },
    {
        "id": 7835,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Jin Y, Cai XY, Shi YX, et al. published a comparison of five cisplatin-based regimens in J Cancer Res Clin Oncol 2012;138:1717-1725."
    },
    {
        "id": 7837,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Jacobs C, Lyman G, Velez-Garcia E, et al. published a phase III randomized study in J Clin Oncol 1992;10:257-263."
    },
    {
        "id": 7839,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Burtness B, Goldwasser MA, Flood W, et al. published a phase III randomized trial in J Clin Oncol 2005;23:8646-8654."
    },
    {
        "id": 7841,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Grau JJ, Caballero M, Verger E, et al. published a study on weekly paclitaxel in Acta Otolaryngol 2009;129:1294-1299."
    },
    {
        "id": 7843,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Guardiola E, Peyrade F, Chaigneau L, et al. published a randomized phase II study in Eur J Cancer 2004;40:2071-2076."
    },
    {
        "id": 7845,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 234,
        "content": "Catimel G, Verweij J, Mattijssen V, et al. published a study on docetaxel in Ann Oncol 1994;5:533-537."
    },
    {
        "id": 7854,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Stewart JS, Cohen EE, Licitra L, et al. published a phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck in 2009."
    },
    {
        "id": 7856,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Fury MG, Pfister DG published current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer in 2011."
    },
    {
        "id": 7858,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Price KA, Cohen EE published current treatment options for metastatic head and neck cancer in 2012."
    },
    {
        "id": 7860,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Martinez-Trufero J, Isla D, Adansa JC, et al. published a phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment in 2010."
    },
    {
        "id": 7862,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Zhang L, Zhang Y, Huang P-Y, et al. published a phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy in 2008."
    },
    {
        "id": 7864,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Colevas AD published chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck in 2006."
    },
    {
        "id": 7866,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Forastiere AA, Shank D, Neuberg D, et al. published a final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck in 1998."
    },
    {
        "id": 7868,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Yang Y, Qu S, Li J, et al. published a multicentre, randomised, double-blind, phase 3 trial of camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma in 2021."
    },
    {
        "id": 7870,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Mai HQ, Chen QY, Chen D, et al. published a multicenter randomized phase 3 trial of toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma in 2021."
    },
    {
        "id": 7872,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Zhang L, Yang Y, Pan J, et al. published an updated progression-free survival, PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer in 2022."
    },
    {
        "id": 7874,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Hsu C, Lee SH, Ejadi S, et al. published a study on safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma in 2017."
    },
    {
        "id": 7876,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Marabelle A, Fakih M, Lopez J, et al. published a prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-028 study in 2020."
    },
    {
        "id": 7878,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 235,
        "content": "Delord JP, Hollebecque A, de Boer JP, et al. presented an open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors at the ASCO Annual Meeting in 2024."
    },
    {
        "id": 7886,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Ma BBY, Lim WT, Goh BC, et al. conducted an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742) on the antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma."
    },
    {
        "id": 7889,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Lee NY, Zhang Q, Pfister DG, et al. conducted a phase 2 multi-institutional trial on the addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615)."
    },
    {
        "id": 7892,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Tang LL, Huang CL, Zhang N, et al. conducted an open-label, non-inferiority, multicentre, randomised phase 3 trial on elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma."
    },
    {
        "id": 7895,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Salama JK, Haddad RI, Kies MS, et al. provided clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer."
    },
    {
        "id": 7898,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Ng WT, Soong YL, Ahn YC, et al. provided international recommendations on reirradiation by intensity modulated radiation therapy for locally recurrent nasopharyngeal carcinoma."
    },
    {
        "id": 7901,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Takiar V, Garden AS, Ma D, et al. published a study on reirradiation of head and neck cancers with intensity modulated radiation therapy."
    },
    {
        "id": 7910,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Rodel RM, Steiner W, Muller RM, et al. published a study on endoscopic laser surgery of early glottic cancer."
    },
    {
        "id": 7913,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Zouhair A, Azria D, Coucke P, et al. published a study on decreased local control following radiation therapy alone in early-stage glottic carcinoma with anterior commissure extension."
    },
    {
        "id": 7916,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Silver CE, Beitler JJ, Shaha AR, et al. published a study on current trends in initial management of laryngeal cancer."
    },
    {
        "id": 7919,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Warner L, Chudasama J, Kelly CG, et al. published a study on radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer."
    },
    {
        "id": 7922,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Warner L, Lee K, Homer JJ published a study on transoral laser microsurgery versus radiotherapy for T2 glottic squamous cell carcinoma."
    },
    {
        "id": 7925,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Mo HL, Li J, Yang X, et al. published a study on transoral laser microsurgery versus radiotherapy for T1 glottic carcinoma."
    },
    {
        "id": 7928,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 236,
        "content": "Yoo J, Lacchetti C, Hammond JA, Gilbert RW published a study on the role of endolaryngeal surgery (with or without laser) versus radiotherapy in the management of early glottic squamous cell carcinoma."
    },
    {
        "id": 8043,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "The NCCN Guidelines Version 2.2024 is about Head and Neck Cancers."
    },
    {
        "id": 8011,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Resto VA, Eisele DW, Forastiere A, et al. wrote about Esthesioneuroblastoma: the Johns Hopkins experience."
    },
    {
        "id": 8012,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Dirix P, Nuyts S, Geussens Y, et al. wrote about Malignancies of the nasal cavity and paranasal sinuses: long-term outcome with conventional or three-dimensional conformal radiotherapy."
    },
    {
        "id": 8014,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Hoppe BS, Stegman LD, Zelefsky MJ, et al. wrote about Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience."
    },
    {
        "id": 8016,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Chen AM, Daly ME, Bucci MK, et al. wrote about Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?"
    },
    {
        "id": 8018,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Porceddu S, Martin J, Shanker G, et al. wrote about Paranasal sinus tumors: Peter MacCallum Cancer Institute experience."
    },
    {
        "id": 8020,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Al-Mamgani A, Monserez D, Rooij P, et al. wrote about Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation."
    },
    {
        "id": 8022,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Dirix P, Vanstraelen B, Jorissen M, et al. wrote about Intensity-modulated radiotherapy for sinonasal cancer: improved outcome compared to conventional radiotherapy."
    },
    {
        "id": 8028,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Magrini SM, Buglione M, Corvo R, et al. wrote about Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial."
    },
    {
        "id": 8030,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Patil VM, Noronha V, Menon N, et al. wrote about Results of phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation."
    },
    {
        "id": 8032,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Suntharalingam M, Haas ML, Conley BA, et al. wrote about The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck."
    },
    {
        "id": 8034,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Beckmann GK, Hoppe F, Pfreundner L, Flentje MP wrote about Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer."
    },
    {
        "id": 8036,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 239,
        "content": "Medina JA, Rueda A, de Pasos AS, et al. wrote about A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas."
    },
    {
        "id": 8044,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Kiyota N is the author of a multicenter, noninferiority, phase II/III randomized controlled trial about postoperative head and neck cancer."
    },
    {
        "id": 8047,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Garden AS is the author of a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck."
    },
    {
        "id": 8050,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Taylor SG is the author of a randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer."
    },
    {
        "id": 8053,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Sun XS is the author of an approach to oligometastatic disease in head and neck cancer."
    },
    {
        "id": 8056,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Bonomo P is the author of a clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma."
    },
    {
        "id": 8059,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Bates JE is the author of oligometastatic squamous cell carcinoma of the head and neck treated with stereotactic body ablative radiotherapy."
    },
    {
        "id": 8062,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Molin Y is the author of current chemotherapies for recurrent/metastatic head and neck cancer."
    },
    {
        "id": 8065,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Hoffmann TK is the author of systemic therapy strategies for head-neck carcinomas."
    },
    {
        "id": 8068,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Browman GP is the author of standard chemotherapy in squamous cell head and neck cancer."
    },
    {
        "id": 8071,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Clavel M is the author of a randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 8074,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Vermorken JB is the author of platinum-based chemotherapy plus cetuximab in head and neck cancer."
    },
    {
        "id": 8077,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Burtness B is the author of pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 8080,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Cohen EEW is the author of pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma."
    },
    {
        "id": 8083,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 240,
        "content": "Ferris RL is the author of nivolumab for recurrent squamous-cell carcinoma of the head and neck."
    },
    {
        "id": 8091,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Harrington KJ, Burtness B, Greil R, et al. published a study on pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma."
    },
    {
        "id": 8094,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Bossi P, Miceli R, Locati LD, et al. published a randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 8097,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Guigay J, Fayette J, Dillies A-F, et al. published a study on cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)."
    },
    {
        "id": 8100,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Herbst RS, Arquette M, Shin DM, et al. published a phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck."
    },
    {
        "id": 8103,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Tahara M, Kiyota N, Yokota T, et al. published a phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)."
    },
    {
        "id": 8106,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Guigay J, Auperin A, Fayette J, et al. published a study on cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme)."
    },
    {
        "id": 8109,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Sacco AG, Chen R, Worden FP, et al. published an open-label, multi-arm, non-randomised, multicentre, phase 2 trial of pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma."
    },
    {
        "id": 8112,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Chung CH, Li J, Steuer CE, et al. published a phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma."
    },
    {
        "id": 8115,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Urba S, van Herpen CM, Sahoo TP, et al. published a randomized, double-blind, placebo-controlled, phase 3 study of pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer."
    },
    {
        "id": 8118,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Malhotra B, Moon J, Kucuk O, et al. published a phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 8121,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Haigentz M, Jr., Hartl DM, Silver CE, et al. published a study on distant metastases from head and neck squamous cell carcinoma."
    },
    {
        "id": 8124,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Vermorken JB, Trigo J, Hitt R, et al. published an open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy."
    },
    {
        "id": 8127,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 241,
        "content": "Janot F, de Raucourt D, Benhamou E, et al. published a randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck cancer."
    },
    {
        "id": 8147,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 242,
        "content": "Ward et al. published a study on refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT era in Int J Radiat Oncol Biol Phys in 2018."
    },
    {
        "id": 8143,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 242,
        "content": "Tanvetyanon et al. published a study on prognostic factors for survival after salvage reirradiation of head and neck cancer in J Clin Oncol in 2009."
    },
    {
        "id": 8145,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 242,
        "content": "Lee et al. published a study on predictors of severe long-term toxicity after re-irradiation for head and neck cancer in Oral Oncol in 2016."
    },
    {
        "id": 8149,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 242,
        "content": "Stoiber et al. published a study on regional cumulative maximum dose to the spinal cord in head-and-neck cancer in Radiother Oncol in 2013."
    },
    {
        "id": 8151,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 242,
        "content": "Nieder et al. published an update on human spinal cord reirradiation tolerance based on additional data from 38 patients in Int J Radiat Oncol Biol Phys in 2006."
    },
    {
        "id": 8153,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 242,
        "content": "Phan et al. published a study on reirradiation of head and neck cancers with proton therapy in Int J Radiat Oncol Biol Phys in 2016."
    },
    {
        "id": 8155,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 242,
        "content": "Romesser et al. published a study on proton beam reirradiation for recurrent head and neck cancer in Int J Radiat Oncol Biol Phys in 2016."
    },
    {
        "id": 8157,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 242,
        "content": "Verma et al. published a systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation in Radiother Oncol in 2017."
    },
    {
        "id": 8159,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 242,
        "content": "Caudell et al. published a study on volume, dose, and fractionation considerations for IMRT-based reirradiation in head and neck cancer in Int J Radiat Oncol Biol Phys in 2018."
    },
    {
        "id": 8169,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Seiwert TY, Burtness B, Mehra R, et al. published a study on the safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in Lancet Oncol 2016."
    },
    {
        "id": 8172,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Chow LQ, Haddad R, Gupta S, et al. published a study on the antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma in J Clin Oncol 2016."
    },
    {
        "id": 8174,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Mehra R, Seiwert TY, Gupta S, et al. published a study on the efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma in Br J Cancer 2018."
    },
    {
        "id": 8177,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Harrington KJ, Soulieres D, Le Tourneau C, et al. published a study on the quality of life with pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma in J Natl Cancer Inst 2021."
    },
    {
        "id": 8179,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Marabelle A, Le DT, Ascierto PA, et al. published a study on the efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer in J Clin Oncol 2020."
    },
    {
        "id": 8181,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Bauml J, Seiwert TY, Pfister DG, et al. published a study on pembrolizumab for platinum- and cetuximab-refractory head and neck cancer in J Clin Oncol 2017."
    },
    {
        "id": 8183,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Machiels JP, Haddad RI, Fayette J, et al. published a study on afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck in Lancet Oncol 2015."
    },
    {
        "id": 8185,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Seiwert TY, Fayette J, Cupissol D, et al. published a study on afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck in Ann Oncol 2014."
    },
    {
        "id": 8187,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Roh JL, Kim JS, Lee JH, et al. published a study on the utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors in Oral Oncol 2009."
    },
    {
        "id": 8189,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Hohenstein NA, Chan JW, Wu SY, et al. published a systematic review on the diagnosis, staging, radiation treatment response assessment, and outcome prognostication of head and neck cancers using PET imaging in PET Clin 2020."
    },
    {
        "id": 8191,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Furniss CS, McClean MD, Smith JF, et al. published a study on human papillomavirus 16 and head and neck squamous cell carcinoma in Int J Cancer 2007."
    },
    {
        "id": 8193,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Fakhry C, Gillison ML published a study on the clinical implications of human papillomavirus in head and neck cancers in J Clin Oncol 2006."
    },
    {
        "id": 8195,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 243,
        "content": "Loughrey M, Trivett M, Lade S, et al. published a study on the diagnostic application of Epstein-Barr virus-encoded RNA in situ hybridisation in Pathology 2004."
    },
    {
        "id": 8206,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 244,
        "content": "Fakhry C, Lacchetti C, Rooper LM, et al. wrote about human papillomavirus testing in head and neck carcinomas."
    },
    {
        "id": 8209,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 244,
        "content": "Boscolo-Rizzo P, Schroeder L, Romeo S, Pawlita M. wrote about the prevalence of human papillomavirus in squamous cell carcinoma of unknown primary site metastatic to neck lymph nodes."
    },
    {
        "id": 8212,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 244,
        "content": "Bussu F, Sali M, Gallus R, et al. wrote about HPV and EBV infections in neck metastases from occult primary squamous cell carcinoma."
    },
    {
        "id": 8215,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 244,
        "content": "Frank SJ, Rosenthal DI, Petsuksiri J, et al. wrote about intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site."
    },
    {
        "id": 8218,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 244,
        "content": "Svajdler M, Jr., Kaspirkova J, Hadravsky L, et al. wrote about the origin of cystic squamous cell carcinoma metastases in head and neck lymph nodes."
    },
    {
        "id": 8239,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 244,
        "content": "Vander Poorten V, Bradley PJ, Takes RP, et al. wrote about the diagnosis and management of parotid carcinoma with a special focus on recent advances in molecular biology."
    },
    {
        "id": 8242,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 244,
        "content": "Timoshchuk MA, Dekker P, Hippe DS, et al. wrote about the efficacy of neutron radiation therapy in treating salivary gland malignancies."
    },
    {
        "id": 8245,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 244,
        "content": "Laramore GE, Krall JM, Griffin TW, et al. wrote about neutron versus photon irradiation for unresectable salivary gland tumors."
    },
    {
        "id": 8256,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Eppsteiner RW, Fowlkes JW, Anderson CM, et al. published an article in Ann Otol Rhinol Laryngol in 2017."
    },
    {
        "id": 8258,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Terhaard CH, Lubsen H, Rasch CR, et al. published an article in Int J Radiat Oncol Biol Phys in 2005."
    },
    {
        "id": 8260,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Tanvetyanon T, Qin D, Padhya T, et al. published an article in Arch Otolaryngol Head Neck Surg in 2009."
    },
    {
        "id": 8262,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Skalova A published an article in Head Neck Pathol in 2013."
    },
    {
        "id": 8264,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Hanna GJ, Guenette JP, Chau NG, et al. published an article in Cancer in 2020."
    },
    {
        "id": 8266,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Williams L, Thompson LD, Seethala RR, et al. published an article in Am J Surg Pathol in 2015."
    },
    {
        "id": 8268,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Udager AM, Chiosea SI published an article in Head Neck Pathol in 2017."
    },
    {
        "id": 8270,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Simpson RH published an article in Head Neck Pathol in 2013."
    },
    {
        "id": 8272,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Fan CY, Wang J, Barnes EL published an article in Am J Surg Pathol in 2000."
    },
    {
        "id": 8274,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Schmitt NC, Kang H, Sharma A published an article in Oral Oncol in 2017."
    },
    {
        "id": 8276,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Drilon A, Laetsch TW, Kummar S, et al. published an article in N Engl J Med in 2018."
    },
    {
        "id": 8278,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Hong DS, Bauer TM, Lee JJ, et al. published an article in Ann Oncol in 2019."
    },
    {
        "id": 8280,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 245,
        "content": "Doebele RC, Drilon A, Paz-Ares L, et al. published an article in Lancet Oncol in 2020."
    },
    {
        "id": 8289,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Boon E, van Boxtel W, Buter J, et al. wrote a study on androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma."
    },
    {
        "id": 8292,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Yamamoto N, Minami S, Fujii M wrote a clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy."
    },
    {
        "id": 8294,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Fushimi C, Tada Y, Takahashi H, et al. conducted a prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma."
    },
    {
        "id": 8296,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Gilbert MR, Sharma A, Schmitt NC, et al. wrote a 20-year review of 75 cases of salivary duct carcinoma."
    },
    {
        "id": 8298,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Thorpe LM, Schrock AB, Erlich RL, et al. reported significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer."
    },
    {
        "id": 8300,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Correa TS, Matos GDR, Segura M, Dos Anjos CH wrote a case report on second-line treatment of HER2-positive salivary gland tumor with ado-trastuzumab emtansine (T-DM1) after progression on trastuzumab."
    },
    {
        "id": 8304,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Takahashi H, Tada Y, Saotome T, et al. conducted a phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma."
    },
    {
        "id": 8306,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Kurzrock R, Bowles DW, Kang H, et al. reported on targeted therapy for advanced salivary gland carcinoma based on molecular profiling."
    },
    {
        "id": 8310,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Lin VTG, Nabell LM, Spencer SA, et al. reported on first-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition."
    },
    {
        "id": 8312,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Subbiah V, Wolf J, Konda B, et al. reported on tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours."
    },
    {
        "id": 8314,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Licitra L, Cavina R, Grandi C, et al. conducted a phase II trial of cisplatin, doxorubicin, and cyclophosphamide in advanced salivary gland carcinoma."
    },
    {
        "id": 8316,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 246,
        "content": "Airoldi M, Pedani F, Succo G, et al. conducted a phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies."
    },
    {
        "id": 8323,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 247,
        "content": "Nakano K, Sato Y, Sasaki T, et al. published a study on combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients in Acta Otolaryngol 2016."
    },
    {
        "id": 8326,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 247,
        "content": "Laurie SA, Siu LL, Winquist E, et al. published a phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer in Cancer 2010."
    },
    {
        "id": 8328,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 247,
        "content": "Sousa LG, Wang K, Torman D, et al. published a study on treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified in Cancer 2022."
    },
    {
        "id": 8330,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 247,
        "content": "Gilbert J, Li Y, Pinto HA, et al. published a phase II trial of taxol in salivary gland malignancies in Head Neck 2006."
    },
    {
        "id": 8332,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 247,
        "content": "Locati LD, Cavalieri S, Bergamini C, et al. published a phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract in Head Neck 2019."
    },
    {
        "id": 8334,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 247,
        "content": "Thomson DJ, Silva P, Denton K, et al. published a phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck in Head Neck 2015."
    },
    {
        "id": 8336,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 247,
        "content": "Chau NG, Hotte SJ, Chen EX, et al. published a phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands in Ann Oncol 2012."
    },
    {
        "id": 8338,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 247,
        "content": "Keam B, Kim SB, Shin SH, et al. published a phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma in Cancer 2015."
    },
    {
        "id": 8340,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 247,
        "content": "Tchekmedyian V, Sherman EJ, Dunn L, et al. published a phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma in J Clin Oncol 2019."
    },
    {
        "id": 8342,
        "document_name": "data\\1 - NCCN2024.pdf",
        "page": 247,
        "content": "Locati LD, Galbiati D, Calareso G, et al. published a study on patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib in Cancer 2020."
    },
    {
        "id": 8414,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 0,
        "content": "The document is a guideline for the diagnosis, treatment, prevention, and aftercare of oropharyngeal and hypopharyngeal carcinoma."
    },
    {
        "id": 8415,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 0,
        "content": "The guideline is evidence-based."
    },
    {
        "id": 8456,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The guideline has a section on Epidemiology."
    },
    {
        "id": 8457,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Epidemiology section has a subsection on Prevalence/incidence."
    },
    {
        "id": 8458,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Epidemiology section has a subsection on Prevalence of HPV16 in oropharyngeal carcinoma."
    },
    {
        "id": 8459,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Epidemiology section has a subsection on Risk factors."
    },
    {
        "id": 8460,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Risk factors subsection has a sub-subsection on Epidemiological risk factors."
    },
    {
        "id": 8461,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Risk factors subsection has a sub-subsection on Histological precursor versions."
    },
    {
        "id": 8462,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Risk factors subsection has a sub-subsection on HPV16 in oropharyngeal carcinoma."
    },
    {
        "id": 8463,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The guideline has a section on Early detection, prevention."
    },
    {
        "id": 8464,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Early detection, prevention section has a subsection on General view."
    },
    {
        "id": 8465,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Early detection, prevention section has a subsection on HPV vaccination."
    },
    {
        "id": 8466,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Early detection, prevention section has a subsection on HPV screening offers."
    },
    {
        "id": 8467,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The guideline has a section on Prognosis, predictors."
    },
    {
        "id": 8468,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Prognosis, predictors section has a subsection on Prognostic factors of oropharyngeal carcinoma depending on HPV16."
    },
    {
        "id": 8469,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Prognosis, predictors section has a subsection on Importance of p16 as HPV16-Surogat parameter."
    },
    {
        "id": 8470,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Prognosis, predictors section has a subsection on Prognostic factors of oropharyngeal and hypopharyngeal carcinoma (HPV16-negative)."
    },
    {
        "id": 8471,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Prognosis, predictors section has a subsection on Definition of anatomical region, TNM."
    },
    {
        "id": 8472,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Definition of anatomical region, TNM subsection has a sub-subsection on TNM oropharyngeal carcinoma, discrimination according to p16."
    },
    {
        "id": 8473,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Definition of anatomical region, TNM subsection has a sub-subsection on TNM Hypopharyngeal carcinoma."
    },
    {
        "id": 8474,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Prognosis, predictors section has a subsection on Histopathology report."
    },
    {
        "id": 8475,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Prognosis, predictors section has a subsection on Surgical safety distance."
    },
    {
        "id": 8476,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The guideline has a section on Clinical diagnostics."
    },
    {
        "id": 8477,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Clinical diagnostics section has a subsection on Clinical examination."
    },
    {
        "id": 8478,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Clinical diagnostics section has a subsection on cT classification."
    },
    {
        "id": 8479,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Clinical diagnostics section has a subsection on Imaging."
    },
    {
        "id": 8480,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Clinical diagnostics section has a subsection on Panendoscopy."
    },
    {
        "id": 8481,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Clinical diagnostics section has a subsection on Biopsy."
    },
    {
        "id": 8482,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Biopsy subsection has a sub-subsection on Detection of HPV16, p16."
    },
    {
        "id": 8483,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Biopsy subsection has a sub-subsection on Detection of PD-L1."
    },
    {
        "id": 8484,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 2,
        "content": "The Clinical diagnostics section has a subsection on Sentinel lymph nodes."
    },
    {
        "id": 8488,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on patient information and education."
    },
    {
        "id": 8489,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on treatment recommendations in the primary therapy of oropharyngeal and hypopharyngeal carcinoma."
    },
    {
        "id": 8490,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The treatment recommendations consider effectiveness, functionality, and quality of life."
    },
    {
        "id": 8491,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on UICC stage I and II oropharyngeal carcinomas."
    },
    {
        "id": 8492,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "UICC stage I and II oropharyngeal carcinomas can be p16-positive or p16-negative."
    },
    {
        "id": 8493,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "p16-positive oropharyngeal carcinomas can have a T1-T3N2 classification."
    },
    {
        "id": 8494,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "p16-negative oropharyngeal carcinomas can have a T1-T2N0 classification."
    },
    {
        "id": 8495,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on surgical therapy for UICC stage I and II oropharyngeal carcinomas."
    },
    {
        "id": 8496,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on radiotherapy for UICC stage I and II oropharyngeal carcinomas."
    },
    {
        "id": 8497,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on primary radiotherapy with or without combination with drug-based tumour therapy for UICC stage I and II oropharyngeal carcinomas."
    },
    {
        "id": 8498,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on adjuvant radiotherapy with or without combination with drug-based tumour therapy for UICC stage I and II oropharyngeal carcinomas."
    },
    {
        "id": 8499,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on neoadjuvant and adjuvant drug-based tumour therapy for UICC stage I and II oropharyngeal carcinomas."
    },
    {
        "id": 8500,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on oropharyngeal carcinomas in the UICC stages III p16-positive and III and IV-A, -B p16-negative."
    },
    {
        "id": 8501,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "Oropharyngeal carcinomas in the UICC stages III p16-positive can have a T1N3 - T4 classification."
    },
    {
        "id": 8503,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on surgical therapy for oropharyngeal carcinomas in the UICC stages III p16-positive and III and IV-A, -B p16-negative."
    },
    {
        "id": 8504,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on radiotherapy for oropharyngeal carcinomas in the UICC stages III p16-positive and III and IV-A, -B p16-negative."
    },
    {
        "id": 8505,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on primary radiotherapy with or without combination with drug-based tumour therapy for oropharyngeal carcinomas in the UICC stages III p16-positive and III and IV-A, -B p16-negative."
    },
    {
        "id": 8506,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on adjuvant radiotherapy with or without combination with drug-based tumour therapy for oropharyngeal carcinomas in the UICC stages III p16-positive and III and IV-A, -B p16-negative."
    },
    {
        "id": 8507,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on neoadjuvant and adjuvant drug-based tumour therapy for oropharyngeal carcinomas in the UICC stages III p16-positive and III and IV-A, -B p16-negative."
    },
    {
        "id": 8508,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on oropharyngeal carcinomas with distant metastases: UICC stages IV p16-positive and IV-C p16-negative."
    },
    {
        "id": 8509,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on hypopharyngeal carcinomas in UICC stages I and II."
    },
    {
        "id": 8510,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on surgical therapy for hypopharyngeal carcinomas in UICC stages I and II."
    },
    {
        "id": 8511,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on radiotherapy for hypopharyngeal carcinomas in UICC stages I and II."
    },
    {
        "id": 8512,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on primary radiotherapy with or without combination with drug-based tumour therapy for hypopharyngeal carcinomas in UICC stages I and II."
    },
    {
        "id": 8513,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on adjuvant radiotherapy with or without combination with drug-based tumour therapy for hypopharyngeal carcinomas in UICC stages I and II."
    },
    {
        "id": 8514,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on neoadjuvant and adjuvant drug-based tumour therapy for hypopharyngeal carcinomas in UICC stages I and II."
    },
    {
        "id": 8515,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on hypopharyngeal carcinomas in UICC stages III and IV."
    },
    {
        "id": 8516,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on surgical therapy for hypopharyngeal carcinomas in UICC stages III and IV."
    },
    {
        "id": 8517,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on radiotherapy for hypopharyngeal carcinomas in UICC stages III and IV."
    },
    {
        "id": 8518,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on primary radiotherapy with or without combination with drug-based tumour therapy for hypopharyngeal carcinomas in UICC stages III and IV."
    },
    {
        "id": 8519,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on adjuvant radiotherapy with or without combination with drug-based tumour therapy for hypopharyngeal carcinomas in UICC stages III and IV."
    },
    {
        "id": 8520,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on neoadjuvant and adjuvant drug-based tumour therapy for hypopharyngeal carcinomas in UICC stages III and IV."
    },
    {
        "id": 8521,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on hypopharyngeal carcinoma stage IVC."
    },
    {
        "id": 8522,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on neck dissection."
    },
    {
        "id": 8523,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on elective neck dissection."
    },
    {
        "id": 8524,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 3,
        "content": "The guideline has a section on curative neck dissection."
    },
    {
        "id": 8531,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a treatment recommendation if surgery or radiation is still an option."
    },
    {
        "id": 8532,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a possibility of salvage surgery including neck dissection, adjuvant and primary radio- and radiochemotherapy."
    },
    {
        "id": 8533,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a treatment recommendation for radiation reserve, re-irradiation."
    },
    {
        "id": 8534,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a treatment recommendation in case of non-operability or radiation option."
    },
    {
        "id": 8535,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a 'First line' drug-based tumour therapy."
    },
    {
        "id": 8536,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a 'Second line' drug-based tumour therapy."
    },
    {
        "id": 8537,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a supportive therapy."
    },
    {
        "id": 8538,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a prevention, side effects and their treatment."
    },
    {
        "id": 8540,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a swallowing rehabilitation."
    },
    {
        "id": 8541,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a speech and voice rehabilitation."
    },
    {
        "id": 8542,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a psychosocial rehabilitation."
    },
    {
        "id": 8543,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a vocational rehabilitation."
    },
    {
        "id": 8544,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a psycho-oncological care."
    },
    {
        "id": 8545,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a social law support."
    },
    {
        "id": 8546,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a medical rehabilitation."
    },
    {
        "id": 8547,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a nutrition."
    },
    {
        "id": 8548,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a PEG."
    },
    {
        "id": 8549,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a palliative care."
    },
    {
        "id": 8551,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a clinical anamnestic examination."
    },
    {
        "id": 8552,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is an imaging in aftercare."
    },
    {
        "id": 8553,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a value of panendoscopy in follow-up care."
    },
    {
        "id": 8554,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a molecular diagnostics, screening in aftercare."
    },
    {
        "id": 8555,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 4,
        "content": "There is a social and psychosocial counselling."
    },
    {
        "id": 8590,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 8,
        "content": "There is a guideline on Oropharyngeal and Hypopharyngeal Carcinoma."
    },
    {
        "id": 8593,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 8,
        "content": "There are indicators derived from guidelines in the context of certification procedures for organ tumour centres."
    },
    {
        "id": 8811,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "The guideline closes the gap between the existing S3 guidelines on squamous cell carcinoma of the larynx and oral cavity."
    },
    {
        "id": 8812,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "Over the last 20 years in Germany, it has been possible to enormously improve overall survival as well as long-term functionality for oropharyngeal and hypopharyngeal carcinoma."
    },
    {
        "id": 8813,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "The improvement in overall survival and long-term functionality was achieved by standardizing the surgical aims to be achieved."
    },
    {
        "id": 8814,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "The surgical aims to be achieved include R0 resection with at least 5 mm distance to the tumour margin."
    },
    {
        "id": 8815,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "The surgical aims to be achieved include further development of large-lumen defect reconstructions."
    },
    {
        "id": 8816,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "The surgical aims to be achieved include categorizing neck dissection."
    },
    {
        "id": 8817,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "The surgical aims to be achieved include linking postoperative therapy to clear risk criteria."
    },
    {
        "id": 8818,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "The clear risk criteria include extracapsular extension (ECE) of the loco-regional lymph node metastases."
    },
    {
        "id": 8819,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "The improvement in overall survival and long-term functionality was achieved by diversification of radiotherapy techniques."
    },
    {
        "id": 8820,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "The improvement in overall survival and long-term functionality was achieved by diversification of drug-based tumour therapy with standardization of first-line therapy."
    },
    {
        "id": 8821,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "Depending on the respective tumour location, spread and biology, differences in the surgical radicality to be selected are seen."
    },
    {
        "id": 8822,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "Depending on the respective tumour location, spread and biology, differences in the diversified multimodal overall concept are seen."
    },
    {
        "id": 8823,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "Depending on the respective tumour location, spread and biology, differences in the need for early rehabilitation measures are seen."
    },
    {
        "id": 8832,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 16,
        "content": "The guideline contributes to reducing the frequency of avoidable complications and improving the prognosis of treated patients."
    },
    {
        "id": 8795,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 14,
        "content": "RND is an abbreviation for Radical neck dissection."
    },
    {
        "id": 8802,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 15,
        "content": "TLM is an abbreviation for Transoral laser microsurgery."
    },
    {
        "id": 8804,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 15,
        "content": "TORS is an abbreviation for Transoral robotic surgery."
    },
    {
        "id": 8805,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 15,
        "content": "TOS is an abbreviation for Transoral surgery."
    },
    {
        "id": 8803,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 15,
        "content": "TNM is a system of classification for the anatomical spread of malign tumours with the primary tumour (T), regionalry lymph nodes (N), and distant metastases (M)."
    },
    {
        "id": 8800,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 15,
        "content": "SNB is an abbreviation for Sentinel node biopsy."
    },
    {
        "id": 8799,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 15,
        "content": "SIN is an abbreviation for Squamous intraepithelial neoplasia."
    },
    {
        "id": 9032,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 28,
        "content": "The oropharyngeal carcinoma has emerged as the most rapidly increasing carcinoma in the head and neck region in Germany over the last 25 years."
    },
    {
        "id": 9033,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 28,
        "content": "The incidence of hypopharyngeal carcinoma is stable to slightly declining in Germany."
    },
    {
        "id": 9034,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 28,
        "content": "The chapter on epidemiology includes considerations of prevalence and incidence, as well as the risk factors that promote the disease."
    },
    {
        "id": 9035,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 28,
        "content": "The estimated incidence of oropharyngeal carcinoma in Germany is 4-16/100,000 in men and 3-7/100,000 in women."
    },
    {
        "id": 9036,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 28,
        "content": "The average age is given as 61 years for men and 66 years for women with oropharyngeal carcinoma."
    },
    {
        "id": 9037,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 28,
        "content": "The proportion of women with oropharyngeal carcinoma is approximately 20%."
    },
    {
        "id": 9038,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 28,
        "content": "The incidence of hypopharyngeal carcinoma in Germany is currently estimated at 2.3 (men) and 1.7 (women)/100,000 inhabitants."
    },
    {
        "id": 9039,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 28,
        "content": "There has been a slight decline in the incidence of hypopharyngeal carcinoma in recent years."
    },
    {
        "id": 9040,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 28,
        "content": "The average age at diagnosis is 64 years for both sexes with hypopharyngeal carcinoma."
    },
    {
        "id": 9050,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 28,
        "content": "Oropharyngeal carcinomas can be caused particularly frequently by a persistent HPV infection."
    },
    {
        "id": 9051,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 28,
        "content": "HPV-16 is a causative connection with oropharyngeal carcinoma."
    },
    {
        "id": 9052,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "Oropharyngeal carcinoma is differentiated into two separate entities depending on HPV16 status."
    },
    {
        "id": 9054,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "Squamous cell carcinoma of the oropharynx is the sixth most common form of cancer in men."
    },
    {
        "id": 9059,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "There is an increase in new cases of tongue base and tonsil carcinomas, particularly in young adults."
    },
    {
        "id": 9061,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "The incidence of cancer localizing into the base of the tongue/tonsil is increasing slightly according to rough estimates by the RKI Centre for Cancer Registry Data."
    },
    {
        "id": 9062,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "There were 1286 documented new hypopharyngeal carcinomas in Germany in 2015."
    },
    {
        "id": 9065,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "The total age-standardized incidence of hypopharyngeal carcinoma is 2.3 per 100,000."
    },
    {
        "id": 9066,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "The age-standardized incidence of piriform recessus/C13 is 0.4/100,000."
    },
    {
        "id": 9067,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "The age-standardized incidence of hypopharynx/C12 is 1.9/100,000."
    },
    {
        "id": 9068,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "The Rhineland-Palatinate Cancer Registry documented 59 new cases in men and 11 new cases in women in 2018."
    },
    {
        "id": 9069,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "The overall incidence of hypopharyngeal carcinoma in the Rhineland-Palatinate Cancer Registry is 1.7/100,000."
    },
    {
        "id": 9072,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "There was a significant increase in hypopharyngeal carcinomas from 2.4/100,000 to 4.4/100,000 in the Thuringia Cancer Registry for the years 1996-2005."
    },
    {
        "id": 9074,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "There was an increase in the number of cases from 1998 (51 cases) to 2009 (113 cases) and then a continuous decline until 2020 (29 cases) in the Munich Cancer Registry."
    },
    {
        "id": 9077,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "There was an increase in the age-standardized incidence in the Netherlands from 0.81/100,000 in 1989 to 0.95/100,000 in 2013."
    },
    {
        "id": 9080,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 29,
        "content": "There was a significant increase in the age-adjusted incidence from 0.3 per 100,000 in 1980 to 1.1 per 100,000 in 2014 in the Danish Cancer Registry."
    },
    {
        "id": 9082,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "An increase in HPV-positive oropharyngeal cancer has been shown worldwide."
    },
    {
        "id": 9083,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "The increase in HPV-positive oropharyngeal cancer between 1995 and 2009 was between 1.3 and 3.3 cases per year per 100,000."
    },
    {
        "id": 9089,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "For Germany, the figures for HPV-positive tumours in the oropharynx were between 11.5% and 55% in the past decade."
    },
    {
        "id": 9090,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "There was an increase in the proportion of HPV-positive tumours already recorded from 2000 to 2010 in Germany."
    },
    {
        "id": 9091,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "Data from the Rhineland-Palatinate cancer registry showed a significant increase in OPSCCs in women from 2000 to 2009."
    },
    {
        "id": 9092,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "In a monocentric study, the rate of HPV-positive OPSCCs was 28% between 2004 and 2006."
    },
    {
        "id": 9093,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "In a monocentric study, the rate of HPV-positive OPSCCs was 59% between 2012 and 2013."
    },
    {
        "id": 9094,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "Another study showed an increase from 21% to 53% of HPV-positive OPSCCs between 2000 and 2015."
    },
    {
        "id": 9095,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "Data from the Hessian Cancer Registry show an annual increase in the incidence of all OPSCCs of 0.8 cases/100,000 per year."
    },
    {
        "id": 9096,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "Data from the Hessian Cancer Registry show an annual increase in the incidence of HPV-associated OPSCCs of 1/100,000 per year."
    },
    {
        "id": 9097,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "The increase mainly affects tumours of the tonsils and tongue base region."
    },
    {
        "id": 9098,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "Using RKI data and data from the Hessian Cancer Registry in comparison with US data, a comparable significant increase in OPSCCs was shown."
    },
    {
        "id": 9099,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "In the USA, the incidence of HPV-positive OPSCC in 2017 was 12.5 cases per 100,000."
    },
    {
        "id": 9100,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "In the USA, the highest increase in HPV-positive OPSCC was in white men in the 65-69 year age group (4.24% annual increase)."
    },
    {
        "id": 9101,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "In the USA, the proportion of HPV-associated carcinomas of all OPSCCs has been as high as 93% in recent years."
    },
    {
        "id": 9102,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "In Germany, the rate of HPV-positive OPSCCs is now around 45%."
    },
    {
        "id": 9103,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "Patients with HPV-positive OPSCC in the USA have a lower median age (57 vs. 61 years) compared to patients with HPV-negative OPSCC."
    },
    {
        "id": 9104,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "New findings from German studies showed no difference in age and even a trend towards an advanced age at first diagnosis of HPV-positive tumours."
    },
    {
        "id": 9105,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "Overall, a clear increase in HPV-associated OPSCCs can be observed in Germany."
    },
    {
        "id": 9106,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "The trend of the increase is somewhat delayed compared to the USA, but equally pronounced."
    },
    {
        "id": 9107,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "There are indications that the increase in women is higher than in the USA."
    },
    {
        "id": 9108,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 30,
        "content": "Cancer registry data also show an increase, particularly in tonsil and tongue base carcinomas."
    },
    {
        "id": 9111,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 31,
        "content": "The main risk factors for the occurrence of oropharyngeal (HPV16/p16-negative) and hypopharyngeal carcinoma are chronic tobacco or alcohol abuse."
    },
    {
        "id": 9112,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 31,
        "content": "Chronic tobacco or alcohol abuse are predominantly noxious-triggered."
    },
    {
        "id": 9114,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 31,
        "content": "Tobacco and alcohol are the main risk factors for the occurrence of oropharyngeal (HPV16/p16-negative) and hypopharyngeal carcinoma."
    },
    {
        "id": 9116,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 31,
        "content": "Chronic tobacco or alcohol abuse increases the risk of disease up to 6-fold."
    },
    {
        "id": 9117,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 31,
        "content": "A combination of both risk factors increases the risk of disease up to 30-fold."
    },
    {
        "id": 9118,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 31,
        "content": "An unbalanced diet, such as excessive consumption of meat or fried food, can also increase the risk of carcinoma developing in the oral cavity and throat region."
    },
    {
        "id": 9119,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 31,
        "content": "A balanced Mediterranean diet more than halves the risk of developing carcinoma in the throat, adjusted for nicotine consumption and BMI."
    },
    {
        "id": 9128,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "Malignant tumours of the oropharynx and hypopharynx are 95% squamous cell carcinomas."
    },
    {
        "id": 9129,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "Most squamous cell carcinomas have different degrees of differentiation."
    },
    {
        "id": 9130,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "Grading is carried out according to the worst differentiated part of the tumour."
    },
    {
        "id": 9136,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "HPV-associated and toxin-triggered squamous cell carcinomas are clearly differentiated as independent tumour entities."
    },
    {
        "id": 9137,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "HPV-associated oropharyngeal carcinomas are no longer graded according to the conventional scheme as before."
    },
    {
        "id": 9138,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "HPV-associated oropharyngeal carcinomas have been given their own ICD number in the WHO classification (ICD-O 8085/3)."
    },
    {
        "id": 9139,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "A two-stage system (low-grade vs. high-grade dysplasia) has been proposed for the precursors of squamous cell carcinoma."
    },
    {
        "id": 9140,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "Squamous cell carcinomas (PECA) are divided into subtypes according to the WHO classification."
    },
    {
        "id": 9141,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "Verrucous PECA (also known as Ackermann's tumour) is highly differentiated (G1) and exhibits a so-called pushing border phenomenon (displacing growth)."
    },
    {
        "id": 9142,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "Basaloid squamous cell carcinomas are explicitly differentiated (by definition: G3, high-grade)."
    },
    {
        "id": 9143,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "Basaloid squamous cell carcinomas have a worse prognosis than conventional squamous cell carcinomas and are usually advanced at the time of diagnosis."
    },
    {
        "id": 9146,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "Papillary and verrucous squamous cell carcinomas are prognostically more favourable due to their superficial growth, but are very rare tumours overall (1 - 4%)."
    },
    {
        "id": 9148,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "Spindle cell carcinoma (formerly: sarcomatoid carcinoma, carcinosarcoma) can arise de novo or after radiation from a conventional squamous cell carcinoma."
    },
    {
        "id": 9152,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "Good prognostic accuracy has been reported."
    },
    {
        "id": 9153,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 32,
        "content": "Non-invasive precursor lesions of squamous cell carcinoma are referred to as epithelial dysplasia and, according to the 2005 WHO classification, synonymously as intraepithelial neoplasia (squamous intraepithelial neoplasia: SIN)."
    },
    {
        "id": 9154,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 33,
        "content": "The disruption of the epithelial architecture in the lower, middle or upper third is an important criterion for grading intraepithelial neoplasia."
    },
    {
        "id": 9155,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 33,
        "content": "Intraepithelial neoplasia is graded as low-, moderate- and high-grade (SIN 1-3)."
    },
    {
        "id": 9156,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 33,
        "content": "High-grade intraepithelial neoplasia (SIN 3) is equivalent to carcinoma in situ."
    },
    {
        "id": 9157,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 33,
        "content": "The malignancy risk of low- and moderate-grade intraepithelial neoplasia (SIN 1 and SIN 2) is 11%."
    },
    {
        "id": 9158,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 33,
        "content": "The malignancy risk of high-grade intraepithelial neoplasia (SIN 3 = carcinoma in situ) is 90%."
    },
    {
        "id": 9170,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 34,
        "content": "HPV-associated oropharyngeal carcinoma is a genetically diverse tumour entity that is distinct from HPV16-negative oropharyngeal carcinoma."
    },
    {
        "id": 9174,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 34,
        "content": "For a TNM-relevant assessment of the HPV-16 association of an HPV infection, p16 immunohistology should be performed."
    },
    {
        "id": 9182,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 34,
        "content": "The HPV-16 virus plays an almost exclusive role in the genesis of HPV-associated oropharyngeal carcinomas."
    },
    {
        "id": 9187,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 34,
        "content": "Tobacco/alcohol consumption are classic risk factors of oropharyngeal carcinoma."
    },
    {
        "id": 9189,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 34,
        "content": "HPV-associated OPSCC is a genetically diverse tumour subgroup distinct from HPV-negative oropharyngeal carcinomas."
    },
    {
        "id": 9190,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 34,
        "content": "HPV16 is a high-risk subtype of human papillomavirus."
    },
    {
        "id": 9192,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 34,
        "content": "The oncoprotein E7 binds and destabilizes the retinoblastoma tumour suppressor protein (pRb)."
    },
    {
        "id": 9194,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 34,
        "content": "The protein p16INK4A is highly expressed as a by-product of the interaction between E7 and pRb."
    },
    {
        "id": 9195,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "E6 leads to inactivation of p53 and thus to the prevention of cell cycle control, thereby increasing genetic instability."
    },
    {
        "id": 9197,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "Tumours that are purely HPV-associated often show a histological phenotype reminiscent of a basaloid squamous cell carcinoma."
    },
    {
        "id": 9198,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "HPV proteins lead to immune escape, which makes chronic infection and thus possible malignant degeneration more likely."
    },
    {
        "id": 9200,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "E5 supports the expression of growth factors and epidermal growth factor receptor (EGFR) and thus increases cell proliferation."
    },
    {
        "id": 9201,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "EGFR expression is usually reduced in HPV-positive tumours."
    },
    {
        "id": 9202,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "In HPV-driven tumours, the p53 wild type is usually found and no TP53 mutations, which are associated with tumour development by classical noxious agents."
    },
    {
        "id": 9204,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "The detection of HPV16 mRNA E6*I is currently regarded as the most reliable detection method for definitive HPV16 association."
    },
    {
        "id": 9206,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "P16 immunohistology is the most common method currently used to detect an HPV infection."
    },
    {
        "id": 9207,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "P16 immunohistology is indicative of an HPV association of OPSCC if squamous cell carcinomas strongly express p16."
    },
    {
        "id": 9208,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "Up to 23% of p16-positive OPSCCs that are examined using polymerase chain reaction (PCR) and in situ hybridization are ultimately HPV-negative."
    },
    {
        "id": 9209,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "P16 is currently the simplest and cheapest method for indirect HPV16 detection and is therefore unanimously recommended by the AJCC and UICC TNM Committee."
    },
    {
        "id": 9210,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "In routine clinical practice, p16 immunohistology followed by HPV DNA detection (PCR or in situ hybridization) has proven effective in identifying oropharyngeal carcinomas that are truly HPV-associated."
    },
    {
        "id": 9211,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "HPV transmission occurs predominantly through skin and mucous membrane contact."
    },
    {
        "id": 9212,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "HPV is primarily transmitted through sexual intercourse (genital, anal, oral)."
    },
    {
        "id": 9213,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "Contact with public wet surfaces (toilets, door handles, public pools, etc.) is also likely for oncogenic and non-oncogenic HPV types."
    },
    {
        "id": 9215,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "Maura Gillison's group published an observation that the HPV-16-associated risk of developing oropharyngeal carcinoma is particularly associated with high-risk sexual behaviour."
    },
    {
        "id": 9216,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "A highly significant association with the occurrence of oropharyngeal cancer was observed with high-risk sexual behaviour."
    },
    {
        "id": 9217,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 35,
        "content": "Brenner et al. essentially describe risky sexual behaviour (i.e. a high number of sexual partners) as a risk factor for HPV transmission."
    },
    {
        "id": 9218,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 36,
        "content": "A higher number of sexual partners is a risk factor for the occurrence of early HPV antibodies."
    },
    {
        "id": 9219,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 36,
        "content": "Same-sex sex is a risk factor for the occurrence of early HPV antibodies."
    },
    {
        "id": 9220,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 36,
        "content": "A younger age at sexual debut is a risk factor for the occurrence of early HPV antibodies."
    },
    {
        "id": 9221,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 36,
        "content": "Men between the ages of 51 and 60 were described as a high-risk group in the USA."
    },
    {
        "id": 9225,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 36,
        "content": "The consistent absence of HR-SB in the overwhelming majority of HPV-related oropharyngeal cancers was observed in the Leipzig study."
    },
    {
        "id": 9228,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 36,
        "content": "HPV16 is the primary type involved in the genesis of oropharyngeal carcinomas."
    },
    {
        "id": 9229,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 36,
        "content": "Infection with HPV viruses occurs in the basal cells of the squamous epithelium."
    },
    {
        "id": 9230,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 36,
        "content": "The lymphatic tissue in the tonsils enables HPV viruses to gain access to the basal cells even without injury."
    },
    {
        "id": 9234,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 36,
        "content": "Smoking habits of patients may be a major factor responsible for the geographical impact on HPV prevalence rates."
    },
    {
        "id": 9235,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 36,
        "content": "Patients with HPV-positive OPSCC are predominantly non-smokers, particularly in the USA and Canada."
    },
    {
        "id": 9236,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 36,
        "content": "Smoking appears to have a protective effect against the cancer-causing HPV16 infection."
    },
    {
        "id": 9248,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 37,
        "content": "Cannabis promotes the development of HPV16-positive OPSCC."
    },
    {
        "id": 9250,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 38,
        "content": "The Evidence-based Guideline Oropharyngeal and Hypopharyngeal Carcinoma was published in February 2024."
    },
    {
        "id": 9253,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 38,
        "content": "According to STIKO recommendations, boys and girls between the ages of 9 and 14 should be vaccinated against HPV."
    },
    {
        "id": 9262,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 38,
        "content": "Education and raising awareness of risk factors are important for HPV-associated oropharyngeal carcinoma."
    },
    {
        "id": 9263,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 38,
        "content": "Vaccination is an option for HPV-associated oropharyngeal carcinoma."
    },
    {
        "id": 9266,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 38,
        "content": "Men and women who regularly smoke heavily and regularly consume large amounts of alcohol have an increased risk of developing oropharyngeal and hypopharyngeal cancer."
    },
    {
        "id": 9364,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 43,
        "content": "The human papillomavirus, predominantly high-risk subtype HPV-16, is a prominent and sufficiently substantiated causal factor for oropharyngeal carcinoma."
    },
    {
        "id": 9365,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 43,
        "content": "Tobacco/alcohol consumption are classic risk factors of oropharyngeal carcinoma, but they have been overshadowed by the role of HPV-16."
    },
    {
        "id": 9366,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 43,
        "content": "HPV-associated oropharyngeal carcinomas are a genetically diverse subgroup distinct from HPV-negative oropharyngeal carcinomas."
    },
    {
        "id": 9367,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 43,
        "content": "HPV-associated oropharyngeal carcinomas have a significantly better prognosis than HPV-negative oropharyngeal carcinomas."
    },
    {
        "id": 9368,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 43,
        "content": "HPV-associated oropharyngeal carcinomas respond significantly better to previous treatment concepts."
    },
    {
        "id": 9370,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 43,
        "content": "The prognosis of HPV-associated oropharyngeal carcinomas is comparable after primary surgery plus adjuvant treatment and primary radiochemotherapy in retrospective cohorts."
    },
    {
        "id": 9371,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 43,
        "content": "The overall survival after 5 years averages up to 80% for HPV-positive oropharyngeal carcinomas and 30-35% for HPV-negative oropharyngeal carcinomas."
    },
    {
        "id": 9385,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 44,
        "content": "Oropharyngeal and hypopharyngeal carcinomas are squamous cell carcinomas of the upper aerodigestive tract."
    },
    {
        "id": 9386,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 44,
        "content": "Oropharyngeal and hypopharyngeal carcinomas have almost identical risk factors and often premalignant precursor lesions."
    },
    {
        "id": 9387,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 44,
        "content": "The prognosis of oropharyngeal and hypopharyngeal carcinoma essentially depends on the localization, TNM classification, and R status."
    },
    {
        "id": 9316,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 40,
        "content": "Some physicians vaccinate with inactivated vaccine after the occurrence of HPV-associated oropharyngeal carcinoma with reference to the individualized recommendations of this vaccination in cervical carcinoma."
    },
    {
        "id": 9319,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 41,
        "content": "The Guideline Oropharyngeal and Hypopharyngeal Carcinoma recommends that HPV vaccination should not be performed with the aim of therapeutic benefit in the treatment of existing HPV-associated lesions."
    },
    {
        "id": 9320,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 41,
        "content": "The Guideline Oropharyngeal and Hypopharyngeal Carcinoma recommends that HPV vaccination may be considered before or after treatment of cervical intraepithelial neoplasia (CIN) in HPV-vaccine-na\u00efve women with the aim of reducing the recurrence rate."
    },
    {
        "id": 9389,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 44,
        "content": "Oropharyngeal carcinomas have better prognoses than hypopharyngeal carcinomas."
    },
    {
        "id": 9394,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 44,
        "content": "P16 overexpression is caused by the activity of viral HPV oncoproteins, especially E7."
    },
    {
        "id": 9395,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 44,
        "content": "P16 can be used as a surrogate parameter for HPV-associated OPSCC."
    },
    {
        "id": 9396,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 44,
        "content": "P16 detection via immunohistochemical staining with FFPE tumour sections is recommended as a suitable surrogate parameter for HPV status in OPSCC in routine diagnostics."
    },
    {
        "id": 9401,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 45,
        "content": "Patients with a p16+/HPV16- OPSCC have a significantly worse prognosis compared to p16+/HPV+ tumours."
    },
    {
        "id": 9402,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 45,
        "content": "Patients with a p16+/HPV16- OPSCC show a slightly better risk profile than HPV-/p16- tumours."
    },
    {
        "id": 9403,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 45,
        "content": "Mehanna et al. showed that the 5-year overall survival for patients with p16+/HPV16+ status was 81.1%."
    },
    {
        "id": 9404,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 45,
        "content": "Mehanna et al. showed that the 5-year overall survival for patients with p16-/HPV16- status was 40.4%."
    },
    {
        "id": 9405,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 45,
        "content": "Mehanna et al. showed that the 5-year overall survival for patients with p16-/HPV16+ status was 53.2%."
    },
    {
        "id": 9406,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 45,
        "content": "Mehanna et al. showed that the 5-year overall survival for patients with p16+/HPV16- status was 54.7%."
    },
    {
        "id": 9407,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 45,
        "content": "Patients with discordant OPSCC (p16-/HPV+ or p16+/HPV-) had a significantly worse prognosis than patients with p16+/HPV+ OPSCC."
    },
    {
        "id": 9408,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 45,
        "content": "Patients with discordant OPSCC (p16-/HPV+ or p16+/HPV-) had a significantly better prognosis than patients with p16-/HPV16- OPSCC."
    },
    {
        "id": 9418,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 45,
        "content": "The detection of HPV-16 mRNA E6*I is currently regarded as the most reliable detection method for the definitive HPV-16 association in oropharyngeal carcinomas."
    },
    {
        "id": 9419,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 45,
        "content": "A meta-analysis of 24 studies showed a sensitivity of 94% for p16-IHC alone compared to the detection of viral E6/E7 transcripts as a reference."
    },
    {
        "id": 9420,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 45,
        "content": "A meta-analysis of 24 studies showed a specificity of 83% for p16-IHC alone compared to the detection of viral E6/E7 transcripts as a reference."
    },
    {
        "id": 9436,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 46,
        "content": "The 8th edition of the TNM classification introduces a different, p16-associated approach with a reclassification of tumour stages and N-status."
    },
    {
        "id": 9438,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 46,
        "content": "If an OPSCC is p16-positive, not only pT1N0M0 tumours are subsumed under stage I, but now also pT1.2 pN0.1 tumours."
    },
    {
        "id": 9439,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 46,
        "content": "Stage II even allows pT1.2 pN2 and pT3 pN0.1 tumours, compared to only pT2N0 previously."
    },
    {
        "id": 9440,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 46,
        "content": "Stage III includes pT3 pN2 and pT4 pN0-2 (8th edition TNM 2017)."
    },
    {
        "id": 9441,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 46,
        "content": "The staging of p16-positive OPSCC is differentiated clinically and pathologically."
    },
    {
        "id": 9442,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 46,
        "content": "cN2 is stage II and pN2 is stage III."
    },
    {
        "id": 9443,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 46,
        "content": "The N category is categorized according to the number of positive lymph nodes (pN1: 1-4; pN2: \u2265 5)."
    },
    {
        "id": 9455,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 47,
        "content": "The tumour stages according to the TNM classification and the R status are the most important prognostic factors in oropharyngeal and hypopharyngeal carcinoma."
    },
    {
        "id": 9456,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 47,
        "content": "The tumour stages according to the TNM classification and the R status should be indicated in all cases with reference to the current 8th edition."
    },
    {
        "id": 9457,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 47,
        "content": "Additional parameters on the primary tumour should be recorded: Lymphatic vessel, venous and perineural sheath invasion and degree of differentiation."
    },
    {
        "id": 9458,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 47,
        "content": "There is a strong consensus on the importance of recording the tumour stages according to the TNM classification and the R status."
    },
    {
        "id": 9489,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "Clinical cervical lymph node status is classified as cN."
    },
    {
        "id": 9490,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "Clinical criteria for cN apply to non-surgically treated patients without cervical lymph node dissection."
    },
    {
        "id": 9491,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "Clinical assessment for cN summarizes information from physical examination, imaging, and fine needle aspiration."
    },
    {
        "id": 9492,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "NX is a classification of nodal status that cannot be determined."
    },
    {
        "id": 9493,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N0 is a classification of no regionally enlarged or metastasized lymph nodes."
    },
    {
        "id": 9494,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N1 is a classification of metastasis in single ipsilateral node, \u22643 cm, and no extranodal spread, ECS(-)."
    },
    {
        "id": 9495,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N2 is a classification of metastasis in single ipsilateral node, >3 cm, or metastasis in multiple ipsilateral nodes, or metastases in bilateral or contralateral nodes."
    },
    {
        "id": 9496,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N2a is a classification of metastasis in single ipsilateral node, >3 cm and \u22646 cm, and ECS(-)."
    },
    {
        "id": 9497,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N2b is a classification of metastasis in multiple ipsilateral nodes, all \u22646 cm, and ECS(-)."
    },
    {
        "id": 9498,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N2c is a classification of metastases in bilateral or contralateral nodes, all \u22646 cm, and ECS(-)."
    },
    {
        "id": 9499,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N3 is a classification of metastases in one node, >6 cm, or metastases in a node with clinically obvious ECS(+)."
    },
    {
        "id": 9500,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N3a is a classification of metastases in one node, >6 cm, and ECS(-)."
    },
    {
        "id": 9501,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N3b is a classification of metastases in a node with clinically obvious ECS(+)."
    },
    {
        "id": 9502,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "Pathological cervical lymph node status is classified as pN."
    },
    {
        "id": 9503,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "Pathologic criteria for pN apply to surgically treated patients with cervical lymph node dissection."
    },
    {
        "id": 9504,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "Pathologic criteria for pN require multiple whole lymph nodes available for microscopic evaluation."
    },
    {
        "id": 9505,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "NX is a classification of nodal status that cannot be determined in pN."
    },
    {
        "id": 9506,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N0 is a classification of no metastases in the examined lymph nodes in pN."
    },
    {
        "id": 9507,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N1 is a classification of metastasis in single ipsilateral node, \u22643 cm, and no extranodal spread, ECS(-) in pN."
    },
    {
        "id": 9508,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N2 is a classification of metastasis in single ipsilateral node, >3 cm, or metastasis in multiple ipsilateral nodes, or metastases in bilateral or contralateral nodes in pN."
    },
    {
        "id": 9509,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N2a is a classification of metastasis in single ipsilateral node, >3 cm and \u22646 cm, and ECS(-) in pN."
    },
    {
        "id": 9510,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N2a is also a classification of metastasis in single ipsilateral node, \u22643 cm, and ECS(+) in pN."
    },
    {
        "id": 9511,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N2b is a classification of metastasis in multiple ipsilateral nodes, all \u22646 cm, and ECS(-) in pN."
    },
    {
        "id": 9512,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N2c is a classification of metastases in bilateral or contralateral nodes, all \u22646 cm, and ECS(-) in pN."
    },
    {
        "id": 9513,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N3 is a classification of metastases in one node, >6 cm, or metastases in a node with clinically obvious ECS(+) in pN."
    },
    {
        "id": 9514,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 49,
        "content": "N3a is a classification of metastases in one node, >6 cm, and ECS(-) in pN."
    },
    {
        "id": 9517,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "cM0 means no evidence of distant metastases."
    },
    {
        "id": 9518,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "cM1 means high probability of distant metastases present (high evidence in imaging)."
    },
    {
        "id": 9519,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "pM1 means existing distant metastases, histologically confirmed."
    },
    {
        "id": 9520,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "N3b is a category of metastasis in single ipsilateral node, >3 cm, and ECS(+); or multiple ipsilateral, contralateral, or bilateral nodes with ECS(+); or single contralateral node of any size and ECS(+)."
    },
    {
        "id": 9521,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "Distant metastases (M) are classified into cM0, cM1, and pM1."
    },
    {
        "id": 9522,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "TNM 8th edition is a reference for TNM staging."
    },
    {
        "id": 9525,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "T1, T2, T3, and T4 are categories of primary tumour."
    },
    {
        "id": 9526,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "TX means primary tumour cannot be determined."
    },
    {
        "id": 9527,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "Tis means carcinoma in situ."
    },
    {
        "id": 9528,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "T1 means tumour limited to a subunit of the hypopharynx and/or tumour \u2264 2 cm in greatest extension."
    },
    {
        "id": 9529,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "T2 means tumour extends into the adjacent subunits of the hypopharynx or the adjacent neighbouring structures and/or tumour > 2 cm and \u2264 4 cm without fixation of the hemilarynx."
    },
    {
        "id": 9530,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "T3 means tumour >4 cm, or clinical fixation of the hemilarynx, or extension into the oesophageal mucosa."
    },
    {
        "id": 9531,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 50,
        "content": "T4 means moderately or very advanced disease."
    },
    {
        "id": 9532,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 51,
        "content": "The TNM classification defines T4a as moderately advanced disease with infiltration of the thyroid cartilage, cricoid cartilage of the larynx, hyoid bone, thyroid gland, oesophageal muscles, or prelaryngeal soft tissue."
    },
    {
        "id": 9533,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 51,
        "content": "The TNM classification defines T4b as far advanced disease with envelopment of the carotid artery or infiltration of mediastinum or prevertebral fascia."
    },
    {
        "id": 9536,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 51,
        "content": "The R classification generally applies to squamous cell carcinomas in the head and neck region."
    },
    {
        "id": 9537,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 51,
        "content": "The R classification describes the presence of residual tumour after therapy, usually after surgical therapy."
    },
    {
        "id": 9538,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 51,
        "content": "The R classification provides important information on any further treatment that may be necessary and on the patient's prognosis."
    },
    {
        "id": 9539,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 51,
        "content": "R0 is defined as carcinomas that have been resected in sano."
    },
    {
        "id": 9542,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 51,
        "content": "An R1 situation is present if the tumour microscopically reaches one of the preparation margins directly."
    },
    {
        "id": 9543,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 51,
        "content": "An R2 situation is present if the tumour remains in the patient macroscopically."
    },
    {
        "id": 9544,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 51,
        "content": "An RX situation exists if the resection margin cannot be reliably assessed histomorphologically."
    },
    {
        "id": 9546,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the tumour location and size."
    },
    {
        "id": 9547,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the pTN status."
    },
    {
        "id": 9548,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the histological tumour type according to the current WHO classification."
    },
    {
        "id": 9549,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the local tumour extent and infiltrated structures."
    },
    {
        "id": 9550,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the number of LKs examined."
    },
    {
        "id": 9551,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the number of affected LKs."
    },
    {
        "id": 9552,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the largest diameter of the lymph node metastases."
    },
    {
        "id": 9553,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate tumour growth beyond the capsule (ECS, ENE)."
    },
    {
        "id": 9554,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate lymph vessel/venous invasion and perineural invasion."
    },
    {
        "id": 9555,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the presence of an in situ component (with size)."
    },
    {
        "id": 9556,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the differentiation of the tumour according to the established grading scheme."
    },
    {
        "id": 9557,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the distance to the lateral and basal resectate margins for all relevant resection margins as well as for the invasive and in situ components in mm."
    },
    {
        "id": 9558,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the R classification."
    },
    {
        "id": 9559,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "The histopathology report should indicate the p16 expression status (positive, negative) for oropharynx only."
    },
    {
        "id": 9560,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 52,
        "content": "Tumour resection should be performed as an en bloc resection of the primary tumour."
    },
    {
        "id": 9568,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The treatment decision is influenced by the tumour location and size."
    },
    {
        "id": 9569,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The treatment decision is influenced by the histological tumour type according to the current WHO classification."
    },
    {
        "id": 9570,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The treatment decision is influenced by the local tumour extent and infiltrated structures."
    },
    {
        "id": 9571,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The treatment decision is influenced by lymph node metastases separated according to level and side."
    },
    {
        "id": 9572,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The number of lymph nodes examined is a parameter in the pathological assessment."
    },
    {
        "id": 9573,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The number of affected lymph nodes is a parameter in the pathological assessment."
    },
    {
        "id": 9574,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The largest diameter of the lymph node metastases is a parameter in the pathological assessment."
    },
    {
        "id": 9575,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "Tumour growth beyond the capsule is a parameter in the pathological assessment."
    },
    {
        "id": 9576,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "Lymph vessel/venous invasion and perineural invasion are parameters in the pathological assessment."
    },
    {
        "id": 9577,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The presence of an in situ component and its size are parameters in the pathological assessment."
    },
    {
        "id": 9578,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The differentiation of the tumour according to the established grading scheme is a parameter in the pathological assessment."
    },
    {
        "id": 9579,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The distance to the lateral and basal resectate margins for all relevant resection margins and for the invasive and in situ components in mm is a parameter in the pathological assessment."
    },
    {
        "id": 9580,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The R classification is a parameter in the pathological assessment."
    },
    {
        "id": 9581,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The indication of the p16 expression status is a parameter in the pathological assessment."
    },
    {
        "id": 9589,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "If the findings are unclear, the biopsy should be repeated after consultation with the pathologist."
    },
    {
        "id": 9590,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "In the case of resectates, the tumour specimen should be sent to the pathologist by the surgeon with a clear description of the anatomical topography."
    },
    {
        "id": 9592,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "In the case of a neck dissection, the levels must be marked separately or sent in portions as individual specimens for pathohistological examination."
    },
    {
        "id": 9593,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 53,
        "content": "The cut edges on the resectate can be examined by means of a frozen section according to clinical relevance."
    },
    {
        "id": 9594,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "It is preferable to send the resectate 'en bloc' and have the surgeon or pathologist take a frozen section of the resectate margins."
    },
    {
        "id": 9595,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "The surgeon or pathologist should take a frozen section of the resectate margins."
    },
    {
        "id": 9596,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "The procedure of sending the resectate 'en bloc' preserves the integrity of the specimen in the best possible way."
    },
    {
        "id": 9597,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "This procedure allows the most reliable statement on the R status."
    },
    {
        "id": 9599,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "Transoral robotic surgery (TORS) or laser microsurgery (TLM) resections of primary tumours of the oropharynx and hypopharynx are increasingly used approaches for cancer resection in selected patients with accessible tumours."
    },
    {
        "id": 9600,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "Oncologic principles are similar to open procedures."
    },
    {
        "id": 9601,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "If safe en bloc resection is not possible, it is appropriate to send separate margin sections."
    },
    {
        "id": 9602,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "The separate margin sections should ideally also be sent to the pathologists as frozen sections."
    },
    {
        "id": 9608,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "Locoregional metastasis of the primary tumour to the cervical lymph nodes is a reliable negative predictor of prognosis."
    },
    {
        "id": 9609,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "The more lymph nodes involved, the less favourable the course of the disease."
    },
    {
        "id": 9610,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "Involvement of the caudal levels (IV and V) and growth beyond the capsule have a negative impact on the prognosis."
    },
    {
        "id": 9616,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "The histopathological findings of the neck dissection specimens should include the side of the neck."
    },
    {
        "id": 9617,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "The histopathological findings of the neck dissection specimens should include the cleared levels."
    },
    {
        "id": 9618,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "The histopathological findings of the neck dissection specimens should include the total number of lymph nodes with the number of affected lymph nodes per level."
    },
    {
        "id": 9619,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "The histopathological findings of the neck dissection specimens should include the diameter of the largest lymph node metastasis."
    },
    {
        "id": 9620,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "The histopathological findings of the neck dissection specimens should include additionally removed structures."
    },
    {
        "id": 9621,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 54,
        "content": "The histopathological findings of the neck dissection specimens should include - if present - information on growth that exceeds the lymph node capsule (extra nodal extension, ENE)."
    },
    {
        "id": 9631,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "A clear margin is defined as the distance from the invasive tumour front that is 5 mm or more from the resected margin."
    },
    {
        "id": 9633,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "The goal of oncological surgery is complete tumour resection with histological evidence of tumour-free margins."
    },
    {
        "id": 9634,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "Tumour-free margins are a basic principle of surgical strategy to reduce the risk of local tumour recurrence."
    },
    {
        "id": 9635,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "Positive margins increase the risk of local recurrence and are an indication for postoperative adjuvant therapy."
    },
    {
        "id": 9636,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "Classic clinical-pathological studies have shown the significance of narrow or positive margins and their correlation with local tumour recurrence."
    },
    {
        "id": 9638,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "The removal of frozen sections is generally recommended."
    },
    {
        "id": 9639,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "A recent multicentre Italian study showed that in patients in whom R0 resection was verified intraoperatively by frozen sections, the local control rate was twice as high as in those without frozen section verification."
    },
    {
        "id": 9640,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "Frozen section assessment is a quality indicator of surgical and pathological procedures and their effectiveness."
    },
    {
        "id": 9641,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "If there is an initial incision through an invasive tumour at the surgical margin, additional harvested adjacent margins from the patient may mean a higher risk of local recurrence."
    },
    {
        "id": 9644,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "If positive surgical margins are reported, a repeat resection should be considered if possible."
    },
    {
        "id": 9645,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "If positive surgical margins are reported, adjuvant therapy should be considered if repeat resection is not reasonably possible."
    },
    {
        "id": 9646,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "The patient's prognosis is not worsened by an initial R1, or close R0 situation, which leads to a final stable R0 situation through resection at the correct site."
    },
    {
        "id": 9647,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "Assessment of frozen section margins is always at the surgeon's discretion."
    },
    {
        "id": 9648,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "Assessment of frozen section margins should be considered if it facilitates complete removal of the tumour."
    },
    {
        "id": 9649,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 56,
        "content": "Achieving sufficiently wide margins may require resection of an adjacent structure in the oral cavity."
    },
    {
        "id": 9650,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "The surgical safety distance is defined by current international consensus as clean resection margins with at least sufficient distance from the gross tumour to obtain a clear frozen section and permanently free margins."
    },
    {
        "id": 9651,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "Clean resection margins can often mean 1.0-1.5 cm of visible and palpable normal mucosa."
    },
    {
        "id": 9652,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "A frozen section examination of the margins is usually performed intraoperatively and when a resection line is not clear due to indistinct tumour margins or when residual disease is suspected."
    },
    {
        "id": 9653,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "Residual disease is suspected in cases of soft tissue, cartilage, carotid artery or mucosal irregularities."
    },
    {
        "id": 9654,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "For transoral endoscopic and robotic approaches for oropharyngeal and hypopharyngeal cancers, margins of 1.5-2.0 mm may be acceptable."
    },
    {
        "id": 9656,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "Margins of 1.5-2.0 mm would in principle be considered 'narrow or closed' and are considered too narrow for certain sites, such as the base of the tongue."
    },
    {
        "id": 9657,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "A clear resection margin is defined as the distance from the invasive tumour front that is 5 mm or more from the resected margin."
    },
    {
        "id": 9658,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "There is international agreement on the definition of a clear resection margin, which is reflected in the current NCCN guidelines."
    },
    {
        "id": 9659,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "For hypopharyngeal carcinomas with diffuse, partially submucosal spread, particularly towards the oesophagus, the 5 mm safety margin should be regarded as the absolute minimum."
    },
    {
        "id": 9660,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "The 5 mm safety margin can be generously extended to 1 cm for safe resection according to international consensus."
    },
    {
        "id": 9661,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "A narrow margin is defined as the distance from the invasive tumour front to the resected margin that is less than 2-5 mm depending on the anatomical site affected."
    },
    {
        "id": 9662,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "A positive margin is defined as carcinoma in situ or invasive carcinoma at the resected margin."
    },
    {
        "id": 9663,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "If carcinoma in situ is present and if additional clean margins can be achieved by resection, this is the preferred approach."
    },
    {
        "id": 9664,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "Carcinoma in situ should not be considered an indication for concomitant postoperative systemic therapy/RT."
    },
    {
        "id": 9668,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "Tumour grading appears to have a greater prognostic role than previously assumed."
    },
    {
        "id": 9669,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 57,
        "content": "In the aforementioned multicentre Italian study, the group of well-differentiated squamous cell carcinomas showed a statistically significant and clinically relevant difference in 5-year tumour relapse-free survival and OS compared to the group of poorly differentiated squamous cell carcinomas."
    },
    {
        "id": 9674,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to an appropriate specialist should be made for any of the following findings if they persist for more than four weeks: blood in the saliva."
    },
    {
        "id": 9675,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to an appropriate specialist should be made for any of the following findings if they persist for more than four weeks: hoarseness."
    },
    {
        "id": 9676,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to an appropriate specialist should be made for any of the following findings if they persist for more than four weeks: difficulty speaking and breathing."
    },
    {
        "id": 9677,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to an appropriate specialist should be made for any of the following findings if they persist for more than four weeks: persistent foreign body sensation, especially on one side."
    },
    {
        "id": 9678,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to an appropriate specialist should be made for any of the following findings if they persist for more than four weeks: pain radiating into the ear."
    },
    {
        "id": 9679,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to an appropriate specialist should be made for any of the following findings if they persist for more than four weeks: dysphagia and/or pain when swallowing."
    },
    {
        "id": 9680,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to an appropriate specialist should be made for any of the following findings if they persist for more than four weeks: unclear coughing up blood."
    },
    {
        "id": 9681,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to an appropriate specialist should be made for any of the following findings if they persist for more than four weeks: swelling of the throat."
    },
    {
        "id": 9682,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to an appropriate specialist should be made for any of the following findings if they persist for more than four weeks: foetor ex ore."
    },
    {
        "id": 9689,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Appropriate endoscopic/mirror examinations must be performed."
    },
    {
        "id": 9690,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "The symptoms vary greatly depending on the location of the carcinoma."
    },
    {
        "id": 9691,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Hypopharyngeal and tongue base carcinomas are characterized by difficulty swallowing, a lumpy sensation and swallowing pain (radiating into the ear)."
    },
    {
        "id": 9692,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Changes in voice and hoarseness may also occur, and in the later stages, breathing may also be impaired."
    },
    {
        "id": 9693,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "If the above-mentioned symptoms persist for more than four weeks, a specialist should be consulted."
    },
    {
        "id": 9694,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Initially, there may be swelling of the lymph nodes in the neck, which can be confused with inflammatory diseases such as pharyngo-laryngitis or lymphadenitis."
    },
    {
        "id": 9695,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Progressive tumour growth leads to increasing functional impairments such as considerable voice and breathing disorders as well as difficulties in swallowing and nutritional disorders with weight loss."
    },
    {
        "id": 9696,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Severe pain develops, radiating to the entire head and neck region."
    },
    {
        "id": 9697,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "In up to 40% of patients, the cervical lymph nodes may already be affected at the time of initial diagnosis despite a clinically unremarkable neck."
    },
    {
        "id": 9698,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to a specialist should be made for the following findings if they persist for more than three weeks: blood in the saliva."
    },
    {
        "id": 9699,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to a specialist should be made for the following findings if they persist for more than three weeks: hoarseness."
    },
    {
        "id": 9700,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 58,
        "content": "Immediate referral to a specialist should be made for the following findings if they persist for more than three weeks: difficulty speaking and breathing."
    },
    {
        "id": 9701,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "The clinical examination for suspected oropharyngeal or hypopharyngeal carcinoma includes specific ENT examinations following a general medical history, full body examination and recording of relevant comorbidities."
    },
    {
        "id": 9702,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "The clinical examination involves endoscopy of the oral cavity, oro- and hypopharynx and larynx in the phonation and respiratory position."
    },
    {
        "id": 9703,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "A 90\u00b0 magnifying laryngoscope should be used for the clinical examination."
    },
    {
        "id": 9704,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "Surface anaesthesia of the pharynx usually improves the examination options."
    },
    {
        "id": 9709,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "Particular attention must be paid to vocal fold mobility during the clinical examination."
    },
    {
        "id": 9710,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "A phoniatric examination to assess the vibration behaviour of the vocal folds, particularly in hypopharyngeal carcinomas with incipient vocal fold fixation with the aid of a stroboscope, is recommended."
    },
    {
        "id": 9711,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "Systemic tumour seeding, especially in the lungs, is also possible."
    },
    {
        "id": 9712,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "Multilocular tumour growth occurs when several regions of the pharynx and larynx are affected at the same time."
    },
    {
        "id": 9713,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "Endoscopy of the neighbouring mucosal areas, e.g. with a 90\u00b0 loupe laryngoscope or with a flexible rhino-pharyngo-laryngoscope, is part of the primary clinical diagnosis of oropharyngeal and hypopharyngeal carcinoma."
    },
    {
        "id": 9714,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "During panendoscopy under anaesthesia, the tracheo-bronchial system and the oesophagus can also be examined in order to rule out further secondary carcinomas and to determine the exact extent of the tumour by palpation and endoscopy while the patient is relaxed."
    },
    {
        "id": 9715,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "Suspect lesions distant from the primary tumour should be biopsied separately."
    },
    {
        "id": 9716,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "A mapping biopsy in inconspicuous areas of the mucosa may also be useful."
    },
    {
        "id": 9717,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "The clinical examination also includes palpation of the neck to detect lymph node metastases."
    },
    {
        "id": 9718,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "Palpation of the neck is supplemented by ultrasound and CT/MRI if neoplasia is suspected."
    },
    {
        "id": 9719,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "Newer endoscopic procedures such as coherence tomography, autofluorescence and electronic chromoendoscopy (narrow band imaging) can also be used."
    },
    {
        "id": 9720,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 59,
        "content": "The clinical examination includes the systematic recording of comorbidities and so-called 'frailty' (a state of decreased physical function and mobility)."
    },
    {
        "id": 9743,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 61,
        "content": "CT (contrast-enhanced) or MRI should be performed to determine the local extent of an oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 9745,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 61,
        "content": "The tumour biopsy should only be performed after the slice imaging has been performed to avoid distortions of the contrast agent behaviour on the primary tumour."
    },
    {
        "id": 9747,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 61,
        "content": "If artifacts are expected in the oropharynx due to metal in the oral cavity, MRI should be preferred to CT for the assessment of the primary tumour."
    },
    {
        "id": 9749,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 61,
        "content": "In locoregionally advanced tumours, an FDG-PET/CT should be performed to exclude distant metastases before function-restricting therapeutic measures."
    },
    {
        "id": 9753,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 62,
        "content": "The entire region from the base of the skull to the upper thoracic aperture should be examined with CT or MRI to determine the N category."
    },
    {
        "id": 9758,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 62,
        "content": "Ultrasound-guided fine-needle biopsy can improve the diagnostic specificity of lymph node staging in the neck."
    },
    {
        "id": 9762,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 62,
        "content": "FDG-PET-CT/MRI can improve the diagnostic specificity and sensitivity of lymph node staging in the neck."
    },
    {
        "id": 9765,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 62,
        "content": "In patients with confirmed oropharyngeal and hypopharyngeal carcinoma, a chest CT should be performed to rule out pulmonary tumour involvement."
    },
    {
        "id": 9770,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 63,
        "content": "As part of the primary diagnosis, imaging should be performed to rule out liver metastases."
    },
    {
        "id": 9773,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 63,
        "content": "In patients with suspected recurrence in the head and neck region, PET-CT can be performed if this cannot be confirmed or ruled out with CT and/or MRI."
    },
    {
        "id": 9775,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 63,
        "content": "A sonography of the head and neck region may be indicated to justify the indication for further measures in patients with suspected recurrence in the head and neck region."
    },
    {
        "id": 9777,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 63,
        "content": "Clinical examination and imaging measures such as ultrasound diagnostics, CT or MRI, chest X-ray or chest CT are part of the diagnosis of oropharyngeal and hypopharyngeal carcinoma."
    },
    {
        "id": 9778,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 63,
        "content": "Panoramic tomography should be available to assess the dental status, also with regard to possible radiotherapy."
    },
    {
        "id": 9789,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "A meta-analysis included 2 studies focusing on T-stage, 1 study focusing on T- and N-stage and 3 studies focusing on N-stage."
    },
    {
        "id": 9790,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "The pooled sensitivity/specificity was 89.3% / 89.5% for PET/CT."
    },
    {
        "id": 9791,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "The pooled sensitivity/specificity was 71.6% / 78.0% for conventional cross-sectional imaging (CT and MRI)."
    },
    {
        "id": 9792,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "CT and MRI are of similar accuracy for the diagnosis of cervical lymph node metastases."
    },
    {
        "id": 9793,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "CT and MRI are clearly superior to clinical examination for the diagnosis of cervical lymph node metastases."
    },
    {
        "id": 9794,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "CT appears to be slightly more reliable than MRI for the visualization of infrahyoid lymph node metastases."
    },
    {
        "id": 9795,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "MRI appears to visualize the nodes along the vascular nerve sheath better than CT."
    },
    {
        "id": 9796,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "MRI is recommended for routine diagnostics to determine soft tissue infiltration and lymph node status."
    },
    {
        "id": 9797,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "In a direct comparative study, MRI performed better than CT for the determination of cervical lymph node metastases in terms of sensitivity, specificity and accuracy."
    },
    {
        "id": 9798,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "The diagnostic accuracy of MRI can be increased in combination with FDG-PET."
    },
    {
        "id": 9799,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "FDG-PET does not allow a reliable statement to be made about the dignity of the detected lymph nodes."
    },
    {
        "id": 9800,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "PET is much less informative as a stand-alone method than in combination with CT or MRI."
    },
    {
        "id": 9801,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "PET should always be performed as a hybrid procedure (PET-CT or PET-MRI)."
    },
    {
        "id": 9802,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "The accuracy of CT, MRI and ultrasound in the assessment of lymph node metastases is comparable."
    },
    {
        "id": 9803,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "In the case of borderline large lymph nodes on CT or MRI without signs of central necrosis, a targeted ultrasound-guided fine needle biopsy or FDG-PET can increase diagnostic accuracy."
    },
    {
        "id": 9804,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "The value of PET-CT for the diagnosis of cervical lymph nodes is controversial due to the high number of false positive findings."
    },
    {
        "id": 9805,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "PET-CT is considered particularly unsuitable for lymph nodes less than 10 mm in size."
    },
    {
        "id": 9806,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "In the 8th edition of the TNM classification, the determination of extranodal tumour growth (ENE, extranodal extension) was excluded in pretherapeutic staging for HPV16/p16-positive oropharyngeal carcinomas."
    },
    {
        "id": 9807,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "The determination of extranodal tumour growth (ENE, extranodal extension) remains highly valid for postoperative adjuvant therapy decisions."
    },
    {
        "id": 9808,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "In a meta-analysis that included 2478 patients from 22 studies, the pooled sensitivity/specificity was 0.73/0.83 (CT) and 0.60/0.96 (MRI)."
    },
    {
        "id": 9809,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "The pooled specificity for HPV-positive oropharyngeal cancers was lower than for HPV-negative oropharyngeal cancers (0.74 vs. 0.87)."
    },
    {
        "id": 9810,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "Ultrasonography is a standard method for assessing the cervical lymph nodes."
    },
    {
        "id": 9811,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "Ultrasonography has a higher sensitivity and specificity than CT or MRI in individual studies."
    },
    {
        "id": 9812,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "Ultrasonography is an inexpensive method that can often be repeated during follow-up."
    },
    {
        "id": 9813,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "The accuracy and informative value of ultrasonography depend heavily on the experience of the examiner."
    },
    {
        "id": 9815,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "Few studies have looked at the sensitivity of ultrasound-guided fine-needle biopsy (FNB) to determine pathologic lyphatic node dignity."
    },
    {
        "id": 9816,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "The sensitivity of ultrasound-guided fine-needle biopsy (FNB) is low for small tumours with a clinical N0 neck."
    },
    {
        "id": 9817,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "Ultrasound-guided fine-needle biopsy (FNB) can be helpful for preoperative confirmation of dignity in palpable LKs."
    },
    {
        "id": 9818,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "Ultrasound-guided fine-needle aspiration has a higher specificity than CT for palpable lumps."
    },
    {
        "id": 9820,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "A combination of the examination modalities CT, MRI and PET-CT does not lead to any significant improvement."
    },
    {
        "id": 9821,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 64,
        "content": "Despite its high sensitivity, PET-CT has no improved diagnostic value for primary tumours and therefore cannot replace the clinical examination."
    },
    {
        "id": 9836,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "A chest CT is generally recommended as part of the diagnosis of the primary tumour."
    },
    {
        "id": 9837,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "Chest X-ray overview is obsolete for staging."
    },
    {
        "id": 9838,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "Both LK metastases and a second pulmonary carcinoma can be detected by CT with high sensitivity and specificity."
    },
    {
        "id": 9839,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "In patients with suspected recurrence in the head and neck region, sonography of the neck regions may also be indicated."
    },
    {
        "id": 9840,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "CT proved to be the safest screening method for detecting distant metastases."
    },
    {
        "id": 9841,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "CT detected either metastasis or a synchronous second carcinoma in approximately 11% of cases."
    },
    {
        "id": 9842,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "Chest CT is recommended as an important imaging modality for primary staging in all patients with head and neck tumours."
    },
    {
        "id": 9843,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "Despite the very low overall incidence of liver metastases, liver imaging is recommended as an obligatory part of pre-therapeutic staging."
    },
    {
        "id": 9844,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "If a metastasis is detected in a single lymph node of category N2b or N2c, or if an involved lymph node measures more than 3 cm in maximum diameter (N2a or N3), there is a higher risk of distant metastases."
    },
    {
        "id": 9845,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "A whole-body FDG-PET-CT is recommended as an alternative to CT thorax/abdomen to rule out or objectify distant metastases."
    },
    {
        "id": 9846,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "The sensitivity for the detection of distant metastases is 96.8%."
    },
    {
        "id": 9847,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "The specificity for the detection of distant metastases is 95.4%."
    },
    {
        "id": 9848,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "The positive predictive value for the detection of distant metastases is 69.8%."
    },
    {
        "id": 9849,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 65,
        "content": "The negative predictive value for the detection of distant metastases is 99.6%."
    },
    {
        "id": 9860,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 66,
        "content": "FDG-PET showed a higher reliability with a sensitivity of 100% and a specificity of 61-71% than CT and/or MRI for recurrence detection."
    },
    {
        "id": 9864,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 66,
        "content": "After combined radio-chemotherapy, surveillance using FDG-PET-CT should precede a planned salvage neck dissection in node-positive patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 9868,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 66,
        "content": "If the FDG-PET-CT is negative, the salvage neck dissection can be omitted."
    },
    {
        "id": 9877,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 67,
        "content": "Mehanna et al. conducted a prospective randomized study on the role of PET-CT surveillance in node-positive patients."
    },
    {
        "id": 9882,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 67,
        "content": "Breik et al. favours PET/CT for the follow-up of patients with oral cavity, oropharyngeal and hypopharyngeal carcinomas in the 3-6 month period after the end of therapy."
    },
    {
        "id": 9886,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 67,
        "content": "Panendoscopy should be performed as part of the primary diagnosis of oropharyngeal and hypopharyngeal carcinomas."
    },
    {
        "id": 9889,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "Panendoscopy is a central part of primary diagnostics for a more precise diagnosis of the extent of the primary tumour and for the detection of secondary carcinomas."
    },
    {
        "id": 9890,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "The frequency of clinically occult secondary carcinomas varies considerably in the literature from 1% to over 10%."
    },
    {
        "id": 9891,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "There are indications that the frequency of secondary carcinomas depends on the stage of the primary tumour."
    },
    {
        "id": 9892,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "Patients with oropharyngeal and hypopharyngeal carcinoma who smoke and regularly drink large amounts of alcohol have a probability that these noxious substances have also caused carcinomas or precursor lesions in other regions of the upper airways and oropharynx."
    },
    {
        "id": 9893,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "St\u00f6ckli et al. dealt intensively with the topic of secondary carcinomas in 2001."
    },
    {
        "id": 9894,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "St\u00f6ckli et al. described 16.2% secondary carcinomas in 358 patients examined in 2001."
    },
    {
        "id": 9895,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "40% of synchronous secondary carcinomas were found in the primary tumour of the oral cavity and pharynx in St\u00f6ckli et al.'s study."
    },
    {
        "id": 9896,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "20% of synchronous secondary carcinomas were detected exclusively by panendoscopy in St\u00f6ckli et al.'s study."
    },
    {
        "id": 9897,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "Haughey et al. found 14% of secondary carcinomas with the highest prevalence in oral cavity, oropharyngeal and hypopharyngeal carcinomas in 1992."
    },
    {
        "id": 9898,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "Di Martino et al. evaluated the tumour registry of the ENT clinic at RWTH Aachen and found 7.7% metachronous carcinomas in 843 patients with head and neck carcinomas in 2000."
    },
    {
        "id": 9899,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "15.3% of metachronous carcinomas were in the lungs in Di Martino et al.'s study."
    },
    {
        "id": 9900,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "Figures of 0.8% are given for the explicit occurrence of second tumours in the oesophagus in oral cavity carcinoma."
    },
    {
        "id": 9901,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "Koo et al. observed second carcinomas for small oral cavity and pharyngeal carcinoma (tongue T1-2) patients with existing tobacco and alcohol consumption in 14.5-16.3% of patients."
    },
    {
        "id": 9902,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "In the few never smokers/drinkers, the second carcinoma rate was 0% in Koo et al.'s study."
    },
    {
        "id": 9903,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "Hung et al. found an odds ratio of 55.3 for synchronous oesophageal cancer in patients with oral cavity/pharyngeal cancer compared to the normal population group in 2000."
    },
    {
        "id": 9904,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "Hung et al. strongly recommended performing panendoscopy in routine primary diagnostics in 2000."
    },
    {
        "id": 9905,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "Sharma et al. saw 5.56% second cancers (predominantly in the hypopharynx) in 234 patients in Germany in 2018."
    },
    {
        "id": 9906,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "Davidson et al. concluded on the basis of a 154-patient series that routine panendoscopy was unnecessary for 2.6% of secondary cancers in 2000."
    },
    {
        "id": 9907,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "The 'Tumour Assessment and Staging: UK National Multidisciplinary Guidelines' recommends panendoscopy under general anaesthesia as part of the primary diagnosis in England."
    },
    {
        "id": 9908,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "The authors of the 'Tumour Assessment and Staging: UK National Multidisciplinary Guidelines' critically concede that although there is a documented proportion of secondary cancers for panendoscopy in the literature, according to a review by McGarey et al. the proportion of secondary cancers has decreased in the last three decades."
    },
    {
        "id": 9909,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "McGarey et al. reviewed that the proportion of secondary cancers has decreased in the last three decades."
    },
    {
        "id": 9910,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 68,
        "content": "Rigid oesophagoscopy in particular should only be performed in patients with primary tumours in whom an increased incidence of secondary cancers has been described (oropharynx and hypopharynx are addressed) according to McGarey et al.'s review."
    },
    {
        "id": 9911,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "The anaesthesia- and surgery-associated risk of panendoscopy is considered to be subordinate or negligible in relation to the more precise initial diagnosis and thus undisputed added value for the patient."
    },
    {
        "id": 9912,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "The NCCN Guidelines, Version 2.2022, explicitly recommend performing panendoscopy under general anaesthesia as part of the pre-therapeutic staging examination."
    },
    {
        "id": 9913,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "Clinical experience has shown that the imaging of small and early, superficially located squamous cell carcinomas of the mucous membranes of the upper aerodigestive tract is often inadequate."
    },
    {
        "id": 9914,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "Panendoscopy is considered more important than imaging when it comes to determining the exact extent of the tumour and visualizing metachronous secondary carcinomas."
    },
    {
        "id": 9915,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "A distinction must be made between panendoscopy and the targeted biopsy endoscopy performed for histological verification in the case of apparent abnormalities in the mirror examination or imaging."
    },
    {
        "id": 9916,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "The proposal that panendoscopy should only be performed in cases where there is a history of increased risk is not expedient in the light of the literature."
    },
    {
        "id": 9917,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "Many head and neck tumour patients dissimulate in their medical history as part of the primary diagnosis and to a large extent provide unreliable information on tobacco and alcohol consumption."
    },
    {
        "id": 9918,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "Panendocopy should remain an obligatory diagnostic component even for p16-positive oropharyngeal carcinomas, as combined risk factor constellations are predominant, particularly in Germany."
    },
    {
        "id": 9919,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "Second cancers can occur synchronously or metachronously."
    },
    {
        "id": 9920,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "Synchronous secondary carcinomas may already be clinically apparent at the time of the manifestation of oropharyngeal and hypopharyngeal carcinoma during the ear, nose and throat examination."
    },
    {
        "id": 9921,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "Panendoscopy is suitable for the exclusion or detection of clinically occult secondary carcinomas and their precursors and cannot be replaced by imaging."
    },
    {
        "id": 9922,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "Panendoscopy is one of the mandatory diagnostic measures to be performed prior to a therapeutic decision on histologically proven oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 9923,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "Panendoscopy is usually performed together with endoscopy of the expected tumour region, which also includes a tissue sample (biopsy)."
    },
    {
        "id": 9924,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "Palpation of the oral cavity, in particular the tongue, the base of the tongue and the accessible pharyngeal region under anaesthesia during the initial phase of maximum muscle relaxation is considered an important step during panendoscopy."
    },
    {
        "id": 9925,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 69,
        "content": "Panendoscopy addresses the entire upper airway and alimentary canal, i.e. the entire oral cavity, the entire naso-, oro- and hypopharynx and the larynx are inspected."
    },
    {
        "id": 9926,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "The tracheobronchial system and the oesophagus can be inspected during a biopsy."
    },
    {
        "id": 9927,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "The oral cavity and oropharynx can be inspected directly without an endoscope."
    },
    {
        "id": 9928,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "The mucosa, base of the tongue, hypopharynx and larynx should be assessed with an endoscope."
    },
    {
        "id": 9929,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "Laryngoscopes, such as the 'Kleinsasser tube', are usually used for inspecting the larynx."
    },
    {
        "id": 9930,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "Endoscopy of the tracheobronchial system can be performed using rigid endoscopes with different angles."
    },
    {
        "id": 9931,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "Oesophagoscopy can also be performed with a rigid, preferably pneumatic oesophagoscope."
    },
    {
        "id": 9932,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "Performing oesophagoscopy with a flexible endoscope is recommended by some authors due to the possible complications of rigid endoscopy."
    },
    {
        "id": 9933,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "Rigid endoscopy is advantageous for inspecting the postcricoid area."
    },
    {
        "id": 9934,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "Tracheobronchoscopy can also be performed optically with flexibility."
    },
    {
        "id": 9935,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "In the presence of hypopharyngeal carcinoma with laryngeal involvement, microlaryngoscopy is of particular importance."
    },
    {
        "id": 9936,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "Microlaryngoscopy can define the extent of the primary tumour."
    },
    {
        "id": 9937,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "Superficial mucosal changes that cannot be detected by imaging can be easily recognized during microlaryngoscopy."
    },
    {
        "id": 9938,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "The piriform sinus is often compressed in sectional imaging."
    },
    {
        "id": 9939,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "The exact extent of the tumour can often not be precisely determined if there is surrounding oedema."
    },
    {
        "id": 9940,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "Endoscopic 'stretching' of the piriform sinus region is of great additional diagnostic benefit."
    },
    {
        "id": 9941,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "Microlaryngoscopy can determine whether the entire larynx can be adjusted endoscopically."
    },
    {
        "id": 9942,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "A mapping biopsy may also be useful in these situations."
    },
    {
        "id": 9943,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "The findings concerning the primary tumour extension obtained during panendoscopy including palpation are entered or drawn into a prefabricated pictogram."
    },
    {
        "id": 9944,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "It is advisable to check the resectability and enter this on the document."
    },
    {
        "id": 9945,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "In the event of resectability, the exact surgical procedure should be determined."
    },
    {
        "id": 9946,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "The sample for biopsy should be taken from the edge of the tumour and, if possible, centrally from the base of the tumour."
    },
    {
        "id": 9947,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "The removal of a tissue sample and its subsequent histopathological examination is an essential prerequisite for the initiation of tumour-specific treatment."
    },
    {
        "id": 9948,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 70,
        "content": "A biopsy is usually performed as part of panendoscopy."
    },
    {
        "id": 9949,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "Biopsy treatment is carried out before a tissue sample is taken."
    },
    {
        "id": 9950,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "A tissue sample should preferably be taken from the peripheral area of the tumour."
    },
    {
        "id": 9951,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "A tissue sample should not be taken from the necrotic centre only."
    },
    {
        "id": 9952,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "It is desirable to collect tumour bases from non-necrotic areas where feasible."
    },
    {
        "id": 9953,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "The usual form of biopsy for macroscopically clear, advanced tumours is an incisional biopsy with microshears or sharp forceps (Blakesley)."
    },
    {
        "id": 9954,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "An excisional biopsy should only be performed for circumscribed lesions without deep infiltration."
    },
    {
        "id": 9955,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "Excisional biopsy is particularly suitable for older patients in order to avoid a second procedure under anaesthesia in the case of in sano resection (R0)."
    },
    {
        "id": 9956,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "Areas of mucosa that are suspicious for the presence of a precursor lesion should also be biopsied."
    },
    {
        "id": 9957,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "A so-called brush biopsy is not recommended."
    },
    {
        "id": 9958,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "Photo documentation of the tumour during panendoscopy under anaesthesia and prior to sampling is recommended."
    },
    {
        "id": 9959,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "Photo documentation of the tumour during panendoscopy under anaesthesia and prior to sampling is of great benefit in the subsequent treatment decision."
    },
    {
        "id": 9960,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "If the histology findings are unexpectedly negative, the biopsy should be repeated at least once."
    },
    {
        "id": 9961,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "P16 immunohistology can be used in many scenarios as a surrogate marker of HPV infection in squamous cell carcinoma of the head and neck."
    },
    {
        "id": 9962,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "A case should be considered positive if more than 70% of the tumour cells express p16 at least moderately in nuclear and cytoplasmic levels."
    },
    {
        "id": 9963,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "Different p16 antibodies show slightly different positivity rates, but result in comparable expression patterns overall."
    },
    {
        "id": 9964,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "The inter-observer variability in the evaluation appears to be rather low."
    },
    {
        "id": 9965,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "HPV detection using molecular methods can be used confirmatively in cases with unclear p16 staining or other limitations in the predictivity of a p16 immunohistology for an HPV association."
    },
    {
        "id": 9966,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "The variety of molecular methods available is large, and no single one can be recommended here as being particularly sensitive."
    },
    {
        "id": 9967,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "The method used should be checked regularly in inter-laboratory tests, it seems desirable to include positive controls."
    },
    {
        "id": 9968,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "PD-L1 positivity plays a role in the stratification of squamous cell carcinomas of the head and neck region for treatment with immune checkpoint inhibitors."
    },
    {
        "id": 9969,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "Determination of PD-L1 as part of the primary diagnosis is useful, but according to the current approval situation, it can only be recommended as mandatory in the diagnosis of recurrence or distant metastasis."
    },
    {
        "id": 9970,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "As distant metastases can often not be confirmed with biopsy, the PD-L1 status obtained during primary diagnosis is a valuable marker for the initiation of first or second-line therapy."
    },
    {
        "id": 9971,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 71,
        "content": "Of four established different PD-L1 scoring algorithms, two are currently relevant for approval for squamous cell carcinomas of the head and neck region: the CPS and the TPS."
    },
    {
        "id": 9972,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "CPS describes the proportion of PD-L1-positive tumour and immune cells in relation to all tumour cells, multiplied by 100."
    },
    {
        "id": 9973,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "CPS is given as a pure number, not as a percentage."
    },
    {
        "id": 9974,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "PD-L1-positive cells include tumour cells, lymphocytes, and macrophages."
    },
    {
        "id": 9975,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "CPS is calculated by dividing the number of PD-L1-positive cells by the total number of vital tumour cells and multiplying by 100."
    },
    {
        "id": 9976,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "TPS is the proportion of tumour cells that are PD-L1-positive."
    },
    {
        "id": 9977,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "TPS is given as a percentage."
    },
    {
        "id": 9978,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "TPS is calculated by dividing the number of PD-L1-positive tumour cells by the total number of vital tumour cells and multiplying by 100."
    },
    {
        "id": 9979,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "CPS and TPS cannot be converted into each other mathematically."
    },
    {
        "id": 9980,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "CPS and TPS should both be requested diagnostically when asking about the PD-L1 status."
    },
    {
        "id": 9981,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "The IC score indicates the percentage of the tumour area that is occupied by PD-L1-positive tumour-infiltrating immune cells."
    },
    {
        "id": 9982,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "The TAP score can also be considered."
    },
    {
        "id": 9983,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "The IC score and the TAP score are currently less relevant."
    },
    {
        "id": 9984,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "The evaluation according to IC or TAP score currently plays no role in treatment decisions for oropharyngeal and hypopharyngeal carcinoma in the first or second line."
    },
    {
        "id": 9985,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "The interchangeability of different assay systems for PD-L1 measurement appears to be broadly possible in different entities."
    },
    {
        "id": 9986,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "Evaluator variability is acceptable according to current studies."
    },
    {
        "id": 9987,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "Participation in quality assurance programs seems advisable."
    },
    {
        "id": 9989,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "Sentinel lymph nodes are those lymph nodes that are closest to the tumour in the lymph drainage area of a malignant tumour."
    },
    {
        "id": 9990,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 72,
        "content": "If tumour cells have already been carried into these lymph nodes with the lymph flow and have led to a metastasis, they are called sentinel lymph nodes."
    },
    {
        "id": 9991,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "Metastasis in sentinel lymph nodes indicates that further metastases are likely to be found in downstream lymph nodes."
    },
    {
        "id": 9993,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "If no metastases are found in the removed sentinel lymph node, there is a low probability that further lymph node metastases are present."
    },
    {
        "id": 9994,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "The sentinel lymph node technique is a clinically established technique for breast carcinoma, prostate carcinoma and melanoma."
    },
    {
        "id": 9995,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "The oral cavity is considered to be an important primary tumour site that can be considered for meaningful sentinel lymph node biopsy (SNB)."
    },
    {
        "id": 9999,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "Liu et al. conducted a meta-analysis of 66 studies with 3566 tongue cancer patients."
    },
    {
        "id": 10000,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "The sensitivity of SLN biopsy with regard to the detection of lymph node metastasis is stated as 0.87 [0.85-0.89]."
    },
    {
        "id": 10001,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "Considering only the studies in which patients with negative SLN were followed up and the false negatives were detected over the course, the sensitivity is 0.85 [0.82-0.88]."
    },
    {
        "id": 10002,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "SLN biopsy is equivalent in terms of survival after conventional neck dissections for small squamous cell carcinomas (T1/T2)."
    },
    {
        "id": 10003,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "There are advantages for SLN biopsy in terms of postoperative quality of life and functionality."
    },
    {
        "id": 10004,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "There are advantages for SLN biopsy in terms of lower complication rates."
    },
    {
        "id": 10005,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "According to the S3 Guideline on Oral Cavity Carcinoma, SLN biopsy can be offered for early, transorally resectable oral cavity carcinomas that do not require a transcervical approach in the same procedure."
    },
    {
        "id": 10006,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "If the sentinel lymph node is positive and detection is uncertain, a complete neck dissection should be performed."
    },
    {
        "id": 10007,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "Van den Bosch et al. conducted a meta-analysis of 19 studies and 377 patients."
    },
    {
        "id": 10008,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "The sensitivity and negative predictive value of SLN biopsy were estimated at 0.93 (95% CI: 0.86-0.96) and 0.97 (95% CI: 0.94-0.98)."
    },
    {
        "id": 10009,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "According to the authors, the accuracy of the SNB justifies its place in the diagnosis of patients with oropharyngeal and hypopharyngeal carcinomas."
    },
    {
        "id": 10011,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "Further meta-analyses underline the high sensitivity and specificity in oropharyngeal and hypopharyngeal carcinoma."
    },
    {
        "id": 10012,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 73,
        "content": "Werner et al. showed that SNB is safest when several detected lymph nodes (up to three) are removed."
    },
    {
        "id": 10040,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 75,
        "content": "Oropharyngeal and hypopharyngeal carcinoma can impair functions such as voice production, swallowing and breathing."
    },
    {
        "id": 10041,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 75,
        "content": "The patient must be given a detailed explanation of the possible disorders that may arise after a specific therapy."
    },
    {
        "id": 10042,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 75,
        "content": "The initial informative discussion with the patient and their relatives is important so that they can decide on the right therapy for them."
    },
    {
        "id": 10043,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 75,
        "content": "The patient will often follow the doctor's recommendation, so it is all the more important to explain the consequences of the treatment."
    },
    {
        "id": 10050,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 75,
        "content": "If information is provided on the probability of recovery, this should be given as absolute (and not relative) frequencies where possible."
    },
    {
        "id": 10051,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 75,
        "content": "The probable risks and consequences of non-therapy should also be explained."
    },
    {
        "id": 10058,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 76,
        "content": "The patient should be informed about the prognosis with regard to voice production."
    },
    {
        "id": 10059,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 76,
        "content": "The patient should be informed about the prognosis with regard to breathing."
    },
    {
        "id": 10060,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 76,
        "content": "The patient should be informed about the prognosis with regard to swallowing."
    },
    {
        "id": 10061,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 76,
        "content": "The patient should be informed about visible changes to the face and neck after the therapeutic procedure."
    },
    {
        "id": 10062,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 76,
        "content": "The patient should be informed about possibly stigmatizing changes to the face and neck after the therapeutic procedure."
    },
    {
        "id": 10063,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 76,
        "content": "The patient should be informed about whether a permanent tracheostomy or a temporary tracheostomy is being performed."
    },
    {
        "id": 10064,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 76,
        "content": "The patient should be informed about whether a tracheostomy tube needs to be worn."
    },
    {
        "id": 10065,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 76,
        "content": "Aspiration is not an insignificant problem in operations in the oropharyngeal and hypopharyngeal region and must be explained to the patient."
    },
    {
        "id": 10066,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 76,
        "content": "The patient must be informed about the possible impairment of swallowing function."
    },
    {
        "id": 10067,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 76,
        "content": "The patient must be informed about the possible impairment of voice production."
    },
    {
        "id": 10096,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 77,
        "content": "The majority of oropharyngeal and hypopharyngeal carcinomas are caused by noxious substances."
    },
    {
        "id": 10097,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 77,
        "content": "Noxious substances include smoking and alcohol abuse."
    },
    {
        "id": 10098,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 77,
        "content": "The connection between noxious substances and oropharyngeal and hypopharyngeal carcinomas must be clearly explained to the patient."
    },
    {
        "id": 10119,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 78,
        "content": "The treatment of oropharyngeal and hypopharyngeal carcinoma should be carried out on an interdisciplinary basis."
    },
    {
        "id": 10120,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 78,
        "content": "The treatment should be carried out after coordination of each individual case within tumour boards involving the specialist disciplines of otorhinolaryngology, oral and maxillofacial surgery, radiation oncology, oncology, pathology and radiology."
    },
    {
        "id": 10121,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 79,
        "content": "The patient should be informed in detail and repeatedly about their illness, treatment options and subsequent disorders."
    },
    {
        "id": 10124,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 79,
        "content": "Patients with oropharyngeal and hypopharyngeal carcinoma should be examined by an experienced dentist to determine their dental status before starting treatment."
    },
    {
        "id": 10126,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 79,
        "content": "Therapy breaks beyond the planned weekend breaks should be avoided during radiotherapy."
    },
    {
        "id": 10127,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 79,
        "content": "Radiotherapy should not have therapy breaks beyond the planned weekend breaks."
    },
    {
        "id": 10130,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 79,
        "content": "The treatment recommendations for oropharyngeal and hypopharyngeal carcinoma are compiled on the basis of the 8th edition of the TNM classification."
    },
    {
        "id": 10134,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 79,
        "content": "HPV/p16-positive tumours have a significantly better prognosis."
    },
    {
        "id": 10135,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 79,
        "content": "Registry studies show that in HPV/p16-positive oropharyngeal carcinomas, the results of radiochemotherapy are still positive for relatively high tumour burden up to cT3 tumours."
    },
    {
        "id": 10136,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 79,
        "content": "Radiochemotherapy results are equivalent to the primary surgical approach with regard to all important outcomes in HPV/p16-positive oropharyngeal carcinomas with bilateral lymph node involvement (N2)."
    },
    {
        "id": 10138,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 80,
        "content": "The guideline provides information on oncological and functional endpoints for HPV/p16-negative tumours with a smaller tumour burden (cT1-2 cN0)."
    },
    {
        "id": 10141,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 80,
        "content": "The treatment recommendations do not differ between HPV/p16+ and HPV/p16-."
    },
    {
        "id": 10147,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 80,
        "content": "The maximum therapy includes either primary surgical therapy with adjuvant radiochemotherapy with cisplatin or primary radiochemotherapy with cisplatin."
    },
    {
        "id": 10159,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 81,
        "content": "There is evidence that the results of primary surgical therapy (+/- adjuvant radio/radiochemotherapy) and primary radio/radiochemotherapy do not differ significantly in terms of overall survival, relapse-free survival, locoregional relapse rate and distant metastasis-free survival in patients with HPV/p16-positive oropharyngeal carcinoma in stages I-II (UICC 8th edition)."
    },
    {
        "id": 10160,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 81,
        "content": "Patients with HPV/p16 positive oropharyngeal carcinoma in stages I-II (UICC 8th edition) should receive either primary surgical therapy (+/- adjuvant radiotherapy or radiochemotherapy) or primary radiotherapy or radiochemotherapy."
    },
    {
        "id": 10161,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 81,
        "content": "Patients with HPV/p16 negative oropharyngeal carcinoma in stages I, II (cT1N0, cT2N0; UICC 8th edition) should receive either primary surgical therapy (+/- adjuvant radio- or radiochemotherapy) or primary radio- or radiochemotherapy."
    },
    {
        "id": 10165,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 82,
        "content": "In the case of a primary surgical approach, a transoral procedure for primary tumour resection should be preferred to a procedure with a transcervical approach for T1 and T2 tumours of the oropharynx, HPV/p16 positive and negative."
    },
    {
        "id": 10166,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 82,
        "content": "The transoral procedure for primary tumour resection includes transoral laser microsurgery (TLM) and transoral robotic surgery (TORS)."
    },
    {
        "id": 10169,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 82,
        "content": "If a transoral surgical technique is chosen for a laterally located tumour with an increased risk of postoperative bleeding, consideration should be given to clipping/bandaging the arterial vessels supplying the tumour side transcervically."
    },
    {
        "id": 10170,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 82,
        "content": "Clipping/bandaging the arterial vessels supplying the tumour side transcervically can reduce the intraoperative and postoperative risk of bleeding."
    },
    {
        "id": 10189,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 83,
        "content": "Primary radiochemotherapy and surgery followed by adjuvant radiochemotherapy were equivalent in patients with stage II disease."
    },
    {
        "id": 10190,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 83,
        "content": "In patients with stage III disease, triple-modality therapy was associated with significantly improved survival."
    },
    {
        "id": 10192,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 83,
        "content": "Definitive radiochemotherapy alone was compared to treatment with triple-modality therapy in patients with stage III disease."
    },
    {
        "id": 10193,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 83,
        "content": "A trend towards transoral resection + neck dissection + adjuvant radio- (chemo-) therapy has been observed over the last 20 years."
    },
    {
        "id": 10194,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 83,
        "content": "Transoral surgery techniques have been promoted as gentle, minimally invasive procedures with good late functional outcomes."
    },
    {
        "id": 10199,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 83,
        "content": "TORS may have better disease-free survival and a reduced risk of free flap reconstruction compared to open surgery."
    },
    {
        "id": 10200,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 83,
        "content": "TORS was associated with fewer tumour-positive resection margins, a lower number of recurrences, fewer intraoperative tracheostomies, a shorter hospital stay and a shorter duration of postoperative nasal tube feeding compared to open surgery."
    },
    {
        "id": 10201,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 83,
        "content": "TORS appears to be less time-consuming and associated with less access morbidity compared to conventional surgery."
    },
    {
        "id": 10202,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 83,
        "content": "The ORATOR 1 and ORATOR 2 trials are the only prospective randomized trials that have directly compared TOS with radiochemotherapy."
    },
    {
        "id": 10217,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 84,
        "content": "Primary transoral surgery or the primary non-surgical approach are relevant treatment options for stage I-II oropharyngeal carcinomas."
    },
    {
        "id": 10232,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 85,
        "content": "The UICC stage I and II oropharyngeal carcinomas are p16-positive: T1-T3N2 and p16-neg.: T1-T2N0."
    },
    {
        "id": 10254,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 86,
        "content": "The UICC stage I and II oropharyngeal carcinomas are p16-positive: T1-T3N2 and p16-neg.: T1-T2N0."
    },
    {
        "id": 10270,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 87,
        "content": "The UICC stage I and II oropharyngeal carcinomas are p16-positive: T1-T3N2 and p16-neg.: T1-T2N0."
    },
    {
        "id": 10273,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 87,
        "content": "The total dose of radiotherapy should be de-escalated for primary and adjuvant radiotherapy or radiochemotherapy for HPV/p16 positive oropharyngeal carcinoma within clinical trials."
    },
    {
        "id": 10275,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 87,
        "content": "Radiotherapy has undergone significant technical development in the last 20 years."
    },
    {
        "id": 10276,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 87,
        "content": "Intensity-modulated radiotherapy (IMRT) is available throughout Germany."
    },
    {
        "id": 10280,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 87,
        "content": "IMRT reduces both acute and late side effects compared to older 3D-conformal radiotherapy."
    },
    {
        "id": 10283,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 87,
        "content": "A randomized study has demonstrated the benefit of Swallowing Sparing IMRT compared to standard IMRT."
    },
    {
        "id": 10289,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 87,
        "content": "Interruptions of radiotherapy lead to repopulation of remaining tumour stem cells."
    },
    {
        "id": 10290,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 87,
        "content": "If there are interruptions to radiotherapy, it is possible to make up for lost time by radiotherapy twice a day at intervals of >6 hours with an unchanged single dose."
    },
    {
        "id": 10292,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 87,
        "content": "Tumour stem cells are also repopulated in the interval between surgical resection and the start of radio- or radiochemotherapy."
    },
    {
        "id": 10293,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 87,
        "content": "If the interval between tumour resection and the start of radiotherapy exceeds 6 weeks, a meta-analysis of the available data shows a significant increase in relapse rates."
    },
    {
        "id": 10298,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 88,
        "content": "The primary non-surgical treatment of patients with HPV/p16-positive and -negative oropharyngeal carcinoma in stage T1 cN0 should be radiotherapy alone."
    },
    {
        "id": 10299,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 88,
        "content": "The primary non-surgical treatment for patients with oropharyngeal carcinoma in stage I cN1 (>1 LK <=3 cm) with HPV/p16+ or stage II should be radiochemotherapy."
    },
    {
        "id": 10300,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 88,
        "content": "Simultaneous chemotherapy should be cisplatin-based in the case of primary radiochemotherapy for HPV/p16-positive and -negative oropharyngeal carcinoma."
    },
    {
        "id": 10313,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 89,
        "content": "Cetuximab should not be used in patients with HPV/p16-positive oropharyngeal carcinoma who do not have a contraindication to cisplatin-based chemotherapy."
    },
    {
        "id": 10314,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 89,
        "content": "Cetuximab should not be used in patients with HPV/p16-positive oropharyngeal carcinoma due to its proven inferiority in terms of survival."
    },
    {
        "id": 10321,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 89,
        "content": "Radiotherapy should be carried out with 5x2 Gy per week up to a target volume dose of 70 Gy in the area of the affected lymph nodes and the primary tumour or another established regimen with a biologically equivalent total dose."
    },
    {
        "id": 10325,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 90,
        "content": "The UICC stage I and II oropharyngeal carcinomas are p16-positive with T1-T3N2 and p16-negative with T1-T2N0."
    },
    {
        "id": 10349,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 91,
        "content": "The UICC stage I and II oropharyngeal carcinomas are p16-positive with T1-T3N2 and p16-negative with T1-T2N0."
    },
    {
        "id": 10332,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 90,
        "content": "Randomized studies and large registry databases show 5-year survival rates of around 90% in stage I, around 80% in stage II, and around 70% in stage III."
    },
    {
        "id": 10334,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 90,
        "content": "There is a question of whether it is possible to de-escalate the therapy without compromising survival in order to reduce the toxicity of the therapy."
    },
    {
        "id": 10356,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 91,
        "content": "Conventionally fractionated radiotherapy with 5x2 Gy per week up to a total dose of 70 Gy in IMRT technique in combination with 3 x 100 mg/m\u00b2 cisplatin or 40 mg/m\u00b2 weekly cisplatin parallel to radiotherapy is the best investigated treatment concept."
    },
    {
        "id": 10364,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 91,
        "content": "A significant advantage was shown in terms of survival and locoregional tumour control for combination chemotherapies applied simultaneously with radiotherapy."
    },
    {
        "id": 10383,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "The MACH-NC meta-analysis from 2021 shows that only simultaneous radiochemotherapy leads to an improvement in overall survival and PFS."
    },
    {
        "id": 10389,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "The benefit of simultaneous chemotherapy applied in addition to radiotherapy was the same for oropharyngeal carcinoma as for squamous cell carcinoma of the larynx, hypopharynx, and oral cavity."
    },
    {
        "id": 10391,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "The benefit of simultaneous chemotherapy is the same for HPV/p16- and HPV16+."
    },
    {
        "id": 10392,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "The benefit of additional simultaneous chemotherapy in stages I-II is not well documented."
    },
    {
        "id": 10396,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "Patients over 70 years of age did not benefit from simultaneous chemotherapy in the MACH-NH meta-analysis."
    },
    {
        "id": 10397,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "The NCDB and SEER registry databases documented survival benefits in patients over 70 years of age."
    },
    {
        "id": 10398,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "Excluding patients over 70 years of age from simultaneous chemotherapy does not appear justified."
    },
    {
        "id": 10399,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "For patients with a contraindication to cisplatin, randomized studies have demonstrated a survival benefit for the simultaneous application of carboplatin and 5-FU."
    },
    {
        "id": 10400,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "Randomized studies have also demonstrated a survival benefit for the simultaneous application of mitomycin and 5-FU or weekly docetaxel."
    },
    {
        "id": 10403,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "Weekly applications of carboplatin and paclitaxel concurrently with radiotherapy have been investigated in non-randomized phase II trials and retrospective cohort studies."
    },
    {
        "id": 10409,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "Radiotherapy should be carried out using the IMRT technique with the best possible protection of the salivary glands, the swallowing tract, and the oral cavity."
    },
    {
        "id": 10410,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "The standard fractionation for simultaneous chemotherapy is conventional fractionation with 5x2 Gy per week up to a target volume dose of 70 Gy."
    },
    {
        "id": 10411,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 92,
        "content": "Accelerated radiotherapy with a reduction of the total treatment time to 6 weeks or less has not shown any benefit in combination with simultaneous chemotherapy."
    },
    {
        "id": 10415,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 93,
        "content": "Several randomized trials compared hyperfractionated radiotherapy with simultaneous chemotherapy to hyperfractionated radiotherapy alone."
    },
    {
        "id": 10417,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 93,
        "content": "Adding chemotherapy to hyperfractionated radiotherapy improved survival and locoregional tumour control."
    },
    {
        "id": 10418,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 93,
        "content": "Hyperfractionated radiotherapy was significantly superior to other radiotherapy fractionations in terms of overall survival."
    },
    {
        "id": 10419,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 93,
        "content": "Accelerated radiotherapy regimens only improved locoregional tumour control but did not result in a survival benefit."
    },
    {
        "id": 10421,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 93,
        "content": "Hyperfractionated radiotherapy with simultaneous chemotherapy has not been compared to conventionally fractionated radiotherapy with simultaneous chemotherapy."
    },
    {
        "id": 10422,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 93,
        "content": "A network meta-analysis predicted that hyperfractionated radiotherapy with simultaneous chemotherapy may be more effective than conventionally fractionated radiotherapy with simultaneous chemotherapy."
    },
    {
        "id": 10436,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "Post-operative radiotherapy should be started as soon as possible after the wound has healed."
    },
    {
        "id": 10437,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "Post-operative radiotherapy should be started within 6 weeks of the operation."
    },
    {
        "id": 10438,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "There is strong consensus on the recommendation for post-operative radiotherapy."
    },
    {
        "id": 10439,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "Patients with HPV/p16 positive oropharyngeal carcinoma in stages I, II who have undergone primary surgical treatment should receive adjuvant radio/radiochemotherapy if R1 or <5mm resection has been performed in healthy tissue."
    },
    {
        "id": 10440,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "Patients with HPV/p16 positive oropharyngeal carcinoma in stages I, II who have undergone primary surgical treatment should receive adjuvant radio/radiochemotherapy if solitary lymph node >3cm has been histologically proven."
    },
    {
        "id": 10441,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "Patients with HPV/p16 positive oropharyngeal carcinoma in stages I, II who have undergone primary surgical treatment should receive adjuvant radio/radiochemotherapy if more than one tumour-involved lymph node has been histologically proven."
    },
    {
        "id": 10442,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "Patients with HPV/p16 positive oropharyngeal carcinoma in stages I, II who have undergone primary surgical treatment should receive adjuvant radio/radiochemotherapy if >= 1 lymph node with ECS has been histologically proven."
    },
    {
        "id": 10443,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "There is strong consensus on the recommendation for adjuvant radio/radiochemotherapy for patients with HPV/p16 positive oropharyngeal carcinoma."
    },
    {
        "id": 10444,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "In patients with HPV/p16-negative oropharyngeal carcinoma in stages pT1, pT2 N0 who have undergone primary surgical treatment, adjuvant radio/radiochemotherapy should be given if resection R1 <5mm has been performed in healthy tissue."
    },
    {
        "id": 10445,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "There is strong consensus on the recommendation for adjuvant radio/radiochemotherapy for patients with HPV/p16-negative oropharyngeal carcinoma."
    },
    {
        "id": 10446,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "In pT1-pT2 pN0 (M0) HPV/p16-positive and -negative oropharyngeal carcinoma, adjuvant radiotherapy should be dispensed with if the resection >5 mm has been performed in healthy tissue."
    },
    {
        "id": 10447,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 94,
        "content": "There is strong consensus on the recommendation for dispensing with adjuvant radiotherapy for pT1-pT2 pN0 (M0) HPV/p16-positive and -negative oropharyngeal carcinoma."
    },
    {
        "id": 10453,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 95,
        "content": "In pT1-pT2 (M0) HPV/p16-positive and HPV/p16-negative oropharyngeal carcinoma with only one affected lymph node <3cm (without ECS), adjuvant radiotherapy can be dispensed with if all of the following criteria are met."
    },
    {
        "id": 10459,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 95,
        "content": "There is strong consensus on the criteria for dispensing with adjuvant radiotherapy."
    },
    {
        "id": 10460,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 95,
        "content": "Adjuvant irradiation of the region with affected lymph node levels without capsular rupture in HPV/p16-positive and HPV/p16-negative oropharyngeal carcinomas should be carried out with 54 - 60 Gy in single doses of 1.8 Gy - 2.0 Gy."
    },
    {
        "id": 10461,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 95,
        "content": "Adjuvant irradiation of affected lymph node levels with capsule breakthrough should be carried out with 66 Gy in single doses of 2.0 - 2.2 Gy."
    },
    {
        "id": 10462,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 95,
        "content": "There is strong consensus on the irradiation dose for affected lymph node levels."
    },
    {
        "id": 10463,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 95,
        "content": "Adjuvant irradiation of unaffected lymph node levels in HPV/p16-positive oropharyngeal carcinomas should be carried out with 45- 54 Gy with single doses of 1.5 Gy - 1.8 Gy."
    },
    {
        "id": 10465,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 95,
        "content": "There is strong consensus on the irradiation dose for unaffected lymph node levels."
    },
    {
        "id": 10471,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 96,
        "content": "If adjuvant radiochemotherapy is indicated for HPV/p16-positive or HPV/p16-negative oropharyngeal carcinoma, cisplatin-based chemotherapy should be administered simultaneously with radiotherapy."
    },
    {
        "id": 10472,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 96,
        "content": "In patients who cannot receive cisplatin, mitomycin C + 5-FU, carboplatin + 5-FU or docetaxel can be used as simultaneous systemic therapy."
    },
    {
        "id": 10473,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 96,
        "content": "There is strong consensus on this recommendation."
    },
    {
        "id": 10474,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 96,
        "content": "Postoperative radiotherapy has not been investigated in randomized studies."
    },
    {
        "id": 10475,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 96,
        "content": "Cohort studies and prospective registry data showed a superiority of adjuvant radiotherapy in patients with more than one tumour-involved lymph node, extracapsular tumour growth at the lymph nodes (ECE) or with tumours only barely resected in healthy tissue (<5mm)."
    },
    {
        "id": 10484,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 96,
        "content": "Adjuvant radiotherapy reduces the locoregional recurrence rate and improves survival in oropharyngeal carcinoma regardless of HPV/p16 status, provided that more than one regional lymph node is affected or the primary tumour was only barely resected in healthy tissue (<5mm)."
    },
    {
        "id": 10489,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 97,
        "content": "It can be assumed that the majority of oropharyngeal carcinomas in these studies were HPV/p16-."
    },
    {
        "id": 10490,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 97,
        "content": "The results of the studies consistently showed that patients with evidence of ECE in the affected lymph nodes or R1 resection had a survival benefit from adjuvant radiochemotherapy compared to adjuvant radiotherapy alone."
    },
    {
        "id": 10491,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 97,
        "content": "An analysis based on the NCDB registry compared the results of adjuvant radiochemotherapy with those of adjuvant radiotherapy alone in 1127 patients with HPV/p16+ and 424 patients with HPV/p16- oropharyngeal carcinoma."
    },
    {
        "id": 10495,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 97,
        "content": "The detection of ECE in the lymph nodes of oropharyngeal carcinomas is associated with a significantly higher recurrence rate and poorer survival regardless of HV/p16 status."
    },
    {
        "id": 10494,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 97,
        "content": "Lymph node involvement with ECE in HPV/p16+ oropharyngeal carcinomas is not taken into account in the N classification and staging."
    },
    {
        "id": 10496,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 97,
        "content": "The available data from the registry studies consistently show no benefit of adjuvant radiochemotherapy compared to adjuvant radiotherapy alone for HPV/p16+ oropharyngeal carcinoma."
    },
    {
        "id": 10498,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 97,
        "content": "Data on the relapse pattern after adjuvant radiotherapy or radiochemotherapy for HPV/p16+ oropharyngeal carcinoma indicate that the poorer prognosis in patients with ECE to the lymph nodes is almost exclusively due to a higher rate of distant metastasis."
    },
    {
        "id": 10500,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 97,
        "content": "Adjuvant radiotherapy alone may be sufficient for HPV/p16+ oropharyngeal carcinoma, even in cases of lymph node involvement with evidence of ECE, and that additional chemotherapy may not be necessary."
    },
    {
        "id": 10501,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 97,
        "content": "The available registry data show a clear advantage for platinum-containing chemotherapy applied simultaneously with adjuvant radiotherapy for HPV/p16- oropharyngeal carcinomas with evidence of ECE in the lymph nodes."
    },
    {
        "id": 10502,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 97,
        "content": "Less well documented is the influence of positive (<1 mm) or narrow resection margins (<5 mm) on the recurrence rate and survival of oropharyngeal carcinomas depending on HPV/p16 status."
    },
    {
        "id": 10503,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 97,
        "content": "The available data from registry studies show a greater negative impact on the recurrence rate and survival for HPV/p16- oropharyngeal carcinomas than for HPV/p16+ tumours."
    },
    {
        "id": 10509,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 98,
        "content": "Larger resection margins are associated with better treatment results compared to narrow resection margins."
    },
    {
        "id": 10513,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 98,
        "content": "HPV/p16+ oropharyngeal carcinomas have significantly better treatment results in terms of recurrence rate and survival."
    },
    {
        "id": 10515,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 98,
        "content": "A large collective of NCDB patients with HPV/p16+ oropharyngeal carcinoma showed no difference in survival whether adjuvant radiotherapy alone or radiochemotherapy was received."
    },
    {
        "id": 10516,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 98,
        "content": "ECE was detected in the affected lymph nodes of the NCDB patients."
    },
    {
        "id": 10517,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 98,
        "content": "Positive resection margin was present in the NCDB patients."
    },
    {
        "id": 10521,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 98,
        "content": "Cisplatin or cisplatin + 5-FU have shown a significant reduction in the relapse rate or an improvement in survival in randomized studies."
    },
    {
        "id": 10532,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 98,
        "content": "For patients with an intermediate risk of recurrence, 60 Gy was applied in the region of the former primary tumour and the affected lymph nodes in the clinical trials and the registry data."
    },
    {
        "id": 10533,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 98,
        "content": "45-50 Gy with 5x 1.8-2.0 Gy per week were administered electively in the neighbouring unaffected lymph node regions."
    },
    {
        "id": 10534,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 98,
        "content": "There is an international consensus for the selection of the lymph node levels to be electively irradiated."
    },
    {
        "id": 10536,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 98,
        "content": "Lower doses of 50 Gy in conventional fractionation were investigated in smaller phase II studies for HPV/p16+ oropharyngeal carcinomas."
    },
    {
        "id": 10537,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 98,
        "content": "30 Gy with 2x1.5 Gy per day were also investigated in smaller phase II studies for HPV/p16+ oropharyngeal carcinomas."
    },
    {
        "id": 10558,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 100,
        "content": "Primary surgical therapy followed by adjuvant radiotherapy or radiochemotherapy is recommended for patients with HPV/p16-positive stage III or HPV/p16-negative stage III-IVb oropharyngeal carcinoma if a good functional outcome and R0 resection are likely to be achievable."
    },
    {
        "id": 10559,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 100,
        "content": "Primary radiochemotherapy is recommended for patients with HPV/p16-positive stage III or HPV/p16-negative stage III-IVb oropharyngeal carcinoma if a good functional outcome and R0 resection are not likely to be achievable."
    },
    {
        "id": 10560,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 100,
        "content": "In patients with HPV/p16-positive and HPV/p16-negative oropharyngeal carcinomas who are not treated with surgery, primary radiochemotherapy should be preferred to radiotherapy alone, especially in the age group up to 70 years."
    },
    {
        "id": 10589,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "There is an Evidence-based Recommendation for de-escalation of the total dose of radiotherapy for HPV/p16-positive oropharyngeal carcinoma within clinical trials."
    },
    {
        "id": 10590,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "The Grade of Recommendation for de-escalation of the total dose of radiotherapy is B."
    },
    {
        "id": 10591,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "The Level of Evidence for de-escalation of the total dose of radiotherapy is \u2295\u2295\u229d\u229d."
    },
    {
        "id": 10593,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "There is a Strong Consensus for de-escalation of the total dose of radiotherapy."
    },
    {
        "id": 10596,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "There is an Evidence-based Recommendation for primary conservative therapy for patients with HPV/p16-positive stage III and HPV/p16-negative stage III-IVb oropharyngeal carcinoma."
    },
    {
        "id": 10597,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "The Grade of Recommendation for primary conservative therapy is A."
    },
    {
        "id": 10598,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "The Level of Evidence for primary conservative therapy is \u2295\u2295\u229d\u229d."
    },
    {
        "id": 10600,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "There is a Strong Consensus for primary conservative therapy."
    },
    {
        "id": 10601,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "There is an Evidence-based Recommendation for locoregional tumour control and overall survival in patients with HPV/p16-positive stage III and HPV/p16-negative stage III-IVb oropharyngeal carcinoma."
    },
    {
        "id": 10602,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "The Grade of Recommendation for locoregional tumour control and overall survival is A."
    },
    {
        "id": 10603,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "The Level of Evidence for locoregional tumour control and overall survival is 1a."
    },
    {
        "id": 10605,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 102,
        "content": "There is a Strong Consensus for locoregional tumour control and overall survival."
    },
    {
        "id": 10609,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 103,
        "content": "In HPV/p16-positive oropharyngeal carcinoma, simultaneous chemotherapy should be cisplatin-based in the case of primary radiochemotherapy."
    },
    {
        "id": 10610,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 103,
        "content": "The recommendation is evidence-based and has a level of evidence of \u2295\u2295\u2295\u2295."
    },
    {
        "id": 10619,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 103,
        "content": "The recommendation is evidence-based and has a level of evidence of \u2295\u2295\u2295\u2295."
    },
    {
        "id": 10612,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 103,
        "content": "There is strong consensus on the recommendation."
    },
    {
        "id": 10617,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 103,
        "content": "There is strong consensus on the recommendation."
    },
    {
        "id": 10621,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 103,
        "content": "There is strong consensus on the recommendation."
    },
    {
        "id": 10613,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 103,
        "content": "In HPV/p16-negative oropharyngeal carcinoma, simultaneous chemotherapy should be cisplatin-based in the case of primary radiochemotherapy."
    },
    {
        "id": 10614,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 103,
        "content": "The recommendation is consensus-based and has a strong consensus."
    },
    {
        "id": 10615,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 103,
        "content": "In patients who cannot receive cisplatin due to impaired renal function, alternative simultaneous systemic therapies can be used."
    },
    {
        "id": 10616,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 103,
        "content": "Alternative simultaneous systemic therapies include carboplatin + 5-FU, mitomycin C + 5-FU, a taxane, or cetuximab (HPV/p16+)."
    },
    {
        "id": 10618,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 103,
        "content": "Cetuximab should not be used for HPV/p16-positive and HPV/p16-negative oropharyngeal carcinomas that have no contraindication to cisplatin-based chemotherapy."
    },
    {
        "id": 10625,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "For primary radiotherapy or radiochemotherapy of HPV/p16-positive and HPV/p16-negative oropharyngeal carcinomas in stages I-III, radiotherapy should be carried out with 5x2 Gy per week up to a target volume dose of 70 Gy."
    },
    {
        "id": 10626,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "The target volume dose of 70 Gy should be applied to the area of the affected lymph nodes and the primary tumour."
    },
    {
        "id": 10627,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "An alternative established regimen with a biologically equivalent total dose can be used."
    },
    {
        "id": 10628,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "There is strong consensus on the recommendation for radiotherapy."
    },
    {
        "id": 10629,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "In primary radiotherapy or radiochemotherapy of HPV/p16-positive and -negative oropharyngeal carcinomas, irradiation of non-affected lymph node levels should be carried out with 45-54 Gy with single doses of 1.5 Gy - 2 Gy."
    },
    {
        "id": 10630,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "The elective lymph node levels to be irradiated should be based on the current international consensus."
    },
    {
        "id": 10656,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 106,
        "content": "The elective lymph node levels to be irradiated should be based on the current international consensus."
    },
    {
        "id": 10631,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "For HPV/p16-negative oropharyngeal carcinomas, the dose should be between 50 Gy and 60 Gy with individual doses of 1.5 to 2.0 Gy, depending on the risk."
    },
    {
        "id": 10632,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "The dose for HPV/p16-negative oropharyngeal carcinomas should be applied to the lymph node levels to be electively irradiated."
    },
    {
        "id": 10633,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "There is strong consensus on the recommendation for the dose for HPV/p16-negative oropharyngeal carcinomas."
    },
    {
        "id": 10634,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "Primary radio- or radiochemotherapy of HPV/p16-positive and HPV/p16-negative oropharyngeal carcinomas in stages III or III-IVb should be carried out using the IMRT technique."
    },
    {
        "id": 10635,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "The IMRT technique should be used with the best possible protection of the salivary glands, the unaffected swallowing tract and the oral cavity."
    },
    {
        "id": 10636,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "The recommended doses in the target volumes should not be fallen below when using the IMRT technique."
    },
    {
        "id": 10637,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 104,
        "content": "There is strong consensus on the recommendation for the use of the IMRT technique."
    },
    {
        "id": 10642,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 105,
        "content": "Post-operative radiotherapy should be started as soon as possible after the wound has healed and within 6 weeks of the operation."
    },
    {
        "id": 10643,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 105,
        "content": "There is strong consensus on the recommendation for post-operative radiotherapy."
    },
    {
        "id": 10644,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 105,
        "content": "Patients with HPV/p16-positive stage III and HPV/p16-negative stage III-IVb oropharyngeal carcinoma who have undergone primary surgical treatment should receive adjuvant radiotherapy or radiochemotherapy."
    },
    {
        "id": 10645,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 105,
        "content": "There is strong consensus on the recommendation for adjuvant radiotherapy or radiochemotherapy."
    },
    {
        "id": 10647,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 105,
        "content": "Adjuvant radiochemotherapy should be given after primary surgical treatment of HPV/p16-positive and HPV/p16-negative oropharyngeal carcinomas in stage III or III-IVb if the resection <5mm has been performed in healthy tissue or if extracapsular tumour growth in one or more lymph nodes has been histologically proven."
    },
    {
        "id": 10648,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 105,
        "content": "There is strong consensus on the recommendation for adjuvant radiochemotherapy."
    },
    {
        "id": 10655,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 106,
        "content": "Adjuvant irradiation of unaffected lymph node levels in HPV/p16-positive and HPV/p16-negative oropharyngeal carcinomas should be carried out with 45-54 Gy with single doses of 1.5 Gy - 1.8 Gy."
    },
    {
        "id": 10657,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 106,
        "content": "There is a strong consensus on the recommendation for adjuvant irradiation of unaffected lymph node levels."
    },
    {
        "id": 10662,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 106,
        "content": "If adjuvant radiochemotherapy is indicated for HPV/p16-positive or HPV/p16-negative oropharyngeal carcinoma, cisplatin-based chemotherapy should be administered simultaneously with radiotherapy."
    },
    {
        "id": 10663,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 106,
        "content": "In patients who cannot receive cisplatin, mitomycin C + 5-FU, carboplatin + 5-FU or docetaxel can be used as simultaneous systemic therapy."
    },
    {
        "id": 10664,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 106,
        "content": "There is a strong consensus on the recommendation for adjuvant radiochemotherapy."
    },
    {
        "id": 10667,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 107,
        "content": "Neoadjuvant chemotherapy prior to planned definitive radio- or radiochemotherapy should not be carried out for HPV/p16-negative oropharyngeal carcinomas."
    },
    {
        "id": 10668,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 107,
        "content": "This recommendation is based on evidence with a level of evidence of 1++ and a grade of recommendation of A."
    },
    {
        "id": 10670,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 107,
        "content": "There is strong consensus on this recommendation."
    },
    {
        "id": 10673,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 107,
        "content": "There is strong consensus on this recommendation."
    },
    {
        "id": 10671,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 107,
        "content": "Neoadjuvant or adjuvant systemic therapy should only be used for primary surgical therapy or definitive radio- or radiochemotherapy for HPV/p16-positive and HPV/p16-negative oropharyngeal carcinomas within clinical trials."
    },
    {
        "id": 10672,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 107,
        "content": "This recommendation is based on consensus and has an evidence category of EC."
    },
    {
        "id": 10674,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 107,
        "content": "Induction concepts and adjuvant, purely drug-based therapy concepts are not generally recommended for the primary treatment of oropharyngeal carcinoma."
    },
    {
        "id": 10677,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 107,
        "content": "Oropharyngeal carcinomas with distant metastases are classified as UICC stages IV p16-positive:M1 and stage IV-C p16-neg."
    },
    {
        "id": 10678,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 107,
        "content": "In the case of a tumour that has already metastasized at a distance at the time of initial diagnosis, the limited curative treatment options and the very limited prognosis must be strictly weighed in the interdisciplinary tumour board."
    },
    {
        "id": 10679,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 107,
        "content": "The treatment options for oropharyngeal carcinomas with distant metastases are subsumed under the generic term of palliative medical treatment."
    },
    {
        "id": 10680,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 107,
        "content": "The principles in these tumour standards apply equally to squamous cell carcinoma of the oral cavity, oropharynx (p16-pos. and -neg.), hypopharynx and larynx."
    },
    {
        "id": 10689,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": "A further important observation on the field carcinogenization of hypopharyngeal carcinomas was observed after very good survival rates of T4b hypopharyngeal carcinomas with infiltration of the upper oesophagus after radical laryngohypopharyngoesophagectomy."
    },
    {
        "id": 10690,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": "Radical laryngohypopharyngoesophagectomy involves resection of the hypopharynx with the entire oesophagus with consecutive gastric pull-up as oesophageal replacement and adjuvant radiotherapy with 60 Gy in conventional fractionation."
    },
    {
        "id": 10693,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": "The analysis revealed a group of 45 aberrantly expressed proteins that were only detectable in the cancer patients."
    },
    {
        "id": 10695,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": "The 5-year survival rates of these patients showed that the signature proved to be predictive of the presence of field cancerization in the oesophagus."
    },
    {
        "id": 10696,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": "All patients with hypopharyngeal carcinoma and the named signature in the oesophagus had died."
    },
    {
        "id": 10697,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": "80% of patients without this signature in the oesophagus survived."
    },
    {
        "id": 10698,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": "Squamous cell carcinomas of the hypopharynx behave in a similar aggressive manner to those of the oesophagus."
    },
    {
        "id": 10700,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": "Locoregional metastases occur very early in hypopharyngeal carcinoma and the stage distribution at initial diagnosis tends to be predominantly advanced compared to other head and neck entities."
    },
    {
        "id": 10701,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": ">80% of hypopharyngeal carcinomas are diagnosed at stages III, IV at initial diagnosis."
    },
    {
        "id": 10702,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": "The comparatively poor prognosis decreases further with increasing patient age."
    },
    {
        "id": 10703,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": "In a registry study (SEER 1780 patients), the following were shown to have an unfavourable prognosis: older patients with a higher T category, advanced N category, hypopharyngeal posterior wall involvement, multiple distant metastases and no reasonably possible surgical treatment with the aim of R0 resection (inoperability) of the primary tumour."
    },
    {
        "id": 10704,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 108,
        "content": "A subgroup of 21% of patients with HPV/p16-positive hypopharyngeal carcinomas in a registry study (NCDB, 2004 - 2016; 9314 patients) showed significantly better therapy-independent overall survival."
    },
    {
        "id": 10713,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 109,
        "content": "Primary surgical treatment +/- adjuvant radio- or radiochemotherapy and primary radio- or radiochemotherapy have been established as primary treatments for localized hypopharyngeal carcinomas."
    },
    {
        "id": 10717,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 110,
        "content": "There is no evidence that transoral treatment procedures (TLM, TORS) are inferior to open transcervical surgical procedures for T1 and T2 hypopharyngeal carcinoma in terms of tumour recurrence rate and survival."
    },
    {
        "id": 10720,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 110,
        "content": "Hypopharyngeal carcinomas in stages cT1-cT2 cN0 cM0 should be treated either with primary resection +/- adjuvant radio- or radiochemotherapy or with primary radio- or radiochemotherapy."
    },
    {
        "id": 10723,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 110,
        "content": "Organ-preserving surgery is only rarely considered for carcinomas of the hypopharynx due to the advanced stage of the tumour at the time of diagnosis."
    },
    {
        "id": 10725,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 110,
        "content": "Patients with hypopharyngeal carcinomas are often in an unfavourable general clinical condition due to extensive comorbidities."
    },
    {
        "id": 10727,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 110,
        "content": "Hypopharyngeal carcinoma has the least favourable prognosis of all squamous cell carcinomas of the head and neck in Europe."
    },
    {
        "id": 10729,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 110,
        "content": "A careful preoperative risk assessment is necessary before therapeutic considerations, especially primary surgical measures, and intensive postoperative monitoring is often planned."
    },
    {
        "id": 10730,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 110,
        "content": "Advances in open laryngeal surgery and TLM have enabled oncologically safe R0 tumour resections with acceptable functional restrictions in some patients with hypopharyngeal carcinomas."
    },
    {
        "id": 10731,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 110,
        "content": "One of the basic principles of oncological surgery is that a complete, histologically verifiable R0 resection (>5mm) must be guaranteed."
    },
    {
        "id": 10732,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 110,
        "content": "If a complete tumour resection is not reliably possible as part of an intended surgical procedure, alternative treatment options must be chosen as a matter of priority."
    },
    {
        "id": 10733,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 110,
        "content": "In the case of hypopharyngeal carcinomas, whether a complete tumour resection will be possible can only be assessed by reviewing the endoscopic findings and meaningful imaging and preoperative swallowing diagnostics by FEES."
    },
    {
        "id": 10734,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "The treatment of hypopharyngeal carcinoma worldwide includes TORS."
    },
    {
        "id": 10736,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "Patients with smaller tumours of the medial wall of the piriform sinus and the postcricoid region are particularly suitable for TLM."
    },
    {
        "id": 10737,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "Patients with smaller and superficially growing tumours of the lateral wall of the piriform sinus and the posterior wall of the hypopharynx are particularly suitable for TLM."
    },
    {
        "id": 10738,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "TLM is not feasible for tumours in the area of the apex of the piriform sinus and the oesophageal orifice."
    },
    {
        "id": 10739,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "In a TLM clinic, surgical treatment was only possible in 136 patients out of 228 consecutive patients with hypopharyngeal carcinomas."
    },
    {
        "id": 10742,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "Only around 20% of all patients with hypopharyngeal carcinoma can undergo larynx-preserving surgery."
    },
    {
        "id": 10744,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "If the tumour reaches the resection margins, a subsequent resection should be attempted in order to achieve an R0 result."
    },
    {
        "id": 10746,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "The indications for organ-preserving TLM in the hypopharynx range from T1 to T4a tumours with good results."
    },
    {
        "id": 10747,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "Steiner et al. published local control rates over five years of 84% pT1; 70% pT2; 75% pT3; 57% pT4a."
    },
    {
        "id": 10748,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "Steiner et al. published recurrence-free 5-year survival of 73% for stages I and II, 59% for stage III, 47% for stage IVa."
    },
    {
        "id": 10749,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "Eckel et al. showed an uncorrected survival of 59.3% and a local control rate of 73.3% in large collectives after 5 years."
    },
    {
        "id": 10750,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "Eckel et al. showed that 76.5% of all patients had a functioning larynx after 5 years."
    },
    {
        "id": 10751,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "Rudert et al. showed an uncorrected survival of 48% and a disease-specific survival of 58%."
    },
    {
        "id": 10752,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "Rudert et al. showed a disease-specific survival of 71% in stages I and II."
    },
    {
        "id": 10753,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "In carefully selected patients with early hypopharyngeal carcinoma, transoral laser surgery leads to very good oncological and functional results."
    },
    {
        "id": 10754,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 111,
        "content": "There is only one comparative study worldwide to date on TORS versus open surgery, in which only hypopharyngeal carcinomas were treated."
    },
    {
        "id": 10783,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 113,
        "content": "Primary non-surgical therapy for patients with hypopharyngeal carcinomas in stages I-II (UICC 8th edition) should receive radiotherapy alone."
    },
    {
        "id": 10784,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 113,
        "content": "Radiochemotherapy may be offered for larger T2 tumours."
    },
    {
        "id": 10785,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 113,
        "content": "Cisplatin-based chemotherapy should be administered simultaneously with radiotherapy for stage II hypopharyngeal carcinoma."
    },
    {
        "id": 10787,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 113,
        "content": "For primary radiotherapy or radiochemotherapy of hypopharyngeal carcinoma in stages I-II (UICC 8th edition), radiotherapy should be carried out with 5 x 2 Gy per week up to a target volume dose of 70 Gy in the area of the affected lymph nodes and the primary tumour."
    },
    {
        "id": 10789,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 113,
        "content": "Irradiation of unaffected lymph node levels should be carried out with 45 - 54 Gy with individual doses of 1.5 Gy - 1.8 Gy."
    },
    {
        "id": 10790,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 113,
        "content": "The elective lymph node levels to be irradiated should be based on the current international consensus."
    },
    {
        "id": 10791,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 114,
        "content": "The primary radio- or radiochemotherapy of hypopharyngeal carcinomas in stages I and II should be carried out using the IMRT technique."
    },
    {
        "id": 10792,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 114,
        "content": "The IMRT technique should provide the best possible protection of the salivary glands, the unaffected parts of the swallowing tract and the oral cavity."
    },
    {
        "id": 10793,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 114,
        "content": "The recommended doses in the target volumes should not be fallen below."
    },
    {
        "id": 10797,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 114,
        "content": "Organ preservation by means of primary radiochemotherapy or induction chemotherapy followed by radiotherapy should be discussed on an interdisciplinary basis for larger T2 tumours."
    },
    {
        "id": 10798,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 114,
        "content": "The same principles apply to the dosage and fractionation of radiotherapy as for HPV/p16-positive oropharyngeal carcinomas."
    },
    {
        "id": 10799,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 114,
        "content": "Radiotherapy was carried out in most studies on radio- or radiochemotherapy with 5 x 2 Gy per week up to target volume doses of 70 Gy in the area of the primary tumour and the affected lymph nodes."
    },
    {
        "id": 10800,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 114,
        "content": "Slightly accelerated and also hyperfractionated radiation regimens with biologically equivalent doses give approximately equivalent results."
    },
    {
        "id": 10801,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 114,
        "content": "No advantage in terms of relapse-free survival or overall survival with simultaneous radiochemotherapy compared to radiochemotherapy alone has been established for squamous cell carcinoma of the pharynx, larynx and oral cavity in stages I+II."
    },
    {
        "id": 10808,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 115,
        "content": "Patients with stage I+II hypopharyngeal carcinoma who have undergone primary surgical treatment should receive adjuvant radiotherapy or radiochemotherapy if resection R1 or <5mm has been performed in healthy tissue."
    },
    {
        "id": 10809,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 115,
        "content": "Adjuvant radiotherapy can also be offered for G3, L1, V1 or Pn1."
    },
    {
        "id": 10810,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 115,
        "content": "The recommendation to receive adjuvant radiotherapy or radiochemotherapy is based on strong consensus."
    },
    {
        "id": 10811,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 115,
        "content": "If adjuvant radiotherapy is indicated for hypopharyngeal carcinoma in stages I+II, radiotherapy should be given with 60 - 66 Gy in the area of the narrow resection margins."
    },
    {
        "id": 10812,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 115,
        "content": "Radiotherapy should be given with 45 - 54 Gy with single doses of 1.5 Gy - 1.8 Gy in the area of unaffected lymph node levels."
    },
    {
        "id": 10813,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 115,
        "content": "The recommendation for the dosage of radiotherapy is based on strong consensus."
    },
    {
        "id": 10814,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 115,
        "content": "Postoperative radiotherapy or radiochemotherapy of hypopharyngeal carcinomas in stages I-II should be started as soon as possible after wound healing has been completed within a period of 6 weeks after surgery."
    },
    {
        "id": 10815,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 115,
        "content": "Postoperative radiotherapy or radiochemotherapy should be carried out using the IMRT technique with the best possible protection of the salivary glands, the swallowing tract and the oral cavity, without falling below the recommended doses in the target volumes."
    },
    {
        "id": 10816,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 115,
        "content": "The recommendation for the timing and technique of postoperative radiotherapy or radiochemotherapy is based on strong consensus."
    },
    {
        "id": 10821,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 115,
        "content": "For T1-2N0 carcinomas resected <=5 mm in healthy tissue, the available data suggest that postoperative radio- or radiochemotherapy is likely to be beneficial."
    },
    {
        "id": 10822,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 115,
        "content": "For patients with other risk factors (G3, L1, V1), a benefit of postoperative radio- or radiochemotherapy can neither be excluded nor confirmed."
    },
    {
        "id": 10846,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 117,
        "content": "A laryngectomy may require neoadjuvant chemotherapy followed by radio- or radiochemotherapy."
    },
    {
        "id": 10847,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 117,
        "content": "Neoadjuvant chemotherapy followed by radio- or radiochemotherapy can be carried out if there is a good response to neoadjuvant therapy."
    },
    {
        "id": 10848,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 117,
        "content": "Subsequent resection can be carried out if there is a poor response to neoadjuvant therapy."
    },
    {
        "id": 10849,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 117,
        "content": "There is evidence that neoadjuvant chemotherapy followed by radio- or radiochemotherapy is effective."
    },
    {
        "id": 10855,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 117,
        "content": "Patients with hypopharyngeal carcinomas of stage cT4a cN0-cN3 should undergo primary surgical treatment if an R0 resection appears surgically possible."
    },
    {
        "id": 10856,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 117,
        "content": "Alternatively, radiochemotherapy or neoadjuvant chemotherapy can be carried out, accepting a higher local recurrence rate."
    },
    {
        "id": 10858,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 117,
        "content": "If an R0 resection of a hypopharyngeal carcinoma in stage cT4a cN0-cN3 cM0 is probably not achievable, primary radiochemotherapy should be given."
    },
    {
        "id": 10859,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 117,
        "content": "There is evidence that primary radiochemotherapy is effective."
    },
    {
        "id": 10863,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 118,
        "content": "Primary surgical therapy +/- adjuvant radio- or radiochemotherapy and primary radio- or radiochemotherapy have been established as primary therapies for localized hypopharyngeal carcinomas."
    },
    {
        "id": 10866,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 118,
        "content": "For T1N0 -T2N0 squamous cell carcinomas of the hypopharynx, there are no relevant differences between primary surgical and primary non-surgical treatment in terms of overall survival and the locoregional recurrence rate."
    },
    {
        "id": 10867,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 118,
        "content": "For T4 (N0/N+) tumours, the registry data show a significant survival advantage for primary surgical treatment followed by adjuvant radio- or radiochemotherapy compared to primary radiochemotherapy."
    },
    {
        "id": 10876,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 119,
        "content": "A tracheostomy performed before a laryngectomy has a negative effect on the prognosis."
    },
    {
        "id": 10877,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 119,
        "content": "Stoma recurrences can occur more frequently after a tracheostomy before a laryngectomy."
    },
    {
        "id": 10879,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 119,
        "content": "A tracheotomy should be avoided before a planned total laryngopharyngectomy."
    },
    {
        "id": 10880,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 119,
        "content": "Transoral tumour debulking can be performed as part of the initial diagnosis to avoid a tracheotomy."
    },
    {
        "id": 10889,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 119,
        "content": "The laryngeal skeleton can be built up with a rib cartilage graft in transcervical laryngeal and partial hypopharyngeal resection."
    },
    {
        "id": 10890,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 119,
        "content": "The hypopharynx can be reconstructed with a forearm graft in transcervical laryngeal and partial hypopharyngeal resection."
    },
    {
        "id": 10893,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 119,
        "content": "The laryngotracheal flap (LTF) is a local tissue transfer that can be used to reconstruct the hypopharyngeal defect."
    },
    {
        "id": 10898,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 119,
        "content": "Pharyngolaryngectomy is still an important part of the therapeutic options for advanced-stage carcinomas."
    },
    {
        "id": 10902,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 120,
        "content": "The ideal method for hypopharyngeal reconstruction should preferably have the following characteristics: single-stage procedure, high success rate of tissue transfer, low removal morbidity, low fistula and stenosis rates, restoration of the ability to speak and swallow, successful reconstruction achievable in a heavily irradiated area and tolerance of postoperative radiotherapy."
    },
    {
        "id": 10903,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 120,
        "content": "Complete, i.e. circular hypopharyngeal resection generally requires reconstruction of the alimentary canal."
    },
    {
        "id": 10912,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 120,
        "content": "Voice rehabilitation is performed with voice prostheses that are placed in the anterior esophageal wall below the caudal anastomosis."
    },
    {
        "id": 10913,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 120,
        "content": "Jejunum transfer is recommended as a replacement after circular laryngopharyngectomy."
    },
    {
        "id": 10928,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 121,
        "content": "Hypopharyngeal carcinomas in UICC stages III and IV may require pre-therapeutic tracheostomy."
    },
    {
        "id": 10930,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 121,
        "content": "Tracheotomy, which is necessary before a laryngectomy or partial laryngectomy, can have a negative effect on the prognosis."
    },
    {
        "id": 10934,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 121,
        "content": "A laryngectomy should be performed promptly in the event of dyspnoea in order to prevent a pre-therapeutic tracheostomy."
    },
    {
        "id": 10939,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 121,
        "content": "Pharyngolaryngectomy + oesophageal resection + gastric pull-up is a very radical and extensive surgery for T4b hypopharyngeal carcinomas with oesophageal infiltration."
    },
    {
        "id": 10945,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 121,
        "content": "Radiotherapy for locally advanced hypopharyngeal carcinomas follows the same principles as for HPV/p16-negative oropharyngeal carcinomas."
    },
    {
        "id": 10948,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 122,
        "content": "The primary non-surgical therapy for patients with stage III-IVb hypopharyngeal carcinoma (UICC 8th edition) should be radiochemotherapy."
    },
    {
        "id": 10950,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 122,
        "content": "In patients with stage III-IVb hypopharyngeal carcinoma (UICC 8th edition), locoregional tumour control and overall survival are statistically significantly better after primary radiochemotherapy than after radiotherapy alone."
    },
    {
        "id": 10954,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 122,
        "content": "In stage III-IVb hypopharyngeal carcinoma, simultaneous chemotherapy should be cisplatin-based in the case of primary radiochemotherapy."
    },
    {
        "id": 10959,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 122,
        "content": "In patients who cannot receive cisplatin, for example due to impaired renal function, carboplatin + 5-FU, mitomycin C + 5-FU or a taxane can be used as simultaneous systemic therapy."
    },
    {
        "id": 10989,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 124,
        "content": "For patients in whom cisplatin is not an option, carboplatin in combination with 5-FU has been used as an alternative."
    },
    {
        "id": 10990,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 124,
        "content": "Mitomycin C in combination with 5-FU has been used as an alternative to cisplatin."
    },
    {
        "id": 10991,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 124,
        "content": "Weekly docetaxel simultaneously with radiotherapy has been used as an alternative to cisplatin."
    },
    {
        "id": 10992,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 124,
        "content": "Monochemotherapy with carboplatin has been investigated in several studies."
    },
    {
        "id": 10993,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 124,
        "content": "Mitomycin C monotherapy in parallel with radiotherapy has been investigated in several studies."
    },
    {
        "id": 10994,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 124,
        "content": "Weekly applications of carboplatin and paclitaxel concurrently with radiotherapy have been investigated in several studies."
    },
    {
        "id": 10996,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 124,
        "content": "Carboplatin + paclitaxel has been compared to weekly therapy with 40mg/m\u00b2 cisplatin in parallel with radiotherapy."
    },
    {
        "id": 10999,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 124,
        "content": "Simultaneous radiochemotherapy with cisplatin and other chemotherapies increases hematotoxicity."
    },
    {
        "id": 11000,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 124,
        "content": "Simultaneous radiochemotherapy with cisplatin and other chemotherapies increases the severity of acute mucositis with the associated swallowing difficulties."
    },
    {
        "id": 11002,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 124,
        "content": "Radiochemotherapy is significantly more stressful for patients overall."
    },
    {
        "id": 11005,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 124,
        "content": "The working group led by J.A Langendijk was able to prove that the rate of long-term swallowing disorders after combined radiochemotherapy is significantly higher than after radiotherapy alone."
    },
    {
        "id": 11007,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "Hypopharyngeal carcinomas in UICC stages III and IV are associated with swallowing disorders."
    },
    {
        "id": 11009,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "A laryngopharyngectomy may be required surgically for hypopharyngeal carcinomas."
    },
    {
        "id": 11010,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "Neoadjuvant chemotherapy followed by radio- or radiochemotherapy can be carried out in addition to surgical treatment if there is a good response to neoadjuvant therapy."
    },
    {
        "id": 11012,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "The evidence level for the recommendation of neoadjuvant chemotherapy followed by radio- or radiochemotherapy is 1a."
    },
    {
        "id": 11013,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "The recommendation of neoadjuvant chemotherapy followed by radio- or radiochemotherapy is based on studies [367], [374], [2], [373], [368]."
    },
    {
        "id": 11014,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "The recommendation of neoadjuvant chemotherapy followed by radio- or radiochemotherapy is a strong consensus."
    },
    {
        "id": 11015,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "All patients in the stages where a laryngectomy would be necessary should be discussed in the interdisciplinary tumour board."
    },
    {
        "id": 11016,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "A joint therapy recommendation should be made by the ear, nose and throat specialist and the radiation oncologist."
    },
    {
        "id": 11017,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "The treatment recommendation and the alternatives should be communicated to the patient by both disciplines."
    },
    {
        "id": 11018,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "The topic of laryngeal organ preservation programs was initiated in the 1990s."
    },
    {
        "id": 11021,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "There are only a few randomized studies for organ preservation of advanced hypopharyngeal carcinoma as an alternative to pharyngolaryngectomy."
    },
    {
        "id": 11022,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "The EORTC 1996 study recruited 202 patients with untreated, operable hypopharyngeal and laryngeal carcinomas."
    },
    {
        "id": 11023,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 125,
        "content": "Patients in the EORTC 1996 study were randomized into an experimental arm with induction chemotherapy followed by radiotherapy and a standard arm with partial pharyngolaryngectomy and postoperative radiotherapy."
    },
    {
        "id": 11027,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 126,
        "content": "After induction chemotherapy, 54% of patients developed a complete remission in the area of the primary tumour."
    },
    {
        "id": 11028,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 126,
        "content": "After induction chemotherapy, 43% of patients developed a complete remission in the area of the primary tumour and the locoregional lymphatic drainage pathways."
    },
    {
        "id": 11029,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 126,
        "content": "After five years, there was no significant difference in survival between the two study arms (30% versus 35% in the surgical arm)."
    },
    {
        "id": 11030,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 126,
        "content": "The 3- and 5-year survival rates with functional larynx were 42% and 35%, respectively."
    },
    {
        "id": 11031,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 126,
        "content": "In patients who achieved complete remission after induction chemotherapy and subsequently received only radiotherapy, a functional larynx was still present in 58% of patients after 5 years."
    },
    {
        "id": 11040,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 126,
        "content": "A taxane-containing chemotherapy protocol has proven to be advantageous for functional laryngeal preservation using induction chemotherapy."
    },
    {
        "id": 11042,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 126,
        "content": "The additional application of docetaxel during induction therapy increased the laryngeal preservation rate 3 years after therapy from 57.5% to 70.3% (p=0.03) in a randomized study."
    },
    {
        "id": 11054,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 127,
        "content": "The S3 guideline on laryngeal cancer includes the option of primary non-surgical laryngeal organ preservation as an alternative to laryngectomy."
    },
    {
        "id": 11055,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 127,
        "content": "This option should not be withheld from patients as a realistic treatment option in the consultation."
    },
    {
        "id": 11056,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 127,
        "content": "This recommendation is adopted for hypopharyngeal carcinoma in the same way as for laryngeal carcinoma."
    },
    {
        "id": 11057,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 127,
        "content": "Postoperative radio- or radiochemotherapy should be used for hypopharyngeal carcinomas with pT3 carcinomas and pT4 carcinomas."
    },
    {
        "id": 11058,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 127,
        "content": "Postoperative radio- or radiochemotherapy should be used for hypopharyngeal carcinomas with pN2-pN3."
    },
    {
        "id": 11059,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 127,
        "content": "Postoperative radio- or radiochemotherapy should be used for hypopharyngeal carcinomas with narrow or positive resection margins (R0 < 5mm; R1)."
    },
    {
        "id": 11060,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 127,
        "content": "Postoperative radio- or radiochemotherapy should be used for hypopharyngeal carcinomas with perineural invasion."
    },
    {
        "id": 11061,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 127,
        "content": "Postoperative radio- or radiochemotherapy should be used for hypopharyngeal carcinomas with vascular invasion (lymph vessel invasion and/or venous invasion)."
    },
    {
        "id": 11062,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 127,
        "content": "Postoperative radio- or radiochemotherapy should be used for hypopharyngeal carcinomas in the case of an affected lymph node with extracapsular tumour growth."
    },
    {
        "id": 11068,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "There is evidence-based recommendation for adjuvant radiochemotherapy in UICC stages III and IV hypopharyngeal carcinomas."
    },
    {
        "id": 11069,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "The recommendation is to carry out chemotherapy with a simultaneous cisplatin-containing regimen."
    },
    {
        "id": 11073,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "There is strong consensus for this recommendation."
    },
    {
        "id": 11076,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "There is strong consensus for this recommendation."
    },
    {
        "id": 11082,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "There is strong consensus for this recommendation."
    },
    {
        "id": 11087,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "There is strong consensus for this recommendation."
    },
    {
        "id": 11074,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "There is a consensus-based recommendation for patients who cannot receive cisplatin."
    },
    {
        "id": 11075,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "The alternative chemotherapy regimens are mitomycin C + 5-FU, carboplatin + 5-FU, or docetaxel."
    },
    {
        "id": 11077,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "There is a consensus-based recommendation for adjuvant irradiation in stage III-IVb hypopharyngeal carcinomas."
    },
    {
        "id": 11078,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "Adjuvant irradiation should be given to affected lymph nodes with capsular perforation with 60-66 Gy and single doses of 2.0-2.2 Gy."
    },
    {
        "id": 11079,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "Adjuvant irradiation should be given to affected lymph node levels without capsular perforation with 54-60 Gy and single doses of 1.8-2.0 Gy."
    },
    {
        "id": 11080,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 128,
        "content": "Adjuvant irradiation should be given to unaffected lymph node levels with 45-54 Gy and single doses of 1.5-1.8 Gy."
    },
    {
        "id": 11092,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 129,
        "content": "The voice and swallowing function should be examined and documented pre-therapeutically during larynx-preserving therapy."
    },
    {
        "id": 11096,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 129,
        "content": "The indication and implementation of adjuvant radiotherapy and radiochemotherapy do not differ in principle from those of HPV/p16-negative oropharyngeal carcinoma."
    },
    {
        "id": 11098,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 129,
        "content": "Cohort studies and prospective registry data indicate that in patients with more than one tumour-involved lymph node, with extracapsular tumour growth at the lymph nodes (ECE) or with tumours only barely resected in healthy tissue (<5mm), adjuvant radiotherapy is clearly superior."
    },
    {
        "id": 11099,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 129,
        "content": "The studies included squamous cell carcinomas of the larynx, oropharynx, hypopharynx and oral cavity."
    },
    {
        "id": 11101,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 129,
        "content": "Adjuvant radiotherapy reduces the locoregional recurrence rate and improves survival in hypopharyngeal carcinomas if more than one regional lymph node is affected or if the primary tumour was resected just inside the healthy area (<5mm)."
    },
    {
        "id": 11103,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 129,
        "content": "There is an international consensus that patients with pT3/pT4 tumours, lymph node involvement with ECE or R1 resection require adjuvant radiotherapy."
    },
    {
        "id": 11104,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 129,
        "content": "For patients with an intermediate risk of recurrence (no ECE and resection >=5 mm in healthy tissue), 60 Gy (5x 2 Gy per week) was applied independently in the region of the former primary tumour and the affected lymph nodes in the vast majority of patients in the clinical trials and the registry data."
    },
    {
        "id": 11106,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 129,
        "content": "There is an international consensus for the selection of the lymph node levels to be electively irradiated, which can be regarded as a standard guideline."
    },
    {
        "id": 11107,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 129,
        "content": "IMRT techniques are also considered standard for postoperative radiotherapy."
    },
    {
        "id": 11108,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 129,
        "content": "The value of additional cisplatin-containing chemotherapy administered simultaneously with radiotherapy has been investigated in 3 large randomized trials."
    },
    {
        "id": 11117,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 130,
        "content": "Postoperative radiochemotherapy is considered standard for patients with evidence of ECE in the affected lymph nodes or an R1 resection."
    },
    {
        "id": 11118,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 130,
        "content": "Results of randomized studies are only available for cisplatin or cisplatin + 5-FU, which have shown a significant reduction in the relapse rate or an improvement in survival."
    },
    {
        "id": 11119,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 130,
        "content": "A randomized Japanese study compared 3 x 100 mg/m\u00b2 cisplatin at intervals of 3 weeks with weekly 40 mg/m\u00b2 cisplatin simultaneously with postoperative radiotherapy."
    },
    {
        "id": 11138,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 131,
        "content": "Induction chemotherapy prior to radiotherapy has a firm place in the organ-preserving treatment of hypopharyngeal carcinoma."
    },
    {
        "id": 11143,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 131,
        "content": "Primary radiochemotherapy is recommended for laryngeal carcinoma for laryngeal organ preservation."
    },
    {
        "id": 11144,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 131,
        "content": "Primary radiochemotherapy is also relevant for hypopharyngeal carcinoma by analogy."
    },
    {
        "id": 11145,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 131,
        "content": "There is level IVA evidence for primary radiochemotherapy in hypopharyngeal carcinoma."
    },
    {
        "id": 11146,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 131,
        "content": "Hypopharyngeal carcinoma stage IVC has limited curative treatment options and a very limited prognosis."
    },
    {
        "id": 11149,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 131,
        "content": "Neck dissection should take functional aspects into account and preserve structures such as the accessory nerve, the sternocleidomastoid muscle and the internal jugular vein."
    },
    {
        "id": 11150,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 131,
        "content": "The preservation of the accessorius nerve during neck dissection leads to an improvement in quality of life."
    },
    {
        "id": 11151,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 131,
        "content": "Neck dissection is an integral part of the primary surgical treatment of oropharyngeal and hypopharyngeal carcinoma."
    },
    {
        "id": 11167,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 132,
        "content": "According to the ASCO consensus, an adequate dissection should include at least 18 lymph nodes."
    },
    {
        "id": 11168,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 132,
        "content": "Elective neck dissection is considered in a cN0 situation."
    },
    {
        "id": 11169,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 132,
        "content": "The indication for an elective neck dissection should be based on the risk of occult metastasis in the corresponding neck level."
    },
    {
        "id": 11170,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 132,
        "content": "Curative neck dissection is used in the N+ situation."
    },
    {
        "id": 11176,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 132,
        "content": "Selective neck dissection for oropharynx involves Levels II-IV."
    },
    {
        "id": 11177,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 132,
        "content": "Selective neck dissection for hypopharynx involves Levels II-IV and Level VI, if necessary."
    },
    {
        "id": 11178,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 132,
        "content": "cN1-cN2a-c patients should undergo selective or modified radical neck dissection."
    },
    {
        "id": 11179,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 132,
        "content": "cN3 patients should undergo modified radical neck dissection."
    },
    {
        "id": 11180,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 132,
        "content": "Modified radical neck dissection is recommended for R0-resectable cases."
    },
    {
        "id": 11181,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 132,
        "content": "Ligation of endangered supply blood vessels should be performed in patients with lateralized oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11182,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 132,
        "content": "Ligation of endangered supply blood vessels reduces the severity and incidence of postoperative bleeding."
    },
    {
        "id": 11189,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 133,
        "content": "At least one unilateral selective neck dissection (level IIa, III, IV) should be performed as part of a primary surgical procedure for strictly lateral localization in these patients regardless of p16 status."
    },
    {
        "id": 11190,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 133,
        "content": "In patients with tumours close to the midline and independent of the midline, all soft palate and tongue base carcinomas, a bilateral elective selective neck dissection (level IIa, III, IV) should already be performed in stage T1 as part of a primary surgical procedure, regardless of the p16 status."
    },
    {
        "id": 11192,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 133,
        "content": "There is a consensus-based recommendation for patients with cT1 cN0 hypopharyngeal carcinoma clearly located lateral to the midline and cN0 status."
    },
    {
        "id": 11193,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 133,
        "content": "At least one elective ipsilateral selective neck dissection (level IIa, III and IV) should be performed as part of a primary surgical procedure in these patients."
    },
    {
        "id": 11195,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 133,
        "content": "There is a consensus-based recommendation for patients with cN0 hypopharyngeal carcinomas with tumour localization close to the midline or indications of deep tumour infiltration or from category T2."
    },
    {
        "id": 11196,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 133,
        "content": "A bilateral elective selective neck dissection (level IIa, III, IV) should be performed in the case of a primary surgical approach in these patients."
    },
    {
        "id": 11201,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "In patients with lateralized oro-, hypopharyngeal carcinoma undergoing neck dissection simultaneously or prior to transoral endoscopic head and neck surgery, ligation/clipping of compromised supplying blood vessels may be considered to reduce the severity and incidence of postoperative bleeding."
    },
    {
        "id": 11204,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "The indication for elective neck dissection in patients with oropharyngeal and hypopharyngeal carcinomas in tumour stages T1 and T2 with a clinically negative lymph node status depends largely on the expected occult cervical metastasis rate."
    },
    {
        "id": 11205,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "Cervical lymph node sonography, computed tomography and/or magnetic resonance imaging are currently standardly used to determine the clinical N-status."
    },
    {
        "id": 11206,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "The detection accuracy can be increased by advanced procedures such as positron emission tomography and/or sentinel lymph node biopsy."
    },
    {
        "id": 11207,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "Studies on sentinel lymph node biopsy indicate that it could be equivalent to elective neck dissection in terms of patient survival in patients with early-stage head and neck tumours with clinically negative neck lymph node status."
    },
    {
        "id": 11208,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "Elective neck dissection is currently the gold standard for determining nodal status."
    },
    {
        "id": 11209,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "Elective neck dissection is indicated for an expected occult metastatic probability of 15% to 20%."
    },
    {
        "id": 11210,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "If the expected occult metastasis rate is lower, watchful waiting can also be performed."
    },
    {
        "id": 11211,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "If a neck dissection is nevertheless performed, the potential patient benefit and the expected morbidity must be carefully weighed against each other."
    },
    {
        "id": 11212,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "Relevant complications that must be taken into consideration are, in addition to bleeding events, primarily sensory or motor nerve damage, chronic lymphedema, chyle fistulas and wound healing disorders."
    },
    {
        "id": 11213,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "For oropharyngeal carcinomas in the early stages T1 and T2N0M0, the rates of occult lymph node metastasis described in the literature range from approximately 12 - 39%."
    },
    {
        "id": 11214,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "The difference between patients with tumour size T1 compared to T2 is remarkable."
    },
    {
        "id": 11215,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "For T1 tumours, the risk of occult lymph node metastases is less than 15%."
    },
    {
        "id": 11216,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "Rates of around 30% are described for T2 and above."
    },
    {
        "id": 11217,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "The latter corresponds to the occult metastasis rates in patients with primary tumours in the advanced tumour sizes T3 and T4."
    },
    {
        "id": 11218,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "In the case of primary tumours clearly located laterally to the midline, there is also a difference in the lateral distribution of metastases."
    },
    {
        "id": 11219,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "While ipsilateral occult metastases are found in 17 - 33% of patients with T1 and T2 oropharyngeal carcinomas across all stages, the rate for contralateral occult metastases is 0 - 29%."
    },
    {
        "id": 11220,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "Occult contralateral metastases are found in 0 - 20% of cases of T1 tumours and in 5 - 35% of cases of T2 tumours."
    },
    {
        "id": 11221,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 134,
        "content": "Anatomical differences within the oropharynx must also be taken into account."
    },
    {
        "id": 11222,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "The base of the tongue are affected, the rates of contralateral occult metastasis are higher than for tumours in the tonsil area."
    },
    {
        "id": 11224,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "The rates of contralateral occult metastasis are higher for tumours in the base of the tongue than for tumours in the tonsil area due to the intersecting lymphatic drainage pathways."
    },
    {
        "id": 11225,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "Occult bilateral metastasis rates of approximately 14% have been described for soft palate carcinomas as early as stage T1."
    },
    {
        "id": 11226,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "Occult bilateral metastasis rates of up to 20% have been described for tongue base carcinomas."
    },
    {
        "id": 11227,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "From stage T2, the rates are approximately 32% for soft palate carcinomas and approximately 35% for tongue base carcinomas."
    },
    {
        "id": 11228,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "There are clear differences with regard to the involvement of the lymph node levels."
    },
    {
        "id": 11229,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "With cN0 status, occult lymph node metastases predominantly manifest themselves in the ipsilateral levels II and III."
    },
    {
        "id": 11230,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "The distribution according to lymph node regions is as follows ipsilaterally: Level Ib: 0 - 9%, Level IIa: 26 - 75%, Level IIb: 5 - 14.9%, Level III: 0% - 41%, Level IV: 0% - 9%, Level V: 0 - 12%."
    },
    {
        "id": 11231,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "A higher T-stage, extracapsular growth, clinically ipsilateral lymph node involvement, lymphangiosis carcinomatosa or oropharyngeal carcinoma of the tonsil increase the probability of ipsilateral level IIb involvement."
    },
    {
        "id": 11232,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "HPV-associated oropharyngeal carcinomas in tumour stages T1 and T2 metastasize lymphogenously more frequently than non-HPV-associated tumours."
    },
    {
        "id": 11234,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "Elective ipsilateral selective neck dissection is always indicated in patients with oropharyngeal carcinomas of the tonsil and the lateral pharyngeal wall that are clearly lateral to the midline, i.e. already at tumour size T1."
    },
    {
        "id": 11235,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "In patients with stage T2, bilateral elective selective neck dissection should be performed."
    },
    {
        "id": 11236,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "In patients with tumours close to the midline, soft palate and tongue base carcinomas, bilateral selective neck dissection is already recommended at stage T1."
    },
    {
        "id": 11237,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "This applies to patients with both HPV-positive and HPV-negative oropharyngeal carcinomas."
    },
    {
        "id": 11238,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "Both ipsilateral and contralateral elective selective neck dissection can be limited to levels II, III and IV."
    },
    {
        "id": 11239,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "Hypopharyngeal carcinomas have a high occult ipsilateral metastasis rate of 24 - 41% regardless of the extent of the primary tumour in stage cN0."
    },
    {
        "id": 11240,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "A cN0 stage is rarely found in affected patients at initial diagnosis; cervical lymph node metastases are usually already clinically manifest."
    },
    {
        "id": 11241,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "With a primary tumour size of T1, the occult contralateral metastasis rate is 8%."
    },
    {
        "id": 11242,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "The location of the primary tumour significantly influences the contralateral metastasis rate."
    },
    {
        "id": 11243,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "In T1 tumours of the anterior wall of the piriform sinus, the lateral hypopharyngeal wall or the posterior hypopharyngeal wall, the rate is around 5%."
    },
    {
        "id": 11244,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "Occult contralateral metastases are already present in around 13% of T1 cases with infiltration of the medial wall of the piriform sinus."
    },
    {
        "id": 11245,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 135,
        "content": "Tumour involvement of the postcricoid region, the medial wall of the piriform sinus, tumour growth close to the midline in the area of the posterior pharyngeal wall or tumour infiltration of more than 1 mm in depth increase the risk of contralateral lymph node metastasis."
    },
    {
        "id": 11246,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "For primary tumours in stage T2, the rate of occult contralateral metastasis is up to 21%."
    },
    {
        "id": 11247,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "The rate of occult contralateral metastasis corresponds to the rate for advanced tumour stages T3 and T4."
    },
    {
        "id": 11248,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "The distribution of occult lymph node metastases according to metastasis level is as follows: Level Ib: 3.8%, Level IIa: 53.8%, Level IIb: 7.7%, Level III: 50%, Level IV: 19.2%, Level V: 7.7%."
    },
    {
        "id": 11250,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "An ipsilateral elective neck dissection on the side affected by the tumour can be performed in patients with strictly unilateral tumour localization in the area of the hypopharyngeal side wall or posterior wall in stage T1."
    },
    {
        "id": 11251,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "Bilateral elective neck dissection is recommended in the case of tumour localization close to the midline or indications of deep tumour infiltration or from category T2."
    },
    {
        "id": 11252,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "Selective neck dissection of levels II, III and IV should be performed both ipsilaterally and contralaterally."
    },
    {
        "id": 11253,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "Level VI neck dissections are performed in the hypopharynx as needed to resect the primary tumour and all clinically suspicious neck nodes."
    },
    {
        "id": 11254,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "Elective dissection depends on the extent and location of the primary tumour."
    },
    {
        "id": 11255,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "In nodal-positive oropharyngeal and hypopharyngeal carcinoma, at least ipsilateral curative neck dissection should be performed as part of a primary surgical procedure, regardless of the stage."
    },
    {
        "id": 11256,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "The extent of a curative neck dissection as part of a primary surgical procedure for nodal-positive oropharyngeal and hypopharyngeal carcinomas should be made dependent on the extent of lymph node involvement."
    },
    {
        "id": 11257,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "The minimum extent of a curative neck dissection includes selective neck dissection of level IIa, III, IV and can be increased up to radical neck dissection."
    },
    {
        "id": 11258,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "Curative neck dissection is indicated as an essential component of definitive surgery in the N+ situation."
    },
    {
        "id": 11259,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "In the case of unilateral nodal-positive laterally located oropharyngeal and hypopharyngeal carcinoma, at least one ipsilateral curative neck dissection should be performed as part of a primary surgical procedure, regardless of the stage."
    },
    {
        "id": 11260,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "If the tumour location is close to or even exceeds the midline, a bilateral neck dissection should be performed even in a unilateral cN+ situation."
    },
    {
        "id": 11261,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 136,
        "content": "The extent of a curative neck dissection as part of a primary surgical procedure for nodal-positive oropharyngeal or hypopharyngeal carcinomas should depend on the extent of lymph node involvement."
    },
    {
        "id": 11262,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 137,
        "content": "The minimum extent of neck dissection for oropharyngeal and hypopharyngeal carcinoma patients includes selective neck dissection of level IIa, III, IV."
    },
    {
        "id": 11263,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 137,
        "content": "Neck dissection can be increased to radical neck dissection."
    },
    {
        "id": 11264,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 137,
        "content": "Ligation of vulnerable supplying blood vessels should be performed to reduce the severity and incidence of postoperative bleeding in patients with lateralized oropharyngeal and hypopharyngeal carcinoma undergoing neck dissection."
    },
    {
        "id": 11265,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 137,
        "content": "Patients with cN+ disease who have either clear extranodal extension into the surrounding soft tissue or involvement of the carotid artery or cranial nerve should be offered a non-surgical approach."
    },
    {
        "id": 11266,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 137,
        "content": "Patients with biopsy-proven distant metastases should not undergo routine surgical resection of metastatic cervical lymph nodes."
    },
    {
        "id": 11267,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 137,
        "content": "For advanced hypopharyngeal carcinoma treated primarily by surgery, level VI dissection and hemithyroidectomy up to total thyroidectomy may be indicated."
    },
    {
        "id": 11270,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 137,
        "content": "Planned neck dissection after definitive radiochemotherapy for node-positive oropharyngeal and hypopharyngeal carcinomas should only be considered immediately after primary therapy if the FDG-PET-CT proves positive."
    },
    {
        "id": 11299,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 138,
        "content": "Malnutrition leads to a third, central field of action for caregivers: the nutritional situation."
    },
    {
        "id": 11300,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Patients with oropharyngeal or hypopharyngeal carcinoma have a high risk of malnutrition due to impaired chewing and swallowing function."
    },
    {
        "id": 11301,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Malnutrition is caused by impaired chewing and swallowing function in patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11302,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Malnutrition leads to weight loss in patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11303,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Malnutrition affects the ability of patients with oropharyngeal or hypopharyngeal carcinoma to cope with surgery, chemotherapy, or radiotherapy."
    },
    {
        "id": 11304,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Malnutrition increases treatment-related morbidity and mortality in patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11305,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "The more advanced the carcinoma, the greater the chewing and swallowing deficits in patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11306,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Chewing and swallowing deficits often lead to gastric tube or PEG insertion in patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11307,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Early recognition of nutritional needs is essential for patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11308,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Screenings and regular assessments are necessary for early recognition of nutritional needs in patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11309,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Continuous monitoring and nutritional support are essential for patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11310,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Nutritional support must be guaranteed beyond inpatient treatment in the outpatient sector for patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11311,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Targeted discharge management is important for ensuring nutritional support beyond inpatient treatment in patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11312,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Regular training to maintain or restore chewing and swallowing function is one of the central tasks of caregivers for patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11313,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Speech exercises, singing, tongue movements, and pharyngeal stimulation are examples of regular training to maintain or restore chewing and swallowing function."
    },
    {
        "id": 11314,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "The application of nutrition via nasogastric tube or PEG is used in various places for patients with oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11315,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Regular consumption of alcohol or cigarettes is often cited as a cause of oropharyngeal and hypopharyngeal carcinoma."
    },
    {
        "id": 11320,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 139,
        "content": "Reducing or quitting alcohol and/or cigarettes as a preventative measure can already significantly reduce the risk of disease."
    },
    {
        "id": 11321,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 140,
        "content": "The GGPO published an evidence-based guideline for oropharyngeal and hypopharyngeal carcinoma in February 2024."
    },
    {
        "id": 11323,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 140,
        "content": "Table 9 in the guideline presents special nursing care for OPC patients."
    },
    {
        "id": 11342,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "Patients with locoregional recurrences have undergone pretreatment consisting of surgery and/or postoperative radio- or radiochemotherapy or primary radio- or radiochemotherapy."
    },
    {
        "id": 11343,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "Unless it is a rare second carcinoma in a different location, patients with locoregional recurrences have new tumour growth in a previously treated area."
    },
    {
        "id": 11344,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "The criteria for a recurrent tumour according to the Odense-Birmingham definition are: same anatomical subregion or adjacent subregion within 3 cm of the primary lesion, time interval of occurrence not more than 3 years, and same p16 status for oropharyngeal carcinoma."
    },
    {
        "id": 11346,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "The biological background of tissue changes after pre-treatment is diverse."
    },
    {
        "id": 11347,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "Locoregional recurrences most frequently grow in areas that have been pre-irradiated with high doses."
    },
    {
        "id": 11348,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "Locoregional recurrences less frequently grow in areas that have only been pre-operated on and not irradiated."
    },
    {
        "id": 11349,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "Locoregional recurrences generally represent a particular challenge for further treatment."
    },
    {
        "id": 11350,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "The in vitro radiosensitivity of recurrent squamous cell carcinoma cell lines established from a pre-irradiated area is significantly lower than the radiosensitivity of primary squamous cell carcinoma cell lines."
    },
    {
        "id": 11351,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "In animal models, tumour cells introduced by injection into a tissue pre-irradiated at a higher dose grow significantly slower into a tumour of the same size than in a non-pre-irradiated area."
    },
    {
        "id": 11352,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "The reason for this is the reduced ability of the pre-irradiated tissue to provide sufficient neoangiogenesis for faster tumour growth."
    },
    {
        "id": 11353,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "The tumours also tend to develop central tumour necrosis more quickly than in tissue that has not been pre-irradiated."
    },
    {
        "id": 11354,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "This effect can also contribute to a reduced effect of radiotherapy or radiochemotherapy."
    },
    {
        "id": 11355,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "In animal models, a significantly increased rate of the formation of distant metastases was also observed."
    },
    {
        "id": 11357,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "There is the problem that the radiation tolerance of normal tissue is reduced when tumours in pre-irradiated tissue are re-irradiated."
    },
    {
        "id": 11358,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 141,
        "content": "In an animal model, it has been shown that the tolerance of the cervical myelon in rhesus monkeys to re-radiation therapy increases again with a certain time interval."
    },
    {
        "id": 11361,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "The radiation sensitivity of tumours decreases after 12 months, with at least 61% of the original tolerance remaining."
    },
    {
        "id": 11362,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "The initial conditions for re-irradiation +/- chemotherapy of recurrences in the pre-irradiated area are probably worse than in the context of primary therapy."
    },
    {
        "id": 11363,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "The lower radiation sensitivity of the tumours and the reduced tolerance of the normal tissue contribute to the worse initial conditions."
    },
    {
        "id": 11364,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "Re-irradiation is hardly an option in the first 3-6 months after primary therapy due to the low re-tolerance of the normal tissue and the obvious resistance of the irradiated tumours."
    },
    {
        "id": 11365,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "With a longer interval (at least 6 months, preferably >1 year) to pre-irradiation, the data from animal models suggest somewhat more favourable starting conditions for re-irradiation +/- chemotherapy."
    },
    {
        "id": 11366,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "The treatment of recurrent tumours and second carcinomas without distant metastases follows the same principles as primary therapy."
    },
    {
        "id": 11367,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "The previous therapy and the particularities of renewed tumour growth in the previously treated area must be taken into account."
    },
    {
        "id": 11368,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "Recurrences after primary treatment in the oropharynx and hypopharynx are significantly less favourable prognostically than in the oral cavity and larynx."
    },
    {
        "id": 11369,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "Surgical treatment (R0 resection; salvage surgery) and, if necessary, adjuvant radio- or radiochemotherapy or definitive radio- or radiochemotherapy should be considered for recurrent tumours."
    },
    {
        "id": 11370,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "If the locoregional recurrence is in an area that has been pre-irradiated with a higher dose, a new course of radiotherapy or radiochemotherapy can only be given with the understanding that the risk of late side effects is increased and, in some cases, that the total dose is reduced."
    },
    {
        "id": 11371,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "Re-radiation +/- chemotherapy is a potentially curative option if a meaningful resection is no longer possible due to the extent of the tumour."
    },
    {
        "id": 11372,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "If neither resection +/- radio- or radiochemotherapy, nor radio- or radiochemotherapy are feasible, there is the option of systemic therapy (drug-based tumour therapy)."
    },
    {
        "id": 11373,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "In drug-based tumour therapy, a distinction is made between first-line, second-line and possibly third-line therapy."
    },
    {
        "id": 11374,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "First-line therapy is now internationally standardized."
    },
    {
        "id": 11375,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "In the case of distant metastases (M1), resection and targeted radiotherapy can be considered in the presence of individual metastases (oligometastasis)."
    },
    {
        "id": 11376,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "If resection and targeted radiotherapy are no longer possible, drug-based tumour therapy is also used in this situation."
    },
    {
        "id": 11377,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 142,
        "content": "In the case of distant metastases, drug-based tumour therapy can also be combined with targeted radiotherapy of metastases and, if necessary, resection."
    },
    {
        "id": 11392,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 143,
        "content": "The diffuse, often multicentric and submucosal tumour growth increases the risk of underestimating the extent of the tumour."
    },
    {
        "id": 11393,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 143,
        "content": "The conditions for both salvage surgery and radio- or radiochemotherapy are worsened compared to primary therapy in an untreated area."
    },
    {
        "id": 11397,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 143,
        "content": "The term 'salvage surgery' is commonly used to describe rescue surgery following failed radiotherapy."
    },
    {
        "id": 11398,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 143,
        "content": "The term 'salvage surgery' has become very prominent in the context of laryngeal organ preservation programs."
    },
    {
        "id": 11399,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 143,
        "content": "Laryngectomy was performed as salvage after tumour persistence or short-term recurrence following successful radiochemotherapy."
    },
    {
        "id": 11401,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 143,
        "content": "Salvage surgery is no longer limited to patients who failed radiotherapy or radiochemotherapy."
    },
    {
        "id": 11402,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 143,
        "content": "Salvage surgery also includes patients who previously underwent surgical treatment for tumours located from the base of the skull to the lower neck areas (including thyroid cancer)."
    },
    {
        "id": 11403,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 143,
        "content": "Salvage surgery includes patients who previously underwent surgical treatment for tumours located in the head and neck area."
    },
    {
        "id": 11405,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 143,
        "content": "Repeat surgery is also referred to as 'salvage surgery'."
    },
    {
        "id": 11406,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 144,
        "content": "The biological characteristics of tumour recurrences or second carcinomas in previously treated areas cannot be equated with therapy-na\u00efve, i.e. non-pretreated tissue situations in primary therapy from a radiotherapeutic and surgical perspective."
    },
    {
        "id": 11407,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 144,
        "content": "The treatment of recurrent tumours, secondary carcinomas without distant metastases after completion of primary treatment of oropharyngeal and hypopharyngeal carcinoma follows the same principles as primary treatment with regard to testing R0 operability and radiation or radiochemotherapy capability."
    },
    {
        "id": 11408,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 144,
        "content": "The treatment of recurrent tumours, secondary carcinomas without distant metastases takes particular account of the changed initial situation in the pre-treated area."
    },
    {
        "id": 11409,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 144,
        "content": "In the case of locoregional oropharyngeal and hypopharyngeal carcinoma recurrences or second carcinomas, the possibility of surgical treatment in patients without distant metastases should always be reviewed."
    },
    {
        "id": 11410,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 144,
        "content": "If R0 resection is likely to be achievable, surgical treatment should be favoured in the multidisciplinary tumour board."
    },
    {
        "id": 11413,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 144,
        "content": "Salvage surgery for oropharyngeal and hypopharyngeal carcinomas, especially in pre-irradiated areas, is subject to significantly higher complications than primary surgery in non-pretreated tissue."
    },
    {
        "id": 11414,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 144,
        "content": "Salvage surgery should therefore include reconstructions with transfer of non-pretreated tissue."
    },
    {
        "id": 11415,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 144,
        "content": "The initial conditions for good efficacy of salvage surgery, radio- or radiochemotherapy in oropharyngeal and hypopharyngeal carcinoma recurrences or secondary carcinomas are better in solely preoperated areas than after additional pre-irradiation or primary radiochemotherapy."
    },
    {
        "id": 11416,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 144,
        "content": "The initial conditions for good efficacy of salvage surgery, radio- or radiochemotherapy in oropharyngeal and hypopharyngeal carcinoma recurrences or secondary carcinomas are worse overall than in therapy-na\u00efve tissue."
    },
    {
        "id": 11417,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 144,
        "content": "The diffuse, often multicentric and submucosal tumour growth in pre-treated areas increases the risk of underestimating the tumour extent and the actual degree of hypoxia."
    },
    {
        "id": 11418,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 144,
        "content": "The diffuse, often multicentric and submucosal tumour growth in pre-treated areas worsens the conditions for salvage surgery as well as radio- or radiochemotherapy compared to primary therapy."
    },
    {
        "id": 11419,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 145,
        "content": "Scarring in the previously treated area can make it difficult or impossible to show the exact extent of the tumour on imaging."
    },
    {
        "id": 11421,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 145,
        "content": "Biopsy confirmation of the recurrence can be difficult due to the diffuse extension in the pre-treated area."
    },
    {
        "id": 11422,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 145,
        "content": "The tumour often eludes direct visualization during panendoscopy."
    },
    {
        "id": 11423,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 145,
        "content": "An urgent oropharyngeal or hypopharyngeal carcinoma recurrence/secondary tumour can be suspected in pre-treated tissue."
    },
    {
        "id": 11424,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 145,
        "content": "A targeted biopsy may not be expedient due to diffuse tumour spread that is not visible externally/endoscopically."
    },
    {
        "id": 11425,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 145,
        "content": "Exploratory salvage surgery with limited resection of suspicious masses can be performed in the pre-treated primary tumour and in the neck area."
    },
    {
        "id": 11426,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 145,
        "content": "Exploratory salvage surgery is performed for histological confirmation and visualization of the tumour spread."
    },
    {
        "id": 11427,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 145,
        "content": "Recurrences after primary treatment in the oropharynx and hypopharynx are significantly less favourable prognostically than in the oral cavity and larynx."
    },
    {
        "id": 11431,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 146,
        "content": "A biopsy should be performed to histologically confirm a recurrent tumour/secondary carcinoma in a previously treated area."
    },
    {
        "id": 11432,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 146,
        "content": "A limited excisional biopsy should be performed to histologically confirm a recurrent tumour/secondary carcinoma in a previously treated area if a scar is present."
    },
    {
        "id": 11433,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 146,
        "content": "Exploratory salvage surgery with limited resection of suspicious masses in the oropharynx/hypopharynx as well as in the neck area can be performed for histological confirmation and visualization of the tumour spread if a targeted biopsy is not expedient."
    },
    {
        "id": 11434,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 146,
        "content": "A functionally meaningful R0 salvage resection should be checked for possibility in the case of locoregional recurrence in the pre-treated area."
    },
    {
        "id": 11435,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 146,
        "content": "R0 salvage resection should be performed if possible in the case of locoregional recurrence in the pre-treated area."
    },
    {
        "id": 11436,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 146,
        "content": "Resection +/- adjuvant radio- or radiochemotherapy should be performed if R0 resection is reasonably possible in the case of locoregional recurrences or double carcinomas in the oropharynx or hypopharynx in the pre-operated but not pre-irradiated area."
    },
    {
        "id": 11437,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 146,
        "content": "Primary radio- or radiochemotherapy should be performed if R0 resection is not reasonably possible in the case of locoregional recurrences or double carcinomas in the oropharynx or hypopharynx in the pre-operated but not pre-irradiated area."
    },
    {
        "id": 11439,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 147,
        "content": "Salvage resection should be preferred to non-surgical treatment if R0 resectability is functionally feasible in the case of locoregional recurrences or double carcinomas in the oropharynx or hypopharynx in the pre-irradiated area."
    },
    {
        "id": 11440,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 147,
        "content": "Postoperative re-irradiation can be offered in particular after salvage resection if certain criteria are met."
    },
    {
        "id": 11441,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 147,
        "content": "A long interval to the 1st radiation series (at least 6 months) is one of the criteria for postoperative re-irradiation."
    },
    {
        "id": 11442,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 147,
        "content": "No grade IV late effects of the 1st radiation series in the area to be re-irradiated is one of the criteria for postoperative re-irradiation."
    },
    {
        "id": 11443,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 147,
        "content": "No major wound healing disorders after salvage resection is one of the criteria for postoperative re-irradiation."
    },
    {
        "id": 11444,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 147,
        "content": "Risk factors (e.g. resection <5mm i.G., >1 affected LK or ECE) are considered for postoperative re-irradiation."
    },
    {
        "id": 11445,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 147,
        "content": "A total dose of at least 50 Gy (R0) - 60 Gy (R1/2) in 2 Gy equivalent dose for an alpha/beta value of 10 Gy should be aimed for in post-operative re-irradiation."
    },
    {
        "id": 11446,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 147,
        "content": "The CTV should be kept as small as reasonably possible (e.g. former tumour region 5-10 mm) in order to minimize the volume of normal tissue that cumulatively receives >100 Gy."
    },
    {
        "id": 11447,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 147,
        "content": "Simultaneous chemotherapy can be selected analogous to primary radiochemotherapy in post-operative re-irradiation."
    },
    {
        "id": 11448,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 147,
        "content": "With a short interval (6-12 months) to the previous chemotherapy, an alternative chemotherapy regimen should be preferred in post-operative re-irradiation."
    },
    {
        "id": 11449,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 147,
        "content": "A salvage neck dissection should be performed if functionally feasible in the case of a locoregional recurrence of the cervical lymph nodes of an original oropharyngeal (regardless of HPV status) or hypopharyngeal carcinoma in a pre-irradiated/pre-operated area."
    },
    {
        "id": 11479,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 149,
        "content": "Salvage laryngopharyngectomy for recurrences in the hypopharynx after primary radio(chemo)therapy is often the only curative treatment option for patients with advanced hypopharyngeal carcinomas."
    },
    {
        "id": 11480,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 149,
        "content": "Salvage laryngopharyngectomy is an integral part of multimodal therapy for advanced hypopharyngeal carcinomas."
    },
    {
        "id": 11481,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 149,
        "content": "Salvage laryngopharyngectomy is characterized by a more difficult intraoperative preparation."
    },
    {
        "id": 11482,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 149,
        "content": "Radiotherapy in the tissue leads to a scarred transformation and reduced blood supply to the tissue."
    },
    {
        "id": 11483,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 149,
        "content": "Salvage surgery, especially in pre-irradiated areas, is subject to a significantly higher degree of complications."
    },
    {
        "id": 11484,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 149,
        "content": "Free and pedicled tissue transfer with non-pretreated, well-vascularized tissue and competent wound management are recommended."
    },
    {
        "id": 11489,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 149,
        "content": "In patients who developed a fistula, the persistence of the fistula was significantly longer with primary closure compared to pectoralis major flap reconstruction or free flap reconstruction."
    },
    {
        "id": 11490,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 149,
        "content": "A more recent study by Piazza et al. described impressively low fistula rates after salvage surgery with free tissue transfer."
    },
    {
        "id": 11492,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "Pharyngocutaneous fistulas occurred in 5.4% of patients, and one pharyngoesophageal stenosis occurred in 1.8% of patients."
    },
    {
        "id": 11493,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "Introducing tissue from a non-irradiated area can significantly reduce the risk of fistula in salvage laryngopharyngectomy."
    },
    {
        "id": 11498,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "FDG-PET had a significantly higher pooled sensitivity than the combination of CT and/or MRI for recurrence detection of oropharyngeal and hypopharyngeal carcinomas."
    },
    {
        "id": 11499,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "FDG-PET showed a higher reliability with a sensitivity of 100% and a specificity of 61-71% than CT and/or MRI."
    },
    {
        "id": 11500,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "Planned neck dissection after definitive radiochemotherapy for node-positive oropharyngeal and hypopharyngeal carcinomas should only be considered immediately after primary therapy if the FDG-PET-CT proves positive."
    },
    {
        "id": 11502,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "Postoperative radiochemotherapy after salvage surgery demonstrated a statistically significant and clinically relevant advantage in locoregional tumor control and relapse-free survival."
    },
    {
        "id": 11504,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "Radiochemotherapy was administered using the Chicago regimen with 60 Gy in 30 fractions over 11 weeks in combination with simultaneous 5-fluorouracil and hydroxyurea."
    },
    {
        "id": 11505,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "Postoperative radiotherapy +/- chemotherapy with total doses >60 Gy did not show any benefit over total doses of 40 Gy - 60 Gy in terms of survival and locoregional relapse rate."
    },
    {
        "id": 11506,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "The rate of >= grade 3 late side effects was 24% for total doses <60 Gy compared to 32% for total doses above 60 Gy."
    },
    {
        "id": 11507,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "There was a trend in favour of hyperfractionated radiotherapy for locoregional relapse rate."
    },
    {
        "id": 11508,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "Elective irradiation of unaffected adjacent lymph node levels did not improve the results."
    },
    {
        "id": 11509,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 150,
        "content": "Radio- or radiochemotherapy should be examined for patients without distant metastases where R0 resection does not appear to be feasible for locoregional recurrences and second carcinomas."
    },
    {
        "id": 11510,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "The treatment recommendation is for patients who were treated with re-radiation with or without chemotherapy without prior salvage surgery."
    },
    {
        "id": 11511,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "The overall survival after 2 years was 30% to 41%."
    },
    {
        "id": 11512,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "The overall survival after 5 years was 16%."
    },
    {
        "id": 11514,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "The median total dose was 60 Gy."
    },
    {
        "id": 11515,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Some series used hyperfractionated radiotherapy with 2 x 1.5 Gy per day."
    },
    {
        "id": 11516,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Total doses of >50 Gy or >60 Gy were associated with better survival and a lower locoregional recurrence rate."
    },
    {
        "id": 11517,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "No advantage was seen for hyperfractionated radiotherapy with 2 x 1.5 Gy per day."
    },
    {
        "id": 11518,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Elective irradiation of adjacent, unaffected lymph node regions did not show any benefit."
    },
    {
        "id": 11519,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Hypofractionated stereotactic radiotherapy with total doses of 10 - 50 Gy in 1 - 8 fractions reported survival rates comparable to those of conventional fractionation."
    },
    {
        "id": 11520,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "There is more experience with conventionally fractionated reirradiation."
    },
    {
        "id": 11521,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Re-irradiation with protons has theoretical advantages over photon therapy in terms of dose distribution."
    },
    {
        "id": 11522,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "The first major published case series showed results that are in the upper range of the data published with photon therapy."
    },
    {
        "id": 11523,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Systemic therapy with cisplatin, carboplatin, cetuximab, docetaxel, paclitaxel, 5-FU, capecitabine, hydroxyurea or a combination of two of these substances was used in the majority of patients."
    },
    {
        "id": 11526,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Cisplatin-containing chemotherapy in combination with reirradiation makes sense if no cisplatin was used during primary treatment."
    },
    {
        "id": 11525,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Additional systemic therapy is considered a sensible option and was therefore frequently used in the case series cited."
    },
    {
        "id": 11527,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "There are no reliable data on the use of induction therapies prior to reirradiation +/- simultaneous chemotherapy and the use of immune checkpoint inhibitors in combination with reirradiation."
    },
    {
        "id": 11528,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "The acute toxicity of re-irradiation +/- chemotherapy does not differ significantly from the toxicity of therapy in patients who have not been previously irradiated."
    },
    {
        "id": 11529,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "There is an increased risk of late toxicities with re-irradiation +/- chemotherapy."
    },
    {
        "id": 11530,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "The published rates of >=3 late effects are between approximately 10% and 40% in most studies."
    },
    {
        "id": 11531,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "The more frequent grade 3-4 late effects include trismus, fibrosis, pharyngeal stenosis and fistulas as well as osteoradionecrosis."
    },
    {
        "id": 11532,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Osteoradionecrosis occurred in up to 17% of patients."
    },
    {
        "id": 11533,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Treatment-related deaths have been observed with these therapies in 0.1% - 8.4% of patients."
    },
    {
        "id": 11534,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Mass bleeding from the carotid artery accounts for only a small proportion of these deaths, unless the carotid artery is largely overgrown by the recurrent tumour."
    },
    {
        "id": 11535,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "The grade 3-4 late side effects are often associated with a reduced quality of life due to predominantly poorer swallowing function."
    },
    {
        "id": 11536,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Total doses of re-irradiation of more than 60 Gy in conventional fractionation are associated with an approximately 10% increased risk of grade 3-4 late effects."
    },
    {
        "id": 11537,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "In the collectives that received postoperative re-radiation +/- chemotherapy, grade 3-4 late effects are on average approximately 5-20% higher than with re-radiation +/- chemotherapy alone."
    },
    {
        "id": 11538,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "Patients with grade 4 late effects of pre-irradiation were not treated with re-irradiation."
    },
    {
        "id": 11539,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 151,
        "content": "The interval from the first radiotherapy in almost all patients was >6 months."
    },
    {
        "id": 11540,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 152,
        "content": "There are indications from some case series that grade 4 side effects occur more frequently in tissues that have been exposed to a cumulative dose of more than 120 Gy."
    },
    {
        "id": 11541,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 152,
        "content": "The alpha/beta value of the respective normal tissue is 2 Gy equivalent dose."
    },
    {
        "id": 11542,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 152,
        "content": "Volumes receiving cumulative total doses of >120 Gy should be kept as small as possible."
    },
    {
        "id": 11543,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 152,
        "content": "Total cumulative doses of >130 Gy to a maximum of 137 Gy have only been reported in exceptional cases in the available case series."
    },
    {
        "id": 11545,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 152,
        "content": "The greater the distance from the previous irradiation and the fewer late effects from the previous therapies, the lower the risk of severe late effects can be estimated."
    },
    {
        "id": 11546,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 152,
        "content": "The influence of additional simultaneous chemotherapy on the higher-grade late effects of re-radiation is insufficiently documented in the case series."
    },
    {
        "id": 11547,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 152,
        "content": "Very little data is available on the effect of primary radiotherapy or radiochemotherapy in patients with recurrences after surgery alone who have not received prior radiotherapy."
    },
    {
        "id": 11548,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 152,
        "content": "A 5-year survival proportion of 76% was observed after approximately 70 Gy in 2 Gy single dose +/- cisplatin-containing chemotherapy in a collection of cases of locoregional recurrences of hypopharyngeal and laryngeal carcinomas."
    },
    {
        "id": 11549,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 152,
        "content": "Radio- or radio-chemotherapy should be given according to the same principles and recommendations as for primary therapy, taking into account the possible altered lymphatic drainage due to the surgical procedure and the scar situation."
    },
    {
        "id": 11550,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 152,
        "content": "In this particular situation, preference should therefore also be given to salvage surgery +/- adjuvant radiotherapy or radiochemotherapy, where this appears feasible."
    },
    {
        "id": 11555,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "There is a consensus-based recommendation for re-radiation in the event of locoregional recurrences or second cancers in the oropharynx or hypopharynx."
    },
    {
        "id": 11556,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "Re-radiation can be carried out if R0 resection is not feasible."
    },
    {
        "id": 11557,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "Re-radiation can be carried out in combination with simultaneous chemotherapy."
    },
    {
        "id": 11558,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "There are criteria for re-irradiation to be met."
    },
    {
        "id": 11559,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "A long interval to the 1st radiation series is a criterion for re-irradiation."
    },
    {
        "id": 11560,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "The interval to the 1st radiation series should be at least 6 months."
    },
    {
        "id": 11561,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "No grade IV late effects of the 1st radiation series in the area to be re-irradiated is a criterion for re-irradiation."
    },
    {
        "id": 11562,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "Simultaneous chemotherapy can be selected in the same way as primary radiochemotherapy."
    },
    {
        "id": 11563,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "With a short interval to the previous chemotherapy, an alternative chemotherapy regimen should be preferred."
    },
    {
        "id": 11564,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "There is a consensus-based recommendation for the total dose of re-irradiation."
    },
    {
        "id": 11565,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "The total dose of re-irradiation should be approximately 60 Gy."
    },
    {
        "id": 11566,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "The equivalent dose for an alpha/beta value of 10 Gy should be 2 Gy."
    },
    {
        "id": 11567,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "The CTV should be kept as small as reasonably possible in re-irradiation."
    },
    {
        "id": 11568,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "The CTV should be GTV + 5 mm in re-irradiation."
    },
    {
        "id": 11569,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "The volume of normal tissue that cumulatively receives >100 Gy should be minimized in re-irradiation."
    },
    {
        "id": 11570,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 153,
        "content": "Patients should be informed of the significantly increased risk of grade IV late effects of radiotherapy in re-irradiation."
    },
    {
        "id": 11571,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "The treatment recommendation for patients with a good general and performance status who are not operable or have a radiation option is palliative, usually cisplatin-based, systemic therapy."
    },
    {
        "id": 11572,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "Salvage surgery and/or radio- or radiochemotherapy should be exhausted or deemed no longer possible before considering palliative systemic therapy."
    },
    {
        "id": 11573,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "Patients with advanced, relapsed or metastatic oropharyngeal or hypopharyngeal carcinoma can achieve response rates of 10-43% with palliative chemotherapy."
    },
    {
        "id": 11574,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "Palliative chemotherapy may be used in combination with immuno-checkpoint inhibitors."
    },
    {
        "id": 11575,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "The selection of active substances for palliative chemotherapy depends on the expression of PD-L1 in the tumour tissue."
    },
    {
        "id": 11576,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "The selection of active substances for palliative chemotherapy depends on the remission pressure at the time of therapy indication."
    },
    {
        "id": 11577,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "The selection of active substances for palliative chemotherapy depends on whether cisplatin-based radiochemotherapy has already taken place within the last 6 months."
    },
    {
        "id": 11578,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "If more than 6 months have passed since the previous platinum-containing first-line combination, renewed platinum therapy can also be considered."
    },
    {
        "id": 11579,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "Renewed platinum therapy may be used as a combination."
    },
    {
        "id": 11580,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "Chemotherapy with docetaxel + cisplatin + cetuximab (TPEx) shows a survival benefit for patients with p16-positive oropharyngeal carcinoma."
    },
    {
        "id": 11581,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "Chemotherapy with docetaxel + cisplatin + cetuximab (TPEx) does not show a survival benefit for patients with p16-negative oropharyngeal carcinoma."
    },
    {
        "id": 11582,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "For the combination FU + cisplatin + cetuximab (EXTREME), a difference in survival between patients with p16-positive versus p16-negative tumours has not been proven."
    },
    {
        "id": 11583,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "Immunotherapy with PD1 or PD-L1 inhibitors (nivolumab, pembrolizumab, durvalumab) has shown no difference between patients with p16-positive and p16-negative tumours with regard to the endpoint 'overall survival'."
    },
    {
        "id": 11584,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 154,
        "content": "The response to immunotherapy is generally better in p16-positive tumours than in p16-negative tumours."
    },
    {
        "id": 11585,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 155,
        "content": "The antibody pembrolizumab is directed against the PD-1 receptor."
    },
    {
        "id": 11586,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 155,
        "content": "Pembrolizumab is to be used in patients with metastatic or recurrent oropharyngeal and hypopharyngeal carcinoma with PD-L1-expressing tumour and immune cells (CPS \u2265 1) that cannot be treated locally."
    },
    {
        "id": 11587,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 155,
        "content": "Pembrolizumab is to be used as first-line monotherapy (especially in CPS \u2265 20 and with low disease burden) or in combination with platinum and 5-fluorouracil."
    },
    {
        "id": 11589,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 155,
        "content": "After 4-6 cycles of combination therapy, maintenance therapy should be given until progression or intolerance with pembrolizumab in PD-L1 positive patients."
    },
    {
        "id": 11590,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 155,
        "content": "After 4-6 cycles of combination therapy, maintenance therapy should be given until progression or intolerance with cetuximab according to the EXTREME/TPEx protocol in negative PD-L1 status (CPS < 1) if the disease is not progressive."
    },
    {
        "id": 11592,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 155,
        "content": "Cetuximab should be used as first-line therapy in combination with platinum (preferably cisplatin) and 5-fluorouracil (EXTREME protocol) or with docetaxel instead of 5-FU (TPEx protocol) in patients with metastatic or non-locally treatable recurrent oropharyngeal and hypopharyngeal carcinoma in good general condition (ECOG PS \u2264 1) who have no immunohistochemical evidence of PD-L1-expressing tumour or immune cells (CPS < 1)."
    },
    {
        "id": 11594,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 155,
        "content": "Nivolumab can also be considered as first-line monotherapy (regardless of PD-L1 expression) instead of monotherapy with pembrolizumab, particularly in patients who are not suitable for combined chemo(immune) therapy or in whom there is low remission pressure."
    },
    {
        "id": 11598,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "There is a consensus-based recommendation for patients with metastatic or recurrent oropharyngeal and hypopharyngeal carcinoma with CPS < 1."
    },
    {
        "id": 11600,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "Combination therapy with docetaxel (or paclitaxel) and cetuximab, or nivolumab monotherapy can be used in these patients."
    },
    {
        "id": 11601,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "Nivolumab monotherapy can be used after prior platinum-based radio-chemotherapy or platinum-based chemotherapy alone."
    },
    {
        "id": 11603,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "There is a consensus-based recommendation for patients with metastatic or recurrent oropharyngeal and hypopharyngeal carcinoma that cannot be treated locally in a reduced general condition (ECOG PS \u2265 2)."
    },
    {
        "id": 11605,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "Monotherapy, for example with docetaxel or cetuximab (off label), should primarily be considered and weighed against symptom-oriented supportive therapy alone in these patients."
    },
    {
        "id": 11607,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "Patients with early relapse after cisplatin-based radiochemotherapy can choose between immunotherapy with nivolumab or pembrolizumab or monochemotherapy, for example with docetaxel or paclitaxel."
    },
    {
        "id": 11610,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "Pembrolizumab is administered as monotherapy or in combination with chemotherapy (platinum and 5-FU) in patients with recurrence after (more than) 6 months or patients with a first diagnosis of R/M HNSCC without a curative option and CPS \u2265 1."
    },
    {
        "id": 11611,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "Pembrolizumab monotherapy can be considered for patients with PD-L1 expression of CPS \u2265 1 if there is no high time-to-remission pressure."
    },
    {
        "id": 11614,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "Pembrolizumab alone showed an improved overall survival of 12.3 versus 10.4 months compared to EXTREME in a population with a CPS \u2265 1."
    },
    {
        "id": 11615,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "Pembrolizumab in combination with chemotherapy improved overall survival by 3 months (13.6 versus 10.6 months) in the population with CPS \u2265 1."
    },
    {
        "id": 11616,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "Pembrolizumab as monotherapy in patients with high PD-L1 expression (CPS \u2265 20) led to an extension of overall survival from 10.7 to 14.9 months, with a significantly better side effect profile."
    },
    {
        "id": 11617,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 156,
        "content": "A combination of pembrolizumab with cisplatin and 5-FU is typically administered in cases of high time-to-remission pressure."
    },
    {
        "id": 11619,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 157,
        "content": "The combination of pembrolizumab, cisplatin and 5-FU achieves a significant extension of overall survival with a comparable remission rate compared to the EXTREME protocol in patients with PD-L1 expression CPS \u2265 1."
    },
    {
        "id": 11620,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 157,
        "content": "The rate of side effects of the combination of pembrolizumab with platinum/5-FU is comparable to the side effect rate in the EXTREME arm and significantly higher than under monotherapy with pembrolizumab."
    },
    {
        "id": 11621,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 157,
        "content": "Fatal treatment-related adverse events with pembrolizumab were reported in 1% (monotherapy) and 4% (in combination with chemotherapy)."
    },
    {
        "id": 11622,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 157,
        "content": "Fatal treatment-related adverse events with cetuximab in combination with chemotherapy were reported in 3%."
    },
    {
        "id": 11623,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 157,
        "content": "Combined chemo-immunotherapy according to the protocol of the KN048 study has prevailed over the previous EXTREME standard and replaced it at the highest level of evidence (evidence level A1)."
    },
    {
        "id": 11624,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 157,
        "content": "The combination of platinum with the monoclonal EGFR antibody cetuximab and 5-fluorouracil (with subsequent cetuximab maintenance therapy) had been considered the standard in this situation since 2008 based on data from the randomized phase III EXTREME trial."
    },
    {
        "id": 11642,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "Patients with recurrent or metastatic squamous cell carcinoma of the head and neck should undergo regular cross-sectional imaging every 6-12 weeks during ongoing therapy."
    },
    {
        "id": 11643,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "Regular cross-sectional imaging allows for switching to second-line therapy in good time."
    },
    {
        "id": 11644,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "Second-line therapy with a checkpoint inhibitor should be carried out after failure of primary platinum-containing combination therapy with cetuximab."
    },
    {
        "id": 11645,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "Pembrolizumab or nivolumab can be used as monotherapy for second-line therapy."
    },
    {
        "id": 11646,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "There is strong consensus on the use of pembrolizumab or nivolumab as monotherapy for second-line therapy."
    },
    {
        "id": 11647,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "After failure of primary platinum-containing combination therapy with pembrolizumab, second-line therapy with docetaxel or paclitaxel can be carried out."
    },
    {
        "id": 11648,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "Docetaxel or paclitaxel can be used in combination with cetuximab for second-line therapy."
    },
    {
        "id": 11649,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "There is strong consensus on the use of docetaxel or paclitaxel with cetuximab for second-line therapy."
    },
    {
        "id": 11650,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "After failure of first-line therapy with pembrolizumab or nivolumab as monotherapy, second-line therapy with platinum/5-FU and cetuximab can be carried out."
    },
    {
        "id": 11651,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "Second-line therapy with docetaxel or paclitaxel and cetuximab can be carried out after failure of first-line therapy with pembrolizumab or nivolumab as monotherapy."
    },
    {
        "id": 11652,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "There is strong consensus on the use of platinum/5-FU and cetuximab or docetaxel or paclitaxel and cetuximab for second-line therapy."
    },
    {
        "id": 11653,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "Patients who do not show tumour progression under second-line therapy including cetuximab or pembrolizumab or nivolumab should be offered continuation of therapy."
    },
    {
        "id": 11654,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "There is strong consensus on the continuation of therapy for patients who do not show tumour progression."
    },
    {
        "id": 11655,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "Nivolumab significantly extended survival to 7.5 versus 5.1 months compared to monotherapy with a taxane, methotrexate or cetuximab."
    },
    {
        "id": 11656,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 158,
        "content": "Nivolumab has been approved independently of PD-L1 status in progression after platinum-containing therapy since 2017."
    },
    {
        "id": 11658,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 159,
        "content": "Pembrolizumab achieved the highest significance for patients with a PD-L1 TPS \u2265 50%."
    },
    {
        "id": 11661,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 159,
        "content": "Nivolumab should be used in second-line therapy after platinum-based therapy in the absence of contraindications to a checkpoint inhibitor."
    },
    {
        "id": 11662,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 159,
        "content": "Pembrolizumab should be used in second-line therapy after platinum-based therapy in the absence of contraindications to a checkpoint inhibitor for patients with TPS \u2265 50%."
    },
    {
        "id": 11692,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 160,
        "content": "The diagnosis of oropharyngeal or hypopharyngeal carcinoma is shocking for most patients and can seriously change their life plans."
    },
    {
        "id": 11693,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 160,
        "content": "The patient must come to terms with the information about the possible changes in swallowing function, voice production, breathing, facio-oral functions, and stigmatizing changes in the neck area."
    },
    {
        "id": 11696,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 160,
        "content": "Surgical treatment of oropharyngeal or hypopharyngeal carcinoma usually leads to functional impairments of varying degrees."
    },
    {
        "id": 11697,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 160,
        "content": "Functional impairments are typical phenomena that can always be expected after surgery, even if they occur in varying degrees."
    },
    {
        "id": 11698,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "The least functional impairment occurs after transoral surgical techniques (TLM, TORS) for T1 carcinomas of the oropharynx and hypopharynx."
    },
    {
        "id": 11700,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Dysphonia or dysphagia that occurs after transoral surgical techniques usually regresses significantly after a few weeks."
    },
    {
        "id": 11701,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Dysphonia or dysphagia is supported by speech therapy."
    },
    {
        "id": 11702,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Larger resections in the oropharynx can lead to permanent functional disorders."
    },
    {
        "id": 11703,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Permanent functional disorders include disorders of the tongue, palate closure, swallowing, voice production, and articulation."
    },
    {
        "id": 11704,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Aspiration is one of the frequent side effects after more extensive partial resections of smaller hypopharyngeal carcinomas."
    },
    {
        "id": 11705,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "The larynx separates the airway from the alimentary canal."
    },
    {
        "id": 11706,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "The protective mechanisms of the laryngeal inlet are restricted after more extensive partial resections of smaller hypopharyngeal carcinomas."
    },
    {
        "id": 11707,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Aspiration does not occur with complete removal of the larynx."
    },
    {
        "id": 11708,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "In this situation, the airway is separated from the alimentary canal."
    },
    {
        "id": 11709,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "If a voice prosthesis is inserted, there is a risk of a pharyngo-tracheal fistula forming."
    },
    {
        "id": 11710,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Widening of the tracheoesophageal fistula occurs in early and late stages after the insertion of voice prostheses."
    },
    {
        "id": 11711,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Shortness of breath due to tissue swelling close to the glottis can be a typical side effect."
    },
    {
        "id": 11712,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Shortness of breath requires a temporary or even a permanent tracheostomy."
    },
    {
        "id": 11713,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "After a laryngopharyngectomy, there is a loss of smell."
    },
    {
        "id": 11714,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "The loss of smell is due to the lack of nasal breathing."
    },
    {
        "id": 11715,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "There is a risk of recurrent inflammation of the trachea due to the loss of the nose as a filter and humidifier."
    },
    {
        "id": 11716,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "This can lead to the development of obstructive tracheitis."
    },
    {
        "id": 11717,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Obstructive tracheitis requires intensive inpatient treatment."
    },
    {
        "id": 11718,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "After a laryngectomy, the abdominal press is also not possible."
    },
    {
        "id": 11719,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "The abdominal press is not possible when lifting heavy loads."
    },
    {
        "id": 11720,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Loss of voice after laryngectomy must be regarded as one of the serious side effects."
    },
    {
        "id": 11721,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Loss of voice is due to the removal of the vocal organ."
    },
    {
        "id": 11722,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Various rehabilitation measures are available to develop a replacement voice again."
    },
    {
        "id": 11723,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Specific supportive measures following laryngectomy are described in detail in Chapter 7.9.1.1 of the S3 Guideline for Laryngeal Carcinoma."
    },
    {
        "id": 11724,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "A less frequently observed functional disorder after laryngectomy is stenosis of the hypopharynx."
    },
    {
        "id": 11725,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Stenosis of the hypopharynx can occur particularly after extensive resection of the hypopharynx and adjuvant radiotherapy."
    },
    {
        "id": 11726,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Stenosis of the hypopharynx can lead to considerable dysphagia and even aphagia."
    },
    {
        "id": 11727,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Many of these typical side effects can be eliminated or reduced by intensive swallowing or voice training."
    },
    {
        "id": 11728,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "In many cases, it is not possible to treat side effects with medication or surgery."
    },
    {
        "id": 11729,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "In individual cases, postoperative adhesions of the tongue can be surgically removed."
    },
    {
        "id": 11730,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Relevant hypopharyngeal stenoses can be eliminated by bougienage or dilatation plasty."
    },
    {
        "id": 11731,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "After a neck dissection, swelling may occur in the head and neck area."
    },
    {
        "id": 11732,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Swelling is due to congestion and drainage disorders in the lymph vessels."
    },
    {
        "id": 11733,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Movement of the head, e.g. turning and tilting, may also be restricted."
    },
    {
        "id": 11734,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "This can occur mainly after adjuvant radiotherapy and the onset of radiation fibrosis."
    },
    {
        "id": 11735,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "This can also occur after lesions of the accessorius nerve."
    },
    {
        "id": 11736,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Physical and physiotherapeutic treatments can lead to an improvement."
    },
    {
        "id": 11737,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "There are no studies that prove the effect of lymphatic drainage."
    },
    {
        "id": 11738,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 161,
        "content": "Damage to other nerves (hypoglossal nerve, lingual nerve, vagus nerve, border cord and phrenic nerve) can also occur."
    },
    {
        "id": 11739,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "The acute side effects of radio(chemo)therapy include skin reaction, mucositis, xerostomia, and radiation effects on nerve tissue."
    },
    {
        "id": 11740,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "During radio(chemo)therapy, other side effects include loss of taste, nausea/vomiting, fatigue, and weakness."
    },
    {
        "id": 11741,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Pronounced side effects can lead to the patient wishing to discontinue or pause the therapy."
    },
    {
        "id": 11742,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Discontinuing or pausing the therapy can significantly compromise the effect of the therapy."
    },
    {
        "id": 11743,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Optimal prophylaxis and therapy are essential components of successful tumour therapy."
    },
    {
        "id": 11745,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "There are chronic side effects that can potentially occur in the long term."
    },
    {
        "id": 11746,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Adequate prophylaxis can reduce the probability of chronic side effects."
    },
    {
        "id": 11747,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Chronic side effects include changes to the teeth and jaw, chronic xerostomia, and trismus."
    },
    {
        "id": 11748,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Other chronic side effects of combined therapy include lymphoedema, functional limitations of the neck and throat muscles, and chronically delayed wound healing with a tendency to scarring and fistula formation."
    },
    {
        "id": 11749,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Chronic swallowing disorders, aspiration, or hoarseness can be triggered by various changes."
    },
    {
        "id": 11750,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Examples of changes that can trigger chronic swallowing disorders, aspiration, or hoarseness include progressive fibrosis of the pharyngeal muscles."
    },
    {
        "id": 11751,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Chronic mucosal oedema in the area of the laryngeal entrance, the ariepiglottic fold, and the pocket folds can trigger chronic swallowing disorders, aspiration, or hoarseness."
    },
    {
        "id": 11752,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Late oedema in the area of the entire larynx can trigger chronic swallowing disorders, aspiration, or hoarseness."
    },
    {
        "id": 11753,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Neuropathies and scarring of the mucosa can trigger chronic swallowing disorders, aspiration, or hoarseness."
    },
    {
        "id": 11754,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Fibrosis of the entire oropharyngeal area and the masticatory muscles with consecutive difficulties in opening the mouth can trigger chronic swallowing disorders, aspiration, or hoarseness."
    },
    {
        "id": 11755,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Cartilage necrosis in the laryngeal area can trigger chronic swallowing disorders, aspiration, or hoarseness."
    },
    {
        "id": 11756,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "All these side effects require close patient care, ideally by an interdisciplinary team."
    },
    {
        "id": 11768,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Chemotherapy is often administered simultaneously with radiotherapy (primary or adjuvant) and also alone in palliative treatment situations."
    },
    {
        "id": 11769,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "Substances from immuno-oncology and EGFR targeting are also used."
    },
    {
        "id": 11770,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 162,
        "content": "The most common potential side effects of the substances used include tumour therapy-induced nausea and vomiting, diarrhea, altered hematopoiesis, oral mucositis due to systemic tumour therapy, skin toxicities, nephrotoxicity, chemotherapy-induced peripheral neuropathy, osseous complications, and extravasations."
    },
    {
        "id": 11771,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 163,
        "content": "Pembrolizumab and nivolumab are PD-1 inhibitors."
    },
    {
        "id": 11772,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 163,
        "content": "Immune-mediated adverse events, including severe cases with sometimes fatal outcomes, have occurred in patients receiving pembrolizumab or nivolumab."
    },
    {
        "id": 11773,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 163,
        "content": "Most immune-mediated adverse events that occurred during treatment with PD-1 inhibitors were reversible and manageable by discontinuation of pembrolizumab therapy, administration of corticosteroids and/or supportive measures."
    },
    {
        "id": 11855,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 166,
        "content": "Patients who have undergone surgery and/or radiotherapy for oropharyngeal or hypopharyngeal carcinoma should have their chewing ability restored through masticatory rehabilitation with implants or conventional prosthetic restorations."
    },
    {
        "id": 11856,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 166,
        "content": "Patients who have undergone surgery and/or radiotherapy for oropharyngeal or hypopharyngeal carcinoma should be regularly monitored by a dentist."
    },
    {
        "id": 11857,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 166,
        "content": "Dental surgery should be performed on patients who have undergone surgery and/or radiotherapy for oropharyngeal or hypopharyngeal carcinoma by specialists experienced in this clinical picture."
    },
    {
        "id": 11858,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 166,
        "content": "A dental check-up should be carried out before the start of radio- or radiochemotherapy for oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11859,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 166,
        "content": "The patient should be informed about prophylactic measures before the start of radio- or radiochemotherapy for oropharyngeal or hypopharyngeal carcinoma."
    },
    {
        "id": 11860,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 167,
        "content": "The best possible functional outcome can be achieved by including pre-, peri- and/or post-therapeutic rehabilitative measures in the treatment concept."
    },
    {
        "id": 11861,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 167,
        "content": "There is strong consensus on the importance of including rehabilitative measures in the treatment concept."
    },
    {
        "id": 11864,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 167,
        "content": "In cases of pre-operative swallowing disorder, dysphagia diagnostics and swallowing training should be carried out pre-operatively or pre-therapeutically."
    },
    {
        "id": 11865,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 167,
        "content": "Swallowing function should be examined as early as possible post-operatively or post-therapeutically."
    },
    {
        "id": 11866,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 167,
        "content": "The aim of swallowing rehabilitation is rapid oral food intake and, if necessary, swallowing training, depending on the healing process and the therapy methods used."
    },
    {
        "id": 11867,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 167,
        "content": "There is strong consensus on the importance of early examination and rehabilitation of swallowing function."
    },
    {
        "id": 11868,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 167,
        "content": "Swallowing function may already be impaired pre-therapeutically in patients with oropharyngeal and hypopharyngeal carcinoma."
    },
    {
        "id": 11869,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 167,
        "content": "Therapy often results in dysphagia or inability to swallow, which can be alleviated or overcome with timely and appropriate therapy."
    },
    {
        "id": 11873,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 167,
        "content": "FEES (fiberoptic endoscopic evaluation of swallowing) performed by doctors plays a central role in diagnosis and therapy monitoring."
    },
    {
        "id": 11874,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 167,
        "content": "Swallowing therapy in the inpatient setting begins as early as possible after surgery."
    },
    {
        "id": 11875,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "The treatment can begin to promote the elasticity of the throat, neck, face and speech muscles in consultation with the doctors if there are no complications."
    },
    {
        "id": 11876,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "The treatment aims to optimize the therapy results."
    },
    {
        "id": 11877,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Adequate pain and nutrition therapy should be provided at an early stage if necessary."
    },
    {
        "id": 11878,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Dysphagia therapy should be carried out promptly, on an outpatient basis or as part of inpatient follow-up treatment if indicated."
    },
    {
        "id": 11879,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Sensory disorders or tongue paralysis can occur in the oral cavity following damage to the hypoglossal nerve caused by neck dissection."
    },
    {
        "id": 11880,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Promoting the elasticity of the throat muscles, swallowing aids and dietary adaptation of consistencies can be helpful."
    },
    {
        "id": 11881,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "The dietary reconstruction after laryngopharyngectomy is usually uncomplicated, provided no stenosis has occurred."
    },
    {
        "id": 11882,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Aspirations can occur due to inadequate control of swallowing in the event of sensory disturbances in the hypopharynx and laryngeal inlet, substance deficits in the laryngeal inlet area and a leaky shunt valve after laryngectomy."
    },
    {
        "id": 11883,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Swallowing disorders in the sense of passage disorders with retention in the pharynx occur with mechanical and motor deficits in the area of the oral cavity and pharynx or may only develop after a few weeks or after radiation due to stenosis."
    },
    {
        "id": 11884,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "The most common causes of swallowing disorders are mucosal swelling, scarring or recurrences, which must be clarified diagnostically."
    },
    {
        "id": 11885,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Partial resections of the hypopharynx/larynx are generally function-preserving measures, but can lead to functional impairments depending on the surgical procedure."
    },
    {
        "id": 11886,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Breathing/swallowing coordination can be severely impaired after a partial hypopharyngeal resection."
    },
    {
        "id": 11887,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Swallowing disorders, aspirations and the wearing of a blocked tracheostomy tube, which makes voiced speech impossible, are the result of a partial hypopharyngeal resection."
    },
    {
        "id": 11889,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Swallowing should be trained as early as possible."
    },
    {
        "id": 11890,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "The therapy includes elements of elasticity promotion to improve mobility and coordination of the processes in the respiratory-swallowing tract."
    },
    {
        "id": 11891,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "The therapy includes compensatory procedures such as head posture changes during swallowing, swallowing maneuvers."
    },
    {
        "id": 11892,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Various studies on head and neck tumours in general show a decrease in dysphagia when therapy is started early."
    },
    {
        "id": 11894,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Kulbersh et al. confirm clinical observations according to which the swallowing results after radiotherapy were significantly better if speech therapy was started 14 days before radiotherapy."
    },
    {
        "id": 11895,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Adequate pain and nutrition therapy is necessary at an early stage for the patient to withstand the stress of therapy."
    },
    {
        "id": 11896,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "If possible, tube feeding should not be the patient's sole form of nutrition."
    },
    {
        "id": 11897,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "Gillespie et al. showed that swallowing ability deteriorated after 14 days following tube feeding alone without oral nutrition."
    },
    {
        "id": 11898,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 168,
        "content": "During regular oral intake, even of small amounts, all structures involved in the swallowing process are moved and kept elastic several times a day."
    },
    {
        "id": 11901,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 169,
        "content": "Speech and voice rehabilitation should be carried out as part of inpatient rehabilitation or on an outpatient basis."
    },
    {
        "id": 11902,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 169,
        "content": "Speech and voice function should be taken into account even before the start of tumour therapy."
    },
    {
        "id": 11904,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 169,
        "content": "When deciding which procedure to use for speech and voice rehabilitation after treatment of oropharyngeal or hypopharyngeal cancer, the expected anatomical conditions after treatment, the findings of the voice and articulation diagnostics and the patient's preference should be taken into account."
    },
    {
        "id": 11905,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 169,
        "content": "Motor function restrictions of the soft palate and tongue, as well as sensitivity disorders, can lead to pronunciation disorders."
    },
    {
        "id": 11907,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 169,
        "content": "Targeted speech therapy (dysglossia therapy) should be carried out for patients with pronunciation disorders."
    },
    {
        "id": 11908,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 169,
        "content": "Patients who have not undergone direct laryngeal surgery but have been treated with radiotherapy or radiochemotherapy often develop a voice disorder and can benefit from voice therapy."
    },
    {
        "id": 11909,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 169,
        "content": "Voice rehabilitation after laryngectomy and partial laryngectomy for hypopharyngeal carcinoma is discussed in detail in section 7.10.2 of the S3 guideline on laryngeal carcinoma."
    },
    {
        "id": 12001,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 173,
        "content": "Up to 50% of pre-therapeutic head and neck cancer patients do not return to work after tumour therapy."
    },
    {
        "id": 12002,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 173,
        "content": "Job changes and reductions in working hours are common among head and neck cancer patients after tumour therapy."
    },
    {
        "id": 12003,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 173,
        "content": "Rehabilitation measures and reintegration programs have shown positive effects for head and neck cancer patients."
    },
    {
        "id": 12005,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 173,
        "content": "The psychosocial counselling offered by the social services should be low-threshold for patients with oropharyngeal and hypopharyngeal carcinoma."
    },
    {
        "id": 12006,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 173,
        "content": "Patients with oropharyngeal and hypopharyngeal carcinoma should receive initial oncological counselling from the social workers at acute hospitals and rehabilitation facilities in an inpatient context."
    },
    {
        "id": 12008,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 173,
        "content": "Occupational therapy is particularly emphasized in the occupational rehabilitation of head and neck tumour patients."
    },
    {
        "id": 12010,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 173,
        "content": "Occupational therapy can positively impact the debilitating stress and anxiety associated with head and neck cancer diagnosis, treatment and recovery."
    },
    {
        "id": 12012,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 174,
        "content": "The Evidence-based Guideline Oropharyngeal and Hypopharyngeal Carcinoma recommends immediate and long-term needs-oriented psycho-oncological care."
    },
    {
        "id": 12013,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 174,
        "content": "Immediate and long-term needs-oriented psycho-oncological care should be ensured for patients with head and neck tumours."
    },
    {
        "id": 12014,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 174,
        "content": "Around 30% of all patients with head and neck tumours suffer from severe psychological stress."
    },
    {
        "id": 12015,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 174,
        "content": "Relatives of patients with head and neck tumours frequently suffer from anxiety and depression."
    },
    {
        "id": 12020,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 174,
        "content": "Psycho-oncological care has been shown to help improve the psychological well-being of cancer patients and increase their quality of life."
    },
    {
        "id": 12021,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 174,
        "content": "All patients with increased psychological stress should be offered psycho-oncological care."
    },
    {
        "id": 12022,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 174,
        "content": "Psycho-oncological care should not only be offered during the patient's inpatient treatment, but should also be considered during aftercare."
    },
    {
        "id": 12023,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 174,
        "content": "Psycho-oncological care should be based on the S3 Guideline: 'Psycho-oncological diagnostics, counselling and therapy'."
    },
    {
        "id": 12024,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 174,
        "content": "The treatment phase and the disease- and therapy-related effects on physical, psychological and social functioning often lead to dramatic changes in the social lives of people with cancer and their caregivers."
    },
    {
        "id": 12028,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 174,
        "content": "Medical-occupational orientation in rehabilitation is important for the targeted, interdisciplinary promotion of occupational integration."
    },
    {
        "id": 12029,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 175,
        "content": "The psychosocial rehabilitation enables patients to test the skills they need for their profession."
    },
    {
        "id": 12030,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 175,
        "content": "The psychosocial rehabilitation enables patients to train any deficits in a targeted manner."
    },
    {
        "id": 12031,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 175,
        "content": "Patients and relatives should be informed about possible psychosocial consequences during primary therapy."
    },
    {
        "id": 12032,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 175,
        "content": "Patients and relatives should receive help during primary therapy if necessary."
    },
    {
        "id": 12035,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 175,
        "content": "The non-medical aspects and stresses should be taken into account during the initial process of providing information about the tumour disease."
    },
    {
        "id": 12036,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 175,
        "content": "The non-medical aspects and stresses should be taken into account during the initial process of providing information about the treatment options."
    },
    {
        "id": 12037,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 175,
        "content": "The non-medical aspects and stresses should be taken into account during the initial process of providing information about the course of the disease."
    },
    {
        "id": 12038,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 175,
        "content": "The doctor should point out the additional contacts in the various areas."
    },
    {
        "id": 12039,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 175,
        "content": "The doctor should point out the wide range of support options."
    },
    {
        "id": 12040,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "Patients with oropharyngeal/hypopharyngeal carcinoma are entitled under social law to follow-up treatment (FUT) and subsequently to medical rehabilitation."
    },
    {
        "id": 12041,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "Follow-up treatment (FUT) and medical rehabilitation should be recommended by the doctor."
    },
    {
        "id": 12042,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "Patients with oropharyngeal and hypopharyngeal cancer should be rehabilitated in appropriately specialized facilities."
    },
    {
        "id": 12043,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "Pre-, peri- and post-therapeutic rehabilitative measures should be part of the treatment concept for the best possible functional outcome."
    },
    {
        "id": 12044,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "Primary therapy should be followed by inpatient rehabilitation in the form of follow-up treatment (FUT) depending on the need for rehabilitation and the patient's ability and willingness to undergo rehabilitation."
    },
    {
        "id": 12045,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "The aim of medical rehabilitation is to promote the patient's self-determined participation in the sense of an independent and responsible social life despite health and functional limitations and to enable reintegration into working life."
    },
    {
        "id": 12046,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "Follow-up treatment is prescribed by the attending physicians as part of the inpatient stay or as part of outpatient tumour aftercare."
    },
    {
        "id": 12047,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "The social services of the acute hospitals provide advice and initiate rehabilitation."
    },
    {
        "id": 12048,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "Patients with oropharyngeal or hypopharyngeal cancer who have received radiotherapy/radiochemotherapy should start rehabilitation at the earliest six weeks after the end of radiotherapy."
    },
    {
        "id": 12050,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "Lymphoedema increasingly develops in the skin and mucous membrane of the head and neck area after radiotherapy."
    },
    {
        "id": 12051,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "Lymphoedema is fully developed after six weeks and must be treated with lymphatic drainage."
    },
    {
        "id": 12052,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "The period for commencing FUT after radiotherapy/radiochemotherapy is extended to up to 10 weeks."
    },
    {
        "id": 12053,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 176,
        "content": "In individual cases, FUT can be started earlier as a complex medical inpatient measure with swallowing therapy."
    },
    {
        "id": 12054,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Psychosocial rehabilitation includes tests and training, nutritional stabilization, lymph drainage, exercise therapy, and adapted medication and pain therapy."
    },
    {
        "id": 12055,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Patients have the option of repeating the inpatient rehabilitation measure depending on the extent of the symptoms and functional impairments."
    },
    {
        "id": 12056,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Prehabilitation is the targeted preparation for an operation or a debilitating therapy."
    },
    {
        "id": 12057,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Prehabilitation combines various components that are individually tailored to the patient, including physiotherapy, muscle and breathing training, weight loss, and nutritional therapy."
    },
    {
        "id": 12058,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Initial studies have shown the positive effects of prehabilitation in endoprosthetics."
    },
    {
        "id": 12059,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Prehabilitation is still in its infancy in Germany and is only widespread for hip and knee replacements."
    },
    {
        "id": 12060,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Current studies show clear evidence of the positive effects of more intensive preparation for surgery in patients with frailty and malnutrition."
    },
    {
        "id": 12061,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Frailty and malnutrition have a significant influence on peri- and post-therapeutic morbidity and oncological functional outcome."
    },
    {
        "id": 12062,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "More than a third of hospitalized patients suffer from malnutrition."
    },
    {
        "id": 12063,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "The aim of oncological prehabilitation is to identify malnutrition, frailty, and anaemia in particular and to improve them before the start of therapy."
    },
    {
        "id": 12064,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "The increased therapy-related morbidity risk of increasingly elderly and multimorbid head and neck tumour patients is well known."
    },
    {
        "id": 12065,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "The frailty score can be recorded for head and neck tumour patients."
    },
    {
        "id": 12066,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "The S3 guidelines on oral cavity and laryngeal carcinoma do not yet contain any clear recommendations on targeted pre-therapeutic preparation."
    },
    {
        "id": 12067,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Recommendations largely focus on improving therapies and on classic rehabilitation measures."
    },
    {
        "id": 12068,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "In Germany, professional swallowing therapy is usually only carried out when symptoms occur, as part of a specific rehabilitation measure, usually postoperatively or following radio(chemo)therapy."
    },
    {
        "id": 12069,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Head and neck tumour patients are particularly susceptible to malnutrition due to the location of the tumours in the upper aerodigestive tract and the resulting dysphagia."
    },
    {
        "id": 12070,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Possible serious consequences of dysphagia include malnutrition, the risk of aspiration pneumonia, and the associated increased mortality, social isolation, and loss of quality of life."
    },
    {
        "id": 12071,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "The prevalence of dysphagia among head and neck tumour patients is up to 80%, depending on tumour location and extent."
    },
    {
        "id": 12072,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Study results increasingly indicate that head and neck tumour patients benefit if dysphagia therapy begins before or during radiotherapy."
    },
    {
        "id": 12073,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 177,
        "content": "Preventive exercises can reduce the consequences of pre-existing dysphagia or dysphagia that occurs as a result of therapy."
    },
    {
        "id": 12074,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "The result of therapy shows that active exercises to improve swallowing function immediately after radio(chemo)therapy lead to demonstrably better outcomes."
    },
    {
        "id": 12075,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "Evidence of long-term benefit of active exercises to improve swallowing function immediately after radio(chemo)therapy is still lacking."
    },
    {
        "id": 12076,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "Collectives with primarily surgically treated patients have hardly been studied to date with regard to the effectiveness of prehabilitative measures."
    },
    {
        "id": 12077,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "Suitable criteria for patient selection have not been developed for collectives with primarily surgically treated patients."
    },
    {
        "id": 12078,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "Frailty scores have been systematically introduced."
    },
    {
        "id": 12079,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "There is a growing awareness of individualized therapy preparation."
    },
    {
        "id": 12080,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "The diet must be adapted to the treatment procedure and the resulting function of the swallowing act."
    },
    {
        "id": 12081,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "Sensitivity disorders in the oral cavity following damage to the lingual nerve can impair food intake."
    },
    {
        "id": 12082,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "Mucositis following radiotherapy can impair food intake."
    },
    {
        "id": 12083,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "Compensatory swallowing techniques and dietary adjustment of consistencies can be helpful."
    },
    {
        "id": 12084,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "Aspiration of saliva, liquids and food are typical consequences in the first few weeks after immediate larynx-preserving surgery/radiation of the hypopharynx or surgery near the larynx/radiation in the base of the tongue."
    },
    {
        "id": 12085,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "It takes time for compensatory replacement strategies to develop to create new closures."
    },
    {
        "id": 12086,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "After partial laryngectomy, unilateral hyperplasia of the base of the tongue and the contralateral arytenoid cartilage can develop after a few weeks and form the new closure."
    },
    {
        "id": 12087,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 178,
        "content": "Initial postoperative swelling may also subside after a few weeks."
    },
    {
        "id": 12103,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 179,
        "content": "Oro- and hypopharyngeal carcinomas can lead to swallowing difficulties with significant weight loss and aspiration with consecutive pneumonia even before the diagnosis is made."
    },
    {
        "id": 12104,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 179,
        "content": "Surgical therapies and adjuvant radiotherapy or radiochemotherapy cause relevant swallowing problems with the risk of serious malnutrition and/or aspiration pneumonia, just like primary radiotherapy or radiochemotherapy."
    },
    {
        "id": 12105,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 180,
        "content": "Early nutritional support must be ensured for all patients with oropharyngeal and hypopharyngeal carcinomas."
    },
    {
        "id": 12106,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 180,
        "content": "Repeated nutritional counselling with dietary modifications contribute to the success of treatment and quality of life in patients with head and neck cancer who have difficulty swallowing."
    },
    {
        "id": 12107,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 180,
        "content": "Risk factors for prolonged postoperative dysphagia include pharyngotomy, resection at the base of the tongue, reconstruction with a pectoralis major flap, advanced tumour growth, alcohol abuse and radiation and radiation chemotherapy."
    },
    {
        "id": 12108,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 180,
        "content": "In uncomplicated cases, nutrition can be provided with soft or liquid high-calorie food, possibly supported by local and systemic analgesic therapies, provided the patient does not aspirate."
    },
    {
        "id": 12109,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 180,
        "content": "If these measures are not sufficient, nutrition must be provided via a PEG or nasogastric tube or parenterally."
    },
    {
        "id": 12110,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 180,
        "content": "The PEG tube has proven to be safe and effective."
    },
    {
        "id": 12112,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 180,
        "content": "Early swallowing training led to a significant reduction in the duration of PEG tube placement."
    },
    {
        "id": 12117,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 180,
        "content": "Palliative care has been described in detail in a current S3 guideline, backed up with the latest evidence and has also been comprehensively agreed to for patients with oropharyngeal and hypopharyngeal carcinomas."
    },
    {
        "id": 12118,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 180,
        "content": "The basic aim of palliative care is to improve or maintain the quality of life of patients and their families by alleviating and preventing suffering, despite incurable illness."
    },
    {
        "id": 12131,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 181,
        "content": "Patients with oropharyngeal or hypopharyngeal carcinoma require special attention to maintain their ability to communicate and overcome social isolation."
    },
    {
        "id": 12132,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 181,
        "content": "Patients with oropharyngeal or hypopharyngeal carcinoma require special attention even at the end of life."
    },
    {
        "id": 12136,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "The maximum follow-up intervals should be 3 months for the 1st and 2nd year and 6 months for the 3rd to 5th year, even if there are no symptoms."
    },
    {
        "id": 12137,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "A risk-adapted specialist aftercare plan should be drawn up for each patient."
    },
    {
        "id": 12138,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "Quality of life and pain should be assessed regularly."
    },
    {
        "id": 12139,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "After the 5th year, regular specialist check-ups should be offered."
    },
    {
        "id": 12140,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "Regular tumour follow-up care is an essential part of the overall treatment."
    },
    {
        "id": 12141,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "The radio-oncologist in charge and the specialist colleague in charge should carry out tumour follow-up care on an interdisciplinary basis and in communication with each other."
    },
    {
        "id": 12142,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "Around a quarter of patients with oropharyngeal and hypopharyngeal carcinoma experience a local tumour recurrence, which usually occurs within the first two years."
    },
    {
        "id": 12143,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "Recurrences still develop in a few cases even in the third year after primary treatment has been completed."
    },
    {
        "id": 12144,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "The main aim of tumour follow-up care is the careful examination of the larynx and neck to rule out recurrent carcinomas."
    },
    {
        "id": 12145,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "Recurrent carcinomas only lead to symptoms in 61% of cases and are therefore not noticed by 39% of patients."
    },
    {
        "id": 12146,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "Tumour follow-up care detects metachronous secondary tumours in the upper aerodigestive tract and lungs."
    },
    {
        "id": 12147,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 182,
        "content": "Metachronous secondary tumours in the upper aerodigestive tract and lungs are associated with a similar risk profile to oro- (excluding HPV) and hypopharyngeal carcinomas and occur in 4-33% of patients."
    },
    {
        "id": 12163,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 183,
        "content": "Imaging plays an important role in the aftercare of oropharyngeal and hypopharyngeal cancer."
    },
    {
        "id": 12165,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 183,
        "content": "High-resolution CT is very sensitive in the area of the oropharynx and hypopharynx."
    },
    {
        "id": 12166,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 183,
        "content": "High-resolution CT is the procedure of first choice."
    },
    {
        "id": 12167,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 183,
        "content": "High-resolution CT can visualize the lymphatic drainage channels of the neck to detect or rule out metastases."
    },
    {
        "id": 12168,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 183,
        "content": "MRI can be advantageous when it comes to the question of cartilage infiltration in hypopharyngeal carcinoma."
    },
    {
        "id": 12169,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 183,
        "content": "MRI can be advantageous when it comes to the question of soft tissue contrast."
    },
    {
        "id": 12197,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 185,
        "content": "Patients with laryngeal carcinoma receive initial oncological counselling from the social services of acute hospitals and rehabilitation facilities in an inpatient context."
    },
    {
        "id": 12203,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 186,
        "content": "The multidisciplinary care of patients with oropharyngeal and hypopharyngeal carcinomas should be provided by facilities that meet the certification requirements of the German Cancer Society (certified head and neck tumour centres)."
    },
    {
        "id": 12205,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 186,
        "content": "The patient should receive the best possible care in accordance with the latest medical knowledge."
    },
    {
        "id": 12207,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 186,
        "content": "Highly qualified centres, preferably certified head and neck tumour centres according to the German Cancer Society, are required for comprehensive care."
    },
    {
        "id": 12208,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 186,
        "content": "The chosen therapy, including psycho-oncological and phoniatric care, and rehabilitation can be implemented at certified head and neck tumour centres."
    },
    {
        "id": 12204,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 186,
        "content": "The German Cancer Society has certification requirements for head and neck tumour centres."
    },
    {
        "id": 12226,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 187,
        "content": "The current findings support concentrating the multidisciplinary care of patients with oropharyngeal and hypopharyngeal carcinomas in certified treatment facilities."
    },
    {
        "id": 12228,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 187,
        "content": "Primary care ENT physicians/specialists and general practitioners must be involved in the care of patients with oropharyngeal and hypopharyngeal carcinomas."
    },
    {
        "id": 12229,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 187,
        "content": "The involvement of primary care ENT physicians/specialists and general practitioners is necessary to ensure optimal care."
    },
    {
        "id": 12233,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 187,
        "content": "The coordination of patient care by the primary treating clinic is of great importance."
    },
    {
        "id": 12234,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 187,
        "content": "The primary treating clinic should preferably be a certified centre."
    },
    {
        "id": 12270,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 190,
        "content": "GGPO published an evidence-based guideline for oropharyngeal and hypopharyngeal carcinoma in February 2024."
    },
    {
        "id": 12246,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 188,
        "content": "Quality Indicator 1 is p16 Immunohistology."
    },
    {
        "id": 12250,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 188,
        "content": "Quality Indicator 2 is Information in the histopathology report after resection."
    },
    {
        "id": 12273,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 190,
        "content": "Quality Indicator 3 is about CT/MRI neck for lymph node staging."
    },
    {
        "id": 12277,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 190,
        "content": "Quality Indicator 4 is about thoracic CT to rule out pulmonary tumour involvement."
    },
    {
        "id": 12281,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 190,
        "content": "Quality Indicator 5 is about imaging to exclude liver metastases."
    },
    {
        "id": 12291,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 191,
        "content": "Panendoscopy should be performed as part of the primary diagnosis of oropharyngeal and hypopharyngeal carcinomas."
    },
    {
        "id": 12292,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 191,
        "content": "Panendoscopy is a central component of primary diagnostics for more precise expansion of the primary tumour and for the detection of secondary carcinomas."
    },
    {
        "id": 12296,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 191,
        "content": "The treatment of oropharyngeal and hypopharyngeal carcinoma should be carried out on an interdisciplinary basis after coordination of each individual case within tumour boards involving the specialist disciplines of otorhinolaryngology, oral and maxillofacial surgery, radiation oncology, oncology, pathology and radiology."
    },
    {
        "id": 12301,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 191,
        "content": "In stage III-IVb hypopharyngeal carcinoma, simultaneous chemotherapy should be performed."
    },
    {
        "id": 12315,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 192,
        "content": "Hypopharyngeal carcinomas with pT3/pT4, pN2-pN3, or narrow or positive resection margins (R0 <5mm) should receive postoperative radio- or radiochemotherapy."
    },
    {
        "id": 12306,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 192,
        "content": "Quality Indicator 1 has a denominator of all patients with a first diagnosis of stage I/II or III oropharyngeal carcinoma or HPV/p16 negative oropharyngeal carcinoma stage IV-A/IV-B or stage III/IV-A/IV-B hypopharyngeal carcinoma and primary simultaneous radiochemotherapy cisplatin-based in the case of primary radiochemotherapy."
    },
    {
        "id": 12309,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 192,
        "content": "Quality Indicator 9 has a denominator of all patients with a first diagnosis of stage III oropharyngeal carcinoma or HPV/p16 negative oropharyngeal carcinoma stage IV-A/IV-B or stage III/IV-A/IV-B hypopharyngeal carcinoma \u2264 70 years without resection."
    },
    {
        "id": 12312,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 192,
        "content": "Quality Indicator 10 has a denominator of all patients with an initial diagnosis of hypopharyngeal carcinoma and surgical treatment and pT3/pT4 and/or pN2/pN3 and/or R1 resection/R0<5mm."
    },
    {
        "id": 12322,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 193,
        "content": "Quality Indicator 11 recommends that swallowing function should be examined as early as possible post-operatively or post-therapeutically."
    },
    {
        "id": 12327,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 193,
        "content": "Quality Indicator 12 recommends that patients with oropharyngeal/hypopharyngeal carcinoma should be informed about their entitlement to follow-up treatment and medical rehabilitation under social law."
    },
    {
        "id": 12331,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 194,
        "content": "Quality Indicator 13 is about 30d mortality."
    },
    {
        "id": 12389,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 197,
        "content": "Roesch-Ely M, Leipold A, Nees M, Holzinger D, Dietz A, Flechtenmacher C, et al. wrote an article titled Proteomic analysis of field cancerization in pharynx and oesophagus: a prospective pilot study."
    },
    {
        "id": 12394,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 197,
        "content": "Ang K, Harris J, Wheeler R, Weber R, Rosenthal D, Nguyen-T\u00e2n P, et al. wrote an article titled Human papillomavirus and survival of patients with oropharyngeal cancer."
    },
    {
        "id": 12397,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 197,
        "content": "Klussmann J, Weissenborn S, Wieland U, Dries V, Eckel H, Pfister H, et al. wrote an article titled Human papillomavirus-positive tonsillar carcinomas: a different tumor entity?."
    },
    {
        "id": 12403,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 197,
        "content": "Guntinas-Lichius O, Wendt T, Buentzel J, Esser D, Lochner P, Mueller A, et al. wrote an article titled Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database."
    },
    {
        "id": 12406,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 197,
        "content": "Petersen J, Timmermans A, van Dijk B, Overbeek L, Smit L, Hilgers F, et al. wrote an article titled Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands."
    },
    {
        "id": 12409,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 197,
        "content": "Jakobsen K, Gr\u00f8nh\u00f8j C, Jensen D, Karnov K, Agander T, Specht L, et al. wrote an article titled Increasing incidence and survival of head and neck cancers in Denmark: a nation-wide study from 1980 to 2014."
    },
    {
        "id": 12412,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Menezes F et al. published a systematic review of population-based studies on global incidence trends in head and neck cancer for HPV-related and -unrelated subsites in Oral Oncol in 2021."
    },
    {
        "id": 12415,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Klussmann J et al. published a study on the prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas in Cancer in 2001."
    },
    {
        "id": 12418,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Castellsagu\u00e9 X et al. published a comprehensive assessment of biomarkers in 3680 patients with head and neck cancers in J Natl Cancer Inst in 2016."
    },
    {
        "id": 12421,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Reuschenbach M et al. published a systematic review of the HPV-attributable fraction of oropharyngeal squamous cell carcinomas in Germany in Cancer Med in 2019."
    },
    {
        "id": 12424,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Bayer O et al. published a study on changes in incidence and mortality trends of head and neck cancer in Rhineland-Palatinate from 2000-2009 in Laryngorhinootologie in 2015."
    },
    {
        "id": 12427,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Tinhofer I et al. published a study on the contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence in Eur J Cancer in 2015."
    },
    {
        "id": 12430,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Wittekindt C et al. published a study on HPV and head and neck cancer in Laryngorhinootologie in 2018."
    },
    {
        "id": 12433,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Wittekindt C et al. published a study on increasing incidence rates of oropharyngeal squamous cell carcinoma in Germany and significance of disease burden attributed to human papillomavirus in Cancer Prev Res in 2019."
    },
    {
        "id": 12436,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Liao C et al. published a study on trends in human papillomavirus-associated cancers, demographic characteristics, and vaccinations in the US from 2001-2017 in JAMA Netw Open in 2022."
    },
    {
        "id": 12439,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Suchan M et al. published a study on HPV-related oropharyngeal squamous cell carcinoma in HNO in 2021."
    },
    {
        "id": 12442,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Dietz A et al. published a study on update treatment HPV-16-positive oropharyngeal carcinoma in Laryngorhinootologie in 2021."
    },
    {
        "id": 12445,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Maier H et al. published a study on occupation and cancer of the oral cavity, pharynx, and larynx in HNO in 1990."
    },
    {
        "id": 12448,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 198,
        "content": "Maier H et al. published a study on tobacco- and alcohol-associated cancer risk of the upper respiratory and digestive tract in Laryngorhinootologie in 1990."
    },
    {
        "id": 12451,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Maier H, Dietz A, Zielinski D, J\u00fcnemann K, and Heller W published a study on risk factors for squamous epithelial carcinoma of the mouth, the oropharynx, the hypopharynx, and the larynx in 1990."
    },
    {
        "id": 12454,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Bosetti C, Gallus S, Trichopoulou A, Talamini R, Franceschi S, Negri E, et al published a study on the influence of the Mediterranean diet on the risk of cancers of the upper aerodigestive tract in 2003."
    },
    {
        "id": 12457,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Levi F, Pasche C, Lucchini F, Chatenoud L, Jacobs D, and La Vecchia C published a study on refined and whole grain cereals and the risk of oral, oesophageal, and laryngeal cancer in 2000."
    },
    {
        "id": 12460,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Uzcudun A, Retolaza I, Fern\u00e1ndez P, S\u00e1nchez Hern\u00e1ndez J, Grande A, Garc\u00eda A, et al published a study on nutrition and pharyngeal cancer in 2002."
    },
    {
        "id": 12463,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Franceschi S, Favero A, Conti E, Talamini R, Volpe R, Negri E, et al published a study on food groups, oils and butter, and cancer of the oral cavity and pharynx in 1999."
    },
    {
        "id": 12466,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Riechelmann H published a study on occupational exposure and cancer of the oral cavity and pharynx in 2002."
    },
    {
        "id": 12469,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Dietz A, Heller W, and Maier H published a study on epidemiologic aspects of cancers of the head-neck area in 1991."
    },
    {
        "id": 12472,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Dietz A and Maier H published a study on occupational cancer in 1997."
    },
    {
        "id": 12475,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Maier H, Gewelke U, Dietz A, Thamm H, Heller W, and Weidauer H published a study on laryngeal cancer and occupation in 1992."
    },
    {
        "id": 12478,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Weichert W, Ihrler S, Boxberg M, Agaimy A, Mollenhauer M, and Hartmann A published a study on morphology of non-cutaneous head and neck squamous cell carcinoma in 2018."
    },
    {
        "id": 12482,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Agaimy A and Hartmann A published a study on head and neck neoplasms in 2018."
    },
    {
        "id": 12486,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 199,
        "content": "Wichmann G published a study on variation of HPV subtypes with focus on HPV-infection and cancer in the head and neck region in 2016."
    },
    {
        "id": 12493,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 201 is about mutations in diagnostic and prognostic profiling of head and neck cancer."
    },
    {
        "id": 12495,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 43 is about HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management."
    },
    {
        "id": 12501,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 44 is about etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control."
    },
    {
        "id": 12509,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 45 is about expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus."
    },
    {
        "id": 12516,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 46 is about tumor immunity and immunotherapy for HPV-related cancers."
    },
    {
        "id": 12523,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 47 is about the innate immune system in oropharyngeal squamous cell carcinoma: immune modulation by HPV."
    },
    {
        "id": 12530,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 48 is about combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer."
    },
    {
        "id": 12538,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 49 is about HPV infection in head and neck cancer."
    },
    {
        "id": 12543,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 50 is about prognostic implications of p16 and HPV discordance in oropharyngeal cancer."
    },
    {
        "id": 12551,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 51 is about prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 0202 phase III trial."
    },
    {
        "id": 12559,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 52 is about extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 12567,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 53 is about the expanding role of cytopathology in the diagnosis of HPV-related squamous cell carcinoma of the head and neck."
    },
    {
        "id": 12571,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 54 is about case-control study of human papillomavirus and oropharyngeal cancer."
    },
    {
        "id": 12579,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 200,
        "content": "The literature reference 55 is about characterization of human papillomavirus (HPV) 16 E6 seropositive individuals without HPV-associated malignancies after 10 years of follow-up in the UK Biobank."
    },
    {
        "id": 12614,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "Schroeder L is an author of a research paper published in Int J Cancer in 2018."
    },
    {
        "id": 12615,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Schroeder L et al. is about antibodies against human papillomaviruses as diagnostic and prognostic biomarker in patients with neck squamous cell carcinoma from unknown primary tumor."
    },
    {
        "id": 12616,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Schroeder L et al. was published in Int J Cancer in 2018."
    },
    {
        "id": 12617,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "Faden D is an author of a research paper published in Cancer Cytopathol in 2022."
    },
    {
        "id": 12618,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Faden D is about liquid biopsy for the diagnosis of HPV-associated head and neck cancer."
    },
    {
        "id": 12619,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Faden D was published in Cancer Cytopathol in 2022."
    },
    {
        "id": 12620,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "Reder H is an author of a research paper published in J Mol Diagn in 2020."
    },
    {
        "id": 12621,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Reder H et al. is about plasma cell-free human papillomavirus oncogene E6 and E7 DNA predicts outcome in oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 12622,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Reder H et al. was published in J Mol Diagn in 2020."
    },
    {
        "id": 12623,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "Dahlstrom K is an author of a research paper published in Oral Oncol in 2021."
    },
    {
        "id": 12624,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Dahlstrom K et al. is about screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men."
    },
    {
        "id": 12625,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Dahlstrom K et al. was published in Oral Oncol in 2021."
    },
    {
        "id": 12626,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "Wichmann G is an author of a research paper published in Cancers (Basel) in 2023."
    },
    {
        "id": 12627,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Wichmann G et al. is about high-risk sexual behavior as a risk factor for oropharyngeal cancer."
    },
    {
        "id": 12628,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Wichmann G et al. was published in Cancers (Basel) in 2023."
    },
    {
        "id": 12629,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "Quabius E is an author of a research paper published in Papillomavirus Res in 2020."
    },
    {
        "id": 12630,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Quabius E et al. is about no association between HPV-status in tonsillar tissue and sexual behavior of the patients in a northern German population."
    },
    {
        "id": 12631,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Quabius E et al. was published in Papillomavirus Res in 2020."
    },
    {
        "id": 12632,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "Reuschenbach M is an author of a research paper published in HNO in 2016."
    },
    {
        "id": 12633,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Reuschenbach M et al. is about human papillomavirus and squamous cell cancer of the head and neck region."
    },
    {
        "id": 12634,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Reuschenbach M et al. was published in HNO in 2016."
    },
    {
        "id": 12635,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "Zimmermann P is an author of a research paper published in Cancers (Basel) in 2021."
    },
    {
        "id": 12636,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Zimmermann P et al. is about upfront surgery vs primary chemoradiation in an unselected, bicentric patient cohort with oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 12637,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Zimmermann P et al. was published in Cancers (Basel) in 2021."
    },
    {
        "id": 12638,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "Wagner S is an author of a research paper published in Br J Cancer in 2017."
    },
    {
        "id": 12639,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Wagner S et al. is about human papillomavirus association is the most important predictor for surgically treated patients with oropharyngeal cancer."
    },
    {
        "id": 12640,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The research paper by Wagner S et al. was published in Br J Cancer in 2017."
    },
    {
        "id": 12650,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "Amin MB is an author of the AJCC cancer staging manual."
    },
    {
        "id": 12651,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "The AJCC cancer staging manual is in its 8th edition."
    },
    {
        "id": 12652,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 203,
        "content": "Fakhry C is an author of the ASCO clinical practice guideline on human papillomavirus testing in head and neck carcinomas."
    },
    {
        "id": 12653,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "The literature reference is from GGPO and is an evidence-based guideline for Oropharyngeal and Hypopharyngeal Carcinoma."
    },
    {
        "id": 12654,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "The guideline is in its 1.0 version and was published in February 2024."
    },
    {
        "id": 12656,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "Chera B et al. studied the rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy."
    },
    {
        "id": 12657,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "The study by Chera B et al. correlated with disease control in HPV-associated oropharyngeal cancer."
    },
    {
        "id": 12659,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "Haring C et al. studied the human papilloma virus circulating tumor DNA assay and its ability to predict treatment response."
    },
    {
        "id": 12660,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "The study by Haring C et al. was conducted in recurrent/metastatic head and neck squamous cell carcinoma."
    },
    {
        "id": 12662,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "Tanaka H et al. studied the performance of oral HPV DNA, oral HPV mRNA, and circulating tumor HPV DNA in the detection of HPV-related oropharyngeal cancer."
    },
    {
        "id": 12663,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "The study by Tanaka H et al. also detected cancer of unknown primary."
    },
    {
        "id": 12665,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "Cao Y et al. studied the early HPV ctDNA kinetics and imaging biomarkers and their ability to predict therapeutic response."
    },
    {
        "id": 12666,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "The study by Cao Y et al. was conducted in p16+ oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 12668,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "Mattox A et al. compared next-generation sequencing, droplet digital PCR, and quantitative real-time PCR for the earlier detection and quantification of HPV."
    },
    {
        "id": 12669,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "The study by Mattox A et al. was conducted in HPV-positive oropharyngeal cancer."
    },
    {
        "id": 12671,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "Haring C et al. discussed the future of circulating tumor DNA as a biomarker in HPV-related oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 12673,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "O'Sullivan B et al. developed and validated a staging system for HPV-related oropharyngeal cancer."
    },
    {
        "id": 12674,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "The study by O'Sullivan B et al. was conducted by the International Collaboration on Oropharyngeal cancer Network for Staging."
    },
    {
        "id": 12676,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "Huang S et al. refined the American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups."
    },
    {
        "id": 12677,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "The study by Huang S et al. was conducted for human papillomavirus-related oropharyngeal carcinomas."
    },
    {
        "id": 12679,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "Haughey B et al. developed a pathology-based staging for HPV-positive squamous carcinoma of the oropharynx."
    },
    {
        "id": 12681,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "Huang S et al. studied the prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma."
    },
    {
        "id": 12682,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "The study by Huang S et al. also refined the TNM-8 cN-classification."
    },
    {
        "id": 12684,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "Boscolo-Rizzo P et al. discussed the AJCC/UICC eighth edition for staging head and neck cancers."
    },
    {
        "id": 12685,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 205,
        "content": "Boscolo-Rizzo P et al. questioned the wisdom of de-escalating treatment regimens in p16-positive oropharyngeal cancer patients."
    },
    {
        "id": 12694,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 206,
        "content": "Sharma et al. wrote an article about the 8th edition AJCC/UICC TNM staging for p16-positive oropharyngeal carcinoma in Eur Arch Otorhinolaryngol in 2018."
    },
    {
        "id": 12701,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 206,
        "content": "Slootweg wrote about tumours of the hypopharynx, larynx, trachea and parapharyngeal space in the WHO Classification of Head and Neck Tumours in 2017."
    },
    {
        "id": 12706,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 206,
        "content": "Byers et al. wrote about detecting or predicting the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue in Head Neck in 1998."
    },
    {
        "id": 12713,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 206,
        "content": "Brasilino de Carvalho wrote about quantitative analysis of the extent of extracapsular invasion and its prognostic significance in Head Neck in 1998."
    },
    {
        "id": 12715,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 206,
        "content": "Tank\u00e9r\u00e9 et al. wrote about the prognostic value of lymph node involvement in oral cancers in Laryngoscope in 2000."
    },
    {
        "id": 12722,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 206,
        "content": "Woolgar et al. wrote about cervical lymph node metastasis in oral cancer in Oral Oncol in 2003."
    },
    {
        "id": 12728,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 206,
        "content": "Suoglu et al. wrote about extracapsular spread in ipsilateral neck and contralateral neck metastases in laryngeal cancer in Ann Otol Rhinol Laryngol in 2002."
    },
    {
        "id": 12741,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 206,
        "content": "Esposito et al. wrote about occult lymph node metastases in supraglottic cancers of the larynx in Otolaryngol Head Neck Surg in 2001."
    },
    {
        "id": 12746,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 206,
        "content": "Enepekides et al. wrote about occult cervical metastases in Otolaryngol Head Neck Surg in 1999."
    },
    {
        "id": 12753,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 206,
        "content": "Ferlito et al. wrote about lymph node micrometastases in head and neck cancer in Acta Otolaryngol in 2001."
    },
    {
        "id": 12758,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 206,
        "content": "Barzan et al. wrote about resection margins in carcinoma of the oral cavity, oro-hypopharynx and larynx in Acta Otorhinolaryngol Ital in 2022."
    },
    {
        "id": 12765,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 207,
        "content": "The significance of 'positive' margins in surgically resected epidermoid carcinomas was studied by Looser K, Shah J, and Strong E."
    },
    {
        "id": 12768,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 207,
        "content": "Scholl P, Byers R, Batsakis J, Wolf P, and Santini H studied microscopic cut-through of cancer in the surgical treatment of squamous carcinoma of the tongue."
    },
    {
        "id": 12771,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 207,
        "content": "Kwok P, Gleich O, H\u00fcbner G, and Strutz J studied the prognostic importance of 'clear versus revised margins' in oral and pharyngeal cancer."
    },
    {
        "id": 12774,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 207,
        "content": "J\u00e4ckel M, Ambrosch P, Martin A, and Steiner W studied the impact of re-resection for inadequate margins on the prognosis of upper aerodigestive tract cancer treated by laser microsurgery."
    },
    {
        "id": 12777,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 207,
        "content": "Haughey B and Sinha P studied prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer."
    },
    {
        "id": 12780,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 207,
        "content": "The National Comprehensive Cancer Network (NCCN) published guidelines for Head and Neck Cancers in 2022."
    },
    {
        "id": 12781,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 207,
        "content": "Rostoft S, O'Donovan A, Soubeyran P, Alibhai S, and Hamaker M wrote about Geriatric Assessment and Management in Cancer."
    },
    {
        "id": 12784,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 207,
        "content": "Chow W, Rosenthal R, Merkow R, Ko C, and Esnaola N wrote about optimal preoperative assessment of the geriatric surgical patient."
    },
    {
        "id": 12787,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 207,
        "content": "Hernandez Torres C and Hsu T wrote a review about Comprehensive Geriatric Assessment in the Older Adult with Cancer."
    },
    {
        "id": 12818,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 208,
        "content": "Krabbe C, Dijkstra P, Pruim J, van der Laan B, van der Wal J, Gravendeel J, et al published an article titled FDG PET in oral and oropharyngeal cancer Value for confirmation of N0 neck and detection of occult metastases in Oral Oncol in 2008."
    },
    {
        "id": 12820,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 208,
        "content": "Nahmias C, Carlson E, Duncan L, Blodgett T, Kennedy J, Long M, et al published an article titled Positron emission tomography/computerized tomography (PET/CT) scanning for preoperative staging of patients with oral/head and neck cancer in J Oral Maxillofac Surg in 2007."
    },
    {
        "id": 12822,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 208,
        "content": "Seitz O, Chambron-Pinho N, Middendorp M, Sader R, Mack M, Vogl T, et al published an article titled 18F-Fluorodeoxyglucose-PET/CT to evaluate tumor, nodal disease, and gross tumor volume of oropharyngeal and oral cavity cancer: comparison with MR imaging and validation with surgical specimen in Neuroradiology in 2009."
    },
    {
        "id": 12804,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 208,
        "content": "Wiegand S, Dietz A, Wichmann G, Kunz V published an article titled [Frailty in Head and Neck Oncology] in Laryngorhinootologie in 2022."
    },
    {
        "id": 12806,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 208,
        "content": "Kunz V, Wichmann G, Lehmann-Laue A, Mehnert-Theuerkauf A, Dietz A, Wiegand S published an article titled Screening for distress, related problems and perceived need for psycho-oncological support in head and neck squamous cell carcinoma (HNSCC) patients: a retrospective cohort study in BMC Cancer in 2021."
    },
    {
        "id": 12808,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 208,
        "content": "Kunz V, Wichmann G, Wald T, Pirlich M, Zebralla V, Dietz A, et al published an article titled Frailty Assessed with FRAIL Scale and G8 Questionnaire Predicts Severe Postoperative Complications in Patients Receiving Major Head and Neck Surgery in J Clin Med in 2022."
    },
    {
        "id": 12810,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 208,
        "content": "Goerres G, Schmid D, Schuknecht B, Eyrich G published an article titled Bone invasion in patients with oral cavity cancer: comparison of conventional CT with PET/CT and SPECT/CT in Radiology in 2005."
    },
    {
        "id": 12812,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 208,
        "content": "Yen T, Chang J, Ng S, Chang Y, Chan S, Wang H, et al published an article titled Staging of untreated squamous cell carcinoma of buccal mucosa with 18F-FDG PET: comparison with head and neck CT/MRI and histopathology in J Nucl Med in 2005."
    },
    {
        "id": 12814,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 208,
        "content": "Hafidh M, Lacy P, Hughes J, Duffy G, Timon C published an article titled Evaluation of the impact of addition of PET to CT and MR scanning in the staging of patients with head and neck carcinomas in Eur Arch Otorhinolaryngol in 2006."
    },
    {
        "id": 12816,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 208,
        "content": "Wax M, Myers L, Gona J, Husain S, Nabi H published an article titled The role of positron emission tomography in the evaluation of the N-positive neck in Otolaryngol Head Neck Surg in 2003."
    },
    {
        "id": 12826,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 208,
        "content": "Dammann F, Horger M, Mueller-Berg M, Schlemmer H, Claussen C, Claussen C, et al published an article titled Rational diagnosis of squamous cell carcinoma of the head and neck region: in an unspecified journal."
    },
    {
        "id": 12828,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 209,
        "content": "Gu D et al. published a study on the assessment of mandibular invasion by squamous cell carcinomas of the oral cavity in Acta Radiol in 2010."
    },
    {
        "id": 12829,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 209,
        "content": "Kyzas P et al. published a meta-analysis on the use of 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma in J Natl Cancer Inst in 2008."
    },
    {
        "id": 12830,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 209,
        "content": "Ng S et al. published a prospective study on the use of 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma in J Nucl Med in 2005."
    },
    {
        "id": 12831,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 209,
        "content": "Ng S et al. published a prospective study on the use of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma in J Clin Oncol in 2006."
    },
    {
        "id": 12832,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 209,
        "content": "Sumi M et al. published a study on the diagnostic performance of MRI relative to CT for metastatic nodes of head and neck squamous cell carcinomas in J Magn Reson Imaging in 2007."
    },
    {
        "id": 12833,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 209,
        "content": "Van den Brekel M et al. published a prospective comparative study on modern imaging techniques and ultrasound-guided aspiration cytology for the assessment of neck node metastases in Eur Arch Otorhinolaryngol in 1993."
    },
    {
        "id": 12834,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 209,
        "content": "Wiener E et al. published a study on the comparison of 16-slice MSCT and MRI in the assessment of squamous cell carcinoma of the oral cavity in Eur J Radiol in 2006."
    },
    {
        "id": 12835,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 209,
        "content": "Takes R et al. published a study on the value of ultrasound with ultrasound-guided fine-needle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative neck in Int J Radiat Oncol Biol Phys in 1998."
    },
    {
        "id": 12836,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 209,
        "content": "Stokkel M et al. published a study on the preoperative evaluation of patients with primary head and neck cancer using dual-head 18fluorodeoxyglucose positron emission tomography in Ann Surg in 2000."
    },
    {
        "id": 12837,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 209,
        "content": "Adams S et al. published a prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer in Eur J Nucl Med in 1998."
    },
    {
        "id": 12838,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 209,
        "content": "Andrle J et al. published a study on the initial staging examinations for head and neck squamous cell carcinoma in J Laryngol Otol in 2009."
    },
    {
        "id": 12842,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 211,
        "content": "Schwartz D et al. wrote about FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma."
    },
    {
        "id": 12845,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 211,
        "content": "Jeong H et al. wrote about sentinel lymph node radiolocalization with 99mTc filtered tin colloid in clinically node-negative squamous cell carcinomas of the oral cavity."
    },
    {
        "id": 12848,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 211,
        "content": "Yamazaki Y et al. wrote about assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer."
    },
    {
        "id": 12851,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 211,
        "content": "Piao Y et al. wrote about evaluation of 18F-FDG PET/CT for diagnosing cervical nodal metastases in patients with oral cavity or oropharynx carcinoma."
    },
    {
        "id": 12854,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 211,
        "content": "Park S et al. wrote about the diagnostic performance of CT and MRI for detecting extranodal extension in patients with head and neck squamous cell carcinoma."
    },
    {
        "id": 12857,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 211,
        "content": "Hohlweg-Majert B et al. wrote about preoperative cervical lymph node size evaluation in patients with malignant head/neck tumors."
    },
    {
        "id": 12860,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 211,
        "content": "Thomsen J et al. wrote about staging N0 oral cancer: lymphoscintigraphy and conventional imaging."
    },
    {
        "id": 12863,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 211,
        "content": "To E et al. wrote about whether neck ultrasound is necessary for early stage oral tongue carcinoma with clinically N0 neck."
    },
    {
        "id": 12866,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 211,
        "content": "Borgemeester M et al. wrote about ultrasound-guided aspiration cytology for the assessment of the clinically N0 neck."
    },
    {
        "id": 12869,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 211,
        "content": "Brouwer J et al. wrote about positron emission tomography using [18F]fluorodeoxyglucose (FDG-PET) in the clinically negative neck."
    },
    {
        "id": 12872,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 211,
        "content": "Yen T et al. wrote about staging of untreated squamous cell carcinoma of buccal mucosa with 18F-FDG PET."
    },
    {
        "id": 12878,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 212,
        "content": "Kaanders J and Hordijk G wrote an article titled 'Carcinoma of the larynx: the Dutch national guideline for diagnostics, treatment, supportive care and rehabilitation' in Radiother Oncol. 2002;63(3):299-307."
    },
    {
        "id": 12880,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 212,
        "content": "Pauleit D and others wrote an article titled '18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer' in J Nucl Med. 2006;47(2):256-61."
    },
    {
        "id": 12882,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 212,
        "content": "H\u00f6ing B and others wrote an article titled 'Abdominal ultrasound in head and neck squamous cell carcinoma staging: yes or no?' in Eur Arch Otorhinolaryngol. 2023;280(4):1885-1891."
    },
    {
        "id": 12884,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 212,
        "content": "Chen P and others wrote an article titled 'Utility of abdominal imaging to assess for liver metastasis in patients with head and neck cancer and abnormal liver function tests' in Am J Otolaryngol. 2014;35(2):137-40."
    },
    {
        "id": 12886,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 212,
        "content": "Haerle S and others wrote an article titled 'The value of (18)F-FDG PET/CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma' in Oral Oncol. 2011;47(7):653-9."
    },
    {
        "id": 12890,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 212,
        "content": "Regelink G and others wrote an article titled 'Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities' in Eur J Nucl Med Mol Imaging. 2002;29(8):1024-30."
    },
    {
        "id": 12892,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 212,
        "content": "Richard C and others wrote an article titled 'Preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography imaging in head and neck cancer: does it really improve initial N staging?' in Acta Otolaryngol. 2010;130(12):1421-4."
    },
    {
        "id": 12894,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 212,
        "content": "Minovi A and others wrote an article titled 'Is PET superior to MRI in the pretherapeutic evaluation of head and neck squamous cell carcinoma?' in Kulak Burun Bogaz Ihtis Derg. 2007;17(6):324-8."
    },
    {
        "id": 12896,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 212,
        "content": "Ozer E and others wrote an article titled 'The value of PET/CT to assess clinically negative necks' in Eur Arch Otorhinolaryngol. 2012;269(11):2411-4."
    },
    {
        "id": 12898,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 212,
        "content": "Mehanna H and others wrote an article titled 'PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer' in N Engl J Med. 2016;374(15):1444-54."
    },
    {
        "id": 12900,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 212,
        "content": "Mehanna H and others wrote an article titled 'Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines' in J Laryngol Otol. 2016;130(S2):S90-S96."
    },
    {
        "id": 12903,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Breik et al. compared PET-CT and MRI post-treatment in follow-up imaging of oral, oropharyngeal, and hypopharyngeal cancer patients."
    },
    {
        "id": 12906,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Davidson et al. published a study about the role of panendoscopy in the management of mucosal head and neck malignancy in the journal Head Neck in 2000."
    },
    {
        "id": 12910,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Di Martino et al. published a study about multiple primary carcinomas in patients with head and neck malignancies in the journal Laryngorhinootologie in 2000."
    },
    {
        "id": 12913,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Haughey et al. published a meta-analysis about second malignant tumors in head and neck cancer in the journal Annals of Otology, Rhinology, and Laryngology in 1992."
    },
    {
        "id": 12917,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Kim et al. published a study about flexible esophagoscopy as part of routine panendoscopy in ENT resident and fellowship training in the journal Ear, Nose, and Throat in 2001."
    },
    {
        "id": 12920,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Rodriguez-Bruno et al. published a study about the role of panendoscopy to identify synchronous second primary malignancies in patients with oral cavity and oropharyngeal squamous cell carcinoma in the journal Head Neck in 2011."
    },
    {
        "id": 12923,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Sj\u00f6gren et al. published a study about second malignant neoplasia in early glottic carcinoma in the journal Head Neck in 2006."
    },
    {
        "id": 12926,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Stoeckli et al. published a study about the role of routine panendoscopy in cancer of the upper aerodigestive tract in the journal Otolaryngology-Head and Neck Surgery in 2001."
    },
    {
        "id": 12929,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Guardiola et al. published a study about the role of triple endoscopy as part of staging for head and neck cancer in the journal Current Opinion in Otolaryngology and Head and Neck Surgery in 2006."
    },
    {
        "id": 12932,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Koo et al. published a study about the role of panendoscopy in second primary tumor in early stage squamous cell carcinoma of the oral tongue in the journal Journal of Laryngology and Otology in 2015."
    },
    {
        "id": 12935,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Hung et al. published a study about routine endoscopy for esophageal cancer in patients with oral, oropharyngeal, and hypopharyngeal cancer in the journal PLoS One in 2013."
    },
    {
        "id": 12938,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Sharma et al. published a study about rigid triple endoscopy improving clinical staging of primary head and neck cancer in the journal Oncology Research and Treatment in 2018."
    },
    {
        "id": 12941,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "McGarey et al. published a study about rigid esophagoscopy for head and neck cancer staging and the incidence of synchronous esophageal malignant neoplasms in the journal JAMA Otolaryngology-Head and Neck Surgery in 2016."
    },
    {
        "id": 12944,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 213,
        "content": "Wang et al. published a study about the feasibility of immunohistochemical p16 staining in the diagnosis of human papillomavirus infection in patients with oropharyngeal squamous cell carcinoma in an unspecified journal."
    },
    {
        "id": 12955,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 215,
        "content": "Nichols A, Theurer J, Prisman E, Read N, Berthelet E, Tran E, and others wrote an article titled 'Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial'."
    },
    {
        "id": 12958,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 215,
        "content": "Palma D, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, and others wrote an article titled 'Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial'."
    },
    {
        "id": 12961,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 215,
        "content": "Lefebvre J, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, and Sahmoud T wrote an article titled 'Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial EORTC Head and Neck Cancer Cooperative Group'."
    },
    {
        "id": 12964,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 215,
        "content": "Yoshida E, Luu M, Mallen-St Clair J, Mita A, Scher K, Lu D, and others wrote an article titled 'Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments?'."
    },
    {
        "id": 12967,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 215,
        "content": "Cheraghlou S, Yu P, Otremba M, Park H, Bhatia A, Zogg C, and others wrote an article titled 'Treatment deintensification in human papillomavirus-positive oropharynx cancer: Outcomes from the National Cancer Data Base'."
    },
    {
        "id": 12970,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 215,
        "content": "Nichols A, Theurer J, Prisman E, Read N, Berthelet E, Tran E, and others wrote an article titled 'Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial'."
    },
    {
        "id": 12973,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 215,
        "content": "Baliga S, Kabarriti R, Jiang J, Mehta V, Guha C, Kalnicki S, and others wrote an article titled 'Utilization of Transoral Robotic Surgery (TORS) in patients with Oropharyngeal Squamous Cell Carcinoma and its impact on survival and use of chemotherapy'."
    },
    {
        "id": 12976,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 215,
        "content": "Kelly J, Park H, An Y, Yarbrough W, Contessa J, Decker R, and others wrote an article titled 'Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer'."
    },
    {
        "id": 12979,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 215,
        "content": "Patel E, Zhu A, Oliver J, Cornwell M, Jacobson A, Hu K, and others wrote an article titled 'Treatment of Early Stage Tonsil Cancer in the Age of Human Papillomavirus-Associated Malignancies'."
    },
    {
        "id": 12982,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 215,
        "content": "Park D, Lee M, Kim S, Lee S wrote an article titled 'Comparative safety and effectiveness of transoral robotic surgery versus open surgery for oropharyngeal cancer: A systematic review and meta-analysis'."
    },
    {
        "id": 12993,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 219,
        "content": "Takahashi M, Hwang M, Misiukiewicz K, Gupta V, Miles B, Bakst R, et al. published Quality of Life Analysis of HPV-Positive Oropharyngeal Cancer Patients in a Randomized Trial of Reduced-Dose Versus Standard Chemoradiotherapy: 5-Year Follow-Up in 2022."
    },
    {
        "id": 12995,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 219,
        "content": "Ferris R, Flamand Y, Weinstein G, Li S, Quon H, Mehra R, et al. published Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311) in 2022."
    },
    {
        "id": 12997,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 219,
        "content": "Gupta T, Sinha S, Ghosh-Laskar S, Budrukkar A, Mummudi N, Swain M, et al. published Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial in 2020."
    },
    {
        "id": 12999,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 219,
        "content": "Vergeer M, Doornaert P, Rietveld D, Leemans C, Slotman B, Langendijk J published Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program in 2009."
    },
    {
        "id": 13001,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 219,
        "content": "Anand A, Chaudhoory A, Shukla A, Negi P, Sinha S, Babu A, et al. published Favourable impact of intensity-modulated radiation therapy on chronic dysphagia in patients with head and neck cancer in 2008."
    },
    {
        "id": 13003,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 219,
        "content": "van der Laan H, Christianen M, Bijl H, Schilstra C, Langendijk J published The potential benefit of swallowing sparing intensity modulated radiotherapy to reduce swallowing dysfunction: an in silico planning comparative study in 2012."
    },
    {
        "id": 13005,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 219,
        "content": "Christianen M, van der Schaaf A, van der Laan H, Verdonck-de Leeuw I, Doornaert P, Chouvalova O, et al. published Swallowing sparing intensity modulated radiotherapy (SW-IMRT) in head and neck cancer: Clinical validation according to the model-based approach in 2016."
    },
    {
        "id": 13007,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 219,
        "content": "Wopken K, Bijl H, van der Schaaf A, van der Laan H, Chouvalova O, Steenbakkers R, et al. published Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer in 2014."
    },
    {
        "id": 13015,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 221,
        "content": "Gillison M and others published a paper in Lancet in 2019."
    },
    {
        "id": 13017,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 221,
        "content": "Seiwert T and others published a paper in Ann Oncol in 2019."
    },
    {
        "id": 13019,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 221,
        "content": "Denis F and others published a paper in J Clin Oncol in 2004."
    },
    {
        "id": 13021,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 221,
        "content": "Bourhis J and others published a paper in Lancet Oncol in 2012."
    },
    {
        "id": 13023,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 221,
        "content": "Olmi P and others published a paper in Int J Radiat Oncol Biol Phys in 2003."
    },
    {
        "id": 13025,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 221,
        "content": "Fallai C and others published a paper in Tumori in 2006."
    },
    {
        "id": 13027,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 221,
        "content": "Semrau R and others published a paper in Int J Radiat Oncol Biol Phys in 2006."
    },
    {
        "id": 13029,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 221,
        "content": "Budach V and others published a paper in Int J Radiat Oncol Biol Phys in 2015."
    },
    {
        "id": 13031,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 221,
        "content": "Keane T and others published a paper in Int J Radiat Oncol Biol Phys in 1993."
    },
    {
        "id": 13050,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 222,
        "content": "The literature reference 324 is a study by Suntharalingam M and others about the use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck."
    },
    {
        "id": 13051,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 222,
        "content": "The literature reference 325 is a study by Agarwala S and others about long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced squamous cell carcinoma of the head and neck."
    },
    {
        "id": 13056,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 224,
        "content": "The literature reference 337 is a study on hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer."
    },
    {
        "id": 13060,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 224,
        "content": "The literature reference 338 is a study on concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer."
    },
    {
        "id": 13064,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 224,
        "content": "The literature reference 339 is a study on the role of radiotherapy fractionation in head and neck cancers."
    },
    {
        "id": 13068,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 224,
        "content": "The literature reference 340 is a study on chemotherapy and radiotherapy in locally advanced head and neck cancer."
    },
    {
        "id": 13072,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 224,
        "content": "The literature reference 341 is a study on adjuvant radiotherapy and survival for patients with node-positive head and neck cancer."
    },
    {
        "id": 13076,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 224,
        "content": "The literature reference 342 is a study on preoperative versus postoperative radiation therapy in advanced head and neck carcinoma."
    },
    {
        "id": 13080,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 224,
        "content": "The literature reference 343 is a study on postoperative strategies after primary surgery for squamous cell carcinoma of the head and neck."
    },
    {
        "id": 13084,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 224,
        "content": "The literature reference 344 is a study on preoperative radiochemotherapy and radical surgery of advanced head and neck cancers."
    },
    {
        "id": 13088,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 224,
        "content": "The literature reference 345 is a study on the epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer."
    },
    {
        "id": 13092,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 224,
        "content": "The literature reference 346 is a study on adjuvant radiotherapy in surgically treated HPV-positive oropharyngeal carcinoma with adverse pathological features."
    },
    {
        "id": 13096,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 224,
        "content": "The literature reference 347 is a study on NCCN Guidelines for head and neck cancers."
    },
    {
        "id": 13102,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 225,
        "content": "Cooper J et al. published a study on postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck in 2012."
    },
    {
        "id": 13105,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 225,
        "content": "Bernier J et al. published a study on postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer in 2004."
    },
    {
        "id": 13108,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 225,
        "content": "Fietkau R et al. published a study on postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck in 2006."
    },
    {
        "id": 13111,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 225,
        "content": "Goel A et al. published a study on patterns of care and survival impact of adjuvant chemoradiotherapy for oropharyngeal cancer with intermediate-risk features in 2019."
    },
    {
        "id": 13114,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 225,
        "content": "An Y et al. published a study on the prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma in 2017."
    },
    {
        "id": 13117,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 225,
        "content": "Day A et al. published a study on extracapsular extension, pathologic node status, and adjuvant treatment in primary surgery patients with human papillomavirus-mediated oropharyngeal cancer in 2021."
    },
    {
        "id": 13120,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 225,
        "content": "Ajmani G et al. published a study on assessment of adjuvant therapy in resected head and neck cancer with high-risk features in 2017."
    },
    {
        "id": 13123,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 225,
        "content": "Iyer N et al. published a study on detailed analysis of clinicopathologic factors demonstrating distinct difference in outcome and prognostic factors between surgically treated HPV-positive and negative oropharyngeal cancer in 2015."
    },
    {
        "id": 13126,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 225,
        "content": "Shevach J et al. published a study on extracapsular extension associated with worse distant control and progression-free survival in patients with lymph node-positive human papillomavirus-related oropharyngeal carcinoma in 2017."
    },
    {
        "id": 13129,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 225,
        "content": "Sunkara P et al. published a study on association of surgical margin distance with survival in patients with resected head and neck squamous cell carcinoma in 2023."
    },
    {
        "id": 13132,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 225,
        "content": "Fenlon J et al. published a study on comparing adjuvant radiation to adjuvant chemoradiation in postsurgical p16+ oropharyngeal carcinoma."
    },
    {
        "id": 13136,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 226,
        "content": "Kiyota N et al. published a study on weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer in J Clin Oncol in 2022."
    },
    {
        "id": 13139,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 226,
        "content": "Haffty B et al. published a study on Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck in Int J Radiat Oncol Biol Phys in 1993."
    },
    {
        "id": 13141,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 226,
        "content": "Moore E et al. published a study on human papillomavirus oropharynx carcinoma in Head Neck in 2021."
    },
    {
        "id": 13143,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 226,
        "content": "Vos J et al. published a study on neoadjuvant immunotherapy with nivolumab and ipilimumab in Nat Commun in 2021."
    },
    {
        "id": 13145,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 226,
        "content": "Leidner R et al. published a study on neoadjuvant immunoradiotherapy in J Immunother Cancer in 2021."
    },
    {
        "id": 13147,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 226,
        "content": "Amin N et al. published a systematic review on neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma in Head Neck in 2022."
    },
    {
        "id": 13151,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 226,
        "content": "Ko H et al. published a study on clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma in Head Neck in 2017."
    },
    {
        "id": 13153,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 226,
        "content": "Pignon J et al. published a meta-analysis on chemotherapy in head and neck cancer in Radiother Oncol in 2009."
    },
    {
        "id": 13155,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 226,
        "content": "Blanchard P et al. published a meta-analysis on chemotherapy in head and neck cancer in Radiother Oncol in 2011."
    },
    {
        "id": 13157,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 226,
        "content": "Amini A et al. published a study on predictors of overall survival in human papillomavirus-associated oropharyngeal cancer in Oral Oncol in 2016."
    },
    {
        "id": 13159,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 227,
        "content": "The literature reference 370 is about clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma."
    },
    {
        "id": 13168,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 227,
        "content": "The literature reference 373 is about concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer."
    },
    {
        "id": 13171,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 227,
        "content": "The literature reference 374 is about long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer."
    },
    {
        "id": 13174,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 227,
        "content": "The literature reference 375 is about radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck."
    },
    {
        "id": 13177,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 227,
        "content": "The literature reference 376 is about postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck."
    },
    {
        "id": 13197,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 383 is about the prevalence and prognostic impact of synchronous distant metastases in patients with hypopharynx squamous cell carcinomas and was published in J Cancer in 2019."
    },
    {
        "id": 13199,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 384 is about the clinical manifestations of hypopharynx squamous cell carcinoma and treatment outcomes according to age at diagnosis and was published in Int J Clin Pract in 2021."
    },
    {
        "id": 13201,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 385 is about the prognostic significance of human papillomavirus status and treatment modality in hypopharyngeal cancer and was published in Head Neck in 2021."
    },
    {
        "id": 13203,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 386 is about treatment options for hypopharyngeal cancer and was published in Adv Otorhinolaryngol in 2019."
    },
    {
        "id": 13205,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 387 is about surgical treatment for hypopharynx carcinoma and was published in Otolaryngol Head Neck Surg in 2001."
    },
    {
        "id": 13207,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 388 is about the natural history of treated and untreated hypopharyngeal cancer and was published in Adv Otorhinolaryngol in 2019."
    },
    {
        "id": 13211,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 390 is about transoral laser surgery for hypopharyngeal carcinomas and was published in Curr Opin Otolaryngol Head Neck Surg in 2012."
    },
    {
        "id": 13213,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 391 is about complications in transoral CO2 laser surgery for carcinoma of the larynx and hypopharynx and was published in Head Neck in 2003."
    },
    {
        "id": 13215,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 392 is about complications of transoral laser surgery for malignant tumors of the larynx and hypopharynx and was published in Laryngorhinootologie in 2009."
    },
    {
        "id": 13217,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 393 is about the learning curve in transoral laser microsurgery for malignant tumors of the larynx and hypopharynx and was published in Eur Arch Otorhinolaryngol in 2013."
    },
    {
        "id": 13219,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 394 is about adjuvant radiotherapy after transoral laser microsurgery for advanced squamous carcinoma of the head and neck and was published in Int J Radiat Oncol Biol Phys in 2005."
    },
    {
        "id": 13221,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 228,
        "content": "The literature reference 395 is about transoral laser microsurgery for treatment for hypopharyngeal cancer in 211 patients and was published in Head Neck in 2017."
    },
    {
        "id": 13226,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Steiner W wrote an article titled 'Therapy of hypopharyngeal cancer Part III: The concept of minimally invasive therapy of cancers of the upper aerodigestive tract with special reference to hypopharyngeal cancer and trans-oral laser microsurgery'."
    },
    {
        "id": 13229,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Martin A, J\u00e4ckel M, Christiansen H, Mahmoodzada M, Kron M, and Steiner W wrote an article titled 'Organ preserving transoral laser microsurgery for cancer of the hypopharynx'."
    },
    {
        "id": 13232,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Steiner W, Stenglein C, Fietkau R, and Sauerbrei W wrote an article titled 'Therapy of hypopharyngeal cancer Part IV: Long-term results of transoral laser microsurgery of hypopharyngeal cancer'."
    },
    {
        "id": 13235,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Rudert H and H\u00f6ft S wrote an article titled 'Transoral carbon-dioxide laser resection of hypopharyngeal carcinoma'."
    },
    {
        "id": 13238,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Hall S and Griffiths R wrote an article titled 'Did the addition of concomitant chemotherapy to radiotherapy improve outcomes in hypopharyngeal cancer? A population-based study'."
    },
    {
        "id": 13241,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Machiels J, Ren\u00e9 Leemans C, Golusinski W, Grau C, Licitra L, and Gregoire V wrote an article titled 'Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up'."
    },
    {
        "id": 13244,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Bernier J, Cooper J, Pajak T, van Glabbeke M, Bourhis J, Forastiere A, et al. wrote an article titled 'Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)'."
    },
    {
        "id": 13247,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Kim Y and Lee R wrote an article titled 'Surgery vs radiotherapy for locally advanced hypopharyngeal cancer in the contemporary era: A population-based study'."
    },
    {
        "id": 13253,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Chen A and Hudgins P wrote an article titled 'Pitfalls in the staging squamous cell carcinoma of the hypopharynx'."
    },
    {
        "id": 13256,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Pameijer F, Mukherji S, Balm A, van der Laan B wrote an article titled 'Imaging of squamous cell carcinoma of the hypopharynx'."
    },
    {
        "id": 13259,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Nemec S, Formanek M, Noebauer-Huhmann I, Krestan C, Fr\u00fchwald J, Peloschek P, et al. wrote an article titled '[Pathological changes of the hypopharynx in the focus of imaging]'."
    },
    {
        "id": 13262,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 229,
        "content": "Peracchia A, Bonavina L, Botturi M, Pagani M, Via A, Saino G wrote an article titled 'Current status of surgery for carcinoma of the hypopharynx and cervical esophagus'."
    },
    {
        "id": 13268,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "Remmert S's literature reference is titled [Major defect reconstruction in the head and neck region]."
    },
    {
        "id": 13272,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 411 is titled Free-flap reconstruction for laryngeal preservation after partial laryngectomy in patients with extended tumors of the oropharynx and hypopharynx."
    },
    {
        "id": 13276,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 412 is titled [Functional long-term results following hemipharyngo-hemilaryngectomy and microvascular reconstruction using the radial forearm flap]."
    },
    {
        "id": 13280,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 413 is titled Contralateral hemilaryngotracheal flap reconstruction of the hypopharynx in pyriform carcinoma resection."
    },
    {
        "id": 13284,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 414 is titled Reconstruction of the hypopharynx after surgical treatment of squamous cell carcinoma."
    },
    {
        "id": 13288,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 415 is titled [Reconstructive procedures for restoring the hypopharynx after tumor excision]."
    },
    {
        "id": 13292,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 416 is titled Reconstruction of the hypopharynx with the free jejunum transfer."
    },
    {
        "id": 13296,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 417 is titled Free jejunal interposition reconstruction after pharyngolaryngectomy: 201 consecutive cases."
    },
    {
        "id": 13300,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 418 is titled Morbidity and functional outcome of free jejunal transfer reconstruction for circumferential defects of the pharynx and cervical esophagus."
    },
    {
        "id": 13304,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 419 is titled Laryngopharyngectomy with reconstruction."
    },
    {
        "id": 13308,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 420 is titled [Revascularized over-long jejunum segments in single stage reconstruction of voice and deglutition function after total laryngopharyngectomy]."
    },
    {
        "id": 13312,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 421 is titled [Voice rehabilitation with the jejunum speech siphon: the biventer rein, a modification for prevention of aspiration]."
    },
    {
        "id": 13316,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 422 is titled Stoma recurrence after laryngectomy: an analysis of risk factors."
    },
    {
        "id": 13320,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 230,
        "content": "The literature reference 423 is titled [Meta-analysis on the risk factors for stomal recurrence after total laryngectomy]."
    },
    {
        "id": 13323,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 424 is about oncologic outcomes of total laryngectomy."
    },
    {
        "id": 13326,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 425 is about stomal recurrence after total laryngectomy for squamous cell carcinoma of the larynx."
    },
    {
        "id": 13329,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 426 is about stomal recurrence in head and neck cancer patients with temporary tracheostomy."
    },
    {
        "id": 13332,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 427 is about stomal recurrence post laryngectomy in University College Hospital, Ibadan."
    },
    {
        "id": 13335,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 428 is about the impact of airway intervention before primary nonsurgical therapy for T3/T4 laryngeal squamous cell carcinoma."
    },
    {
        "id": 13338,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 429 is about gastric transposition for head and neck cancer."
    },
    {
        "id": 13341,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 430 is about pharyngolaryngoesophagectomy with pharyngogastric anastomosis for cancer of the hypopharynx."
    },
    {
        "id": 13344,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 431 is about complications following gastric transposition after total laryngo-pharyngectomy."
    },
    {
        "id": 13347,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 432 is about carcinoma of the hypopharynx and the cervical oesophagus."
    },
    {
        "id": 13353,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 434 is about a phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck."
    },
    {
        "id": 13356,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 435 is about an intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer."
    },
    {
        "id": 13359,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 231,
        "content": "The literature reference 436 is about a five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck."
    },
    {
        "id": 13378,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 232,
        "content": "Lefebvre J is an author of a phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy."
    },
    {
        "id": 13381,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 232,
        "content": "Lefebvre J is an author of a study on induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation."
    },
    {
        "id": 13384,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 232,
        "content": "Dietz A is an author of a study on induction chemotherapy followed by radiotherapy versus cetuximab plus induction chemotherapy and radiotherapy in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy."
    },
    {
        "id": 13387,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 232,
        "content": "Pointreau Y is an author of a randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation."
    },
    {
        "id": 13390,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 232,
        "content": "Blanchard P is an author of a study on taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers."
    },
    {
        "id": 13393,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 232,
        "content": "Fietkau R is an author of a randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin."
    },
    {
        "id": 13400,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 233,
        "content": "The literature reference 449 is a management guideline for the neck in squamous cell carcinoma of the oral cavity and oropharynx by Koyfman S, Ismaila N, Crook D, D'Cruz A, Rodriguez C, Sher D, et al."
    },
    {
        "id": 13420,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 233,
        "content": "The literature reference 454 is a systematic review and meta-analysis of randomized controlled trials comparing elective neck dissection versus sentinel lymph node biopsy in early-stage clinically node-negative oral and/or oropharyngeal squamous cell carcinoma by Gupta T, Maheshwari G, Kannan S, Nair S, Chaturvedi P, Agarwal J."
    },
    {
        "id": 13424,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 233,
        "content": "The literature reference 455 is a review on the current philosophy in the surgical management of neck metastases for head and neck squamous cell carcinoma by Coskun H, Medina J, Robbins K, Silver C, Strojan P, Teymoortash A, et al."
    },
    {
        "id": 13428,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 233,
        "content": "The literature reference 456 is a review on elective and therapeutic selective neck dissection by Ferlito A, Rinaldo A, Silver C, Gourin C, Shah J, Clayman G, et al."
    },
    {
        "id": 13432,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 233,
        "content": "The literature reference 457 is a study on level IIB lymph node metastasis in oropharyngeal squamous cell carcinoma by Gross B, Olsen S, Lewis J, Kasperbauer J, Moore E, Olsen K, et al."
    },
    {
        "id": 13436,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 233,
        "content": "The literature reference 458 is a study on bilateral versus ipsilateral neck dissection in oral and oropharyngeal cancer with contralateral cN0 neck by Knopf A, Jacob S, Bier H, Scherer E."
    },
    {
        "id": 13440,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 233,
        "content": "The literature reference 459 is a retrospective analysis of bilateral cervical metastases in oropharyngeal squamous cell carcinoma by Olzowy B, Tsalemchuk Y, Schotten K, Reichel O, Harr\u00e9us U."
    },
    {
        "id": 13464,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 234,
        "content": "Psychogios G, Mantsopoulos K, Agaimy A, Koch M, Zenk J, Waldfahrer F, and others wrote an article titled 'Prognostic factors in limited (T1-2, N0-1) oropharyngeal carcinoma treated with surgery \u00b1 adjuvant therapy' in Head Neck in 2013."
    },
    {
        "id": 13467,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 234,
        "content": "Shin Y, Kim S, Koh Y, Hong H, Seol J, and Choi E wrote an article titled 'Necessity of level IV dissection in cN0 hypopharyngeal carcinoma' in Acta Otolaryngol in 2011."
    },
    {
        "id": 13470,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 234,
        "content": "Terrell J, Welsh D, Bradford C, Chepeha D, Esclamado R, Hogikyan N, and others wrote an article titled 'Pain, quality of life, and spinal accessory nerve status after neck dissection' in Laryngoscope in 2000."
    },
    {
        "id": 13473,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 234,
        "content": "Finegersh A, Moss W, Saddawi-Konefka R, Faraji F, Coffey C, Califano J, and others wrote an article titled 'Meta-analysis of risk of occult lymph node metastasis in the irradiated, clinically N0 neck' in Head Neck in 2020."
    },
    {
        "id": 13476,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 234,
        "content": "Walvekar R, Li R, Gooding W, Gibson M, Heron D, Johnson J, and others wrote an article titled 'Role of surgery in limited (T1-2, N0-1) cancers of the oropharynx' in Laryngoscope in 2008."
    },
    {
        "id": 13479,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 234,
        "content": "Hosal A, Carrau R, Johnson J, and Myers E wrote an article titled 'Selective neck dissection in the management of the clinically node-negative neck' in Laryngoscope in 2000."
    },
    {
        "id": 13482,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 234,
        "content": "Psychogios G, Mantsopoulos K, Bohr C, Koch M, Zenk J, and Iro H wrote an article titled 'Incidence of occult cervical metastasis in head and neck carcinomas: development over time' in J Surg Oncol in 2013."
    },
    {
        "id": 13485,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 234,
        "content": "Psychogios G, Mantsopoulos K, Kuenzel J, Koch M, Zenk J, Harreus U, and others wrote an article titled 'Primary surgical treatment of T2 oropharyngeal carcinoma' in J Surg Oncol in 2012."
    },
    {
        "id": 13488,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 234,
        "content": "Layland M, Sessions D, Lenox J wrote an article titled 'The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+' in Laryngoscope in 2005."
    },
    {
        "id": 13512,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 235,
        "content": "The literature reference 482 is about Level IIB lymph node metastasis in laryngeal and hypopharyngeal squamous cell carcinoma: single-institution case series and review of the literature by Gross B, Olsen S, Lewis J, Kasperbauer J, Moore E, Olsen K, et al."
    },
    {
        "id": 13515,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 235,
        "content": "The literature reference 483 is about Cervical node metastases in oropharyngeal squamous cell carcinoma: prospective analysis of prevalence and distribution by Jose J, Coatesworth A, Johnston C, MacLennan K."
    },
    {
        "id": 13518,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 235,
        "content": "The literature reference 484 is about Distributions of cervical lymph node metastases in oropharyngeal carcinoma: therapeutic implications for the N0 neck by Lim Y, Koo B, Lee J, Lim J, Choi E."
    },
    {
        "id": 13521,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 235,
        "content": "The literature reference 485 is about Management of contralateral N0 neck in tonsillar squamous cell carcinoma by Lim Y, Lee S, Lim J, Shin H, Lee J, Koo B, et al."
    },
    {
        "id": 13524,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 235,
        "content": "The literature reference 486 is about The use of clinical criteria alone in the management of the clinically negative neck among patients with squamous cell carcinoma of the oral cavity and oropharynx by O'Brien C, Traynor S, McNeil E, McMahon J, Chaplin J."
    },
    {
        "id": 13530,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 235,
        "content": "The literature reference 488 is about Role of primary surgery for early-stage (T1-2N0) squamous cell carcinoma of the oropharynx by Shin H, Lim Y, Jeong H, Choi E."
    },
    {
        "id": 13533,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 236,
        "content": "The literature reference 489 is about the histological distribution of cervical lymph node metastases from intraoral/oropharyngeal squamous cell carcinomas by Woolgar J."
    },
    {
        "id": 13553,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 236,
        "content": "The reference 494 is about the treatment of contralateral N0 neck in early squamous cell carcinoma of the oral tongue: elective neck dissection versus observation."
    },
    {
        "id": 13557,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 236,
        "content": "The reference 495 is about the benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region."
    },
    {
        "id": 13561,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 236,
        "content": "The reference 496 is about clinical nodal staging of T1-2 tonsillar squamous cell carcinoma stratified by p16 status and implications for ipsilateral neck irradiation."
    },
    {
        "id": 13565,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 236,
        "content": "The reference 497 is about the incidence of contralateral-bilateral nodes in the human papillomavirus era."
    },
    {
        "id": 13569,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 236,
        "content": "The reference 498 is about oncologic outcomes of selective neck dissection in HPV-related oropharyngeal squamous cell carcinoma."
    },
    {
        "id": 13573,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 236,
        "content": "The reference 499 is about the distribution of cervical lymph node metastases from squamous cell carcinoma of the oropharynx in the era of risk stratification using human papillomavirus and smoking status."
    },
    {
        "id": 13577,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 236,
        "content": "The reference 500 is about the distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts."
    },
    {
        "id": 13581,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 236,
        "content": "The reference 501 is about occult contralateral nodal disease in oropharyngeal squamous cell carcinoma patients undergoing primary TORS."
    },
    {
        "id": 13582,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 502 is an article by Stanford-Moore G, Ochoa E, Larson A, Han M, Hoppe K, Ryan W titled 'Patterns of Nodal Metastases and Predictors of Occult Disease in HPV-Associated Oropharynx Cancer' published in Otolaryngol Head Neck Surg in 2021."
    },
    {
        "id": 13584,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 503 is an article by Bauwens L, Baltres A, Fiani D, Zrounba P, Buiret G, Fleury B, et al titled 'Prevalence and distribution of cervical lymph node metastases in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma' published in Radiother Oncol in 2021."
    },
    {
        "id": 13586,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 504 is an article by Kato M, Ellis M, Nguyen S, Day T titled 'Predictors of contralateral-bilateral nodal disease in oropharyngeal cancer: A National Cancer Data Base Study' published in Head Neck in 2018."
    },
    {
        "id": 13588,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 505 is an article by Le\u00f3n X, Venegas M, Casasayas M, Rodr\u00edguez C, Neumann E, Holgado A, et al titled 'Prognostic value of the nodal yield in elective neck dissections in patients with head and neck carcinomas' published in Eur Arch Otorhinolaryngol in 2022."
    },
    {
        "id": 13590,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 506 is an article by Shah J, Shaha A, Spiro R, Strong E titled 'Carcinoma of the hypopharynx' published in Am J Surg in 1976."
    },
    {
        "id": 13592,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 507 is an article by Olzowy B, Hillebrand M, Harr\u00e9us U titled 'Frequency of bilateral cervical metastases in hypopharyngeal squamous cell carcinoma: a retrospective analysis of 203 cases after bilateral neck dissection' published in Eur Arch Otorhinolaryngol in 2017."
    },
    {
        "id": 13594,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 508 is an article by Majoufre C, Faucher A, Laroche C, De Bonfils C, Siberchicot F, Renaud-Salis J, et al titled 'Supraomohyoid neck dissection in cancer of the oral cavity' published in Am J Surg in 1999."
    },
    {
        "id": 13596,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 509 is an article by Amar A, Dedivitis R, Rapoport A, Quarteiro A titled 'Indication of elective contralateral neck dissection in squamous cell carcinoma of the hypopharynx' published in Braz J Otorhinolaryngol in 2009."
    },
    {
        "id": 13598,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 510 is an article by Johnson J, Bacon G, Myers E, Wagner R titled 'Medial vs lateral wall pyriform sinus carcinoma: implications for management of regional lymphatics' published in Head Neck in 1994."
    },
    {
        "id": 13600,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 511 is an article by Kowalski L, Santos C, Magrin J, Scopel A titled 'Factors influencing contralateral metastasis and prognosis from pyriform sinus carcinoma' published in Am J Surg in 1995."
    },
    {
        "id": 13602,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 512 is an article by Ye L, Rao J, Fan X, Kong F, Hu C, Ying H titled 'The prognostic value of tumor depth for cervical lymph node metastasis in hypopharyngeal and supraglottic carcinomas' published in Head Neck in 2019."
    },
    {
        "id": 13604,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 513 is an article by Koo B, Lim Y, Lee J, Kim Y, Kim S, Choi E titled 'Management of contralateral N0 neck in pyriform sinus carcinoma' published in Laryngoscope in 2006."
    },
    {
        "id": 13606,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 237,
        "content": "The literature reference 514 is an article by Spector J, Sessions D, Haughey B, Chao K, Simpson J, El Mofty S, et al titled 'Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx' published in Laryngoscope in 2001."
    },
    {
        "id": 13608,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 515 is about lymph-node metastasis following total laryngectomy and total pharyngolaryngectomy for laryngeal and hypopharyngeal squamous cell carcinoma."
    },
    {
        "id": 13611,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 516 is about salvage surgery for head and neck cancer."
    },
    {
        "id": 13614,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 517 is about Health Literacy / Gesundheitskompetenz."
    },
    {
        "id": 13617,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 518 is about the application of a Health Literacy Framework to explore patients' knowledge of the link between HPV and cancer."
    },
    {
        "id": 13620,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 519 is about knowledge and awareness of oral cancer patients regarding its etiology, prevention, and treatment."
    },
    {
        "id": 13623,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 520 is about measuring conceptual health knowledge in the context of oral health literacy."
    },
    {
        "id": 13626,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 521 is about oral sex and oropharyngeal cancer."
    },
    {
        "id": 13629,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 522 is about the role of sexual behavior in head and neck cancer."
    },
    {
        "id": 13632,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 523 is about disparities in knowledge of mouth or throat cancer among rural Floridians."
    },
    {
        "id": 13635,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 524 is about patient awareness/knowledge towards oral cancer."
    },
    {
        "id": 13638,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 525 is about public awareness of the association between human papillomavirus and oropharyngeal cancer."
    },
    {
        "id": 13641,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 526 is about oral cancer knowledge and screening behavior among smokers and non-smokers in rural communities."
    },
    {
        "id": 13644,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 527 is about delay in diagnosis of oral cancer."
    },
    {
        "id": 13647,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 238,
        "content": "The literature reference 528 is about the effect of multimedia-based information services on knowledge and satisfaction in head and neck cancer patients."
    },
    {
        "id": 13650,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "D'Souza V et al. published an article titled 'Multimedia information intervention and its benefits in partners of the head and neck cancer patients' in Eur J Cancer Care in 2017."
    },
    {
        "id": 13744,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "D'Souza V et al. published an article titled 'Multimedia information intervention and its benefits in partners of the head and neck cancer patients' in Eur J Cancer Care in 2017."
    },
    {
        "id": 13651,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "D'Souza V et al.'s article is about the benefits of multimedia information intervention in partners of the head and neck cancer patients."
    },
    {
        "id": 13745,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "D'Souza V et al.'s article is about the benefits of multimedia information intervention in partners of the head and neck cancer patients."
    },
    {
        "id": 13657,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Henry M et al. published an article titled 'Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers: A longitudinal study' in Psychooncology in 2022."
    },
    {
        "id": 13658,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Henry M et al.'s article is about the psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers."
    },
    {
        "id": 13665,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Rieke K et al. published an article titled 'Depression and survival in head and neck cancer patients' in Oral Oncol in 2017."
    },
    {
        "id": 13666,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Rieke K et al.'s article is about depression and survival in head and neck cancer patients."
    },
    {
        "id": 13673,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Wang T et al. published an article titled 'Influences of facial disfigurement and social support for psychosocial adjustment among patients with oral cancer in Taiwan: a cross-sectional study' in BMJ Open in 2018."
    },
    {
        "id": 13674,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Wang T et al.'s article is about the influences of facial disfigurement and social support for psychosocial adjustment among patients with oral cancer in Taiwan."
    },
    {
        "id": 13681,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "You E et al. published an article titled 'Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management' in Curr Oncol in 2019."
    },
    {
        "id": 13682,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "You E et al.'s article is a review of current evidence and management of human papillomavirus-associated oropharyngeal cancer."
    },
    {
        "id": 13686,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Brennan K et al. published an article titled 'Routine follow-up care for head and neck cancer after curative treatment: A 3-year experience of measuring patients' self-reported needs, preferences, quality of life and attitudes towards follow-up' in Eur J Cancer Care in 2022."
    },
    {
        "id": 13687,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Brennan K et al.'s article is about routine follow-up care for head and neck cancer after curative treatment."
    },
    {
        "id": 13694,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Fitzgerald C et al. published an article titled 'Patient-reported outcomes in human papillomavirus-related oropharyngeal cancer' in J Surg Oncol in 2021."
    },
    {
        "id": 13695,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Fitzgerald C et al.'s article is about patient-reported outcomes in human papillomavirus-related oropharyngeal cancer."
    },
    {
        "id": 13700,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Nelke K et al. published an article titled 'Head and neck cancer patients' quality of life' in Adv Clin Exp Med in 2014."
    },
    {
        "id": 13701,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Nelke K et al.'s article is about head and neck cancer patients' quality of life."
    },
    {
        "id": 13706,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Weaver R et al. published an article titled '\u201cMy life's not my own\u201d: A qualitative study into the expectations of head and neck cancer carers' in Support Care Cancer in 2022."
    },
    {
        "id": 13707,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Weaver R et al.'s article is a qualitative study into the expectations of head and neck cancer carers."
    },
    {
        "id": 13714,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Wang T et al. published an article titled 'Correlation Between Postoperative Health-Related Quality of Life and Care Needs of Oral Cancer Patients' in Cancer Nurs in 2020."
    },
    {
        "id": 13715,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Wang T et al.'s article is about the correlation between postoperative health-related quality of life and care needs of oral cancer patients."
    },
    {
        "id": 13721,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Morales C et al. published an article titled 'Return to Work in Survivors of Human Papillomavirus-Associated Oropharyngeal Cancer: An Australian Experience' in Int J Radiat Oncol Biol Phys in 2020."
    },
    {
        "id": 13722,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Morales C et al.'s article is about return to work in survivors of human papillomavirus-associated oropharyngeal cancer in Australia."
    },
    {
        "id": 13736,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Casswell G et al. published an article titled 'Sexual Health and Interpersonal Relationships After Chemoradiation Therapy for Human Papillomavirus-Associated Oropharyngeal Cancer: A Cross-sectional Study' in Int J Radiat Oncol Biol Phys."
    },
    {
        "id": 13737,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Casswell G et al.'s article is about sexual health and interpersonal relationships after chemoradiation therapy for human papillomavirus-associated oropharyngeal cancer."
    },
    {
        "id": 13751,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Henry M et al. published an article titled 'Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers: A longitudinal study' in Psychooncology in 2022."
    },
    {
        "id": 13759,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Rieke K et al. published an article titled 'Depression and survival in head and neck cancer patients' in Oral Oncol in 2017."
    },
    {
        "id": 13767,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Wang T et al. published an article titled 'Influences of facial disfigurement and social support for psychosocial adjustment among patients with oral cancer in Taiwan: a cross-sectional study' in BMJ Open in 2018."
    },
    {
        "id": 13775,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "You E et al. published an article titled 'Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management' in Curr Oncol in 2019."
    },
    {
        "id": 13780,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Brennan K et al. published an article titled 'Routine follow-up care for head and neck cancer after curative treatment: A 3-year experience of measuring patients' self-reported needs, preferences, quality of life and attitudes towards follow-up' in Eur J Cancer Care in 2022."
    },
    {
        "id": 13788,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Fitzgerald C et al. published an article titled 'Patient-reported outcomes in human papillomavirus-related oropharyngeal cancer' in J Surg Oncol in 2021."
    },
    {
        "id": 13794,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Nelke K et al. published an article titled 'Head and neck cancer patients' quality of life' in Adv Clin Exp Med in 2014."
    },
    {
        "id": 13800,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Weaver R et al. published an article titled '\u201cMy life's not my own\u201d: A qualitative study into the expectations of head and neck cancer carers' in Support Care Cancer in 2022."
    },
    {
        "id": 13808,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Wang T et al. published an article titled 'Correlation Between Postoperative Health-Related Quality of Life and Care Needs of Oral Cancer Patients' in Cancer Nurs in 2020."
    },
    {
        "id": 13815,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Morales C et al. published an article titled 'Return to Work in Survivors of Human Papillomavirus-Associated Oropharyngeal Cancer: An Australian Experience' in Int J Radiat Oncol Biol Phys in 2020."
    },
    {
        "id": 13830,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Casswell G et al. published an article titled 'Sexual Health and Interpersonal Relationships After Chemoradiation Therapy for Human Papillomavirus-Associated Oropharyngeal Cancer: A Cross-sectional Study' in Int J Radiat Oncol Biol Phys."
    },
    {
        "id": 13760,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Rieke K et al.'s article is about depression and survival in head and neck cancer patients."
    },
    {
        "id": 13768,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Wang T et al.'s article is about the influences of facial disfigurement and social support for psychosocial adjustment among patients with oral cancer in Taiwan."
    },
    {
        "id": 13776,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "You E et al.'s article is a review of current evidence and management of human papillomavirus-associated oropharyngeal cancer."
    },
    {
        "id": 13781,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Brennan K et al.'s article is about routine follow-up care for head and neck cancer after curative treatment."
    },
    {
        "id": 13789,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Fitzgerald C et al.'s article is about patient-reported outcomes in human papillomavirus-related oropharyngeal cancer."
    },
    {
        "id": 13795,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Nelke K et al.'s article is about head and neck cancer patients' quality of life."
    },
    {
        "id": 13801,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Weaver R et al.'s article is a qualitative study into the expectations of head and neck cancer carers."
    },
    {
        "id": 13809,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Wang T et al.'s article is about the correlation between postoperative health-related quality of life and care needs of oral cancer patients."
    },
    {
        "id": 13816,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Morales C et al.'s article is about return to work in survivors of human papillomavirus-associated oropharyngeal cancer in Australia."
    },
    {
        "id": 13831,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 239,
        "content": "Casswell G et al.'s article is about sexual health and interpersonal relationships after chemoradiation therapy for human papillomavirus-associated oropharyngeal cancer."
    },
    {
        "id": 13745,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Thompson L and Donovan K wrote an article titled Discussions About Sexual Health: An Unmet Need Among Patients With Human Papillomavirus-Related Oropharyngeal Cancer."
    },
    {
        "id": 13748,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "You E, Henry M, and Zeitouni A wrote an article titled human papillomavirus-associated oropharyngeal cancer: review of current evidence and management."
    },
    {
        "id": 13751,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Pingili S, Ahmed J, Sujir N, Shenoy N, and Ongole R wrote an article titled Evaluation of Malnutrition and Quality of Life in Patients Treated for Oral and Oropharyngeal Cancer."
    },
    {
        "id": 13754,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Brewczy\u0144ski A, Jab\u0142o\u0144ska B, Mrowiec S, Sk\u0142adowski K, and Rutkowski T wrote an article titled Nutritional Support in Head and Neck Radiotherapy Patients Considering HPV Status."
    },
    {
        "id": 13757,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Alhambra Exp\u00f3sito M, Herrera-Mart\u00ednez A, Manzano Garc\u00eda G, Espinosa Calvo M, Bueno Serrano C, and G\u00e1lvez Moreno M wrote an article titled Early nutrition support therapy in patients with head-neck cancer."
    },
    {
        "id": 13760,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Gellrich N, Handschel J, Holtmann H, Kr\u00fcskemper G wrote an article titled Oral cancer malnutrition impacts weight and quality of life."
    },
    {
        "id": 13763,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Harrowfield J, Isenring E, Kiss N, Laing E, Lipson-Smith R, and Britton B wrote an article titled The Impact of Human Papillomavirus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) on Nutritional Outcomes."
    },
    {
        "id": 13766,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Harms A, Kansara S, Stach C, Richardson P, Chen G, Lai S, et al wrote an article titled Swallowing Function in Survivors of Oropharyngeal Cancer Is Associated With Advanced T Classification."
    },
    {
        "id": 13769,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Talwar B, Donnelly R, Skelly R, and Donaldson M wrote an article titled Nutritional management in head and neck cancer: United Kingdom National Multidisciplinary Guidelines."
    },
    {
        "id": 13772,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Yao C and Hutcheson K wrote an article titled Quality of Life Implications After Transoral Robotic Surgery for Oropharyngeal Cancers."
    },
    {
        "id": 13775,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Jo S, Yeo M, Shin Y, Shin K, Kim S, Kim H, et al wrote an article titled Therapeutic Singing as a Swallowing Intervention in Head and Neck Cancer Patients With Dysphagia."
    },
    {
        "id": 13778,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Nugent B, Lewis S, and O'Sullivan J wrote an article titled Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy."
    },
    {
        "id": 13781,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 240,
        "content": "Galbiatti A, Padovani-Junior J, Man\u00edglia J, Rodrigues C, Pavarino \u00c9, and Goloni-Bertollo E wrote an article titled Head and neck cancer: causes, prevention and treatment."
    },
    {
        "id": 13784,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 241,
        "content": "The Evidence-based Guideline Oropharyngeal and Hypopharyngeal Carcinoma was published in February 2024."
    },
    {
        "id": 13786,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 241,
        "content": "Petersen P wrote an article titled 'Oral cancer prevention and control--the approach of the World Health Organization' in Oral Oncol in 2009."
    },
    {
        "id": 13788,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 241,
        "content": "Zygogianni A et al. wrote an article titled 'Oral squamous cell cancer: early detection and the role of alcohol and smoking' in Head Neck Oncol in 2011."
    },
    {
        "id": 13790,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 241,
        "content": "Conlon M et al. wrote an article titled 'Cigarette-smoking characteristics and interest in cessation in patients with head-and-neck cancer' in Curr Oncol in 2020."
    },
    {
        "id": 13792,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 241,
        "content": "Goldstein B et al. wrote an article titled 'Alcohol consumption and cancers of the oral cavity and pharynx from 1988 to 2009: an update' in Eur J Cancer Prev in 2010."
    },
    {
        "id": 13794,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 241,
        "content": "Al Feghali K et al. wrote an article titled 'Impact of smoking on pathological features in oral cavity squamous cell carcinoma' in J Cancer Res Ther in 2019."
    },
    {
        "id": 13796,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 241,
        "content": "Montero P et al. wrote an article titled 'Cancer of the oral cavity' in Surg Oncol Clin N Am in 2015."
    },
    {
        "id": 13798,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 241,
        "content": "Braakhuis B et al. wrote an article titled 'Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions' in Head Neck in 2002."
    },
    {
        "id": 13800,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 241,
        "content": "Rohde M et al. wrote an article titled 'Definition of locally recurrent head and neck squamous cell carcinoma: a systematic review and proposal for the Odense-Birmingham definition' in Eur Arch Otorhinolaryngol in 2020."
    },
    {
        "id": 13812,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 241,
        "content": "Zafereo M et al. wrote an article titled 'The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx' in Cancer in 2009."
    },
    {
        "id": 13818,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 242,
        "content": "Zafereo M wrote an article titled 'Surgical salvage of recurrent cancer of the head and neck'."
    },
    {
        "id": 13821,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 242,
        "content": "Mandapathil M, Roessler M, Werner J, Silver C, Rinaldo A, Ferlito A wrote an article titled 'Salvage surgery for head and neck squamous cell carcinoma'."
    },
    {
        "id": 13824,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 242,
        "content": "Goodwin W wrote an article titled 'Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?'."
    },
    {
        "id": 13827,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 242,
        "content": "Bots W, van den Bosch S, Zwijnenburg E, Dijkema T, van den Broek G, Weijs W, et al wrote an article titled 'Reirradiation of head and neck cancer: Long-term disease control and toxicity'."
    },
    {
        "id": 13830,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 242,
        "content": "Ward M, Riaz N, Caudell J, Dunlap N, Isrow D, Zakem S, et al wrote an article titled 'Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative'."
    },
    {
        "id": 13833,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 242,
        "content": "Ward M, Koyfman S, Bakst R, Margalit D, Beadle B, Beitler J, et al wrote an article titled 'Retreatment of Recurrent or Second Primary Head and Neck Cancer After Prior Radiation: Executive Summary of the American Radium Society Appropriate Use Criteria'."
    },
    {
        "id": 13836,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 242,
        "content": "Vargo J, Ward M, Caudell J, Riaz N, Dunlap N, Isrow D, et al wrote an article titled 'A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer'."
    },
    {
        "id": 13839,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 242,
        "content": "Caudell J, Ward M, Riaz N, Zakem S, Awan M, Dunlap N, et al wrote an article titled 'Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis'."
    },
    {
        "id": 13842,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 242,
        "content": "Choi S, Chang J, Choi J, Park S, Keum K, Park K, et al wrote an article titled 'Re-irradiation Using Intensity-modulated Radiotherapy for Recurrent and Second Primary Head and Neck Cancer'."
    },
    {
        "id": 13845,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 242,
        "content": "Zb\u00e4ren P, Nuyens M, Curschmann J, Stauffer E wrote an article titled 'Histologic characteristics and tumor spread of recurrent glottic carcinoma: analysis on whole-organ sections and comparison with tumor spread of primary glottic carcinomas'."
    },
    {
        "id": 13857,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 243,
        "content": "Dietz A et al. published an article in Laryngorhinootologie in 2023."
    },
    {
        "id": 13860,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 243,
        "content": "Lee J et al. published an article in Head Neck in 2020."
    },
    {
        "id": 13963,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 246,
        "content": "The literature reference 620 is about Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer."
    },
    {
        "id": 13967,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 246,
        "content": "The literature reference 621 is about Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma."
    },
    {
        "id": 13971,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 246,
        "content": "The literature reference 622 is about Platinum-based chemotherapy plus cetuximab in head and neck cancer."
    },
    {
        "id": 13975,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 246,
        "content": "The literature reference 623 is about Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab."
    },
    {
        "id": 13979,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 246,
        "content": "The literature reference 624 is about Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck."
    },
    {
        "id": 13983,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 246,
        "content": "The literature reference 625 is about Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma."
    },
    {
        "id": 13987,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 246,
        "content": "The literature reference 626 is about Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma."
    },
    {
        "id": 13991,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 246,
        "content": "The literature reference 627 is about Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma."
    },
    {
        "id": 13995,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 246,
        "content": "The literature reference 628 is about Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 13999,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 246,
        "content": "The literature reference 629 is about Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 14006,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Cohen E et al. published a study on pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040)."
    },
    {
        "id": 14009,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Burtness B et al. published a phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer."
    },
    {
        "id": 14012,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Samlowski W et al. published an evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN)."
    },
    {
        "id": 14015,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Gibson M et al. published a randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395)."
    },
    {
        "id": 14018,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Herbst R et al. published a phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck."
    },
    {
        "id": 14020,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Jacobs C et al. published a phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck."
    },
    {
        "id": 14022,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Al-Sarraf M et al. published a study on platinum analogs in recurrent and advanced head and neck cancer."
    },
    {
        "id": 14025,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Grau J et al. published a study on weekly paclitaxel for platin-resistant stage IV head and neck cancer patients."
    },
    {
        "id": 14027,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Catimel G et al. published a study on docetaxel (Taxotere) for the treatment of patients with advanced squamous cell carcinoma of the head and neck."
    },
    {
        "id": 14029,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Guardiola E et al. published a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer."
    },
    {
        "id": 14031,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Stewart J et al. published a phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck."
    },
    {
        "id": 14033,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 247,
        "content": "Vermorken J et al. published an open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck."
    },
    {
        "id": 14037,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 248,
        "content": "Fury M, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, et al. were the authors of the study."
    },
    {
        "id": 14038,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 248,
        "content": "The literature reference 644 is about a randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer."
    },
    {
        "id": 14041,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 248,
        "content": "The literature reference 645 is about a phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment."
    },
    {
        "id": 14045,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 248,
        "content": "The literature reference 646 is about a study on afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy."
    },
    {
        "id": 14048,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 248,
        "content": "Machiels J, Haddad R, Fayette J, Licitra L, Tahara M, Vermorken J, et al. were the authors of the study."
    },
    {
        "id": 14052,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 248,
        "content": "The literature reference 648 is about a study on chronic laryngeal edema as a late reaction to radiochemotherapy."
    },
    {
        "id": 14056,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 248,
        "content": "The literature reference 649 is about a study on immuno oncology treatment in head and neck cancer."
    },
    {
        "id": 14060,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 248,
        "content": "The literature reference 650 is about the product information of Opdivo."
    },
    {
        "id": 14074,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 248,
        "content": "The literature reference 655 is about dental care in case of head and neck cancer--Part I: Radiotherapy."
    },
    {
        "id": 14078,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 249,
        "content": "The literature reference 655 is about periodontal attachment loss in patients after head and neck radiation therapy by Epstein et al. in 1998."
    },
    {
        "id": 14098,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 249,
        "content": "Bindewald et al. published a study about quality of life and voice intelligibility in laryngeal cancer patients in 2007."
    },
    {
        "id": 14100,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 249,
        "content": "Meyer et al. published a study about swallowing disorders after partial laryngectomy in 2012."
    },
    {
        "id": 14105,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 250,
        "content": "The literature reference 670 is about swallowing-related quality of life after head and neck cancer treatment."
    },
    {
        "id": 14113,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 250,
        "content": "The literature reference 672 is about pretreatment, preoperative swallowing exercises improving dysphagia quality of life."
    },
    {
        "id": 14119,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 250,
        "content": "The literature reference 674 is about the effects of voice rehabilitation on health-related quality of life, communication, and voice in laryngeal cancer patients treated with radiotherapy."
    },
    {
        "id": 14142,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 250,
        "content": "The literature reference 680 is about functional and psychological factors associated with employment status in patients with head and neck cancer."
    },
    {
        "id": 14174,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in Laryngorhinootologie in 2013 is about vocational rehabilitation after total laryngectomy."
    },
    {
        "id": 14177,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in Ann Otol Rhinol Laryngol in 1999 is about psychosocial adjustment after laryngeal cancer surgery."
    },
    {
        "id": 14180,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in J Surg Oncol in 1974 is about speech and vocational rehabilitation of the laryngectomized patient."
    },
    {
        "id": 14183,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in Vestn Otorinolaringol in 1990 is about medico-social and economic aspects of the rehabilitation of patients with laryngeal cancer."
    },
    {
        "id": 14186,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in Rev Prat in 1995 is about surveillance and rehabilitation of cancers of upper respiratory and digestive tracts."
    },
    {
        "id": 14189,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in Zh Ushn Nos Gorl Bolezn in 1976 is about possibilities of vocational rehabilitation after laryngectomy for cancer."
    },
    {
        "id": 14192,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in J Otolaryngol in 1983 is about social, occupational and personal factors related to vocational rehabilitation."
    },
    {
        "id": 14195,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in HNO in 1985 is about rehabilitation following laryngectomy from the viewpoint of the affected patients."
    },
    {
        "id": 14198,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in Z Laryngol Rhinol Otol in 1970 is about how the patient with laryngectomy lives."
    },
    {
        "id": 14201,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in Head Neck in 2015 is about employment pathways and work-related issues in head and neck cancer survivors."
    },
    {
        "id": 14204,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in In Vivo in 2013 is about return to work and quality of life after therapy and rehabilitation in oral cancer."
    },
    {
        "id": 14207,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in Arch Otolaryngol Head Neck Surg in 2006 is about socioeconomic effects of and risk factors for disability in long-term survivors of head and neck cancer."
    },
    {
        "id": 14210,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 251,
        "content": "The study published in Arch Otolaryngol Head Neck Surg in 2006 is about patient-reported factors associated with discontinuing employment following head and neck cancer treatment."
    },
    {
        "id": 14214,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 252,
        "content": "The literature reference Oral Oncol. 2010;46(1):56-60 is about employment and return to work in head and neck cancer survivors."
    },
    {
        "id": 14217,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 252,
        "content": "The literature reference J Cancer Surviv. 2015;9(1):30-9 is about long-term workforce participation patterns following head and neck cancer."
    },
    {
        "id": 14220,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 252,
        "content": "The literature reference Head Neck. 2022;44(12):2904-2924 is about return to work in patients with head and neck cancer."
    },
    {
        "id": 14223,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 252,
        "content": "The literature reference Cancer Treat Res. 2018;174:225-235 is about occupational therapy for the head and neck cancer patient."
    },
    {
        "id": 14228,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 252,
        "content": "The literature reference Onkologie. 2005;28(12):631-6 is about comorbid mental disorders in laryngectomees."
    },
    {
        "id": 14231,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 252,
        "content": "The literature reference Dtsch Med Wochenschr. 2007;132(40):2071-6 is about the prevalence of concomitant psychiatric disorders and the desire for psychosocial help in patients with malignant tumors in an acute hospital."
    },
    {
        "id": 14240,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 252,
        "content": "The literature reference Support Care Cancer. 2015;23(5):1331-9 is about psychological distress and need for psycho-oncological support in spouses of total laryngectomised cancer patients."
    },
    {
        "id": 14243,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 252,
        "content": "The literature reference Psychooncology. 2004;13(4):269-80 is about screening for depression in head and neck cancer."
    },
    {
        "id": 14246,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 252,
        "content": "The literature reference Ann Oncol. 2004;15(8):1243-9 is about the recognition of distress and psychiatric morbidity in cancer patients."
    },
    {
        "id": 14249,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 252,
        "content": "The literature reference Support Care Cancer. 2011;19(11):1697-703 is about identifying tumor patients' depression."
    },
    {
        "id": 14251,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 253,
        "content": "The literature reference 714 is about predictors of emotional distress in patients with head and neck cancer."
    },
    {
        "id": 14254,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 253,
        "content": "The literature reference 715 is about the development of an ICF-based clinical practice guideline for the assessment of function in head and neck cancer."
    },
    {
        "id": 14257,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 253,
        "content": "The literature reference 716 is about the introduction of the Screening Tool OncoFunction for Functional Follow-up of Head and Neck Patients."
    },
    {
        "id": 14260,
        "document_name": "data\\2 - GGPO_Oropharyngeal_and_Hypopharyngeal_Carcinoma_Version_1.0.pdf",
        "page": 253,
        "content": "The literature reference 717 is about the effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer."
    }
]